Terminated Results Sample NCT #,Target Enrollment Sample (1=included; 0=excluded),Brief Title,Primary Purpose,Intervention Model,Blinding,Allocation,Intervention Type,Study Phase,Condition Category,Lead Sponsor Type,DMC (y/n) [Not available to the public - data removed],Single Site/Multiple Sites,Location Countries,Study Start Date,First Received Date,Primary Completion Date,Study Completion Date,Results First Received Date,Why Study Stopped,Why Study Stopped - Detailed Description Text (if any),Termination Category,Enrollment (Protocol),Enrollment (Protocol) Type,First Enrollment (Protocol),First Enrollment (Protocol) Type,Enrollment = n part started Part Flow (Column W=AC),"For adjudicated enrollment, which value was determined to be correct, E=protocol; F=participant flow",Total Number of Participants Started  Part Flow,ADJUDICATED N Participants Enrolled in Trial (use for all analyses),Max N participants Analyzed Any POM,# participants enrolled / first enrollment [Column AD/Y],SeriousAENAffected,SeriousAENAtRisk,"PUBMED LISTING INFO as of 31 Dec 2013 (0 = no, 1 = yes)",PMID as of 31 Dec 2013,"Termination Categories [Column V] 
"
NCT00004500,1,Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Other,Phase 3,"Respiratory Tract (Lung and Bronchial) Diseases|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Diseases and Abnormalities at or before Birth|All Conditions|Symptoms and General Pathology|Wounds and Injuries|Rare Diseases",INDUSTRY,,Single,United States,Mar-00,18-Oct-99,2-Nov,4-Nov,2-Apr-12,Slow enrollment and administrative reasons,,2,69,Actual,200,,TRUE,,69,69,69,0.35,37,69,0,,2 - No Scientific Data
NCT00004859,1,"Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer",Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug|Radiation,Phase 3,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions|Rare Diseases,NIH,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|South Africa,Jan-00,7-Mar-00,9-Dec,11-May,16-Feb-12,Trial was stopped early for futility,,6,589,Actual,588,,TRUE,,589,589,546,1,471,577,1,22271472,1 - Scientific Data
NCT00006478,1,Vaccine Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma,Treatment,Single Group Assignment,Open Label,Non-Randomized,Biological|Biological|Biological|Procedure,Phase 2,Cancers and Other Neoplasms|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Rare Diseases,OTHER,,Single,United States,Sep-00,6-Nov-00,8-Mar,8-Apr,19-Oct-10,"Genitope suspend development of MyVax in light of the decision made by the Food and Drug Administration (FDA) March 6, 2008",,16,19,Actual,20,,TRUE,,19,19,0,0.95,0,19,1,19125383,2 - No Scientific Data
NCT00015847,1,Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia,Treatment,Single Group Assignment,Open Label,Non-Randomized,Biological|Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Blood and Lymph Conditions|Symptoms and General Pathology|Rare Diseases,OTHER,,Multiple,United States|United States,1-Apr,6-May-01,11-May,11-May,6-Jun-12,,,9,25,Actual,40,Anticipated,TRUE,,25,25,25,0.63,8,25,0,,3 - No Reason Provided
NCT00019747,1,Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Procedure|Other,Phase 2,Cancers and Other Neoplasms|Digestive System Diseases|All Conditions,NIH,,Multiple,United States|United States|United States|United States|United States|United States,Aug-99,11-Jul-01,8-Dec,8-Dec,25-Sep-12,DSMB recommended closure of the protocol due to slow accrual.,,2,39,Actual,94,,TRUE,,39,39,0,0.41,9,39,0,,2 - No Scientific Data
NCT00021229,0,Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma,Treatment,Single Group Assignment,Open Label,,Drug|Radiation,Phase 1|Phase 2,Cancers and Other Neoplasms|Nervous System Diseases|All Conditions|Rare Diseases,NIH,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,1-May,11-Jul-01,8-Aug,8-Aug,9-Feb-10,Poor accrual,,2,85,Actual,85,Actual,TRUE,,85,85,32,1,31,85,1,17293590,2 - No Scientific Data
NCT00022490,1,Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Blood and Lymph Conditions|Symptoms and General Pathology|Rare Diseases,OTHER,,Multiple,United States|United States,1-Jun,10-Aug-01,11-May,11-Jul,6-Jun-12,,,9,24,Actual,45,Anticipated,TRUE,,24,24,24,0.53,13,24,0,,3 - No Reason Provided
NCT00029146,1,Carotid Occlusion Surgery Study,Treatment,Parallel Assignment,Single Blind,Randomized,Procedure|Drug,Phase 3,Nervous System Diseases|Heart and Blood Diseases|All Conditions|Symptoms and General Pathology,OTHER,,Single,United States,2-Jul,8-Jan-02,10-Jun,10-Jun,17-Jan-12,Pre-specified futility boundary was reached.,,6,700,Actual,930,,FALSE,F,195,195,195,0.21,16,195,1,22068990,1 - Scientific Data
NCT00048893,1,Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer,Treatment,Single Group Assignment,Open Label,Non-Randomized,Biological|Biological|Biological|Biological|Drug|Drug|Drug|Drug|Drug,Phase 1|Phase 2,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions|Symptoms and General Pathology,NIH,,Multiple,United States|United States,2-Nov,8-Nov-02,11-Jun,11-Jun,25-Oct-11,The study was closed to accrual due to very poor enrollment.,,2,37,Actual,62,,TRUE,,37,37,37,0.6,11,37,0,,2 - No Scientific Data
NCT00057954,1,Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma,Treatment,Single Group Assignment,Open Label,,Procedure|Drug|Radiation|Procedure|Drug|Drug|Drug,Phase 2,Bacterial and Fungal Diseases|All Conditions|Viral Diseases|Cancers and Other Neoplasms|Blood and Lymph Conditions|Immune System Diseases|Symptoms and General Pathology|Rare Diseases,NETWORK,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,5-Jun,7-Apr-03,8-Apr,11-May,7-Jan-13,Slow accrual,,2,6,Actual,36,,TRUE,,6,6,6,0.17,6,6,0,,2 - No Scientific Data
NCT00060346,1,Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia,Treatment,Single Group Assignment,Open Label,,Biological|Drug|Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Heart and Blood Diseases|Rare Diseases,NETWORK,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,4-Jun,6-May-03,11-Dec,12-Aug,10-Jan-13,slow accrual,,2,16,Actual,37,,TRUE,,16,16,16,0.43,16,16,0,,2 - No Scientific Data
NCT00063258,1,Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,OTHER,,Single,United States,3-Jun,24-Jun-03,8-Apr,8-Apr,25-Aug-10,Low accrual rate,,2,5,Actual,40,,TRUE,,5,5,1,0.13,1,5,0,,2 - No Scientific Data
NCT00063934,0,Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer,Treatment,Single Group Assignment,Open Label,,Biological|Drug|Drug|Biological|Biological|Procedure|Other|Other,Phase 1|Phase 2,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions|Rare Diseases,NIH,,Single,United States,3-May,8-Jul-03,8-Feb,,10-Jul-12,,,9,69,Actual,31,Actual,FALSE,F,31,31,30,1,30,30,1,19047121,3 - No Reason Provided
NCT00070291,1,Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma,Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,Cancers and Other Neoplasms|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Rare Diseases,NETWORK,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,5-Sep,3-Oct-03,9-Mar,11-May,7-Jan-13,Slow accrual.,,2,4,Actual,27,,TRUE,,4,4,4,0.15,2,3,0,,2 - No Scientific Data
NCT00073008,1,A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer,Treatment,Single Group Assignment,Open Label,Randomized,Drug,Phase 2,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions|Behaviors and Mental Disorders,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Canada|Canada|Canada|Canada|Canada|Canada,3-Nov,13-Nov-03,8-Jul,8-Jul,15-Jun-09,"Based on interim analysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment was stopped due to lack of efficacy",,6,131,Actual,120,,TRUE,,131,131,56,1.09,32,131,1,20215545,1 - Scientific Data
NCT00074165,1,Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen,Treatment,Single Group Assignment,Open Label,,Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Nervous System Diseases|Rare Diseases,OTHER,,Multiple,United States|United States,3-Jan,10-Dec-03,10-Jun,10-Dec,10-Oct-11,Lack of accrual,,2,17,Actual,25,,TRUE,,17,17,17,0.68,16,17,0,,2 - No Scientific Data
NCT00076804,1,Helping HIV Infected Patients in South Africa Adhere to Drug Regimens,Treatment,Parallel Assignment,Open Label,Randomized,Behavioral,Phase 2,"Viral Diseases|Immune System Diseases|All Conditions|Symptoms and General Pathology|Bacterial and Fungal Diseases|Urinary Tract, Sexual Organs, and Pregnancy Conditions",OTHER,,Single,South Africa,5-Feb,3-Feb-04,8-Sep,8-Sep,1-Jun-10,DSMB stopped trial for futility,,6,274,Actual,600,,TRUE,,274,274,272,0.46,48,274,1,20453627,1 - Scientific Data
NCT00080119,1,Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV,Prevention,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 2|Phase 3,"Bacterial and Fungal Diseases|All Conditions|Respiratory Tract (Lung and Bronchial) Diseases|Viral Diseases|Immune System Diseases|Symptoms and General Pathology|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Rare Diseases",NETWORK,,Multiple,Botswana|South Africa|South Africa|South Africa|South Africa|South Africa,4-Feb,23-Mar-04,9-May,9-May,1-Jul-10,Data Safety Monitoring Board (DSMB) recommended stopping study due to futility,,6,1354,Actual,1300,,FALSE,E,1351,1354,804,1.04,140,1351,1,21732834,1 - Scientific Data
NCT00083759,0,Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate,Treatment,Parallel Assignment,Double-Blind,Randomized,Drug|Drug,Phase 2,"Muscle, Bone, and Cartilage Diseases|All Conditions|Skin and Connective Tissue Diseases|Immune System Diseases",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Canada|Canada,4-May,1-Jun-04,5-Feb,,27-Jan-09,The biological effect seen with natalizumab was not sufficient to warrant further development in RA.,,6,299,Actual,299,Actual,TRUE,,299,299,273,1,,,0,,1 - Scientific Data
NCT00086346,1,Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant Recipients,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 3,,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Belgium|Canada|Canada|Canada|Czech Republic|France|France|France|France|France|France|Germany|Germany|Germany|Italy|Italy|Italy|Netherlands|Portugal|Portugal|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Switzerland|Switzerland|United Kingdom|United Kingdom|United Kingdom,2-Dec,30-Jun-04,8-Jul,8-Jul,6-Jul-09,,,9,607,Actual,600,,TRUE,,607,607,607,1.01,272,,1,22233522,3 - No Reason Provided
NCT00086684,1,Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 4,"Nervous System Diseases|Symptoms and General Pathology|All Conditions|Urinary Tract, Sexual Organs, and Pregnancy Conditions",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada,3-Sep,7-Jul-04,11-Jun,11-Jun,31-May-12,Interim Analysis showed that study continuation was futile. No safety concerns were raised during the trial.,,6,369,Actual,645,,TRUE,,369,369,368,0.57,8,368,0,,1 - Scientific Data
NCT00089076,1,MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma,Treatment,Single Group Assignment,Open Label,,Biological,Phase 1|Phase 2,Cancers and Other Neoplasms|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Rare Diseases,OTHER,,Multiple,United States|United States,4-Jul,4-Aug-04,8-Jul,11-Dec,11-May-12,"Due to study design, this trial closed to accrual prior to opening the phase II portion.",,4,18,Actual,36,,TRUE,,18,18,18,0.5,8,18,1,19808874,2 - No Scientific Data
NCT00089141,1,Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,"Viral Diseases|Cancers and Other Neoplasms|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Skin and Connective Tissue Diseases|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Gland and Hormone Related Diseases|Heart and Blood Diseases|Symptoms and General Pathology|Rare Diseases",OTHER,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Canada,4-May,4-Aug-04,8-Jul,8-Sep,15-Jul-09,Low probability of positive outcome,,6,151,Actual,230,,TRUE,,151,151,151,0.66,,,1,19270260,1 - Scientific Data
NCT00089778,1,Vaccine Treatment of Kidney Cancer,Treatment,Crossover Assignment,Open Label,Randomized,Drug|Drug|Other,Phase 2,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions|Rare Diseases",NIH,,Single,United States,4-Aug,12-Aug-04,8-Nov,8-Nov,25-Jun-12,Finding that fewer tumors than anticipated expressed FGF-5 led to the termination of accrual to cohorts A and B.,,6,11,Actual,210,,TRUE,,11,11,11,0.05,2,11,0,,1 - Scientific Data
NCT00090779,1,Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 2,"Viral Diseases|Immune System Diseases|All Conditions|Symptoms and General Pathology|Bacterial and Fungal Diseases|Urinary Tract, Sexual Organs, and Pregnancy Conditions",NETWORK,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Peru|Peru,5-Jan,3-Sep-04,9-Jul,11-May,2-Jul-12,The DSMB concluded that the findings regarding the primary analysis would persist and that no additional study goals would be achieved by continuing the study.,,6,130,Actual,150,,TRUE,,130,130,130,0.87,1,130,1,22180621,1 - Scientific Data
NCT00090844,1,Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer,Supportive Care,Parallel Assignment,Open Label,Randomized,Drug,Phase 2,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions|Substance Related Disorders|Behaviors and Mental Disorders,OTHER,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States,4-Jul,7-Sep-04,8-May,8-May,30-Nov-12,Early closure due to low accrual,,2,49,Actual,138,,TRUE,,49,49,47,0.36,2,49,1,22231041,2 - No Scientific Data
NCT00095576,1,Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023),Prevention,Parallel Assignment,Double Blind,Randomized,Biological|Drug,Phase 2,"Viral Diseases|Immune System Diseases|All Conditions|Symptoms and General Pathology|Bacterial and Fungal Diseases|Urinary Tract, Sexual Organs, and Pregnancy Conditions",INDUSTRY,,,,4-Nov,5-Nov-04,9-Dec,9-Dec,20-Jul-11,,,9,3000,Actual,1500,Anticipated,FALSE,E,2979,3000,2979,2,36,2979,1,19012954,3 - No Reason Provided
NCT00096460,1,Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma,Treatment,Parallel Assignment,Open Label,Non-Randomized,Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Procedure|Procedure|Procedure|Procedure|Procedure|Procedure,Phase 2|Phase 3,Cancers and Other Neoplasms|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Rare Diseases,NIH,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,4-Aug,9-Nov-04,6-Mar,9-Mar,16-Aug-11,lower than anticipated accrual,,2,30,Actual,75,,TRUE,,30,30,27,0.4,0,27,1,21073974,2 - No Scientific Data
NCT00104728,1,Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates,Treatment,Single Group Assignment,Open Label,,Drug,,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,OTHER,,Single,United States,4-Oct,3-Mar-05,8-May,9-Mar,1-Oct-12,Early Stopping Rule: Would not meet interim analysis goal to proceed with enrollment,,6,42,Actual,50,,TRUE,,42,42,0,0.84,0,42,1,20881637,1 - Scientific Data
NCT00107614,1,"DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's Macroglobulinemia Patients",Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 2,Cancers and Other Neoplasms|Heart and Blood Diseases|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Rare Diseases,OTHER,,Single,United States,2-Nov,5-Apr-05,8-Feb,8-Feb,15-Apr-11,Terminated due to poor accrual.,,2,12,Actual,25,,TRUE,,12,12,0,0.48,6,12,0,,2 - No Scientific Data
NCT00108433,0,Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug,Phase 3,Bacterial and Fungal Diseases|Symptoms and General Pathology|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|Colombia|Colombia|Colombia|India|India|India|India|India|India|Israel|Italy|Poland|Slovakia|Slovakia,5-Sep,15-Apr-05,,6-Sep,28-Jun-12,See Detailed Description,"Pfizer suspended enrollment on 21 August 2006 as a precautionary measure in light of the mortality imbalance seen in a similar study, and terminated the study on April 6, 2007 due to factors affecting the timeline to completion, such as slow enrollment and inclusion of sufficient evaluable subjects.",7,61,Actual,332,,TRUE,,61,61,0,0.18,10,61,0,,2 - No Scientific Data
NCT00109577,1,Clinical Trial of a Nutritional Supplement in Adults With Bipolar Disorder,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Behaviors and Mental Disorders|All Conditions,OTHER,,Multiple,United States|Canada,5-Apr,28-Apr-05,9-Mar,9-Mar,25-Jun-12,Unable to recruit large enough sample; large expectancy effects but no adverse events,,2,40,Actual,96,,TRUE,,40,40,40,0.42,0,40,0,,2 - No Scientific Data
NCT00109850,1,"S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer",Treatment,Single Group Assignment,Open Label,,Biological|Drug|Drug|Radiation,Phase 2,Cancers and Other Neoplasms|All Conditions|Digestive System Diseases|Rare Diseases,NETWORK,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,5-May,3-May-05,9-Sep,12-May,14-Jun-12,Closed due to poor accrual,,2,22,Actual,100,,TRUE,,22,22,21,0.22,3,21,1,22481235,2 - No Scientific Data
NCT00112905,1,Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium,Treatment,Single Group Assignment,Open Label,,Drug|Other|Other|Other,Phase 2,"Cancers and Other Neoplasms|All Conditions|Symptoms and General Pathology|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Rare Diseases",NIH,,Single,United States,5-Oct,2-Jun-05,8-Mar,,30-Dec-10,,,9,27,Actual,53,,TRUE,,27,27,22,0.51,15,27,1,19536901,3 - No Reason Provided
NCT00113022,1,Org 24448 to Treat Major Depression,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Behaviors and Mental Disorders|All Conditions,NIH,,Multiple,United States|United States,5-May,2-Jun-05,7-Feb,7-Feb,13-Apr-11,Terminated due to concerns about adverse events in separate study.,,7,9,Actual,90,,TRUE,,9,9,9,0.1,1,9,0,,2 - No Scientific Data
NCT00113321,1,Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Blood and Lymph Conditions|Symptoms and General Pathology|Rare Diseases,OTHER,,Single,United States,5-Mar,7-Jun-05,8-Nov,8-Nov,25-Sep-09,Low Accrual,,2,16,Actual,40,,TRUE,,16,16,16,0.4,6,16,1,18398735,2 - No Scientific Data
NCT00113386,1,Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer,Treatment,Parallel Assignment,Open Label,Randomized,Biological|Biological|Drug|Drug|Procedure|Procedure|Procedure|Radiation,Phase 3,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions|Rare Diseases,NETWORK,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,5-Apr,7-Jun-05,9-Feb,,27-Nov-12,This study terminated early due to low accrual.,,2,19,Actual,574,,TRUE,,19,19,0,0.03,9,16,0,,2 - No Scientific Data
NCT00113399,1,Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery,Treatment,Parallel Assignment,Open Label,Randomized,Biological|Drug|Drug|Drug|Drug|Radiation,Phase 3,"Cancers and Other Neoplasms|All Conditions|Respiratory Tract (Lung and Bronchial) Diseases|Ear, Nose, and Throat Diseases|Rare Diseases",NETWORK,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,5-Apr,7-Jun-05,9-Feb,,27-Nov-12,Terminated early due to low accrual.,,2,15,Actual,240,,TRUE,,15,15,0,0.06,8,13,0,,2 - No Scientific Data
NCT00113919,1,UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex??) in Multiple Myeloma Patients,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Other,Phase 1|Phase 2,"Cancers and Other Neoplasms|Heart and Blood Diseases|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Rare Diseases",OTHER,,Multiple,United States|United States,4-Jun,10-Jun-05,9-Oct,9-Oct,14-Apr-11,Due to poor accrual,,2,14,Actual,50,,TRUE,,14,14,0,0.28,12,14,0,,2 - No Scientific Data
NCT00115063,1,LOSS- Louisiana Obese Subjects Study,Treatment,Parallel Assignment,Open Label,Randomized,Behavioral|Drug|Behavioral|Other|Other,Phase 4,Nutritional and Metabolic Diseases|Symptoms and General Pathology|All Conditions,OTHER,,Single,United States,5-Jul,20-Jun-05,7-Dec,8-Jan,1-Mar-10,ethical issues of continuing control group without treatment,,12,390,Actual,480,,TRUE,,390,390,187,0.81,28,390,1,20101009,2 - No Scientific Data
NCT00117312,1,Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug|Drug,Phase 2,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,2-Oct,30-Jun-05,5-Nov,5-Nov,22-Jan-09,After 190 weeks [7 patients left] it was terminated for administrative reasons,,4,37,Actual,37,,FALSE,E,82,37,82,1,14,,0,,2 - No Scientific Data
NCT00121186,1,"S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma",Treatment,Single Group Assignment,Open Label,,Drug|Drug|Drug|Drug|Procedure|Procedure,Phase 2,Cancers and Other Neoplasms|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Rare Diseases,NETWORK,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,5-Jul,19-Jul-05,8-Jan,11-Dec,5-Mar-12,poor accrual,,2,1,Actual,50,,TRUE,,1,1,1,0.02,0,1,0,,2 - No Scientific Data
NCT00122980,1,Stroke With Transfusions Changing to Hydroxyurea,Prevention,Parallel Assignment,Open Label,Randomized,Procedure|Procedure|Drug|Procedure,Phase 3,Nervous System Diseases|Heart and Blood Diseases|All Conditions|Blood and Lymph Conditions|Diseases and Abnormalities at or before Birth|Nutritional and Metabolic Diseases|Symptoms and General Pathology,OTHER,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,6-Oct,20-Jul-05,10-Jun,10-Dec,28-Dec-11,The study has been stopped due to safety and futility concerns.,,5,134,Actual,150,,FALSE,E,133,134,133,0.89,43,133,1,22318199,1 - Scientific Data
NCT00124709,1,Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 4,Respiratory Tract (Lung and Bronchial) Diseases|Immune System Diseases|All Conditions|Diseases and Abnormalities at or before Birth|Skin and Connective Tissue Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,3-Oct,26-Jul-05,8-Jan,8-Nov,8-Dec-10,,,9,1091,Actual,1100,,TRUE,,1091,1091,1053,0.99,79,1087,0,,3 - No Reason Provided
NCT00124748,1,Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity),Treatment,Parallel Assignment,Open Label,Randomized,Drug,Phase 3,Cancers and Other Neoplasms|All Conditions|Blood and Lymph Conditions|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Argentina|Argentina|Australia|Australia|Australia|Australia|Australia|Australia|Australia|Australia|Australia|Australia|Australia|Australia|Brazil|Canada|Canada|Canada|Canada|Italy|Italy|Italy|Italy|Italy|Italy,5-Jun,27-Jul-05,10-Nov,10-Nov,2-Nov-11,This study was prematurely discontinued because no improvement was observed in the 800mg dose compared to 400mg dose,,6,476,Actual,420,,TRUE,,476,476,476,1.13,163,473,1,22315495,1 - Scientific Data
NCT00125268,1,Near Infrared Light for the Treatment of Painful Peripheral Neuropathy,Treatment,Parallel Assignment,Double Blind,Randomized,Device|Device,Phase 3,Nervous System Diseases|Symptoms and General Pathology|All Conditions|Diseases and Abnormalities at or before Birth|Substance Related Disorders|Behaviors and Mental Disorders|Rare Diseases,OTHER,,Single,United States,5-Jul,27-Jul-05,10-Apr,10-Apr,2-Aug-12,Unable to enroll enough patients,,2,30,Actual,60,,TRUE,,30,30,0,0.5,1,30,0,,2 - No Scientific Data
NCT00126568,1,Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer,Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Gland and Hormone Related Diseases|Rare Diseases,NIH,,Single,United States,5-Jun,2-Aug-05,11-Sep,,23-May-12,Administratively complete.,,11,36,Actual,36,,FALSE,F,20,20,18,0.56,8,20,1,23113752,2 - No Scientific Data
NCT00126659,1,Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Procedure,Phase 2,"Cancers and Other Neoplasms|All Conditions|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Rare Diseases",OTHER,,Single,United States,6-Jan,2-Aug-05,9-Dec,9-Dec,28-Sep-12,Slow Accrual.,,2,10,Actual,45,,TRUE,,10,10,0,0.22,1,10,0,,2 - No Scientific Data
NCT00127036,1,Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A),Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Digestive System Diseases,OTHER,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,3-Oct,3-Aug-05,10-Dec,10-Dec,5-Jan-12,drug now on market,,7,65,Actual,150,,TRUE,,65,65,0,0.43,20,65,0,,2 - No Scientific Data
NCT00127101,1,An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug,Phase 1,Cancers and Other Neoplasms|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Rare Diseases,INDUSTRY,,,,5-Sep,2-Aug-05,8-Oct,8-Oct,6-Jul-09,The study was stopped due to low enrollment.,,2,23,Actual,42,,TRUE,,23,23,22,0.55,8,,1,22239668,2 - No Scientific Data
NCT00128921,1,Study of Velcade?? and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma,Prevention,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 2,Cancers and Other Neoplasms|Heart and Blood Diseases|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Rare Diseases,OTHER,,Single,United States,6-Apr,8-Aug-05,8-Feb,8-Feb,15-Apr-11,study terminated due to low accrual,,2,18,Actual,30,,TRUE,,18,18,16,0.6,1,16,0,,2 - No Scientific Data
NCT00131508,1,Trial of Oral Glutamine in Patients With Sickle Cell Anemia,Prevention,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Blood and Lymph Conditions|All Conditions|Diseases and Abnormalities at or before Birth|Symptoms and General Pathology|Rare Diseases,OTHER,,Single,United States,4-May,17-Aug-05,9-Apr,9-Apr,19-Feb-10,Due to slow participant accrual,,2,27,Actual,46,,FALSE,F,25,25,25,0.54,0,25,0,,2 - No Scientific Data
NCT00136916,1,Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 2 Diabetes,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 3,Respiratory Tract (Lung and Bronchial) Diseases|Symptoms and General Pathology|All Conditions|Nutritional and Metabolic Diseases|Gland and Hormone Related Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Brazil|Brazil|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Puerto Rico|Puerto Rico|Puerto Rico|Puerto Rico|Puerto Rico,2-Jun,25-Aug-05,8-Dec,8-Dec,10-Dec-09,See termination reason in detailed description.,"Pfizer announced in October 2007 that it would stop marketing Exubera. Nektar, the company from which Pfizer licensed Exubera, announced on April 9, 2008 that it had stopped its search for a new marketing partner. Accordingly, there will be no commercial availability of Exubera. As a result, study A2171029 was terminated on June 9, 2008. Neither safety nor efficacy reasons were the cause of the study termination.",16,635,Actual,600,,TRUE,,635,635,615,1.06,152,627,1,19905885,2 - No Scientific Data
NCT00137046,1,Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 1 Diabetes,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 3,Respiratory Tract (Lung and Bronchial) Diseases|Symptoms and General Pathology|All Conditions|Nutritional and Metabolic Diseases|Gland and Hormone Related Diseases|Immune System Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Argentina|Argentina|Argentina|Argentina|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Mexico|Mexico|Mexico|Mexico,2-May,26-Aug-05,8-Dec,8-Dec,7-Dec-09,See termination reason in detailed description.,"Pfizer announced in October 2007 that it would stop marketing Exubera. Nektar, the company from which Pfizer licensed Exubera, announced on April 9, 2008 that it had stopped its search for a new marketing partner. Accordingly, there will be no commercial availability of Exubera. As a result, study A2171022 was terminated on June 9, 2008. Neither safety nor efficacy reasons were the cause of the study termination.",16,582,Actual,600,,TRUE,,582,582,564,0.97,115,580,1,18824271,2 - No Scientific Data
NCT00138125,1,Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer,Treatment,Single Group Assignment,Open Label,,Drug|Biological,Phase 2,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions,OTHER,,Multiple,United States|United States|United States,5-Apr,29-Aug-05,9-Sep,9-Dec,8-Jan-13,Due to low accrual,,2,2,Actual,120,,TRUE,,2,2,2,0.02,0,2,0,,2 - No Scientific Data
NCT00138424,1,Cidofovir in Renal Transplant Recipients With BKVN,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 1|Phase 2,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions|Rare Diseases",NIH,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,6-May,26-Aug-05,10-Jun,11-Apr,14-Jun-12,,,9,22,Actual,48,,TRUE,,22,22,22,0.46,2,22,0,,3 - No Reason Provided
NCT00138671,1,A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 3,Respiratory Tract (Lung and Bronchial) Diseases|All Conditions|Symptoms and General Pathology|Nutritional and Metabolic Diseases|Gland and Hormone Related Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Brazil|Brazil|Brazil|Brazil|Canada|Canada|Canada|Canada|Canada|Costa Rica|Germany,3-Jan,26-Aug-05,8-Sep,8-Sep,2-Sep-09,See termination reason in detailed description.,"Pfizer announced in October 2007 that it would stop marketing Exubera. At that time recruitment for study A2171030 was placed on hold. Nektar, the company from which Pfizer licensed Exubera, announced on April 9, 2008 that it had stopped its search for a new marketing partner. Accordingly, there will be no commercial availability of Exubera. As a result, study A2171030 was terminated on June 17, 2008. Neither safety nor efficacy reasons were the cause of the study termination.",16,105,Actual,250,,TRUE,,105,105,102,0.42,31,,0,,2 - No Scientific Data
NCT00143247,1,Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 2,Respiratory Tract (Lung and Bronchial) Diseases|Symptoms and General Pathology|All Conditions|Nutritional and Metabolic Diseases|Gland and Hormone Related Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,3-Mar,31-Aug-05,8-Jan,8-Jan,16-Jan-09,See termination reason in detailed description.,"The study was terminated on Oct. 18, 2007. This study is not a post approval commitment study. Pfizer decided to cancel new trials because of the decision to withdraw Exubera? (inhaled insulin) due to lack of market performance and not for safety reasons.",8,173,Actual,85,,TRUE,,173,173,156,2.04,63,,0,,2 - No Scientific Data
NCT00145418,1,Oxaliplatin and Docetaxel as First-line Therapy for Advanced Non-small Cell Lung Cancer,Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,OTHER,,Single,United States,5-Feb,1-Sep-05,9-Aug,10-Mar,20-Jul-11,low enrollment,,2,15,Actual,48,,TRUE,,15,15,15,0.31,9,15,1,19622464,2 - No Scientific Data
NCT00145587,1,Stem Cell Transplantation for Children Affected With Osteopetrosis,Treatment,Single Group Assignment,Open Label,Non-Randomized,Procedure|Device|Drug,,"Muscle, Bone, and Cartilage Diseases|All Conditions|Diseases and Abnormalities at or before Birth|Skin and Connective Tissue Diseases|Nutritional and Metabolic Diseases|Rare Diseases",OTHER,,Single,United States,4-Jul,1-Sep-05,9-Feb,9-Feb,22-Jun-11,Due to the principal investigator having left the institution.,,4,15,Actual,10,,FALSE,F,6,6,6,0.6,6,6,0,,2 - No Scientific Data
NCT00147238,1,"A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast",Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Procedure,,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions",OTHER,,Single,United States,5-Jul,6-Sep-05,7-Jan,7-Jan,24-Apr-09,Terminated at request of sponsor.,,8,10,Actual,80,,TRUE,,10,10,0,0.13,0,10,0,,2 - No Scientific Data
NCT00156936,1,ALK21-006EXT: Long-term Safety of Medisorb?? Naltrexone (VIVITROL??) in Alcohol- or Opioid-dependent Adults (Extension of Study ALK21-006 [NCT01218997]),Treatment,Parallel Assignment,Open Label,Non-Randomized,Drug|Drug,Phase 3,Substance Related Disorders|Behaviors and Mental Disorders|All Conditions,INDUSTRY,,,,4-Aug,7-Sep-05,7-Jan,7-Jan,8-Oct-10,Business decision,,8,108,Actual,400,,TRUE,,108,108,73,0.27,11,108,0,,2 - No Scientific Data
NCT00157248,1,"Long-term, Open-label Follow-up Treatment of Patients With A-fib Who Have Been Previously Treated With BIBR 1048",Prevention,,Open Label,Non-Randomized,Drug|Drug|Drug|Drug,Phase 2,Nervous System Diseases|Heart and Blood Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Denmark|Denmark|Denmark|Denmark|Denmark|Denmark|Denmark|Denmark|Denmark|Denmark|Denmark|Denmark|Denmark|Netherlands|Netherlands|Netherlands|Netherlands|Netherlands|Netherlands|Netherlands|Netherlands|Netherlands|Netherlands|Netherlands|Netherlands|Netherlands|Sweden|Sweden|Sweden|Sweden|Sweden|Sweden|Sweden|Sweden|Sweden|Sweden|Sweden|Sweden,3-Dec,8-Sep-05,9-Jan,,18-Nov-10,,,9,361,Actual,400,,TRUE,,361,361,815,0.9,241,815,0,,3 - No Reason Provided
NCT00157755,1,Enterra Therapy Clinical Study (Gastric Stimulation for Gastroparesis),Treatment,Crossover Assignment,Double Blind,Randomized,Device,,Digestive System Diseases|Symptoms and General Pathology|All Conditions|Nervous System Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States,2-Jun,8-Sep-05,8-Dec,9-Mar,18-Dec-09,,,9,87,Actual,85,,TRUE,,87,87,52,1.02,12,87,1,20538073,3 - No Reason Provided
NCT00160563,1,Prevention of Asthma With Levocetirizine (36 Month Treatment) in Young Children Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and House Dust Mite and Having Completed the Previous EPAAC Trial (NCT00152464),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Other,Phase 3,Respiratory Tract (Lung and Bronchial) Diseases|Immune System Diseases|All Conditions|Diseases and Abnormalities at or before Birth|Skin and Connective Tissue Diseases,INDUSTRY,,Multiple,Australia|Australia|Belgium|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|France|France|France|France|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Poland|South Africa|South Africa|South Africa|South Africa|South Africa|South Africa|South Africa|South Africa|South Africa|Spain|Spain|United Kingdom|United Kingdom|United Kingdom,4-Jun,8-Sep-05,6-Mar,6-Mar,17-Jun-09,The predecessor study A00309 (NCT00152464) did not show statistical significance in time to onset of asthma between the levocetirizine and placebo groups.,,7,207,Actual,300,,TRUE,,207,207,0,0.69,11,207,0,,2 - No Scientific Data
NCT00167206,1,Stem Cell Transplantation for Fanconi Anemia,Treatment,Single Group Assignment,Open Label,Non-Randomized,Procedure|Procedure|Procedure|Drug,Phase 1|Phase 2,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|Diseases and Abnormalities at or before Birth|Nutritional and Metabolic Diseases|All Conditions|Blood and Lymph Conditions|Symptoms and General Pathology|Rare Diseases",OTHER,,Single,United States,4-Mar,9-Sep-05,8-Dec,8-Dec,7-Jul-09,"Treatment with thymic shielding found safe, another study started.",,6,16,Actual,30,,TRUE,,16,16,16,0.53,0,0,0,,1 - Scientific Data
NCT00170950,1,Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug|Drug|Drug|Drug,Phase 3,Heart and Blood Diseases|All Conditions,INDUSTRY,,Multiple,United States|Denmark|Finland|Norway|Sweden,3-Oct,10-Sep-05,8-Jan,8-May,13-Jan-11,The study was terminated early because of significant efficacy results for the primary endpoint in favor of benazepril/amlodipine treatment.,,6,11506,Actual,11464,,TRUE,,11506,11506,11506,1,3870,11497,1,19052124,1 - Scientific Data
NCT00171925,1,Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Dietary Supplement,Phase 3,Cancers and Other Neoplasms|Heart and Blood Diseases|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Symptoms and General Pathology|Rare Diseases,INDUSTRY,,Single,Germany,Aug-00,13-Sep-05,8-Nov,8-Nov,20-Jan-11,Recruitment in study could not be reached after 8 yrs of recruiting,,2,143,Actual,220,,TRUE,,143,143,140,0.65,40,143,0,,2 - No Scientific Data
NCT00174187,1,Treatment With Recombinant Human Growth Hormone (GH) in Children With Short Stature Secondary to a Long Term Corticoid Therapy,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 3,"Cancers and Other Neoplasms|Symptoms and General Pathology|All Conditions|Muscle, Bone, and Cartilage Diseases|Diseases and Abnormalities at or before Birth|Gland and Hormone Related Diseases",INDUSTRY,,Multiple,France|France,Sep-00,9-Sep-05,11-Sep,11-Sep,11-Sep-12,See termination reason in detailed description.,This trial terminated on 10-Jun-2011 due to prolonged issues with drug accountability and data collection discrepancies. The decision to terminate was not based on any safety concerns.,4,30,Actual,30,,TRUE,,30,30,30,1,46,51,0,,2 - No Scientific Data
NCT00174291,1,Prevention of Growth Retardation by Early Treatment With Growth Hormone (GH) in Children With CJA Treated by Corticosteroid Therapy,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 3,"Muscle, Bone, and Cartilage Diseases|All Conditions|Skin and Connective Tissue Diseases|Immune System Diseases",INDUSTRY,,Single,France,2-Mar,9-Sep-05,11-Oct,11-Oct,26-Oct-12,See termination reason in detailed description.,This trial terminated on 10-Jun-2011 due to prolonged issues with drug accountability and data collection discrepancies. The decision to terminate was not based on any safety concerns.,4,21,Actual,30,,TRUE,,21,21,15,0.7,8,21,1,17488793,2 - No Scientific Data
NCT00174382,1,Vaspect Study - An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 3,Nervous System Diseases|Behaviors and Mental Disorders|All Conditions|Heart and Blood Diseases|Symptoms and General Pathology,INDUSTRY,,Multiple,Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada,5-Jun,8-Sep-05,8-Apr,8-Apr,24-Apr-09,See Detailed Description,"The trial was terminated on October 15, 2007 due to difficulties in recruiting the subjects. There were no safety or efficacy concerns regarding the study medication in the decision to terminate the trial.",2,149,Actual,260,,TRUE,,149,149,137,0.57,24,,1,23786741,2 - No Scientific Data
NCT00176839,1,Stem Cell Transplantation for Hematological Malignancies,Treatment,Single Group Assignment,Open Label,,Procedure|Drug,Phase 2|Phase 3,Cancers and Other Neoplasms|All Conditions|Blood and Lymph Conditions|Immune System Diseases|Rare Diseases,OTHER,,Single,United States,Jun-00,12-Sep-05,12-Oct,12-Oct,11-Jan-13,Replaced by a different study,,7,11,Actual,40,,TRUE,,11,11,11,0.28,10,11,0,,2 - No Scientific Data
NCT00183430,1,Prazosin for Treating Noncombat Trauma Post-Traumatic Stress Disorder,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Behavioral,,Nervous System Diseases|Symptoms and General Pathology|Behaviors and Mental Disorders|All Conditions,OTHER,,Single,United States,3-Oct,13-Sep-05,9-May,10-Dec,22-Oct-12,Insufficient Enrollment,,2,20,Actual,95,,TRUE,,20,20,14,0.21,0,14,0,,2 - No Scientific Data
NCT00183963,1,A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS),Treatment,Single Group Assignment,Open Label,Randomized,Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions,OTHER,,Single,United States,6-Aug,12-Sep-05,8-Jun,8-Jun,9-Nov-12,Insufficient accrual,,2,4,Actual,100,Anticipated,TRUE,,4,4,0,0.04,0,4,0,,2 - No Scientific Data
NCT00184548,1,Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Heart and Blood Diseases|Blood and Lymph Conditions|All Conditions|Symptoms and General Pathology,INDUSTRY,,Multiple,United States|Australia|Austria|Belgium|Brazil|Canada|Czech Republic|Finland|France|Germany|Greece|Hong Kong|Hungary|Israel|Italy|Netherlands|New Zealand|Norway|Portugal|Singapore|South Africa|Spain|Sweden|Switzerland|Taiwan|United Kingdom,5-Aug,9-Sep-05,8-Sep,8-Sep,4-Sep-09,See termination reason in detailed description,"The decision to discontinue the F7TRAUMA-1711 trial is not due to any safety concerns. The result of the pre-planned futility analysis performed in June 2008 predicted a very low likelihood of reaching a successful outcome on the primary efficacy endpoint at the end of the trial and as a consequence, the company has decided to close the trial as this juncture.",6,554,Actual,1002,,FALSE,F,573,573,460,0.57,362,560,1,20838118,1 - Scientific Data
NCT00187135,1,Study of Fentanyl-Propofol-EMLA of L.M.X4 Technique for Bone Marrow Aspiration,Treatment,Crossover Assignment,Double Blind,Randomized,Drug|Drug|Drug|Drug,Phase 3,Nervous System Diseases|Symptoms and General Pathology|All Conditions|Blood and Lymph Conditions,OTHER,,Single,United States,2-Mar,12-Sep-05,8-Aug,8-Aug,13-Oct-09,The study was terminated due to slow accrual.,,2,168,Actual,185,,FALSE,F,162,162,150,0.88,0,316,1,22883421,2 - No Scientific Data
NCT00189423,1,ResQ Trial: Impact of an ITD and Active Compression Decompression CPR on Survival From Out-of-Hospital Cardiac Arrest,Treatment,Parallel Assignment,Single Blind,Randomized,Device|Procedure,,Heart and Blood Diseases|Symptoms and General Pathology|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States,5-Oct,12-Sep-05,10-Jul,10-Jul,1-Mar-12,Terminated due to lack of funding. Follow-up completed for all enrolled subjects.,,1,1653,Actual,2450,,TRUE,,1653,1653,1653,0.67,1553,1653,1,21251705,2 - No Scientific Data
NCT00191477,1,Instillation of Gemcitabine in Patients With Superficial Bladder Cancer,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,"Cancers and Other Neoplasms|All Conditions|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Rare Diseases",INDUSTRY,,Single,Germany,4-Jan,12-Sep-05,8-Mar,8-Jun,17-Mar-09,The study was stopped early for futility reasons.,,6,355,Actual,328,,TRUE,,355,355,328,1.08,27,328,1,19560257,1 - Scientific Data
NCT00202449,1,Prazosin vs Paroxetine in Combat Stress-Related Post-Traumatic Stress Disorder (PTSD) Nightmares & Sleep Disturbance,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,,Nervous System Diseases|Symptoms and General Pathology|Behaviors and Mental Disorders|All Conditions,OTHER,,Multiple,United States|United States,4-Jul,12-Sep-05,8-Feb,8-Feb,24-Feb-12,recruitment difficulties,,2,59,Actual,210,,TRUE,,59,59,25,0.28,0,59,0,,2 - No Scientific Data
NCT00203307,1,A Research Study Examining the Use of Olanzapine for the Prevention of Migraine,Treatment,Crossover Assignment,Double-Blind,Randomized,Drug|Drug,,Nervous System Diseases|All Conditions|Symptoms and General Pathology,OTHER,,Single,United States,4-May,13-Sep-05,6-Mar,6-Jun,24-May-11,Study terminated by sponsor,,8,3,Actual,46,,TRUE,,3,3,3,0.07,0,3,0,,2 - No Scientific Data
NCT00206440,1,Nexium Study To Suppress Nausea During Chemotherapy,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Other,Phase 3,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions|Symptoms and General Pathology,OTHER,,Single,United States,5-Aug,13-Sep-05,9-Feb,12-Feb,1-Feb-12,Accrual was not optimized,,2,43,Actual,192,,TRUE,,43,43,40,0.22,0,43,0,,2 - No Scientific Data
NCT00208949,1,A Comparison of Dendritic Cell Content and T-Cell Phenotype Between Granulocyte Colony-Stimulating Factor (G-CSF) or G-CSF + Granulocyte Macrophage (GM)-CSF,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 2,Blood and Lymph Conditions|All Conditions,OTHER,,Single,United States,2-Sep,13-Sep-05,10-May,12-May,22-Mar-12,slow accrual,,2,50,Actual,20,,TRUE,,50,50,50,2.5,14,50,1,23201472,2 - No Scientific Data
NCT00208975,1,"Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab",Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,Cancers and Other Neoplasms|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Rare Diseases,OTHER,,Single,United States,2-Jul,13-Sep-05,9-Dec,11-Sep,16-Mar-12,slow accrual,,2,15,Actual,20,,TRUE,,15,15,15,0.75,0,15,0,,2 - No Scientific Data
NCT00209027,1,The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia,,Parallel Assignment,Open Label,Non-Randomized,Other|Drug,,Symptoms and General Pathology|All Conditions|Behaviors and Mental Disorders,OTHER,,Single,United States,5-Apr,13-Sep-05,10-Dec,11-Apr,13-Apr-12,"difficulty with technical aspect of fMRI, resources to complete the study ran out",,4,20,Actual,30,,TRUE,,20,20,0,0.67,0,20,0,,2 - No Scientific Data
NCT00209092,1,Randomized Phase II Trial Induction Therapy for Early Stage Breast Cancer,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 2,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions,OTHER,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,6-Aug,14-Sep-05,9-Jul,12-Sep,15-Mar-12,,,9,51,Actual,100,,TRUE,,51,51,51,0.51,17,51,1,23332349,3 - No Reason Provided
NCT00209131,1,Efficacy of Flomax to Improve Stone Passage Following Shock Wave Lithotripsy,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions|Symptoms and General Pathology",OTHER,,Single,United States,5-Apr,14-Sep-05,9-Feb,9-Feb,5-Jun-12,Due to frequent turnover of research coordinators and thus poor study accrual.,,4,24,Actual,24,,FALSE,F,26,26,0,1.08,0,0,0,,2 - No Scientific Data
NCT00209560,0,A Study of AQUAVAN?? Injection in the Presence of Pre-Medication in Patients Undergoing Minor Surgical Procedures,Treatment,Parallel Assignment,Open Label,Randomized,Drug,Phase 3,Nervous System Diseases|Wounds and Injuries|All Conditions|Symptoms and General Pathology|Diseases and Abnormalities at or before Birth|Rare Diseases,INDUSTRY,,,,4-Oct,13-Sep-05,,5-Mar,1-Mar-12,,,9,168,Actual,240,,FALSE,E,163,168,163,0.7,1,163,0,,3 - No Reason Provided
NCT00210626,1,"Assess Functional Outcomes in Anemic, Critically Ill, Trauma Patients When Taking Epoetin Alfa",Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Blood and Lymph Conditions|All Conditions|Symptoms and General Pathology,INDUSTRY,,,,5-Aug,13-Sep-05,8-Jun,8-Jun,26-Jun-09,The study was stopped early due to slow enrollment,,2,192,Actual,204,,TRUE,,192,192,166,0.94,37,188,0,,2 - No Scientific Data
NCT00215540,0,SURFAXIN?? Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.,Prevention,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 2,"Respiratory Tract (Lung and Bronchial) Diseases|Diseases and Abnormalities at or before Birth|All Conditions|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Symptoms and General Pathology|Wounds and Injuries|Rare Diseases",INDUSTRY,,Single,United States,5-Feb,14-Sep-05,6-Jul,6-Jul,2-Apr-12,Concerns related to availability of drug product,,3,136,Actual,136,Actual,TRUE,,136,136,136,1,104,136,1,19117865,2 - No Scientific Data
NCT00215553,0,KL??Surfactant Treatment in Patients With ARDS,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Other,Phase 2,Respiratory Tract (Lung and Bronchial) Diseases|Diseases and Abnormalities at or before Birth|All Conditions|Symptoms and General Pathology|Wounds and Injuries|Rare Diseases,INDUSTRY,,Single,United States,1-May,14-Sep-05,6-Feb,6-Feb,2-Apr-12,Slow enrollment and administrative reasons,,2,124,Actual,124,Actual,TRUE,,124,124,124,1,49,124,0,,2 - No Scientific Data
NCT00215657,1,Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug,Phase 2,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions",INDUSTRY,,,,3-Mar,20-Sep-05,6-Mar,6-Mar,22-Jan-09,The doses were not effective in maintaining testosterone suppression,,6,131,Actual,156,,FALSE,E,180,131,172,0.84,47,,0,,1 - Scientific Data
NCT00217022,1,Budesonide Versus Placebo for the Treatment of Lymphocytic Colitis,Treatment,Parallel Assignment,Double Blind,Randomized,Other|Drug,Phase 2|Phase 3,Digestive System Diseases|All Conditions|Symptoms and General Pathology|Rare Diseases,OTHER,,Single,United States,3-Jun,14-Sep-05,8-Feb,8-Feb,15-Jul-11,"Study closed early, because of low enrollment.",,2,16,Actual,30,,TRUE,,16,16,16,0.53,0,15,0,,2 - No Scientific Data
NCT00217724,1,Glutamine in Preventing Myalgia and/or Arthralgia in Patients Who Are Receiving Paclitaxel For Cancer,Supportive Care,Crossover Assignment,Double Blind,Randomized,Dietary Supplement|Other,,"Muscle, Bone, and Cartilage Diseases|Symptoms and General Pathology|All Conditions|Nervous System Diseases",OTHER,,Single,United States,Jul-99,20-Sep-05,9-Jan,9-Mar,10-Jun-10,Only able to accrue just 18 of the 40 target & funds were limited.,,2,18,Actual,40,,TRUE,,18,18,28,0.45,0,36,0,,2 - No Scientific Data
NCT00238355,1,Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems,Supportive Care,Single Group Assignment,Open Label,,Drug|Drug,Phase 2,Bacterial and Fungal Diseases|All Conditions,OTHER,,Single,United States,3-Aug,12-Oct-05,8-Jun,8-Jun,7-Nov-11,competing study at site,,7,13,Actual,47,,TRUE,,13,13,13,0.28,10,13,0,,2 - No Scientific Data
NCT00239720,1,hOKT3gamma1 (Ala-Ala) for the Treatment of Psoriatic Arthritis,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,"Muscle, Bone, and Cartilage Diseases|All Conditions|Skin and Connective Tissue Diseases|Bacterial and Fungal Diseases|Rare Diseases",NIH,,Multiple,United States|United States,6-Mar,13-Oct-05,6-Dec,8-Jun,15-Feb-12,FDA Clinical Hold,,7,4,Actual,120,,TRUE,,4,4,0,0.03,1,4,0,,2 - No Scientific Data
NCT00245128,0,Imatinib Mesylate in Treating Patients With Myelofibrosis,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 2,Blood and Lymph Conditions|All Conditions|Symptoms and General Pathology|Rare Diseases,OTHER,,Single,United States,5-Aug,25-Oct-05,7-Mar,11-Oct,25-Oct-11,"Per PI, results from another similar study were published prior to study analysis. Negative study results were published therefore analysis was not completed",,7,10,Actual,10,Actual,TRUE,,10,10,0,1,10,10,0,,2 - No Scientific Data
NCT00245466,1,Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer Patients,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug,Phase 2,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions",INDUSTRY,,,,1-Oct,26-Oct-05,6-Mar,6-Mar,22-Jan-09,The maintenance doses were too low to maintain testosterone suppression,,6,88,Actual,120,,FALSE,E,129,88,129,0.73,34,,0,,1 - Scientific Data
NCT00249002,1,Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis,Prevention,Single Group Assignment,Open Label,,Drug,Phase 2,Symptoms and General Pathology|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States,5-Nov,3-Nov-05,7-Nov,7-Nov,21-Feb-12,Terminated due to pipeline prioritization,,8,9,Actual,20,,TRUE,,9,9,9,0.45,6,9,0,,2 - No Scientific Data
NCT00251589,1,A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug|Drug|Drug,Phase 1|Phase 2,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,INDUSTRY,,,,5-Nov,7-Nov-05,7-Oct,7-Dec,27-Oct-08,"This trial is being closed based on lack of substantive efficacy, slow accrual and overall tolerance in patients treated to date.",,6,23,Actual,98,,TRUE,,23,23,12,0.23,,,0,,1 - Scientific Data
NCT00255008,1,Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)(TERMINATED),Treatment,Parallel Assignment,Open Label,Randomized,Biological|Drug|Biological|Drug,Phase 4,Viral Diseases|Digestive System Diseases|All Conditions,INDUSTRY,,,,5-Mar,15-Nov-05,7-Dec,7-Dec,5-Dec-08,Slow enrollment,,2,121,Actual,462,,TRUE,,121,121,30,0.26,6,121,0,,2 - No Scientific Data
NCT00255034,1,"Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)",Treatment,Parallel Assignment,Open Label,Randomized,Biological|Biological|Drug|Drug,Phase 4,Viral Diseases|Digestive System Diseases|All Conditions,INDUSTRY,,,,5-Feb,15-Nov-05,8-Jun,8-Jun,4-Jun-09,Recruitment targets were unachievable in the currently available population.,,2,146,Actual,624,,FALSE,F,143,143,142,0.23,17,143,0,,2 - No Scientific Data
NCT00257192,1,Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Behaviors and Mental Disorders|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Colombia|Colombia|Costa Rica|India|India|India|India|India|India|India|India|India|India|Malaysia|Malaysia|Malaysia|Malaysia|Peru|Peru|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Singapore|Singapore|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine,6-Apr,21-Nov-05,9-Mar,9-Mar,23-Mar-10,Please see Detailed Description for termination reason.,"Termination Reason: On March 24, 2009, Pfizer Inc. stopped late stage Geodon pediatric clinical trials in schizophrenia (A1281134 - placebo controlled; A1281135 - open label). As recommended by the DSMB, these studies were stopped due to lack of efficacy. No safety concerns were identified.",6,284,Actual,276,,TRUE,,284,284,276,1.03,10,283,1,24111983,1 - Scientific Data
NCT00258349,1,Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer,Treatment,Single Group Assignment,Open Label,,Biological|Drug,Phase 1|Phase 2,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions|Rare Diseases,NIH,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,6-Aug,22-Nov-05,9-Sep,10-Sep,28-Aug-12,due to a low response rate in a pre-planned efficacy evaluation,,6,16,Actual,53,,TRUE,,16,16,10,0.3,4,16,0,,1 - Scientific Data
NCT00258440,1,Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer,Supportive Care,Parallel Assignment,Open Label,Randomized,Drug|Drug,,Blood and Lymph Conditions|All Conditions|Symptoms and General Pathology,OTHER,,Single,United States,3-May,23-Nov-05,8-Sep,8-Sep,10-Jun-10,Sponsor discontinued funding of the study,,1,7,Actual,25,,TRUE,,7,7,7,0.28,1,7,0,,2 - No Scientific Data
NCT00259285,1,Pemetrexed and Cisplatin Treatment Before Surgery in Non Small Cell Lung Cancer,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug,Phase 2,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,INDUSTRY,,Multiple,Spain|Spain|Spain|Spain|Spain|Spain,5-Nov,28-Nov-05,7-Dec,7-Dec,19-Dec-08,Trial was stopped early due to low enrollment.,,2,10,Actual,44,,TRUE,,10,10,10,0.23,1,,0,,2 - No Scientific Data
NCT00260208,1,Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus,Prevention,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 4,Viral Diseases|Digestive System Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Multiple,United States|Switzerland,6-Jan,30-Nov-05,10-Sep,,14-Sep-11,Study was prematurely terminated due to poor recruitment.,,2,361,Actual,450,Anticipated,FALSE,E,356,361,165,0.8,286,356,0,,2 - No Scientific Data
NCT00262951,1,Chemoradiation in Locally Advanced Pancreatic Cancer,Treatment,Single Group Assignment,Open Label,,Biological|Drug|Drug|Radiation|Procedure,Phase 2,Cancers and Other Neoplasms|All Conditions|Digestive System Diseases|Gland and Hormone Related Diseases|Rare Diseases,OTHER,,Single,United States,5-Jan,6-Dec-05,11-Apr,11-Aug,14-Nov-11,Closed at a planned interim analysis by meeting a predefined toxicity endpoint,,5,23,Actual,43,,TRUE,,23,23,23,0.53,12,23,1,23509924,1 - Scientific Data
NCT00265382,1,Safety And Tolerability Of Ziprasidone In Adolescents With Schizophrenia,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 3,Behaviors and Mental Disorders|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Colombia|Colombia|Costa Rica|India|India|India|India|India|India|India|India|India|Malaysia|Malaysia|Malaysia|Malaysia|Peru|Peru|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Singapore|Singapore|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine,6-Jun,12-Dec-05,9-Jun,9-Jun,16-Apr-10,Please see Detailed Description for termination reason.,"On March 24, 2009, Pfizer Inc. stopped late stage Geodon pediatric clinical trials in schizophrenia (A1281134 - placebo controlled; A1281135 - open label). As recommended by the DSMB, these studies were stopped due to lack of efficacy. No safety concerns were identified.",6,221,Actual,180,,TRUE,,221,221,221,1.23,16,221,1,24111983,1 - Scientific Data
NCT00265785,1,S0526: Pemetrexed Disodium in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer,Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,NETWORK,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,6-Jul,14-Dec-05,11-Jul,11-Jul,12-Jul-12,Closed due to poor accrual,,2,27,Actual,99,,TRUE,,27,27,24,0.27,0,24,1,23415808,2 - No Scientific Data
NCT00266812,1,Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED),Treatment,Parallel Assignment,Open Label,Randomized,Drug|Procedure,Phase 2,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,,,5-Mar,16-Dec-05,9-Aug,9-Aug,29-Jul-09,Patient target could not be reached within the planned timeframe.,,2,35,Actual,82,,TRUE,,35,35,31,0.43,,,0,,2 - No Scientific Data
NCT00267007,1,A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy,Prevention,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Nervous System Diseases|All Conditions|Diseases and Abnormalities at or before Birth|Symptoms and General Pathology|Substance Related Disorders|Behaviors and Mental Disorders|Rare Diseases,INDUSTRY,,,,6-Jun,16-Dec-05,8-Aug,8-Aug,31-Jul-09,Slow enrollment,,2,32,Actual,120,,FALSE,E,30,32,30,0.27,7,,0,,2 - No Scientific Data
NCT00268983,1,Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR?? Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma,Treatment,Parallel Assignment,Open Label,Randomized,Biological|Biological,Phase 3,Cancers and Other Neoplasms|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Rare Diseases,INDUSTRY,,Multiple,United States|United Kingdom,4-Oct,21-Dec-05,10-May,16-Apr,29-Jun-10,Study was stopped early due to lack of feasibility. Subjects originally treated in SB393220/028 continue long-term follow-up evaluations in Study BEX104528.,,4,14,Actual,506,,TRUE,,14,14,6,0.03,5,14,0,,2 - No Scientific Data
NCT00275262,1,A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Cancers and Other Neoplasms|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Heart and Blood Diseases|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States,6-Feb,9-Jan-06,9-Feb,,5-Feb-10,,,9,25,Actual,80,,TRUE,,25,25,13,0.31,10,25,0,,3 - No Reason Provided
NCT00276159,1,Study of Immune Response Modifier in the Treatment of Hematologic Malignancies,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Blood and Lymph Conditions|Immune System Diseases|Heart and Blood Diseases|Rare Diseases,OTHER,,Single,United States,6-Jan,11-Jan-06,8-Nov,8-Nov,2-Mar-10,Drug was not available.,,3,6,Actual,60,,TRUE,,6,6,6,0.1,4,6,0,,2 - No Scientific Data
NCT00276419,1,Treatment of Breast Pain Using A Medication (Diclofenac) Applied to the Skin,Treatment,Crossover Assignment,Double Blind,Randomized,Drug|Drug,Phase 2|Phase 3,Nervous System Diseases|Symptoms and General Pathology|All Conditions,OTHER,,Single,United States,5-Jun,11-Jan-06,9-May,9-May,16-Nov-12,"Lack of funds; FDA approved a topical form of diclofenac during study, no need to continue study of pharmacy-compounded drug.",,1,25,Actual,30,,FALSE,E,18,25,0,0.83,0,36,0,,2 - No Scientific Data
NCT00279591,1,"Near-Continuous, Noninvasive Blood Pressure Monitoring to Improve Outcomes in Pediatric Transport",Treatment,Parallel Assignment,Double Blind,Randomized,Device|Device,,Symptoms and General Pathology|All Conditions,OTHER,,Single,United States,6-Jun,17-Jan-06,7-Jun,8-Jan,28-Mar-11,Lack of technical support and supplies,,4,94,Actual,115,,TRUE,,94,94,94,0.82,0,94,1,21173006,2 - No Scientific Data
NCT00281099,1,"Managed Ventricular Pacing (""MVP"") Trial",Prevention,Parallel Assignment,Single Blind,Randomized,Device,,Heart and Blood Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Austria|Canada|Canada|Canada|Canada|Canada|Canada|Denmark|France|France|Germany|Germany|Germany|Germany|Germany|Israel|Israel|Israel|Italy|Norway|Spain|Switzerland|United Kingdom,4-Oct,20-Jan-06,8-Jul,8-Jul,30-Jun-09,Inability to reach statistical significance toward primary endpoint,,6,1031,Actual,1000,,TRUE,,1031,1031,1030,1.03,249,1031,1,20685401,1 - Scientific Data
NCT00281528,1,Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 2,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Puerto Rico,6-Feb,24-Jan-06,10-Jul,11-Mar,17-Feb-12,sufficient mature data to complete a final analysis,,6,208,Actual,225,,TRUE,,208,208,208,0.92,70,208,0,,1 - Scientific Data
NCT00281827,1,"Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer",Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug|Drug|Procedure,Phase 2,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions|Rare Diseases,OTHER,,Multiple,United States|United States|United States,2-May,24-Jan-06,8-Mar,8-Jul,23-Jun-09,Due to drug unavailability,,3,22,Actual,21,,TRUE,,22,22,20,1.05,1,19,1,19633472,2 - No Scientific Data
NCT00281879,1,Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer,Treatment,Parallel Assignment,Open Label,Non-Randomized,Biological|Biological|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Procedure|Procedure|Radiation,Phase 2,Viral Diseases|Cancers and Other Neoplasms|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Heart and Blood Diseases|Symptoms and General Pathology|Diseases and Abnormalities at or before Birth|Rare Diseases,OTHER,,Single,United States,6-Feb,24-Jan-06,8-Feb,8-Mar,17-May-12,,,9,200,Actual,43,,TRUE,,200,200,0,4.65,155,200,0,,3 - No Reason Provided
NCT00282971,1,A Clinical Trial Assessing The Impact Of Inhaled Insulin On Glucose Control In Patients With Type 2 Diabetes Mellitus,Treatment,Parallel Assignment,Open Label,Randomized,Other|Drug,Phase 3,Respiratory Tract (Lung and Bronchial) Diseases|Symptoms and General Pathology|All Conditions|Nutritional and Metabolic Diseases|Gland and Hormone Related Diseases,INDUSTRY,,Multiple,Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|Greece|Greece|Greece|Greece|Greece|Portugal|Portugal|Portugal|Portugal|Portugal|Portugal|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Sweden|Sweden|Sweden|Turkey|Turkey|Turkey,6-Mar,26-Jan-06,8-Feb,8-Feb,11-Feb-09,See termination reason in detailed description.,"The study was terminated on Nov. 9, 2007. This study pursued scientific questions that were complementary to the wealth of data already available for Exubera. Pfizer decided to cancel new trials because of the decision to withdraw Exubera due to lack of market performance and not for safety reasons.",16,354,Actual,610,,FALSE,E,351,354,349,0.58,14,,0,,2 - No Scientific Data
NCT00283049,1,"Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control",Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 4,Nutritional and Metabolic Diseases|Gland and Hormone Related Diseases|All Conditions,INDUSTRY,,Single,United States,6-Feb,26-Jan-06,8-Nov,8-Nov,16-Dec-09,Due to technical issues relating to the Electronic diary data.,,4,390,Actual,155,,FALSE,E,386,390,347,2.52,55,386,0,,2 - No Scientific Data
NCT00283842,1,Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Nervous System Diseases|Gland and Hormone Related Diseases|All Conditions|Symptoms and General Pathology|Diseases and Abnormalities at or before Birth|Substance Related Disorders|Nutritional and Metabolic Diseases|Behaviors and Mental Disorders|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,6-Mar,26-Jan-06,8-Jun,8-Jun,30-Jun-09,business reasons,,8,408,Actual,450,,TRUE,,408,408,296,0.91,12,,0,,2 - No Scientific Data
NCT00288054,1,"S0429: Docetaxel, Cetuximab, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer",Treatment,Single Group Assignment,Open Label,Non-Randomized,Biological|Drug|Radiation,Phase 1,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions|Rare Diseases,NETWORK,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,6-Apr,6-Feb-06,12-Apr,12-Apr,26-Nov-12,Study closed early due to poor accrual.,,2,24,Actual,75,,TRUE,,24,24,22,0.32,5,22,1,24010120,2 - No Scientific Data
NCT00290199,1,Foley Catheter for Labor Induction in Women With Term and Near Term Membrane Rupture,Treatment,Parallel Assignment,Open Label,Randomized,Device,,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions|Wounds and Injuries",OTHER,,Multiple,United States|United States|United States,5-Dec,9-Feb-06,8-May,8-May,1-Jun-12,Gathering information from the PI records to provide this response.,,10,169,Actual,164,,TRUE,,169,169,152,1.03,0,169,0,,2 - No Scientific Data
NCT00290238,1,Percutaneous Neuromodulation Therapy (PNT) With Chronic Low Back Pain Patients,Treatment,Parallel Assignment,Double Blind,Randomized,Device|Device,Phase 4,Nervous System Diseases|Symptoms and General Pathology|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States,5-Dec,8-Feb-06,7-Nov,8-Sep,25-Nov-08,Slow recruitment and high dropout rates,,2,122,Actual,150,,TRUE,,122,122,115,0.81,6,,0,,2 - No Scientific Data
NCT00290537,1,Phase II Study of ZD6474 in Advanced NSCLC,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,OTHER,,Single,United States,6-Jan,10-Feb-06,8-Apr,8-Apr,18-Mar-09,Accrual was suboptimal and increasing the number of patients was not feasible.,,2,4,Actual,120,,TRUE,,4,4,4,0.03,,,0,,2 - No Scientific Data
NCT00290771,1,Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM),Treatment,Parallel Assignment,Open Label,Non-Randomized,Drug|Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Rare Diseases,INDUSTRY,,Single,United States,6-Feb,10-Feb-06,8-Aug,8-Aug,20-Dec-10,Lack of efficacy,,6,231,Actual,110,,TRUE,,231,231,462,2.1,115,230,1,19904263,1 - Scientific Data
NCT00291551,1,Paracor Ventricular Support System (PVSS) for Patients With Heart Failure,Treatment,Single Group Assignment,Open Label,Non-Randomized,Device,Phase 1,Heart and Blood Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,5-Jan,10-Feb-06,7-Apr,11-Apr,14-Apr-11,Resources unavailable to continue study follow-up.,,1,39,Actual,30,,TRUE,,39,39,39,1.3,30,39,0,,2 - No Scientific Data
NCT00294723,1,To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl??) on Haemoglobin A1c,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug|Drug|Drug|Drug|Drug,Phase 3,Nutritional and Metabolic Diseases|Gland and Hormone Related Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Mexico|Mexico|Mexico|Mexico|Mexico|Mexico|Mexico|Mexico|Mexico|Mexico|Mexico|Mexico|Mexico,6-Feb,20-Feb-06,8-Nov,10-Mar,23-Feb-10,Trial was terminated at week 195 due to an insufficient number of subjects remaining to obtain reasonable statistical power,,2,746,Actual,702,,TRUE,,746,746,711,1.06,73,888,1,18819705,2 - No Scientific Data
NCT00295490,1,Trial Evaluating Devil's Claw for the Treatment of Hip and Knee Osteoarthritis,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,"Muscle, Bone, and Cartilage Diseases|All Conditions|Skin and Connective Tissue Diseases",OTHER,,Single,United Kingdom,4-Dec,21-Feb-06,7-Nov,8-Jun,19-Jun-09,unexpected withdrawal of funding,,1,67,Actual,264,,TRUE,,67,67,0,0.25,1,67,0,,2 - No Scientific Data
NCT00295880,1,Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer,Treatment,Single Group Assignment,Open Label,,Procedure,Phase 1|Phase 2,Cancers and Other Neoplasms|All Conditions|Blood and Lymph Conditions|Immune System Diseases|Symptoms and General Pathology|Rare Diseases,OTHER,,,,5-Jun,23-Feb-06,8-Aug,8-Aug,25-Mar-09,Time to engraftment would not be improved compared to historical controls.,,6,12,Actual,35,,TRUE,,12,12,10,0.34,5,12,1,19139736,1 - Scientific Data
NCT00300885,1,A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC),Treatment,Parallel Assignment,Double-Blind,Randomized,Drug|Drug,Phase 3,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,INDUSTRY,,Multiple,"United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Argentina|Argentina|Argentina|Argentina|Argentina|Argentina|Argentina|Australia|Australia|Australia|Australia|Australia|Australia|Australia|Belgium|Belgium|Belgium|Belgium|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Canada|Canada|Canada|Canada|Canada|Chile|Chile|Chile|Chile|France|France|France|France|France|France|France|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Hong Kong|Hungary|Hungary|Hungary|Hungary|Hungary|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Korea, Republic of|Korea, Republic of|Korea, Republic of|Netherlands|Netherlands|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Puerto Rico|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Sweden|Sweden|Sweden|Taiwan|Taiwan|Taiwan|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom",6-Feb,8-Mar-06,7-Oct,9-Feb,4-Nov-09,"Based on the results of the interim analysis, it was determined that the study would not meet its primary efficacy endpoint and the study was terminated early.",,6,926,Actual,900,,TRUE,,926,926,926,1.03,467,922,1,20212250,1 - Scientific Data
NCT00302211,1,"The ""VISION"" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension",Treatment,Factorial Assignment,Double Blind,Randomized,Drug|Drug|Drug|Drug|Drug,Phase 3,Respiratory Tract (Lung and Bronchial) Diseases|All Conditions|Symptoms and General Pathology|Heart and Blood Diseases|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,6-Feb,10-Mar-06,7-Dec,9-Nov,27-May-10,Terminated due to slow enrollment,,2,67,Actual,180,,TRUE,,67,67,125,0.37,28,125,0,,2 - No Scientific Data
NCT00306917,1,Clinical Study Comparing Two Implant Surface Finishes in Patients Undergoing Cementless Total Hip Replacement,Treatment,Parallel Assignment,Open Label,Randomized,Device|Device,Phase 4,"Muscle, Bone, and Cartilage Diseases|All Conditions|Skin and Connective Tissue Diseases|Immune System Diseases|Symptoms and General Pathology|Wounds and Injuries",INDUSTRY,,Single,United States,2-Nov,23-Mar-06,9-Jan,9-Jan,29-Jan-10,Terminated due to limited enrollment and follow up.,,2,245,Actual,400,,TRUE,,245,245,245,0.61,7,245,0,,2 - No Scientific Data
NCT00307931,1,Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed Infliximab,Treatment,Single Group Assignment,Open Label,,Biological,Phase 3,Digestive System Diseases|All Conditions,INDUSTRY,,Multiple,Greece|Greece|Greece|Greece|Greece,7-Apr,24-Mar-06,8-Aug,8-Aug,8-Sep-09,Study was terminated early because of slow recruitment,,2,16,Actual,50,Anticipated,TRUE,,16,16,16,0.32,3,16,0,,2 - No Scientific Data
NCT00308087,1,"Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma",Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 2,Cancers and Other Neoplasms|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Puerto Rico,6-May,28-Mar-06,9-Jun,9-Jun,11-Jun-10,Terminated by sponsor due to low enrollment; see details below,The study was terminated early due to low enrollment; significant changes to the protocol would have been required to keep pace with the changing therapeutic landscape of indolent lymphoma.,2,75,Actual,196,Anticipated,TRUE,,75,75,75,0.38,12,75,0,,2 - No Scientific Data
NCT00308620,1,Investigating the Anti-Human Immunodeficiency Virus (HIV) & Anti-inflammatory Effect of Chloroquine,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2|Phase 3,"Viral Diseases|Immune System Diseases|All Conditions|Symptoms and General Pathology|Bacterial and Fungal Diseases|Urinary Tract, Sexual Organs, and Pregnancy Conditions",OTHER,,Single,United States,6-Mar,27-Mar-06,8-Dec,9-Jun,26-Sep-11,Insufficient financial support; lack of efficacy for primary endpoint,,6,13,Actual,25,,TRUE,,13,13,13,0.52,2,13,1,20844049,1 - Scientific Data
NCT00311311,1,Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug|Drug|Drug|Drug|Drug,Phase 3,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions|Heart and Blood Diseases|Nervous System Diseases",INDUSTRY,,Multiple,United States|Canada|Canada|Canada|Canada|Canada|Canada|Canada,6-Apr,3-Apr-06,10-Dec,12-Jan,12-Dec-11,See termination reason in detailed description.,"A decision to terminate the study was taken in November 2011 and a communication to that effect sent to all participating sites on November 18. All sites were asked to have patients returned to the sites and have all end of study procedures performed by Dec 31, 2011.",6,72,Actual,100,,TRUE,,72,72,38,0.72,26,72,0,,1 - Scientific Data
NCT00312221,0,Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis Pain,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 3,"Muscle, Bone, and Cartilage Diseases|All Conditions|Nervous System Diseases|Symptoms and General Pathology|Skin and Connective Tissue Diseases",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,4-Apr,6-Apr-06,5-Jul,5-Aug,15-Jul-10,terminated early for administrative reasons unrelated to safety or efficacy,,4,418,Actual,858,,FALSE,E,652,418,418,0.49,25,1070,0,,2 - No Scientific Data
NCT00313014,0,Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 3,Nervous System Diseases|Symptoms and General Pathology|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,4-Feb,10-Apr-06,5-Sep,5-Sep,28-Jul-10,Terminated early due to administrative reasons unrelated to efficacy or safety.,The decision to terminate this study was made following the conduct of an interim analysis which demonstrated that the study did not reach its primary endpoint. The termination of this study was not driven by any safety concerns and had no impact on subject safety and well-being.,4,660,Actual,891,,TRUE,,660,660,660,0.74,32,1820,1,21807566,2 - No Scientific Data
NCT00313144,1,Aralast alpha1-proteinase Inhibitor Surveillance Study,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 4,Digestive System Diseases|Respiratory Tract (Lung and Bronchial) Diseases|Diseases and Abnormalities at or before Birth|Symptoms and General Pathology|All Conditions|Rare Diseases,INDUSTRY,,Single,United States,6-Jun,10-Apr-06,8-Dec,9-May,4-Mar-11,Study terminated early due to Aralast being phased out of the market.,,16,127,Actual,120,,TRUE,,127,127,212,1.06,39,127,0,,2 - No Scientific Data
NCT00314353,1,Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|Digestive System Diseases|All Conditions,NETWORK,,Single,United States,6-Mar,11-Apr-06,8-May,10-Jun,7-Nov-08,The study was closed early due to low enrollment and new information regarding the benefit of the study regimen.,,2,7,Actual,110,,TRUE,,7,7,0,0.06,0,0,0,,2 - No Scientific Data
NCT00315458,0,Buprenorphine Transdermal Patch in Subjects With Osteoarthritis Pain Requiring Opioids. Includes a 52-Week Safety Extension.,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,"Muscle, Bone, and Cartilage Diseases|All Conditions|Nervous System Diseases|Symptoms and General Pathology|Skin and Connective Tissue Diseases",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,3-Dec,17-Apr-06,5-Mar,5-Mar,28-Jul-10,Administrative reasons.,,4,107,Actual,310,,FALSE,E,305,107,425,0.35,9,425,0,,2 - No Scientific Data
NCT00316004,1,Hypertonic Resuscitation Following Severe Traumatic Brain Injury (TBI),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 3,Nervous System Diseases|Wounds and Injuries|All Conditions,OTHER,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Canada|Canada,6-May,17-Apr-06,9-May,10-Jan,11-Feb-11,Futility,,6,1331,Actual,2122,,TRUE,,1331,1331,1282,0.63,282,1282,1,20924011,1 - Scientific Data
NCT00316017,1,Hypertonic Resuscitation Following Traumatic Injury,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 3,Symptoms and General Pathology|All Conditions|Wounds and Injuries,OTHER,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|Canada|Canada,6-May,17-Apr-06,9-Aug,9-Aug,2-Sep-10,"Futility & potential safety concern (increased early mortality in the HS/HSD arms for those with no PRBC in 1st 24 hr, post-randomization subgp)",,5,895,Actual,3726,,TRUE,,895,895,852,0.24,67,852,1,21178763,1 - Scientific Data
NCT00320190,1,Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Blood and Lymph Conditions|Rare Diseases,INDUSTRY,,Multiple,Belgium|Belgium|Finland|Finland|France|France|France|France|France|France|France|Germany|Italy|Norway|Norway|Portugal|Russian Federation|Russian Federation|Russian Federation|Spain|Sweden|Sweden|Sweden|United Kingdom|United Kingdom|United Kingdom|United Kingdom,6-Aug,1-May-06,10-Jan,10-Jan,6-Jun-11,Terminated due to slow participant accrual,,2,52,Actual,156,,FALSE,F,32,32,0,0.21,4,32,0,,2 - No Scientific Data
NCT00320801,0,Buprenorphine Transdermal Patches (BTDS) in Subjects With Osteoarthritis Pain. Includes a 52-week Extension Phase.,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,"Muscle, Bone, and Cartilage Diseases|All Conditions|Nervous System Diseases|Symptoms and General Pathology|Skin and Connective Tissue Diseases",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,4-Jan,28-Apr-06,5-Mar,5-Mar,28-Jul-10,This study was terminated early due to administrative reasons.,,4,188,Actual,464,,TRUE,,188,188,472,0.41,10,472,0,,2 - No Scientific Data
NCT00323310,1,Safety and Efficacy of MultiHance in Pediatric Patients,Diagnostic,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 3,Nervous System Diseases|All Conditions,INDUSTRY,,Single,United States,6-Apr,5-May-06,8-Sep,8-Sep,16-Aug-10,Adequate statistical power at 92 dosed pts to meet study objectives.,,6,92,Actual,188,,TRUE,,92,92,92,0.49,0,92,0,,1 - Scientific Data
NCT00323609,1,KAVIAR Study - Kyphoplasty And Vertebroplasty In the Augmentation and Restoration of Vertebral Body Compression Fractures,Prevention,Parallel Assignment,Open Label,Randomized,Procedure|Procedure,Phase 4,"Muscle, Bone, and Cartilage Diseases|All Conditions|Nervous System Diseases|Symptoms and General Pathology|Wounds and Injuries",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Canada,6-Aug,5-May-06,11-Jul,11-Jul,29-Jun-12,"Due to high number of patients terminating study early, low patient enrollment and difficulty in patient/investigator willingness for randomization",,4,404,Actual,1234,,TRUE,,404,404,271,0.33,250,381,0,,2 - No Scientific Data
NCT00326911,1,Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer,Treatment,Parallel Assignment,Open Label,Randomized,Biological|Biological|Drug|Biological,Phase 2,Cancers and Other Neoplasms|All Conditions|Digestive System Diseases|Gland and Hormone Related Diseases|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,6-May,15-May-06,8-Oct,8-Dec,3-Nov-09,The planned enrollment was 130 patients and the study was halted prematurely due to lack of efficacy in both arms. Enrolled patients continued treatment.,,6,61,Actual,130,Anticipated,TRUE,,61,61,58,0.47,37,58,1,21629990,1 - Scientific Data
NCT00327470,1,An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 4,Eye Diseases|All Conditions|Symptoms and General Pathology|Rare Diseases,INDUSTRY,,Multiple,Austria|Austria|Austria|Austria|Belgium|Belgium|Belgium|Canada|Canada|Canada|Canada|Canada|Canada|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Denmark|Finland|France|France|France|France|France|France|France|Germany|Germany|Germany|Germany|Greece|Greece|Italy|Italy|Italy|Italy|Italy|Poland|Poland|Poland|Poland|Portugal|Portugal|Portugal|Portugal|Spain|Spain|Spain|Spain|Turkey|Turkey|Turkey|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom,6-Jul,17-May-06,9-Aug,9-Aug,13-Apr-10,See termination reason in detailed description.,A decision was made by the sponsor (08 May 2009) to terminate this study early; the study had achieved the primary objective prior to termination. This study was not terminated due to safety reasons.,6,288,Actual,370,,TRUE,,288,288,285,0.78,55,286,1,22872673,1 - Scientific Data
NCT00329108,1,Ziprasidone And Olanzapine's Outcomes In Mania,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 4,Behaviors and Mental Disorders|All Conditions,INDUSTRY,,Multiple,Germany|Germany|Germany|Greece|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Spain|Spain|Spain|Spain|Turkey|Turkey,6-Nov,5-May-06,7-Jul,8-Jan,22-Dec-08,Please see Brief Summary for Termination Reason.,"Study recruitment was stopped due to difficulty in enrolling the targeted number of patients on July 30, 2007. Subjects that were enrolled at the time completed the study as per protocol. There were no safety concerns involved in the decision to stop enrollment. The Last Subject Last Visit was January 10, 2008.",2,29,Actual,352,,TRUE,,29,29,0,0.08,2,,0,,2 - No Scientific Data
NCT00329732,0,Research Study of Greater Occipital Nerve Block As A Treatment For Prolonged Migraine Attacks,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,,Nervous System Diseases|All Conditions|Symptoms and General Pathology,OTHER,,Single,United States,6-Mar,24-May-06,6-Apr,6-Apr,24-May-11,Study terminated due to inadequate recruitment,,2,2,Actual,2,Actual,TRUE,,2,2,0,1,0,2,0,,2 - No Scientific Data
NCT00330564,1,Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 2,"Cancers and Other Neoplasms|All Conditions|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Symptoms and General Pathology|Nervous System Diseases|Heart and Blood Diseases|Diseases and Abnormalities at or before Birth|Skin and Connective Tissue Diseases|Rare Diseases",OTHER,,Single,United States,6-May,26-May-06,11-May,11-May,1-Jun-11,Slow accrual.,,2,15,Actual,28,,TRUE,,15,15,15,0.54,0,15,1,22105611,2 - No Scientific Data
NCT00330668,1,Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency,Treatment,Single Group Assignment,Open Label,,Drug,Phase 3,"Muscle, Bone, and Cartilage Diseases|Diseases and Abnormalities at or before Birth|Gland and Hormone Related Diseases|All Conditions|Symptoms and General Pathology|Rare Diseases",INDUSTRY,,Single,France,5-Nov,26-May-06,10-Feb,10-Mar,28-Feb-11,Unacceptable frequency of hypoglycemia observed at and above 200 ug/kg/day,,5,114,Actual,135,,TRUE,,114,114,0,0.84,6,114,0,,1 - Scientific Data
NCT00331422,1,"Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer",Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug|Procedure,Phase 2,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Gland and Hormone Related Diseases|All Conditions|Digestive System Diseases|Rare Diseases",OTHER,,Single,United States,5-Oct,30-May-06,8-Mar,9-Mar,23-Nov-09,Study was terminated due to lack of available funding.,,1,7,Actual,42,,TRUE,,7,7,2,0.17,6,7,0,,2 - No Scientific Data
NCT00335959,1,"S0425 Oxaliplatin, Capecitabine, and RT in Treating Patients W/Stomach Cancer That Can Be Removed By Surgery",Treatment,Single Group Assignment,Open Label,,Drug|Drug|Procedure|Radiation,Phase 2,Cancers and Other Neoplasms|Digestive System Diseases|All Conditions|Rare Diseases,NETWORK,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,6-May,8-Jun-06,9-Apr,,12-Jul-12,Closed due to slow accrual,,2,7,Actual,75,,TRUE,,7,7,5,0.09,1,6,0,,2 - No Scientific Data
NCT00337272,1,Treating Chronic Insomnia in Breast Cancer Patients,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 4,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions|Nervous System Diseases|Behaviors and Mental Disorders|Symptoms and General Pathology,OTHER,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,6-Aug,13-Jun-06,8-Aug,9-Jan,2-Jun-09,Lack of enrollment.,,2,16,Actual,60,,FALSE,E,22,16,14,0.27,0,16,0,,2 - No Scientific Data
NCT00338455,1,Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2|Phase 3,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions|Heart and Blood Diseases",INDUSTRY,,,,6-Sep,16-Jun-06,7-Oct,7-Oct,22-Oct-08,"DSMC acknowledged no safety concerns with the trial, recommending that the trial be terminated due to slow enrollment.",,2,16,Actual,120,,TRUE,,16,16,0,0.13,7,15,0,,2 - No Scientific Data
NCT00343512,1,Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Genetic|Other|Procedure|Procedure|Procedure,Phase 2,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions|Rare Diseases,OTHER,,Multiple,United States|United States,4-Feb,22-Jun-06,8-Mar,11-Mar,11-Oct-10,closed due to competing neoadjuvant studies for a small patient population,,7,34,Actual,50,,TRUE,,34,34,34,0.68,9,32,0,,2 - No Scientific Data
NCT00346151,1,Belatacept to Prevent Organ Rejection in Kidney Transplant Patients,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug|Drug|Drug,Phase 2,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions",NIH,,Multiple,United States|United States,6-Dec,27-Jun-06,10-Feb,10-Feb,8-Jun-11,Stopping rules for acute cellular rejections were met based on local biopsies,,5,5,Actual,30,,TRUE,,5,5,5,0.17,4,5,0,,1 - Scientific Data
NCT00346268,1,Morphine-Sparing Efficacy Of Parecoxib In Pain Treatment After Radical Prostatectomy,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 4,Nervous System Diseases|Symptoms and General Pathology|All Conditions,INDUSTRY,,Multiple,Germany|Germany|Germany|Germany,6-Dec,28-Jun-06,10-Sep,10-Sep,21-Sep-11,See termination reason in detailed description.,The study was terminated due to lack of recruitment due to competing alternative operation methods on 13September 2010. The decision to terminate the trial was not based on any safety concerns.,2,105,Actual,152,,TRUE,,105,105,105,0.69,17,105,0,,2 - No Scientific Data
NCT00348556,1,Use of Nesiritide (BNP) in Kidney Function in Patients With Congestive Heart Failure (CHF) and Kidney Failure,Treatment,Single Group Assignment,Open Label,,Drug,Phase 1|Phase 2,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions|Heart and Blood Diseases|Symptoms and General Pathology",OTHER,,Single,United States,5-Dec,30-Jun-06,10-Mar,10-Mar,14-Sep-12,"Company providing catheter bought out, funding and supplies terminated",,1,4,Actual,10,,TRUE,,4,4,0,0.4,0,4,0,,2 - No Scientific Data
NCT00349752,1,Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease,Treatment,Parallel Assignment,Double Blind,Randomized,Biological|Other,Phase 3,Digestive System Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Germany|Germany|Germany|Germany|Germany,6-Nov,30-Jun-06,9-Jul,9-Jul,1-Jul-10,"Recruitment was stopped early due to slow enrolment of this population. With no safety concerns, the study continued normally for subjects already recruited",,2,174,Actual,440,,TRUE,,174,174,174,0.4,17,174,0,,2 - No Scientific Data
NCT00350519,1,The Safety and Effectiveness of PROCRIT (Epoetin Alfa) in Reducing the Number of Blood Transfusions Required by Patients Undergoing Elective Major Abdominal and/or Pelvic Surgery,Treatment,Parallel Assignment,Open Label,Randomized,Drug,Phase 4,,INDUSTRY,,,,6-Jul,7-Jul-06,8-Feb,8-Feb,20-Feb-09,The study was stopped due to slow enrollment,,2,38,Actual,110,,FALSE,F,37,37,33,0.34,13,,0,,2 - No Scientific Data
NCT00350623,0,Investigation of V520 in a HIV Vaccine Dose Refinement Study (V520-027)(TERMINATED),Prevention,Parallel Assignment,Double Blind,Randomized,Biological|Biological|Biological,Phase 2,"Viral Diseases|Immune System Diseases|All Conditions|Symptoms and General Pathology|Bacterial and Fungal Diseases|Urinary Tract, Sexual Organs, and Pregnancy Conditions",INDUSTRY,,,,6-Oct,7-Jul-06,8-May,8-May,20-Oct-10,,,9,210,Actual,210,Actual,TRUE,,210,210,0,1,2,210,0,,3 - No Reason Provided
NCT00351039,1,"Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer",Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug|Drug,Phase 1|Phase 2,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,OTHER,,Single,United States,6-Jul,11-Jul-06,8-Sep,8-Sep,9-Oct-09,slow accrual,,2,8,Actual,57,,TRUE,,8,8,0,0.14,6,8,0,,2 - No Scientific Data
NCT00351741,1,BEST (Burn Center Evaluation of Standard Therapies) Ventilator Mode Study-,Treatment,Parallel Assignment,Open Label,Randomized,Device|Device,,Wounds and Injuries|All Conditions,FED,,Single,United States,6-Jul,11-Jul-06,10-Feb,10-Feb,16-Jul-10,,,9,62,Actual,170,,TRUE,,62,62,62,0.36,26,62,1,20639746,3 - No Reason Provided
NCT00352118,1,Combination Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer,Treatment,Single Group Assignment,Open Label,,Biological|Biological|Drug|Drug|Drug|Procedure|Radiation,Phase 2,"Cancers and Other Neoplasms|All Conditions|Digestive System Diseases|Mouth and Tooth Diseases|Respiratory Tract (Lung and Bronchial) Diseases|Ear, Nose, and Throat Diseases|Rare Diseases",OTHER,,Single,United States,6-Mar,13-Jul-06,8-Apr,8-Apr,2-Jun-09,Low dose radiation treatment was not appropriate for these patients.,,4,4,Actual,36,,TRUE,,4,4,0,0.11,0,4,0,,2 - No Scientific Data
NCT00352664,1,The Effect of Donepezil on Sedation and Other Symptoms,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Nervous System Diseases|Symptoms and General Pathology|All Conditions,OTHER,,Single,United States,3-Nov,12-Jul-06,7-Jul,7-Jul,21-May-09,Low patient accrual,,2,27,Actual,100,,TRUE,,27,27,20,0.27,0,20,0,,2 - No Scientific Data
NCT00354172,1,"Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.",Treatment,Single Group Assignment,Open Label,,Biological|Biological|Biological|Drug|Drug|Drug|Drug|Drug|Procedure|Radiation,Phase 2,Cancers and Other Neoplasms|All Conditions|Blood and Lymph Conditions|Symptoms and General Pathology|Diseases and Abnormalities at or before Birth|Rare Diseases,OTHER,,Single,United States,6-Feb,19-Jul-06,8-Aug,8-Aug,30-Nov-09,Competing study was started.,,7,16,Actual,29,,TRUE,,16,16,15,0.55,16,16,0,,2 - No Scientific Data
NCT00354601,1,"Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer",Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug,Phase 2,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Gland and Hormone Related Diseases|All Conditions|Digestive System Diseases|Rare Diseases",OTHER,,Single,United States,6-Jan,19-Jul-06,8-May,8-Jul,9-Mar-09,funding withdrawn,,1,2,Actual,39,,TRUE,,2,2,0,0.05,1,,0,,2 - No Scientific Data
NCT00356057,1,Investigational Device Exemption (IDE) Study for the Approval of Closed Loop Stimulation (CLS) and Cardiac Resyncronization Pacing Therapies (CRT) for the Treatment of Atrial Fibrillation (AF) With Ablate and Pace,Treatment,Parallel Assignment,Single Blind,Randomized,Device,,Heart and Blood Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,4-Dec,21-Jul-06,8-May,8-Jun,2-Dec-08,Slow enrollment.,,2,153,Actual,265,,TRUE,,153,153,108,0.58,58,153,1,20152225,2 - No Scientific Data
NCT00356200,1,Fluphenazine Decanoate for Psoriasis,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Skin and Connective Tissue Diseases|All Conditions,OTHER,,Single,United States,6-Jul,24-Jul-06,7-Dec,8-Sep,15-Nov-10,Enrollment criteria met,,11,10,Actual,15,,FALSE,E,5,10,20,0.67,0,10,0,,2 - No Scientific Data
NCT00356421,1,A Clinical Trial Comparing Efficacy and Safety of Exubera?? and Humalog??,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 4,Respiratory Tract (Lung and Bronchial) Diseases|Symptoms and General Pathology|All Conditions|Nutritional and Metabolic Diseases|Gland and Hormone Related Diseases|Immune System Diseases,INDUSTRY,,Multiple,United States|United States|Austria|Austria|Belgium|Belgium|Belgium|Denmark|Finland|France|France|France|Ireland|Netherlands|Norway|Portugal|Spain|Spain|Sweden|Sweden|United Kingdom|United Kingdom|United Kingdom,6-Nov,24-Jul-06,8-Jun,8-Jun,24-Jun-09,See termination reason in detailed description.,"Pfizer announced in October 2007 that it would stop marketing Exubera?. At that time recruitment for study, A2171035 was placed on hold. Nektar, the company from which Pfizer licensed Exubera?, announced on April 9, 2008 that it had stopped its search for a new marketing partner. Accordingly, there will be no commercial availability of Exubera?. As a result, study A2171035 was terminated on May 12, 2008. Neither safety nor efficacy reasons were the cause of the study termination.",16,58,Actual,340,,TRUE,,58,58,0,0.17,3,,0,,2 - No Scientific Data
NCT00356525,1,Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Brazil|Brazil|Brazil|India|India|India,6-Sep,24-Jul-06,8-Jun,9-Apr,8-Jun-09,Stopped early due to low enrollment,,2,41,Actual,160,,TRUE,,41,41,41,0.26,10,41,0,,2 - No Scientific Data
NCT00358670,1,"Long-Term Effects of Infliximab in the Treatment of Moderate to Severe Psoriasis [Extension of Study P04271, NCT00251641] (P04563)",Treatment,Parallel Assignment,Open Label,Randomized,Biological|Biological,Phase 3,Skin and Connective Tissue Diseases|All Conditions,INDUSTRY,,,,6-May,31-Jul-06,9-Jan,9-Jan,8-Apr-10,"Infusion reactions during re-induction cycles after a period of no treatment. Please see ""Purpose"" section.","During an interim safety evaluation of the trial, a higher incidence of serious and severe infusion reactions was observed in the intermittent treatment arm, consisting of a re-induction cycle (maximum of 4 infusions at 0, 2, 6 and 14 weeks) after a period of no treatment compared with the maintenance arm (infusions every 8 weeks without an interruption of treatment). Consequently, the sponsor has terminated the trial. The label will be updated to reflect this new information relating to the use of a re-induction regimen with infliximab.",5,441,Actual,500,,TRUE,,441,441,0,0.88,47,441,1,23621698,1 - Scientific Data
NCT00360308,1,"Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations",Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 3,Nervous System Diseases|All Conditions|Cancers and Other Neoplasms|Skin and Connective Tissue Diseases,INDUSTRY,,Single,France,6-Nov,2-Aug-06,8-Apr,8-Apr,23-Oct-12,Study stopped due to lack of efficacy.,,6,723,Actual,700,,TRUE,,723,723,662,1.03,25,723,1,22222634,1 - Scientific Data
NCT00360412,1,A Study of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 3,Nervous System Diseases|All Conditions|Cancers and Other Neoplasms|Skin and Connective Tissue Diseases,INDUSTRY,,Single,Germany,6-Oct,2-Aug-06,8-Apr,8-Apr,23-Oct-12,Study stopped due to lack of efficacy.,,6,997,Actual,1400,,TRUE,,997,997,997,0.71,90,997,0,,1 - Scientific Data
NCT00360828,1,"Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas",Diagnostic,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug,Phase 2,Cancers and Other Neoplasms|Nervous System Diseases|All Conditions|Rare Diseases,OTHER,,Single,United States,6-Feb,3-Aug-06,10-Oct,10-Oct,3-Oct-11,Principal Investigator left Moffitt and study had low accrual.,,4,10,Actual,63,,TRUE,,10,10,10,0.16,0,10,0,,2 - No Scientific Data
NCT00361257,1,Minocycline for the Treatment of Decreased Mental Function in HIV-Infected Adults,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,"Viral Diseases|Immune System Diseases|All Conditions|Symptoms and General Pathology|Bacterial and Fungal Diseases|Urinary Tract, Sexual Organs, and Pregnancy Conditions",NETWORK,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,7-Mar,4-Aug-06,10-Jan,10-Jan,28-Jan-11,This study was terminated early due to futility.,,6,107,Actual,100,,TRUE,,107,107,89,1.07,10,107,1,21900636,1 - Scientific Data
NCT00361439,1,Treatment of Olfactory Dysfunction in Seasonal Allergic Rhinitis,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 4,"Respiratory Tract (Lung and Bronchial) Diseases|Ear, Nose, and Throat Diseases|All Conditions|Immune System Diseases|Bacterial and Fungal Diseases",OTHER,,Single,United States,6-Aug,4-Aug-06,8-Sep,8-Sep,20-Jul-12,Study stopped early due to slow accrual.,,2,17,Actual,30,,TRUE,,17,17,17,0.57,0,17,1,20819468,2 - No Scientific Data
NCT00362466,1,A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 3,Cancers and Other Neoplasms|All Conditions|Blood and Lymph Conditions|Symptoms and General Pathology|Diseases and Abnormalities at or before Birth|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,7-Apr,9-Aug-06,8-Jun,8-Jun,24-Jul-09,Insufficient Enrollment,,2,3,Actual,206,,TRUE,,3,3,0,0.01,0,3,0,,2 - No Scientific Data
NCT00363467,1,Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation,,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug|Drug|Procedure,,Cancers and Other Neoplasms|All Conditions|Rare Diseases,OTHER,,Single,United States,6-May,10-Aug-06,9-May,9-May,9-Aug-10,Low accrual,,2,3,Actual,60,,TRUE,,3,3,2,0.05,0,2,0,,2 - No Scientific Data
NCT00363675,1,Evaluation of Hand Assessments in Children With Severe Hand Burns,Diagnostic,Single Group Assignment,Open Label,Non-Randomized,Behavioral,,Wounds and Injuries|All Conditions,OTHER,,Single,United States,6-Aug,9-Aug-06,11-Aug,11-Aug,29-Feb-12,"This was a pilot study, but the larger study was not funded.",,10,3,Actual,12,,TRUE,,3,3,3,0.25,0,3,0,,2 - No Scientific Data
NCT00364533,1,A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug|Drug,Phase 3,"Muscle, Bone, and Cartilage Diseases|Symptoms and General Pathology|All Conditions|Nervous System Diseases",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Belgium|Belgium|Belgium|Belgium|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Finland|Finland|Finland|New Zealand|Spain|Spain|Spain|Sweden|Sweden|Sweden|Sweden|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom,6-Oct,11-Aug-06,7-Dec,7-Dec,19-Dec-08,Slow enrollment,,2,367,Actual,1100,,FALSE,F,365,365,156,0.33,6,365,0,,2 - No Scientific Data
NCT00366106,1,Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma,Treatment,Single Group Assignment,Open Label,,Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|Heart and Blood Diseases|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Rare Diseases,OTHER,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,6-Jul,16-Aug-06,11-Mar,11-Mar,26-Sep-11,Study was closed to enrollment when it became clear that enrollment was too slow to complete full enrollment target within time frame allowed.,,2,32,Actual,66,,TRUE,,32,32,32,0.48,10,32,0,,2 - No Scientific Data
NCT00366301,1,The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes,Treatment,Factorial Assignment,Open Label,Randomized,Drug|Drug|Drug,Phase 4,Nutritional and Metabolic Diseases|Gland and Hormone Related Diseases|All Conditions|Symptoms and General Pathology,OTHER,,Single,United States,6-Aug,17-Aug-06,9-Apr,9-Apr,26-Oct-10,"Interim analyses demonstrated futility. Thus, recruitment curtailed 10/08.",,6,500,Actual,800,,TRUE,,500,500,487,0.63,13,500,1,19755697,1 - Scientific Data
NCT00368641,1,Heart Failure and Peritoneal Ultrafiltration,Treatment,Parallel Assignment,Open Label,Randomized,Drug,Phase 2,Heart and Blood Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|Australia|Belgium|Belgium|Belgium|Canada|Canada,6-Aug,23-Aug-06,8-Apr,8-Apr,30-Apr-09,Enrollment,,2,12,Actual,104,,TRUE,,12,12,12,0.12,10,,0,,2 - No Scientific Data
NCT00369265,1,Safety and Efficacy of Lansoprazole 30mg Twice Daily in Treatment of Laryngitis Associated With Gastroesophageal Reflux,Treatment,Parallel Assignment,Single Blind,Randomized,Drug|Dietary Supplement,Phase 4,"Digestive System Diseases|All Conditions|Respiratory Tract (Lung and Bronchial) Diseases|Ear, Nose, and Throat Diseases|Nervous System Diseases|Symptoms and General Pathology|Bacterial and Fungal Diseases",OTHER,,Multiple,United States|United States|United States,6-Aug,24-Aug-06,9-Nov,9-Nov,11-Jul-12,Pharmaceutical company purchased by another company and funding was terminated.,,1,18,Actual,160,,FALSE,F,11,11,0,0.07,0,11,0,,2 - No Scientific Data
NCT00372489,0,Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD,Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions|Blood and Lymph Conditions",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States,6-Sep,5-Sep-06,9-Nov,9-Nov,26-Apr-12,Due to more robust long-term data generated in other active-controlled studies,,7,81,Actual,81,Actual,TRUE,,81,81,60,1,58,81,0,,2 - No Scientific Data
NCT00372528,1,An Open-Label Study Of Pregabalin In Subjects With Refractory Partial Seizures,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 3,Nervous System Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Multiple,Canada|Canada|Canada|Canada|Canada,7-Mar,5-Sep-06,11-Oct,11-Oct,21-Sep-12,"This study was terminated on April 8, 2011 as Pfizer Canada could no longer supply study drug. No efficacy or safety concerns factored into this decision.",,3,21,Actual,35,,TRUE,,21,21,21,0.6,3,21,0,,2 - No Scientific Data
NCT00372567,1,Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 3,Cancers and Other Neoplasms|Digestive System Diseases|All Conditions|Rare Diseases,INDUSTRY,,Multiple,"United States|United States|United States|United States|United States|United States|Germany|Germany|Hong Kong|Hong Kong|Hong Kong|Italy|Italy|Italy|Korea, Republic of|Korea, Republic of|Korea, Republic of|Spain|Spain|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom",7-Jun,5-Sep-06,9-Nov,9-Nov,27-Oct-10,See termination reason in detailed description.,"The study prematurely discontinued on July 27, 2009 due to poor recruitment and operational futility as a result of changes in clinical practice. There were no safety or efficacy concerns regarding the study in the decision to terminate the trial.",2,69,Actual,212,,FALSE,E,12,69,28,0.33,16,68,0,,2 - No Scientific Data
NCT00373113,1,A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 3,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions,INDUSTRY,,Multiple,"Argentina|Argentina|Argentina|Argentina|Argentina|Argentina|Argentina|Australia|Australia|Australia|Australia|Australia|Australia|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Bulgaria|Bulgaria|Bulgaria|Bulgaria|Canada|Canada|Canada|Canada|Canada|Canada|Chile|Colombia|Colombia|France|France|France|France|France|France|France|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Hong Kong|Hong Kong|Hong Kong|Hong Kong|India|India|India|India|India|Italy|Italy|Italy|Italy|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of|Mexico|Mexico|Mexico|Mexico|Mexico|Mexico|Mexico|Peru|Peru|Philippines|Philippines|Philippines|Philippines|Singapore|Singapore|South Africa|South Africa|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Taiwan|Taiwan|Taiwan|Taiwan|Taiwan|Taiwan|Taiwan|Turkey|Turkey|United Kingdom|United Kingdom|United Kingdom|United Kingdom",6-Nov,5-Sep-06,9-Oct,11-Jun,20-Oct-10,See termination reason in detailed description.,"Patient enrollment in this trial was discontinued based on statistical assessment for futility. An independent Data Monitoring Committee found that even if the trial had been allowed to continue, treatment with single agent sunitinib would be unable to demonstrate a statistically significant improvement in the primary endpoint of progression-free survival compared with single agent capecitabine in the study population. Pfizer notified clinical trial investigators involved in the study and regulatory agencies of these findings on 25Mar2009. Patients receiving sunitinib will be allowed to receive capecitabine or enter an extension trial if they are receiving clinical benefit from continued sunitinib therapy. There were no safety concerns leading to the decision to terminate the study.",6,482,Actual,700,,TRUE,,482,482,482,0.69,116,478,1,20339913,1 - Scientific Data
NCT00376259,1,Study of Combination Therapy With LdT Plus Adefovir Versus Adefovir Alone,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 3,Viral Diseases|Digestive System Diseases|All Conditions,INDUSTRY,,Multiple,"United States|United States|Hong Kong|Korea, Republic of|Taiwan|Thailand",7-Jan,13-Sep-06,8-Aug,,20-Dec-10,The study was not completed as planned and was terminated early with agreement from the European Medicines Agency (EMEA),,10,43,Actual,150,Anticipated,TRUE,,43,43,0,0.29,1,42,1,21989925,2 - No Scientific Data
NCT00376805,1,Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer,Treatment,Single Group Assignment,Open Label,,Drug|Drug|Radiation|Other|Biological,Phase 2,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions|Rare Diseases,OTHER,,Single,United States,6-Apr,13-Sep-06,9-Sep,10-Jan,13-Jul-10,Withdrawn due to toxicity,,5,6,Actual,10,,TRUE,,6,6,6,0.6,6,6,0,,1 - Scientific Data
NCT00377455,1,Placebo Controlled Trial of Bosentan in Scleroderma Patients,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Respiratory Tract (Lung and Bronchial) Diseases|All Conditions|Heart and Blood Diseases|Skin and Connective Tissue Diseases|Symptoms and General Pathology|Rare Diseases,OTHER,,Multiple,United States|United States,6-Sep,14-Sep-06,9-Sep,10-Mar,28-Mar-11,Study was terminated due to inadequate enrolment,,2,5,Actual,40,,TRUE,,5,5,0,0.13,0,5,0,,2 - No Scientific Data
NCT00378573,1,"Multicenter Evaluation of Docetaxel, Gemcitabine, and Bevacizumab Combination Followed by Bevacizumab Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer",Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,INDUSTRY,,Single,United States,7-Jan,19-Sep-06,8-Sep,8-Sep,17-Sep-09,Incidence of GI Perforation,,5,17,Actual,90,,TRUE,,17,17,0,0.19,9,17,0,,1 - Scientific Data
NCT00380874,1,Prevention And Treatment Of Chemotherapy-Induced Peripheral Neuropathy In Subjects With Advanced Colorectal Cancer,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 4,Cancers and Other Neoplasms|Digestive System Diseases|All Conditions|Nervous System Diseases|Symptoms and General Pathology|Diseases and Abnormalities at or before Birth|Substance Related Disorders|Behaviors and Mental Disorders|Rare Diseases,INDUSTRY,,Multiple,"Australia|Australia|Germany|Germany|Germany|Italy|Italy|Korea, Republic of|Korea, Republic of|Korea, Republic of|Spain|Spain|Spain|Taiwan|Taiwan",7-Jan,25-Sep-06,8-Mar,8-Mar,10-Mar-09,See detailed description for termination reason,"This study was terminated on July 15, 2008. The results of an interim analysis showed that the conditional power to detect a difference in treatment groups was insufficient to warrant study continuation and therefore termination of the trial was recommended. The decision to terminate the trial was not based on safety concerns.",6,64,Actual,200,,FALSE,E,61,64,61,0.32,12,61,0,,1 - Scientific Data
NCT00381095,1,A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 4,"Cancers and Other Neoplasms|Symptoms and General Pathology|All Conditions|Muscle, Bone, and Cartilage Diseases|Nervous System Diseases|Rare Diseases",INDUSTRY,,Multiple,"United States|United States|United States|United States|United States|United States|United States|United States|Canada|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Egypt|Finland|Finland|France|France|Hungary|Hungary|Hungary|Hungary|Hungary|Italy|Italy|Korea, Republic of|Korea, Republic of|Korea, Republic of|Mexico|Mexico|Peru|Peru|Philippines|Philippines|Poland|Poland|Poland|Poland|Poland|Poland|Russian Federation|Russian Federation|Russian Federation|Spain|Spain|Sweden|Sweden|Taiwan|Taiwan|Taiwan|Thailand|Thailand|Venezuela",6-Dec,25-Sep-06,10-Oct,10-Oct,18-Aug-11,See termination reason in detailed description.,Pfizer decided to discontinue additional enrollment into the study effective Sept 5 2010 after assessing the feasibility of completing this study in a realistic timeframe.The study was not stopped for any safety concerns.,2,152,Actual,310,,TRUE,,152,152,151,0.49,24,152,0,,2 - No Scientific Data
NCT00381693,1,Azacitidine in Treating Patients With Myelofibrosis,Treatment,,Open Label,,Drug,Phase 2,Cancers and Other Neoplasms|Symptoms and General Pathology|All Conditions|Blood and Lymph Conditions|Rare Diseases,OTHER,,Multiple,United States|United States,6-Aug,26-Sep-06,8-Mar,9-Apr,9-Nov-10,Due to lack of accrual and trial has demonstrated too little clinical benefit,,6,10,Actual,35,,TRUE,,10,10,10,0.29,4,10,1,18509350,1 - Scientific Data
NCT00381810,1,A Study for Patients Previously Enrolled in Study U2971g to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus,Treatment,Single Group Assignment,Open Label,,Drug|Drug,Phase 2|Phase 3,Skin and Connective Tissue Diseases|Immune System Diseases|All Conditions,INDUSTRY,,,,6-Jun,26-Sep-06,8-Jul,8-Jul,11-Nov-09,"During routine safety review of Studies U2970g and U2971g, the Data Monitoring Committee recommended that enrollment in this extension trial be terminated",,7,31,Actual,250,,TRUE,,31,31,31,0.12,9,31,0,,2 - No Scientific Data
NCT00382863,1,Prospective Evaluation of Elastic Restraint to LESSen the Effects of Heart Failure (PEERLESS-HF) Trial,Treatment,Parallel Assignment,Single Blind,Randomized,Device|Drug,Phase 2|Phase 3,Heart and Blood Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Canada|Canada|Canada|Canada|Canada|Canada,6-Oct,28-Sep-06,11-May,12-May,13-May-11,Resources unavailable to continue study follow-up.,,1,220,Actual,272,,FALSE,E,210,220,210,0.81,104,210,1,22633302,2 - No Scientific Data
NCT00383331,1,Pemetrexed and Gemcitabine Every 14 Days Versus Every 21 Days in Advanced Non Small Cell Lung Cancer,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 2,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,INDUSTRY,,Single,United States,7-Feb,29-Sep-06,8-Jan,8-Jan,6-Jan-09,Trial was stopped early due to low enrollment,,2,19,Actual,72,,TRUE,,19,19,18,0.26,13,,0,,2 - No Scientific Data
NCT00384293,1,Carotid IMT (Intima Media Thickening) Study,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Nutritional and Metabolic Diseases|All Conditions|Diseases and Abnormalities at or before Birth|Rare Diseases,INDUSTRY,,,,6-Sep,3-Oct-06,8-Aug,8-Oct,23-Jul-09,,,9,937,Actual,900,,TRUE,,937,937,0,1.04,23,,0,,3 - No Reason Provided
NCT00385593,0,Symbicort Single Inhaler Therapy vs Conventional Best Practice for the Treatment of Persistent Asthma in Adults,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 3,Respiratory Tract (Lung and Bronchial) Diseases|Immune System Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Multiple,Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain,6-Sep,6-Oct-06,,8-Oct,14-Oct-09,,,9,654,Actual,1000,,TRUE,,654,654,654,0.65,15,652,1,21942354,3 - No Reason Provided
NCT00386152,1,A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 2,Blood and Lymph Conditions|All Conditions,INDUSTRY,,,,6-Oct,6-Oct-06,8-May,8-May,1-Apr-09,No safety signals were noted. The study was stopped because it was no longer consistent with the company's scientific and strategic focus.,,8,235,Actual,450,,FALSE,E,227,235,160,0.52,76,227,0,,2 - No Scientific Data
NCT00386477,1,"Vaginal Cleansing at Cesarean Delivery to Reduce Infection: A Randomized, Controlled Trial",Prevention,Parallel Assignment,Single Blind,Randomized,Procedure,,"Bacterial and Fungal Diseases|Symptoms and General Pathology|All Conditions|Wounds and Injuries|Urinary Tract, Sexual Organs, and Pregnancy Conditions",OTHER,,Multiple,United States|United States|United States,6-Sep,9-Oct-06,9-May,9-May,11-Nov-09,Difficulty recruiting,,2,300,Actual,1000,,TRUE,,300,300,300,0.3,0,300,1,20207251,2 - No Scientific Data
NCT00387010,1,Open-Label Study to Evaluate the Effect of Treatment With Fentanyl Buccal Tablets on Pain Anxiety Symptoms When Used for the Management of Breakthrough Pain,Treatment,Single Group Assignment,Open Label,,Drug,Phase 3,Nervous System Diseases|Symptoms and General Pathology|All Conditions|Behaviors and Mental Disorders,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,6-Dec,10-Oct-06,7-Oct,7-Oct,17-Aug-12,The sponsor felt enough information was available for the exploratory assessment of the effect of treatment with FBT on pain anxiety,,6,218,Actual,300,,TRUE,,218,218,175,0.73,4,218,1,21957829,1 - Scientific Data
NCT00387036,1,Exercise Study in Patient With Chronic Obstructive Pulmonary Disease,Treatment,Crossover Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Respiratory Tract (Lung and Bronchial) Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,,,6-Dec,5-Oct-06,9-Jul,9-Jul,8-Apr-10,Termininated for business reasons,,8,12,Actual,24,,TRUE,,12,12,24,0.5,0,24,0,,2 - No Scientific Data
NCT00387153,0,Phase 1 Clinical Trial MPC-2130 Treatment of Blood Cancers / Refractory Cancer,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 1,Cancers and Other Neoplasms|Blood and Lymph Conditions|All Conditions,INDUSTRY,,Single,United States,5-Aug,10-Oct-06,6-Oct,6-Oct,23-Jun-09,Last subject enrolled experienced bradycardia; study was terminated by Sponsor.,,5,8,Actual,30,,TRUE,,8,8,8,0.27,3,8,0,,1 - Scientific Data
NCT00387348,1,Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer,Supportive Care,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions|Digestive System Diseases|Gland and Hormone Related Diseases|Symptoms and General Pathology|Behaviors and Mental Disorders|Rare Diseases,OTHER,,Single,United States,6-Mar,12-Oct-06,11-Apr,11-Apr,12-Jul-12,DSMB stopped study because placebo arm had more adverse events,,5,24,Actual,220,,TRUE,,24,24,24,0.11,2,24,0,,1 - Scientific Data
NCT00388804,1,External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer,Treatment,Parallel Assignment,Open Label,Randomized,Procedure|Drug|Drug|Drug|Drug|Behavioral,Phase 3,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions",OTHER,,Single,United States,5-Feb,15-Oct-06,11-Apr,11-Apr,29-Jun-12,Slow accrual.,,2,39,Actual,340,,FALSE,F,38,38,38,0.11,0,38,0,,2 - No Scientific Data
NCT00389519,1,A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Heart and Blood Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Argentina|Argentina|Argentina|Argentina|Argentina|Argentina|Chile|Chile|Chile|Chile|Colombia|Colombia|Colombia|Colombia|Colombia|Colombia|Colombia|India|India|India|India|India|India|India|India|India|India|India|India|India|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Poland|South Africa|South Africa|South Africa|South Africa|South Africa|South Africa|South Africa|South Africa|South Africa|Turkey|Turkey|Turkey|Turkey|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine,6-Oct,17-Oct-06,7-Nov,7-Nov,21-Jan-10,"A planned interim analysis was performed after approx. 240 subjects completed the trial. The study was stopped, as permitted by protocol, after the analysis.",,6,422,Actual,240,,TRUE,,422,422,241,1.76,2,242,0,,1 - Scientific Data
NCT00392223,1,Efficacy And Safety Of Azithromycin SR Compared With Minocycline In Acne,Treatment,Parallel Assignment,Double-Blind,Randomized,Drug|Drug|Drug|Drug,Phase 3,Skin and Connective Tissue Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Multiple,Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy,7-Oct,23-Oct-06,8-Jun,8-Jun,11-Jun-09,See Detailed Description,"The study prematurely discontinued on the February 1, 2008 due to slow enrollment.It should be noted that safety concerns have not been seen in this study and have not factored into this decision.",2,118,Actual,212,,TRUE,,118,118,112,0.56,0,118,0,,2 - No Scientific Data
NCT00393094,1,Bevacizumab and Irinotecan to Treat Brain Tumors,Treatment,Single Group Assignment,Open Label,Non-Randomized,Biological|Drug,Phase 2,Cancers and Other Neoplasms|Nervous System Diseases|All Conditions|Symptoms and General Pathology|Rare Diseases,NIH,,Single,United States,6-Sep,25-Oct-06,10-Jan,10-Mar,27-Mar-12,Terminated due to the limitations of accrual.,,2,31,Actual,40,,TRUE,,31,31,30,0.78,9,30,0,,2 - No Scientific Data
NCT00393380,1,Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor,Prevention,Single Group Assignment,Open Label,,Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Blood and Lymph Conditions|Immune System Diseases|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States,6-Sep,25-Oct-06,9-Nov,12-Mar,6-Nov-12,Study stopped because of toxicity concerns.,,5,13,Actual,40,,TRUE,,13,13,13,0.33,0,13,1,22766223,1 - Scientific Data
NCT00394212,1,Incisionless Treatment for Patients With Inadequate Weight Loss Following Roux-en-Y Gastric Bypass,Treatment,Parallel Assignment,Double Blind,Randomized,Device|Other,Phase 3,Nutritional and Metabolic Diseases|Symptoms and General Pathology|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,6-Nov,27-Oct-06,8-Sep,9-May,3-Aug-11,For business reasons,,8,77,Actual,220,,TRUE,,77,77,77,0.35,2,77,0,,2 - No Scientific Data
NCT00394589,1,Re?? (Re-Cube: Retain Remicade?? Response)(Study P04249AM3),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 3,"Muscle, Bone, and Cartilage Diseases|All Conditions|Skin and Connective Tissue Diseases|Immune System Diseases",INDUSTRY,,,,6-Mar,31-Oct-06,8-Oct,8-Oct,28-Oct-09,Study enrollment was stopped due to insufficient subject accrual.,,2,43,Actual,315,,TRUE,,43,43,17,0.14,4,43,0,,2 - No Scientific Data
NCT00394706,1,Resuscitation Outcomes Consortium (ROC) Prehospital Resuscitation Using an Impedance Valve,Treatment,Factorial Assignment,Double Blind,Randomized,Device|Device|Other|Other,Phase 3,Heart and Blood Diseases|All Conditions,OTHER,,Multiple,United States|United States|United States|United States|United States|United States|United States|Canada|Canada,7-Jun,30-Oct-06,9-Nov,10-Jul,23-Mar-12,Terminated because preliminary data suggested no difference in the strategies.,,6,11738,Actual,14154,,TRUE,,11738,11738,18651,0.83,1263,15482,1,21879897; 21879896,1 - Scientific Data
NCT00395057,1,A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug|Drug,Phase 2,Eye Diseases|All Conditions|Symptoms and General Pathology|Rare Diseases,INDUSTRY,,Multiple,United States|Australia|Philippines,7-Jan,31-Oct-06,8-Oct,9-Feb,9-Nov-11,The study was terminated early due to company decision (non-safety related).,,8,138,Actual,135,,TRUE,,138,138,138,1.02,19,138,0,,2 - No Scientific Data
NCT00395226,1,"Zinc Sulfate in the Treatment of Rosacea: A Randomized, Controlled Trial",Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,,Skin and Connective Tissue Diseases|All Conditions,OTHER,,Single,United States,6-Jul,31-Oct-06,8-Jul,8-Jul,3-Jun-11,Difficulty recruiting subjects,,2,65,Actual,80,,FALSE,F,53,53,44,0.66,2,,1,22435439,2 - No Scientific Data
NCT00395967,0,AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 2,Cancers and Other Neoplasms|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Heart and Blood Diseases|Rare Diseases,INDUSTRY,,Single,United States,5-Apr,2-Nov-06,5-Jul,6-Aug,27-Jan-09,Enrollment terminated in 2005 to focus on Phase 3 study enrollment.,,7,5,Actual,15,,TRUE,,5,5,5,0.33,4,5,0,,2 - No Scientific Data
NCT00396383,1,Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 2,Cancers and Other Neoplasms|Heart and Blood Diseases|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Rare Diseases,INDUSTRY,,Multiple,United States|United States,4-Nov,2-Nov-06,7-May,7-May,11-Feb-09,Insufficient cell mobilization for tandem transplants,,6,9,Actual,20,,TRUE,,9,9,9,0.45,0,9,1,20067838,1 - Scientific Data
NCT00396812,1,Rituximab for the Treatment of Early Rheumatoid Arthritis (RA),Treatment,Single Group Assignment,Open Label,,Drug,Phase 1|Phase 2,"Muscle, Bone, and Cartilage Diseases|All Conditions|Skin and Connective Tissue Diseases|Immune System Diseases",NIH,,Single,United States,6-Nov,6-Nov-06,9-Jul,9-Jul,11-Oct-12,The perceived risk-benefit ratio for individuals with early active RA,,5,4,Actual,10,,TRUE,,4,4,3,0.4,1,4,0,,1 - Scientific Data
NCT00398047,1,"Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes",Treatment,,Open Label,Non-Randomized,Drug,,Cancers and Other Neoplasms|All Conditions|Blood and Lymph Conditions|Symptoms and General Pathology|Rare Diseases,OTHER,,Single,United States,6-Sep,9-Nov-06,9-Sep,9-Sep,21-Jan-11,Slow accrual,,2,3,Actual,36,,TRUE,,3,3,3,0.08,1,3,0,,2 - No Scientific Data
NCT00400205,1,"Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil",Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Mouth and Tooth Diseases|Rare Diseases,OTHER,,Single,United States,6-Aug,15-Nov-06,9-Sep,9-Sep,6-Dec-10,Safety reasons,,5,14,Actual,20,,TRUE,,14,14,9,0.7,6,14,0,,1 - Scientific Data
NCT00400764,1,"A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas",Treatment,Single Group Assignment,Open Label,Randomized,Drug|Drug,Phase 1|Phase 2,Cancers and Other Neoplasms|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Rare Diseases,INDUSTRY,,,,6-Jun,15-Nov-06,10-May,,1-Sep-11,,,9,72,Actual,120,,FALSE,E,12,72,71,0.6,7,71,0,,3 - No Reason Provided
NCT00401401,1,Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer,Treatment,Parallel Assignment,Open Label,Non-Randomized,Drug|Drug|Procedure,Phase 1|Phase 2,Cancers and Other Neoplasms|All Conditions,INDUSTRY,,Multiple,United States|Belgium|Belgium|France|France|Netherlands|Sweden,6-Dec,17-Nov-06,10-Oct,10-Oct,7-Oct-11,MTD was established and patients completed 16 months safety f-up and response assessments. It is considered of limited value to follow patients for 3 years.,,6,30,Actual,36,,TRUE,,30,30,30,0.83,27,30,0,,1 - Scientific Data
NCT00403234,1,Safety of Buprenorphine Transdermal System (BTDS) in Subjects With Acute Postoperative Pain After Total Knee Replacement,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug|Drug,Phase 2,Nervous System Diseases|Symptoms and General Pathology|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States,6-Nov,21-Nov-06,7-Apr,7-Aug,28-Jul-10,due to administrative reasons not related to efficacy or safety.,,4,10,Actual,160,,TRUE,,10,10,10,0.06,0,10,0,,2 - No Scientific Data
NCT00406653,1,A Study of Abatacept in Patients With Active Crohn's Disease,Treatment,Crossover Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 3,Digestive System Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Australia|Australia|Australia|Australia|Australia|Australia|Australia|Australia|Australia|Australia|Belgium|Belgium|Belgium|Brazil|Brazil|Brazil|Brazil|Brazil|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Czech Republic|Denmark|Denmark|Denmark|Denmark|France|France|France|France|France|France|Germany|Germany|Germany|India|India|India|India|India|India|Italy|Italy|Italy|Italy|Mexico|Mexico|Mexico|Netherlands|Netherlands|Netherlands|Poland|Puerto Rico|South Africa|South Africa|Switzerland|Switzerland|Switzerland,6-Dec,1-Dec-06,9-Nov,9-Nov,30-Jul-10,Sponsor Decision,,8,451,Actual,689,,TRUE,,451,451,446,0.65,173,865,1,22504093,2 - No Scientific Data
NCT00407797,1,"Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial",Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 4,Nervous System Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Multiple,Mexico|Mexico|Mexico|Mexico|Mexico|Mexico|Mexico|Mexico,7-Mar,1-Dec-06,9-Aug,9-Aug,12-Aug-10,,,9,136,Actual,160,,TRUE,,136,136,121,0.85,8,136,1,22304935,3 - No Reason Provided
NCT00407966,1,"Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",Treatment,Single Group Assignment,Open Label,,Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Symptoms and General Pathology|Blood and Lymph Conditions|Diseases and Abnormalities at or before Birth|Rare Diseases,NIH,,Single,United States,6-Oct,4-Dec-06,8-Jul,9-Aug,1-May-12,subject accrual and data analysis completed,,11,46,Actual,25,,FALSE,F,45,45,45,1.8,19,45,1,22733022,2 - No Scientific Data
NCT00408070,1,"Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer",Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug|Drug,Phase 2,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Gland and Hormone Related Diseases|All Conditions|Digestive System Diseases|Rare Diseases",OTHER,,Single,United States,6-Oct,5-Dec-06,9-Aug,9-Oct,14-Oct-10,Did not meet accrual goals.,,2,5,Actual,100,,TRUE,,5,5,5,0.05,2,5,0,,2 - No Scientific Data
NCT00409331,1,Amifostine With IMRT for Submandibular and Sublingual Salivary Sparing During Head and Neck Cancer Treatment,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Procedure,Phase 2,Cancers and Other Neoplasms|All Conditions|Rare Diseases,OTHER,,Single,United States,6-Dec,7-Dec-06,9-Jan,9-Jan,11-Dec-09,Study terminated by Principal Investigator; no patients completed study.,,8,3,Actual,20,,FALSE,F,1,1,0,0.05,0,0,0,,2 - No Scientific Data
NCT00410150,1,Heliox-Powered Albuterol Therapy in the Treatment of Children Admitted With Acute Asthma Exacerbation,Treatment,Parallel Assignment,Single Blind,Randomized,Drug|Drug,Phase 2,Respiratory Tract (Lung and Bronchial) Diseases|Immune System Diseases|All Conditions,OTHER,,Single,United States,6-Apr,11-Dec-06,7-Dec,7-Dec,15-Sep-10,Study was stopped after interim analysis and slow enrollment.,,6,42,Actual,340,,TRUE,,42,42,42,0.12,0,42,1,20464778,1 - Scientific Data
NCT00412750,1,Efficacy and Safety of Telbivudine in Treatment na??ve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB),Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 3,Viral Diseases|Digestive System Diseases|All Conditions,INDUSTRY,,Single,United States,6-Dec,15-Dec-06,9-Feb,9-Feb,2-Dec-10,Enrollment stopped for safety issues,,5,159,Actual,300,,TRUE,,159,159,155,0.53,15,158,0,,1 - Scientific Data
NCT00414206,1,Safety and Efficacy of ATG003 in Patients With Wet Age-Related Macular Degeneration (AMD),Treatment,Parallel Assignment,Double-Blind,Randomized,Drug|Drug,Phase 2,Eye Diseases|All Conditions,INDUSTRY,,Multiple,Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Mexico|Mexico|Mexico|Mexico|Mexico|Mexico|Poland|Poland|Poland|Poland|Poland|Poland|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine,7-Mar,19-Dec-06,9-Jun,9-Sep,16-Aug-10,Sponsor decision,,8,343,Actual,330,,TRUE,,343,343,338,1.04,23,344,0,,2 - No Scientific Data
NCT00414466,1,A Safety and Effectiveness Study of Intraspinal MDT2004 for the Treatment of Chronic Pain,Treatment,Parallel Assignment,Double Blind,Randomized,Drug,Phase 2,Nervous System Diseases|Symptoms and General Pathology|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,6-Dec,20-Dec-06,9-Dec,10-Aug,22-Dec-10,Study closed and subject follow-up completed following analysis of blinded study data.,,11,254,Actual,144,,FALSE,F,170,170,170,1.18,10,170,1,23835590,2 - No Scientific Data
NCT00414726,1,Normobaric Oxygen Therapy in Acute Ischemic Stroke Trial,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Nervous System Diseases|Heart and Blood Diseases|All Conditions|Symptoms and General Pathology,OTHER,,Multiple,United States|United States,7-Jan,21-Dec-06,9-Jun,9-Jun,1-Jul-10,Imbalance in deaths favoring control arm; deaths not attributed to treatment by the blinded external medical monitor.,,5,85,Actual,240,,TRUE,,85,85,85,0.35,44,84,0,,1 - Scientific Data
NCT00416793,1,Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer,Treatment,Single Group Assignment,Open Label,,Drug|Drug|Other,Phase 2,Cancers and Other Neoplasms|All Conditions|Digestive System Diseases|Gland and Hormone Related Diseases|Rare Diseases,NIH,,Single,United States,6-Dec,27-Dec-06,9-Dec,,14-Jun-11,,,9,9,Actual,39,,TRUE,,9,9,9,0.23,0,9,0,,3 - No Reason Provided
NCT00416884,0,"Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML",Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug|Radiation|Other,Phase 2,Viral Diseases|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions|Cancers and Other Neoplasms|Blood and Lymph Conditions|Rare Diseases,OTHER,,Single,United States,3-May,27-Dec-06,8-Mar,8-Mar,31-May-11,Low enrollment,,2,1,Actual,1,Actual,TRUE,,1,1,1,1,0,1,0,,2 - No Scientific Data
NCT00417885,1,A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug,Phase 1|Phase 2,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions,INDUSTRY,,Multiple,United States|Canada|Canada,7-Jun,2-Jan-07,9-Jul,9-Jul,9-Jul-10,See Detailed Description for Termination Reason,"The trial was terminated prematurely on August 28, 2008 due to the inability to recruit the planned number of subjects in order to provide meaningful efficacy data. There were no safety concerns regarding the study in the decision to terminate the trial.",2,6,Actual,72,,TRUE,,6,6,0,0.08,3,6,0,,2 - No Scientific Data
NCT00418574,1,Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients,Treatment,Parallel Assignment,Double Blind,Randomized,Biological|Biological,Phase 2|Phase 3,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Gland and Hormone Related Diseases|All Conditions|Rare Diseases",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Belgium|Belgium|Belgium|Belgium|Belgium|Belgium|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|France|France|France|France|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Hungary|Hungary|Hungary|Hungary|Hungary|Hungary|Hungary|Hungary|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain,6-Dec,4-Jan-07,10-Dec,11-Jun,1-Jul-11,No benefit on primary end point (RFS); no rationale to collect survival data,,6,888,Actual,870,,TRUE,,888,888,888,1.02,213,886,1,23478059,1 - Scientific Data
NCT00418691,1,Effects of Methylphenidate Versus Sustained Release Methylphenidate on Cognitive Functioning,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug,Phase 3,Cancers and Other Neoplasms|Nervous System Diseases|All Conditions|Symptoms and General Pathology,OTHER,,Single,United States,4-Feb,3-Jan-07,9-Nov,9-Nov,10-Jan-11,Closed early due to slow accrual.,,2,34,Actual,75,,FALSE,F,33,33,33,0.44,0,33,1,21964738,2 - No Scientific Data
NCT00419120,1,Augmentation Cystoplasty Using an Autologous Neo-Bladder,Treatment,Single Group Assignment,Open Label,Non-Randomized,Other,Phase 2,"Nervous System Diseases|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Symptoms and General Pathology|All Conditions|Diseases and Abnormalities at or before Birth|Rare Diseases",INDUSTRY,,Single,United States,6-Dec,4-Jan-07,8-Oct,11-Apr,8-Dec-09,36 months of longterm follow up have been completed without substantial change to the profile. No further studies are currently planned.,,6,10,Actual,10,Anticipated,TRUE,,10,10,10,1,6,11,1,24184366,1 - Scientific Data
NCT00422513,0,A Study Comparing Mircera and Epoetin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 3,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions|Blood and Lymph Conditions",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,7-Mar,15-Jan-07,7-Dec,7-Dec,29-Mar-11,Strategic decision unrelated to safety or efficacy,,8,260,Actual,260,Actual,TRUE,,260,260,0,1,62,252,0,,2 - No Scientific Data
NCT00422669,1,Optimize RV Selective Site Pacing Clinical Trial,Treatment,Parallel Assignment,Single Blind,Randomized,Device|Device,,,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Canada|China|Israel|Italy|Italy|Qatar,7-Jan,12-Jan-07,9-May,9-May,9-Jun-11,Study enrollment significantly below protocol expectations,,2,205,Actual,400,,TRUE,,205,205,0,0.51,50,198,0,,2 - No Scientific Data
NCT00423150,1,Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED),Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Respiratory Tract (Lung and Bronchial) Diseases|Digestive System Diseases|Rare Diseases,INDUSTRY,,,,7-Jan,30-Nov-06,9-Jun,9-Jun,27-May-10,,,9,86,Actual,160,,TRUE,,86,86,82,0.54,37,86,1,23443801,3 - No Reason Provided
NCT00423176,1,The Study of Nasonex?? Compared With Placebo for the Relief of Symptoms Associated With Acute Bacterial Sinusitis When Used With Antibiotics (Study P04824AM3),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,"Respiratory Tract (Lung and Bronchial) Diseases|Ear, Nose, and Throat Diseases|All Conditions|Bacterial and Fungal Diseases",INDUSTRY,,,,6-Dec,17-Jan-07,8-May,8-May,29-Jul-09,Based on business priorities. Not related to any safety or efficacy issue & took place before data were unblinded or analyzed,,8,237,Actual,600,,TRUE,,237,237,202,0.4,1,237,0,,2 - No Scientific Data
NCT00423800,1,Efficacy and Safety of 24 vs 48 Weeks of Pegetron?? (Peginterferon Alfa-2b + Ribavirin) in Na??ve Genotype 1 Hepatitis C (Study P05016)(TERMINATED),Treatment,Parallel Assignment,Open Label,Randomized,Drug,Phase 3,Viral Diseases|Digestive System Diseases|All Conditions,INDUSTRY,,,,6-Dec,17-Jan-07,9-Oct,9-Oct,27-Jan-11,The study was terminated due to difficulty in recruiting participants.,,2,56,Actual,212,,FALSE,F,5,5,5,0.02,2,7,0,,2 - No Scientific Data
NCT00424645,1,Voraxaze for Delayed Methotrexate Clearance,Supportive Care,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 1|Phase 2,Cancers and Other Neoplasms|Blood and Lymph Conditions|All Conditions,OTHER,,Single,United States,7-Jan,17-Jan-07,8-Jan,8-Jan,9-Nov-10,Sponsor terminated due to low accrual.,,2,3,Actual,46,,TRUE,,3,3,0,0.07,0,3,0,,2 - No Scientific Data
NCT00424749,1,Rituxan in Churg Strauss Syndrome With Renal Involvement,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug,Phase 2,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions|Heart and Blood Diseases|Immune System Diseases|Blood and Lymph Conditions|Symptoms and General Pathology|Rare Diseases",OTHER,,Single,United States,7-Jun,19-Jan-07,9-Jul,9-Jul,12-Sep-11,Company providing study drug terminated study due to lack of funds,,1,4,Actual,5,,TRUE,,4,4,3,0.8,0,3,1,21325353,2 - No Scientific Data
NCT00424775,1,A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC),Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 1,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,INDUSTRY,,,,7-Jan,19-Jan-07,7-Oct,,3-Apr-09,,,9,3,Actual,12,,TRUE,,3,3,3,0.25,0,3,0,,3 - No Reason Provided
NCT00427011,1,A Study of E2007 In Patients With Parkinson's Disease,Treatment,Parallel Assignment,Open Label,Non-Randomized,Drug,Phase 2,Nervous System Diseases|All Conditions|Cancers and Other Neoplasms|Skin and Connective Tissue Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States,7-Feb,24-Jan-07,8-Apr,8-Apr,20-Nov-12,Study stopped due to lack of efficacy.,,6,25,Actual,60,,TRUE,,25,25,25,0.42,2,25,0,,1 - Scientific Data
NCT00427934,1,Maraviroc in Rheumatoid Arthritis,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,"Muscle, Bone, and Cartilage Diseases|All Conditions|Skin and Connective Tissue Diseases|Immune System Diseases",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Australia|Australia|Australia|Germany|Germany|Germany|India|India|India|Italy|Italy|Mexico|Mexico|Portugal|Portugal|Portugal|Spain|Spain|Spain|Spain|Ukraine|Ukraine|Ukraine,7-Feb,25-Jan-07,8-Oct,8-Oct,6-Oct-09,See Detailed Description.,"Following a planned interim analysis in the POC component on 21 August 2008 by the internal DMC (Data Monitoring Committee) of study A4001056, the trial was discontinued due to lack of efficacy. All participating investigators/country offices and monitors were notified on 22 August 2008 to cease patient enrollment. The DMC indicated that maraviroc was well tolerated in the Rheumatoid Arthritis patients and there were no safety concerns in the study. The termination date of this trial was 07 October 2008 when the last patient last visit occurred.",6,128,Actual,130,,TRUE,,128,128,110,0.98,0,126,1,22251436,1 - Scientific Data
NCT00427960,1,Study of Asian Patients With Hypercholesterolaemia in the UK - Rosuvastatin 5mg Versus Atorvastatin 10mg,Treatment,Parallel Assignment,Double-Blind,Randomized,Behavioral|Drug|Drug,Phase 4,Nutritional and Metabolic Diseases|All Conditions,INDUSTRY,,Multiple,United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom,6-Dec,25-Jan-07,8-Feb,8-Feb,25-Mar-09,Due to inadequate recruitment,,2,55,Actual,686,,TRUE,,55,55,55,0.08,1,,0,,2 - No Scientific Data
NCT00428077,1,Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia,Treatment,Single Group Assignment,Open Label,,Biological|Genetic,Phase 2,Cancers and Other Neoplasms|All Conditions|Blood and Lymph Conditions|Symptoms and General Pathology|Rare Diseases,OTHER,,Single,United States,5-Oct,25-Jan-07,9-Apr,9-Apr,26-May-11,"Withdrawn because there were no dramatic changes in the main endpoint, as well as low enrollment numbers. The data are not interpretable in terms of efficacy.",,6,4,Actual,20,,TRUE,,4,4,4,0.2,1,4,0,,1 - Scientific Data
NCT00428441,1,D-dimer to Predict Recurrence in Patients With Multiple Episodes of Venous Thromboembolism,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,,Heart and Blood Diseases|All Conditions|Symptoms and General Pathology,OTHER,,Single,Italy,7-May,26-Jan-07,10-Jun,11-May,18-Aug-11,Enrolment was halted prematurely because of the observed excess in recurrences,,6,73,Actual,100,Anticipated,FALSE,F,75,75,75,0.75,0,75,1,22488507,1 - Scientific Data
NCT00428597,1,A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Cancers and Other Neoplasms|All Conditions|Digestive System Diseases|Gland and Hormone Related Diseases|Rare Diseases,INDUSTRY,,Multiple,"United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Australia|Belgium|Belgium|Belgium|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|France|France|France|France|France|France|France|Germany|Germany|Germany|Germany|Germany|Germany|Italy|Italy|Italy|Korea, Republic of|Korea, Republic of|Spain|Spain|Spain|Spain|Spain|Taiwan|Taiwan|United Kingdom|United Kingdom|United Kingdom",7-Jun,29-Jan-07,9-Apr,9-Apr,15-Apr-10,Refer to Detailed Description.,The study was terminated on 11 March 2009 because the independent Data Monitoring Committee determined that the study had met its primary endpoint in demonstrating improvement in progression-free survival. The decision to terminate the trial was not based on safety concerns related to sunitinib administration.,6,171,Actual,340,,TRUE,,171,171,171,0.5,56,165,1,21306237,1 - Scientific Data
NCT00429026,1,Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug|Procedure,Phase 2,"Cancers and Other Neoplasms|All Conditions|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Rare Diseases",OTHER,,Single,United States,4-Jan,29-Jan-07,8-Mar,8-Mar,26-Feb-09,"Slow accrual, study terminated.",,2,40,Actual,480,,TRUE,,40,40,0,0.08,,,0,,2 - No Scientific Data
NCT00429169,1,Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 4,Behaviors and Mental Disorders|All Conditions,OTHER,,Single,United States,4-Jun,29-Jan-07,10-Jan,13-Jan,11-Dec-12,Interim analysis showed differential treatment effects.,,6,101,Actual,100,,FALSE,F,78,78,74,0.78,5,74,1,21993207,1 - Scientific Data
NCT00429403,1,Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer,Treatment,Parallel Assignment,Open Label,Randomized,Drug,Phase 3,"Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Gland and Hormone Related Diseases",OTHER,,Multiple,United States|Japan,6-Aug,29-Jan-07,10-Jul,10-Jul,27-Jun-11,Study stopped due to low accrual.,,2,1,Actual,148,,TRUE,,1,1,1,0.01,0,1,0,,2 - No Scientific Data
NCT00430677,1,Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug|Drug|Drug,Phase 2|Phase 3,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|Skin and Connective Tissue Diseases|Immune System Diseases|All Conditions|Rare Diseases",INDUSTRY,,Multiple,"United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Argentina|Argentina|Argentina|Argentina|Australia|Australia|Australia|Australia|Belgium|Belgium|Brazil|Brazil|Brazil|Brazil|Brazil|Canada|Canada|Canada|Canada|China|China|China|China|China|China|China|China|France|France|France|France|Hong Kong|India|India|India|India|India|India|India|India|India|India|Korea, Republic of|Korea, Republic of|Korea, Republic of|Mexico|Mexico|Mexico|Mexico|Mexico|Mexico|Mexico|Mexico|Poland|Poland|Poland|Russian Federation|Russian Federation|Russian Federation|South Africa|South Africa|South Africa|Taiwan|Taiwan|Taiwan|Taiwan|Taiwan|Turkey|United Kingdom|United Kingdom",7-Jun,1-Feb-07,10-Sep,11-Aug,13-Feb-12,Terminated because of lack of efficacy in the short term phase,,6,423,Actual,300,,FALSE,F,298,298,298,0.99,92,298,1,23529285,1 - Scientific Data
NCT00430716,1,To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug|Drug,Phase 4,Heart and Blood Diseases|All Conditions|Respiratory Tract (Lung and Bronchial) Diseases|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Belgium|Brazil|Brazil|Bulgaria|Bulgaria|China|China|Greece|India|India|India|India|India|Italy|Italy|Latvia|Malaysia|Netherlands|Netherlands|Philippines|Philippines|Poland|Poland|Romania|Romania|Russian Federation|Russian Federation|Thailand|Thailand|United Kingdom|United Kingdom,8-Apr,31-Jan-07,10-May,10-May,22-Apr-11,This study was terminated at the recommendation of an independent Data Monitoring Committee. The decision was not based on any safety concerns.,,6,130,Actual,174,,TRUE,,130,130,123,0.75,14,129,0,,1 - Scientific Data
NCT00430937,1,Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections,Treatment,Parallel Assignment,Single Blind,Randomized,Drug|Drug|Drug,Phase 3,Bacterial and Fungal Diseases|Skin and Connective Tissue Diseases|All Conditions,INDUSTRY,,,,6-Apr,1-Feb-07,8-Mar,,7-Dec-10,,,9,194,Actual,280,,FALSE,E,189,194,105,0.69,33,189,1,21982144,3 - No Reason Provided
NCT00432341,1,Efficacy and Safety of Two Different Botulinum Toxin Type A Treatments for Moderate to Severe Cervical Dystonia,Treatment,Parallel Assignment,Double Blind,Randomized,Biological|Biological,Phase 4,Nervous System Diseases|Symptoms and General Pathology|All Conditions|Rare Diseases,INDUSTRY,,Multiple,Argentina|Australia|India,7-Jun,5-Feb-07,9-Mar,9-Jun,14-Nov-11,Study was terminated early due to difficulties with patient recruitment,,2,54,Actual,160,,TRUE,,54,54,54,0.34,0,54,0,,2 - No Scientific Data
NCT00433017,1,Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 2|Phase 3,Cancers and Other Neoplasms|Symptoms and General Pathology|All Conditions|Eye Diseases|Rare Diseases,INDUSTRY,,Multiple,Austria|Belgium|Denmark|France|Germany|Hungary|Italy|Netherlands|Poland|Spain|Switzerland|United Kingdom,7-May,8-Feb-07,9-Jul,9-Jul,12-Jan-11,Study was terminated based on the results of analyses performed as planned at Month 12.,,6,255,Actual,250,,TRUE,,255,255,253,1.02,53,255,1,22424834,1 - Scientific Data
NCT00434226,1,"A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)",Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,INDUSTRY,,,,7-Mar,11-Feb-07,8-Apr,,9-Jul-09,"Based on data collected, the combination appeared to be poorly tolearated.",,5,56,Actual,130,,TRUE,,56,56,44,0.43,,,1,20032789,1 - Scientific Data
NCT00434278,1,A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 4,Digestive System Diseases|Respiratory Tract (Lung and Bronchial) Diseases|Diseases and Abnormalities at or before Birth|All Conditions|Symptoms and General Pathology|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,7-Mar,11-Feb-07,8-Nov,8-Nov,18-Oct-10,This study was terminated for administrative reasons. There were no safety concerns.,,4,27,Actual,48,,TRUE,,27,27,25,0.56,4,27,0,,2 - No Scientific Data
NCT00434356,1,A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B),Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions,INDUSTRY,,,,7-Mar,9-Feb-07,8-May,,1-Sep-09,"Based on data collected, the combination appeared to be poorly tolearated.",,5,46,Actual,145,,TRUE,,46,46,35,0.32,19,46,1,20497961,1 - Scientific Data
NCT00434590,1,"Efficacy and Tolerability of Full Dose Enteric-coated Mycophenolate Sodium, in Addition to Cyclosporine for Microemulsion Reduced Dose, in Maintenance Renal Transplant Recipients",Prevention,Parallel Assignment,Open Label,Randomized,Drug,Phase 4,,INDUSTRY,,Single,Italy,7-Mar,12-Feb-07,8-May,8-May,13-Dec-10,The study has been stopped because of the lack of enrollment,,2,10,Actual,170,,TRUE,,10,10,0,0.06,0,10,0,,2 - No Scientific Data
NCT00435487,1,Dalteparin Versus Unfractionated Heparin In Patients With Acute Coronary Syndrome,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 4,Heart and Blood Diseases|All Conditions|Symptoms and General Pathology|Nervous System Diseases,INDUSTRY,,Multiple,India|India|India|India|India|India|India|India,7-Jun,13-Feb-07,8-Dec,8-Dec,22-Dec-09,See termination reason in detailed description.,"The study was prematurely discontinued on November 30, 2008 due to delay in meeting pre-defined protocol recruitment milestones. There were no safety concerns regarding the study in the decision to terminate the trial.",2,173,Actual,400,,FALSE,E,174,173,157,0.43,17,171,0,,2 - No Scientific Data
NCT00436345,1,Pharmacoeconomic Consequences Of Analgesia in the Intensive Care Unit (ICU),Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 3,,INDUSTRY,,Multiple,Italy|Italy|Italy|Italy|Italy|Italy,7-Nov,15-Feb-07,8-Aug,8-Sep,7-Aug-09,recruitment issues,,2,39,Actual,196,,TRUE,,39,39,39,0.2,0,39,0,,2 - No Scientific Data
NCT00437073,1,Brain Metastases In ErbB2-Positive Breast Cancer,Treatment,Parallel Assignment,Open Label,Non-Randomized,Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions|Symptoms and General Pathology|Nervous System Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Austria|Canada|Canada|Canada|France|France|France|France|Germany|Germany|Israel|Israel|Israel|Italy|Italy|Spain|Sweden,7-May,15-Feb-07,9-Jan,10-Feb,13-Sep-12,Lapatinib-topotecan arm enrollment closed early per protocol amendment 2. Then enrollment into remaining arm terminated due to operational issues.,,6,22,Actual,110,,TRUE,,22,22,22,0.2,11,22,1,21706359,1 - Scientific Data
NCT00437203,1,PF-00477736 Is Being Studied In Advanced Solid Tumors In Combination With Chemotherapy With Gemcitabine,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug,Phase 1,,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|Australia,6-Dec,16-Feb-07,11-Apr,11-Apr,6-Mar-12,See termination reason in detailed description.,The study was closed to enrollment as of 17 May 2010 due to business reasons. The patient on study continued treatment until 19 April 2011 when stopped for complete response. Premature closure was not prompted by any safety or efficacy concerns.,8,43,Actual,30,,TRUE,,43,43,43,1.43,18,43,0,,2 - No Scientific Data
NCT00437489,1,A Clinical Trial Comparing The Efficacy And Safety Of 2 Different Initial Dose Prescriptions For Exubera.,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 4,Respiratory Tract (Lung and Bronchial) Diseases|Symptoms and General Pathology|All Conditions|Nutritional and Metabolic Diseases|Gland and Hormone Related Diseases,INDUSTRY,,Multiple,Hong Kong|Pakistan|Philippines|Philippines|Philippines|Philippines|Philippines|Singapore|Singapore,7-Jun,20-Feb-07,7-Dec,7-Dec,11-Dec-08,"This protocol was terminated not for safety reasons, but because Pfizer decided to return the worldwide rights for Exubera to Nektar, on 18 October 2007.",,8,49,Actual,424,,TRUE,,49,49,49,0.12,2,,0,,2 - No Scientific Data
NCT00439218,1,Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Type I,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 1|Phase 2,Nervous System Diseases|All Conditions|Symptoms and General Pathology|Diseases and Abnormalities at or before Birth|Rare Diseases,OTHER,,Multiple,United States|United States|United States|United States|United States,8-Jan,22-Feb-07,9-May,9-May,16-Apr-10,Extremely slow enrollment,,2,5,Actual,30,,FALSE,E,4,5,0,0.17,1,5,0,,2 - No Scientific Data
NCT00439569,1,Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Types II or III,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 1|Phase 2,Nervous System Diseases|All Conditions|Symptoms and General Pathology|Diseases and Abnormalities at or before Birth|Rare Diseases,OTHER,,Multiple,United States|United States|United States|United States|United States,8-Jan,21-Feb-07,8-Aug,8-Aug,19-Jan-10,Due to poor compliance with study drug administration.,,4,9,Actual,30,,FALSE,E,7,9,0,0.3,1,9,0,,2 - No Scientific Data
NCT00440271,1,"SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC",Treatment,,,,Drug|Drug,Phase 3,"Viral Diseases|Immune System Diseases|All Conditions|Symptoms and General Pathology|Bacterial and Fungal Diseases|Urinary Tract, Sexual Organs, and Pregnancy Conditions",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Argentina|Argentina|Argentina|Brazil|Brazil|Brazil|Brazil|Canada|Germany|Germany|Italy|Spain|Spain|Spain,7-Feb,26-Feb-07,8-Oct,,20-Oct-09,,,9,33,Actual,400,,TRUE,,33,33,0,0.08,0,33,0,,3 - No Reason Provided
NCT00441584,1,The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833AM2)(TERMINATED),Treatment,Single Group Assignment,Open Label,Non-Randomized,Biological|Drug,Phase 3,Viral Diseases|Digestive System Diseases|All Conditions,INDUSTRY,,,,5-Jul,28-Feb-07,8-Jun,8-Jun,18-Jun-09,Subject accrual was prematurely terminated due slow enrollment.,,2,117,Actual,1200,,TRUE,,117,117,117,0.1,6,117,0,,2 - No Scientific Data
NCT00441766,1,Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndrome Pain,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug|Drug,Phase 2,Digestive System Diseases|All Conditions|Nervous System Diseases|Symptoms and General Pathology,INDUSTRY,,Single,United States,7-Mar,27-Feb-07,8-Feb,8-Feb,16-Dec-11,Study was terminated due to company decision after Part A. Part B was never conducted,,8,213,Actual,200,,TRUE,,213,213,197,1.07,11,212,0,,2 - No Scientific Data
NCT00442351,1,Efficacy and Tolerability of Maintenance Treatment With Asmanex Twisthaler Versus Placebo in Mild/Moderate Persistent Asthmatics (Study P04654)(TERMINATED),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Other,Phase 4,Respiratory Tract (Lung and Bronchial) Diseases|Immune System Diseases|All Conditions,INDUSTRY,,,,6-Sep,28-Feb-07,7-Apr,7-Apr,26-Mar-10,Slow Enrollment,,2,26,Actual,300,,TRUE,,26,26,0,0.09,0,26,0,,2 - No Scientific Data
NCT00443040,1,Asimadoline for the Treatment of Post-Operative Ileus,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Cancers and Other Neoplasms|Symptoms and General Pathology|All Conditions|Digestive System Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States,7-Jan,27-Feb-07,8-Feb,8-Feb,14-Oct-11,poor enrollment (31 of a planned 114 subjects were randomized and evaluable),,2,35,Actual,114,,TRUE,,35,35,0,0.31,2,35,0,,2 - No Scientific Data
NCT00443703,1,MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug|Drug,Phase 3,"Viral Diseases|Immune System Diseases|All Conditions|Symptoms and General Pathology|Bacterial and Fungal Diseases|Urinary Tract, Sexual Organs, and Pregnancy Conditions",INDUSTRY,,,,7-May,2-Mar-07,9-Apr,9-Apr,16-Oct-09,primary efficacy analysis at Week 24 did not demonstrate non-inferiority of raltegravir versus lopinavir (+) ritonavir,,6,352,Actual,340,,TRUE,,352,352,348,1.04,25,348,0,,1 - Scientific Data
NCT00443729,1,MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug|Drug,Phase 3,"Viral Diseases|Immune System Diseases|All Conditions|Symptoms and General Pathology|Bacterial and Fungal Diseases|Urinary Tract, Sexual Organs, and Pregnancy Conditions",INDUSTRY,,,,7-May,2-Mar-07,8-Oct,9-May,12-Oct-09,Primary efficacy analysis at Week 24 did not demonstrate non-inferiority of raltegravir versus lopinavir (+) ritonavir,,6,355,Actual,340,,TRUE,,355,355,354,1.04,12,354,0,,1 - Scientific Data
NCT00445328,1,Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients,Prevention,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 4,Digestive System Diseases|All Conditions|Nervous System Diseases|Symptoms and General Pathology|Heart and Blood Diseases,INDUSTRY,,Multiple,India|India|India|India|India|India|India,7-Jun,7-Mar-07,8-Jul,8-Jul,20-Jul-09,See Detailed Description,"The study was prematurely discontinued due to delay in overall study start-up and inability to meet pre-defined protocol recruitment milestones on June 30th, 2008. There were no safety concerns regarding the study in the decision to terminate the trial.",2,84,Actual,360,,TRUE,,84,84,72,0.23,6,,0,,2 - No Scientific Data
NCT00445549,1,"Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 2,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Gland and Hormone Related Diseases|All Conditions|Digestive System Diseases|Rare Diseases",NIH,,Single,United States,7-Jan,7-Mar-07,8-Dec,9-Oct,30-Jun-11,The study closed because of inadequate early activity.,,6,12,Actual,38,,TRUE,,12,12,12,0.32,0,12,1,20068097,1 - Scientific Data
NCT00445705,1,Safety and Efficacy of AGN 203818 for Pain Associated With Fibromyalgia Syndrome,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug|Drug,Phase 2,"Muscle, Bone, and Cartilage Diseases|Nervous System Diseases|All Conditions|Symptoms and General Pathology|Skin and Connective Tissue Diseases",INDUSTRY,,Multiple,United States|Switzerland|United Kingdom,7-Mar,7-Mar-07,8-Jan,8-Jan,16-Dec-11,This study was terminated early due to company decision. Part B was never conducted.,,8,211,Actual,160,,TRUE,,211,211,201,1.32,3,209,0,,2 - No Scientific Data
NCT00447226,1,"Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists",Treatment,Crossover Assignment,Double Blind,Randomized,Drug,Phase 2,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Gland and Hormone Related Diseases|All Conditions|Digestive System Diseases|Symptoms and General Pathology|Rare Diseases",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,7-May,13-Mar-07,9-May,9-Sep,11-Jan-10,The study had failed to meet the primary objective of tumor response rate at 12 weeks from first dose.,,6,32,Actual,250,,TRUE,,32,32,32,0.13,4,32,1,20857170,1 - Scientific Data
NCT00447265,1,Etanercept for the Treatment of Lupus Nephritis,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 2,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|Skin and Connective Tissue Diseases|Immune System Diseases|All Conditions|Symptoms and General Pathology|Rare Diseases",NIH,,Multiple,United States|United States|United States|United States|United States|United States,8-Feb,12-Mar-07,9-Mar,9-Mar,7-Oct-11,The perceived risk-benefit ratio for individuals with early active RA,,5,1,Actual,28,,TRUE,,1,1,1,0.04,0,1,0,,1 - Scientific Data
NCT00447421,1,"A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy",Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug|Radiation,Phase 1|Phase 2,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,INDUSTRY,,Multiple,Belgium|Netherlands|Netherlands|Netherlands,7-Feb,12-Mar-07,8-May,8-May,28-May-09,Interim results of another trial showed inferior activity of treatment,,7,9,Actual,61,,TRUE,,9,9,0,0.15,6,,0,,2 - No Scientific Data
NCT00447902,1,Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation,Treatment,Parallel Assignment,,,Drug|Drug,Phase 3,"Viral Diseases|Immune System Diseases|All Conditions|Digestive System Diseases|Symptoms and General Pathology|Bacterial and Fungal Diseases|Urinary Tract, Sexual Organs, and Pregnancy Conditions",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|Argentina|Brazil|Brazil|Brazil|Brazil|France|France|France|France|France|France|France|France|France|France|France|France|Germany|Italy|Italy|Italy|Italy|Italy|Spain|Spain,7-Mar,14-Mar-07,8-Oct,,25-Sep-09,,,9,11,Actual,200,,TRUE,,11,11,0,0.06,3,10,0,,3 - No Reason Provided
NCT00448708,1,Safety and Efficacy of Angiotech Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access,Treatment,Parallel Assignment,Single Blind,Randomized,Device|Device|Device,,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,7-Mar,15-Mar-07,9-Apr,9-Apr,8-Jun-11,Due to an imbalance in graft infections between groups.,,5,222,Actual,628,Anticipated,TRUE,,222,222,222,0.35,38,222,0,,1 - Scientific Data
NCT00449150,1,Cetrorelix Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 3,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions|Symptoms and General Pathology",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Bulgaria|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Germany|Germany|Germany|Germany|Germany|Germany|Germany,7-Mar,15-Mar-07,9-Jun,9-Dec,5-Oct-10,Trial did not meet primary efficacy endpoint for double blind phase.,,6,667,Actual,594,,TRUE,,667,667,650,1.12,48,667,0,,1 - Scientific Data
NCT00450242,1,5% Lidocaine Ointment in the Treatment of Vulvar Vestibulitis,Treatment,Single Group Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions|Rare Diseases",OTHER,,Single,United States,6-Dec,21-Mar-07,9-Jan,9-Jan,27-Feb-12,lack of funding,,1,14,Actual,56,,TRUE,,14,14,10,0.25,0,10,0,,2 - No Scientific Data
NCT00450333,1,Dynepo Infrequent Dosing Study,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug|Drug,Phase 3,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions|Blood and Lymph Conditions",INDUSTRY,,Multiple,Austria|Austria|Belgium|Belgium|Belgium|France|France|France|France|France|France|France|France|France|France|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom,6-Oct,21-Mar-07,8-Jul,8-Jul,18-Aug-09,The termination of the study is not linked to a product recall or result of any safety signal. Rather it was sponsor's commercial decision to withdraw the MA,,8,407,Actual,400,,TRUE,,407,407,0,1.02,81,407,0,,2 - No Scientific Data
NCT00452361,1,Study Evaluating of Calcineurin Inhibitors Versus Sirolimus in Renal Allograft Recipient,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 4,,INDUSTRY,,Single,Taiwan,7-Apr,23-Mar-07,8-Aug,8-Aug,24-Sep-09,,,9,31,Actual,120,,TRUE,,31,31,0,0.26,8,31,0,,3 - No Reason Provided
NCT00452387,1,"Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)",Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug|Drug,Phase 2,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions",OTHER,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,7-May,26-Mar-07,8-Jul,9-Jan,17-Aug-09,Early stopping rule,,6,22,Actual,42,,TRUE,,22,22,0,0.52,10,22,0,,1 - Scientific Data
NCT00453193,1,Alemtuzumab and Pentostatin In T-cell Neoplasms,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Blood and Lymph Conditions|Immune System Diseases,OTHER,,Single,United States,4-Sep,26-Mar-07,10-Mar,10-Mar,1-Mar-11,Slow accrual.,,2,26,Actual,60,,FALSE,F,24,24,24,0.4,15,24,1,19805674,2 - No Scientific Data
NCT00453973,1,Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD (EU),Treatment,Parallel Assignment,Open Label,Non-Randomized,Drug|Drug,Phase 2,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions|Blood and Lymph Conditions",INDUSTRY,,Multiple,Bulgaria|Bulgaria|Bulgaria|Bulgaria|Bulgaria|Bulgaria|Poland|Poland|Poland|Romania|Romania|Romania|Romania|Romania|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom,6-Nov,27-Mar-07,9-Sep,9-Sep,26-Apr-12,Due to more robust long-term data generated in other active-controlled studies,,7,114,Actual,125,,TRUE,,114,114,68,0.91,41,114,0,,2 - No Scientific Data
NCT00454246,1,A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug,Phase 3,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions|Blood and Lymph Conditions",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,7-Apr,29-Mar-07,8-Feb,8-Feb,29-Mar-11,Strategic decision unrelated to safety or efficacy,,8,111,Actual,2121,Anticipated,TRUE,,111,111,0,0.05,12,104,0,,2 - No Scientific Data
NCT00459810,1,Paclitaxel Poliglumex and Estradiol in Treating Patients With Stage IV Prostate Cancer,Treatment,Single Group Assignment,Open Label,,Drug|Drug,Phase 2,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions",OTHER,,Multiple,United States|United States,7-Feb,11-Apr-07,9-Jul,9-Jul,25-May-10,,,9,21,Actual,50,,TRUE,,21,21,21,0.42,3,21,1,20016365,3 - No Reason Provided
NCT00460551,1,Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer,Treatment,Single Group Assignment,Open Label,,Biological|Drug|Radiation,Phase 2,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|Belgium|Belgium|Belgium|France|Netherlands|United Kingdom,7-Apr,12-Apr-07,8-Oct,8-Oct,12-Sep-11,Due to considerations regarding the appropriate therapeutic regimen for these patients.,,7,13,Actual,270,,TRUE,,13,13,0,0.05,7,13,0,,2 - No Scientific Data
NCT00463801,1,Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-structure Infections,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 4,Bacterial and Fungal Diseases|Skin and Connective Tissue Diseases|Symptoms and General Pathology|All Conditions|Heart and Blood Diseases|Gland and Hormone Related Diseases,INDUSTRY,,Multiple,Italy|Italy,7-Jan,19-Apr-07,7-Nov,,9-Dec-10,Because of inadequate accrual.,,2,52,Actual,104,,TRUE,,52,52,52,0.5,4,52,0,,2 - No Scientific Data
NCT00467896,1,"The ""Power 15 Study"": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting",Treatment,Single Group Assignment,Open Label,,Drug|Drug,Phase 2,Respiratory Tract (Lung and Bronchial) Diseases|All Conditions|Symptoms and General Pathology|Heart and Blood Diseases|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,6-Sep,27-Apr-07,10-Nov,11-Jun,27-Sep-12,Sponsor's decision,,8,62,Actual,30,Anticipated,TRUE,,62,62,45,2.07,27,62,0,,2 - No Scientific Data
NCT00468299,1,MiMi: A Randomized Trial of Mifepristone and Misoprostol for Treatment of Early Pregnancy Failure,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions",OTHER,,Single,United States,7-Apr,1-May-07,8-Dec,8-Dec,12-Apr-11,poor enrollment,,2,16,Actual,108,Anticipated,FALSE,F,17,17,17,0.16,0,17,0,,2 - No Scientific Data
NCT00471068,1,Study of Travatan and Cosopt in Primary Open-Angle Glaucoma or Ocular Hypertension,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 4,Eye Diseases|All Conditions|Heart and Blood Diseases|Rare Diseases,INDUSTRY,,Single,Portugal,7-Mar,8-May-07,8-Aug,,21-Oct-09,Question raised by Ethics Committee,,12,46,Actual,80,Anticipated,TRUE,,46,46,46,0.58,1,46,0,,2 - No Scientific Data
NCT00471718,1,ABT-751 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 1|Phase 2,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions",OTHER,,Single,United States,4-Jan,8-May-07,9-Aug,9-Aug,26-Oct-11,pharmaceutical company closed study because the treatment was not effective,,6,27,Actual,53,,TRUE,,27,27,19,0.51,7,27,0,,1 - Scientific Data
NCT00472082,1,Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients,Treatment,Single Group Assignment,Open Label,,Drug,Phase 1|Phase 2,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions",OTHER,,Single,United States,7-May,10-May-07,9-Apr,9-Apr,9-Nov-12,This study was terminated at the request of the drug manufacturer.,,8,5,Actual,20,Anticipated,TRUE,,5,5,0,0.25,2,5,0,,2 - No Scientific Data
NCT00473824,1,"Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation",Treatment,Parallel Assignment,Open Label,Randomized,Biological,Phase 2,Viral Diseases|Digestive System Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States,7-May,14-May-07,9-Feb,9-Feb,5-Jan-12,New sponsor's decision to pursue a redesigned clinical study,,8,7,Actual,30,Anticipated,TRUE,,7,7,7,0.23,4,7,0,,2 - No Scientific Data
NCT00473889,1,"A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)",Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug|Drug,Phase 2|Phase 3,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,INDUSTRY,,,,7-May,14-May-07,8-Dec,8-Dec,3-Sep-09,The study was terminated based on the recommendation by the DSMB following a pre-planned protocol interim analysis because the endpoint was not achieved.,,6,253,Actual,1000,Anticipated,TRUE,,253,253,253,0.25,108,248,0,,1 - Scientific Data
NCT00474188,1,A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug,Phase 2,Cancers and Other Neoplasms|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Symptoms and General Pathology|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Australia|Australia|Australia|Australia|Canada,7-May,14-May-07,8-Dec,8-Dec,30-Jun-09,Business decision,,8,26,Actual,40,Anticipated,TRUE,,26,26,0,0.65,,,0,,2 - No Scientific Data
NCT00475332,1,Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar,Treatment,Single Group Assignment,Open Label,,Drug|Procedure,Phase 2,Cancers and Other Neoplasms|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Rare Diseases,OTHER,,Single,United States,7-Sep,16-May-07,9-Apr,9-Apr,28-Nov-11,PI left our institution,,4,2,Actual,25,Anticipated,TRUE,,2,2,0,0.08,1,2,0,,2 - No Scientific Data
NCT00475657,1,Pemetrexed and Cisplatin as Treatment in Small Cell Lung Cancer,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug,Phase 2,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,INDUSTRY,,Multiple,Spain|Spain|Spain|Spain|Spain|Spain,7-Oct,16-May-07,8-Apr,8-Apr,31-Mar-09,Terminated due to lack of efficacy,,6,5,Actual,44,Anticipated,TRUE,,5,5,0,0.11,2,,0,,1 - Scientific Data
NCT00477230,1,Pivotal Clinical Study of Endoscopic Ablation for Atrial Fibrillation (AF) in Patients That Have Failed Drugs,Treatment,Crossover Assignment,Open Label,Randomized,Device|Drug,Phase 3,Heart and Blood Diseases|Symptoms and General Pathology|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,7-Mar,21-May-07,9-May,9-May,26-Jun-12,Study terminated based on decision of Sponsor.,,8,64,Actual,200,Anticipated,TRUE,,64,64,0,0.32,5,64,0,,2 - No Scientific Data
NCT00478244,1,Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa,Treatment,Single Group Assignment,Open Label,,Drug|Drug|Drug|Procedure,,Diseases and Abnormalities at or before Birth|Skin and Connective Tissue Diseases|All Conditions|Rare Diseases,OTHER,,Single,United States,7-Apr,23-May-07,11-Aug,11-Aug,17-Jul-12,Competing studies,,7,7,Actual,10,,TRUE,,7,7,6,0.7,6,7,1,20818854,2 - No Scientific Data
NCT00478673,1,Post-Approval Study of the NexStent Carotid Stent System and the FilterWire EZ Embolic Protection System: SONOMA,Treatment,Single Group Assignment,Open Label,,Device|Device,Phase 4,Nervous System Diseases|Heart and Blood Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,7-May,24-May-07,9-Jul,9-Jul,20-Dec-10,Enrollment was terminated in June 2008 due to market withdrawal of the NexStent Carotid Stent System.,,16,298,Actual,1650,Anticipated,TRUE,,298,298,293,0.18,150,298,0,,2 - No Scientific Data
NCT00479466,1,Dose-Range Finding Study for MK0893 (0893-008),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug|Drug,Phase 2,Nutritional and Metabolic Diseases|Gland and Hormone Related Diseases|All Conditions,INDUSTRY,,,,7-Jun,25-May-07,8-May,8-May,7-Oct-11,Sufficient data regarding the dose-response to MK-0893 had been obtained from the first cohort of the study to assess the safety and efficacy,,6,342,Actual,705,Anticipated,TRUE,,342,342,334,0.49,8,342,0,,1 - Scientific Data
NCT00479856,1,Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer,Treatment,Single Group Assignment,Open Label,,Drug|Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,7-Nov,25-May-07,9-Sep,10-Mar,3-May-10,Study was terminated due to difficulty in identifying eligible subjects,,2,9,Actual,45,,TRUE,,9,9,9,0.2,1,9,0,,2 - No Scientific Data
NCT00480987,1,"Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)",Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug|Drug,Phase 1|Phase 2,Cancers and Other Neoplasms|All Conditions|Blood and Lymph Conditions|Symptoms and General Pathology|Rare Diseases,OTHER,,Single,United States,7-Jul,30-May-07,10-Aug,10-Aug,6-Jun-11,Lack of support.,,1,27,Actual,48,Anticipated,TRUE,,27,27,27,0.56,5,27,0,,2 - No Scientific Data
NCT00482274,1,Docetaxel in Treating Patients With Relapsed Prostate Cancer,Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions",OTHER,,Multiple,United States|United States,7-May,4-Jun-07,9-Jul,9-Jul,27-Jul-10,Drug supplier stopped funding due to loss of study drug (docetaxel) patent.,,1,3,Actual,36,,TRUE,,3,3,2,0.08,0,3,0,,2 - No Scientific Data
NCT00482547,1,Study of a Urethral Catheter Coated With Eluting Silver Salts (SUCCESS),Treatment,Parallel Assignment,Single Blind,Randomized,Device|Device,Phase 4,"Bacterial and Fungal Diseases|Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions",INDUSTRY,,Single,United States,7-Jun,4-Jun-07,8-Apr,8-Aug,6-Apr-09,Terminated for futility reasons.,,6,1188,Actual,1500,Anticipated,TRUE,,1188,1188,133,0.79,105,1133,0,,1 - Scientific Data
NCT00482911,1,"Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma",Treatment,Parallel Assignment,Open Label,Non-Randomized,Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Eye Diseases|Rare Diseases,NIH,,Single,United States,7-Apr,4-Jun-07,9-Apr,9-Apr,11-Oct-12,Investigator left the institute.,,4,12,Actual,50,,FALSE,E,3,12,12,0.24,2,12,0,,2 - No Scientific Data
NCT00485472,0,Trial to Assess Efficacy and Safety of Lacosamide in Subjects With Osteoarthritis of the Knee,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Other,Phase 2,"Muscle, Bone, and Cartilage Diseases|All Conditions|Skin and Connective Tissue Diseases",INDUSTRY,,Multiple,Czech Republic|Czech Republic|Germany|Germany|Germany|Germany|Germany|Hungary|Hungary|Hungary|Hungary|Hungary|Hungary|Poland|Poland|Poland|Poland|Romania|Romania|Romania|Romania|Sweden|United Kingdom|United Kingdom|United Kingdom|United Kingdom,7-Mar,12-Jun-07,7-Nov,8-Jan,12-Aug-09,"Based on the outcome of the planned first interim analysis, it was decided not to continue the trial. No safety concerns were identified.",,6,194,Actual,193,Actual,FALSE,F,149,149,145,0.77,6,148,0,,1 - Scientific Data
NCT00486265,0,"Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)",Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 1,Cancers and Other Neoplasms|All Conditions|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|Canada,7-Jul,13-Jun-07,,9-Jul,20-Jul-10,AML assess. of response in Part B patients find treatment failure in all 8 evaluable for marrow response following a maximum of 2 induction courses of therapy,,6,47,Actual,63,Anticipated,FALSE,F,9,9,8,0.14,3,9,1,21494838,1 - Scientific Data
NCT00486720,1,"Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes",Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 2,Cancers and Other Neoplasms|Blood and Lymph Conditions|All Conditions|Symptoms and General Pathology|Rare Diseases,INDUSTRY,,,,7-Jun,14-Jun-07,9-Jul,9-Jul,19-Apr-10,,,9,22,Actual,80,Anticipated,TRUE,,22,22,21,0.28,7,21,0,,3 - No Reason Provided
NCT00486759,1,"A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma",Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug|Drug,Phase 3,Cancers and Other Neoplasms|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Rare Diseases,INDUSTRY,,Multiple,"United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Argentina|Argentina|Argentina|Argentina|Australia|Australia|Australia|Australia|Australia|Australia|Australia|Australia|Australia|Austria|Austria|Austria|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|China|China|China|China|China|China|China|China|China|China|China|China|Colombia|Colombia|Colombia|Colombia|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Ecuador|Ecuador|Ecuador|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Greece|Hong Kong|Hungary|Hungary|Hungary|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of|Lithuania|Lithuania|Malaysia|Mexico|Mexico|Mexico|Mexico|New Zealand|New Zealand|Panama|Peru|Peru|Peru|Peru|Peru|Philippines|Philippines|Philippines|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Portugal|Portugal|Portugal|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Slovakia|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Sweden|Sweden|Sweden|Sweden|Switzerland|Taiwan|Taiwan|Thailand|Thailand|Thailand|Thailand|Thailand|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom",7-Jul,14-Jun-07,11-Nov,11-Nov,28-Nov-12,Due to an unfavorable benefit/risk ratio.,,5,787,Actual,1060,Anticipated,TRUE,,787,787,787,0.74,397,781,0,,1 - Scientific Data
NCT00487279,1,DEfibrillators To REduce Risk by MagnetIc ResoNance Imaging Evaluation,Treatment,Parallel Assignment,Open Label,Randomized,Device|Other,,Heart and Blood Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,7-Jun,13-Jun-07,10-Dec,11-Apr,4-Jan-12,Study terminated early due to inability to enroll.,,2,81,Actual,1550,Anticipated,TRUE,,81,81,81,0.05,3,44,0,,2 - No Scientific Data
NCT00487552,1,Magnetic Anastomosis Device Relief of Malignant Gastric Outlet Obstruction,Supportive Care,Single Group Assignment,Open Label,Non-Randomized,Device,Phase 1,Cancers and Other Neoplasms|Digestive System Diseases|All Conditions|Symptoms and General Pathology|Rare Diseases,INDUSTRY,,Multiple,Belgium|Italy|Netherlands|Netherlands,8-Jan,15-Jun-07,9-Jan,11-Apr,16-Jan-12,Failure to achieve one of the primary endpoints.,,6,18,Actual,40,Anticipated,TRUE,,18,18,18,0.45,10,12,1,20656288,1 - Scientific Data
NCT00487578,1,Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction,Treatment,Parallel Assignment,Double Blind,Randomized,Drug,Phase 4,Nervous System Diseases|Wounds and Injuries|All Conditions|Symptoms and General Pathology|Behaviors and Mental Disorders|Cancers and Other Neoplasms,INDIV,,Multiple,United States|United States|United States,6-Oct,14-Jun-07,9-Oct,9-Oct,16-Nov-09,Terminated October 2009 (in 4th year) due to low enrollment and anticipated drug expiration November 2009.,,2,12,Actual,56,Anticipated,TRUE,,12,12,0,0.21,0,12,0,,2 - No Scientific Data
NCT00487981,1,Spinal Cord Stimulation for Painful Diabetic Neuropathy,Treatment,Single Group Assignment,Open Label,,Device,Phase 4,Nervous System Diseases|Gland and Hormone Related Diseases|All Conditions|Symptoms and General Pathology|Diseases and Abnormalities at or before Birth|Substance Related Disorders|Nutritional and Metabolic Diseases|Behaviors and Mental Disorders|Rare Diseases,INDUSTRY,,Single,United States,7-Feb,15-Jun-07,8-Sep,8-Sep,13-Feb-12,Insufficient Data Collected,,4,1,Actual,30,Anticipated,TRUE,,1,1,0,0.03,0,0,0,,2 - No Scientific Data
NCT00488059,1,A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug|Drug,Phase 4,"Viral Diseases|Immune System Diseases|All Conditions|Symptoms and General Pathology|Bacterial and Fungal Diseases|Urinary Tract, Sexual Organs, and Pregnancy Conditions",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Puerto Rico|Puerto Rico,7-Jun,18-Jun-07,8-Oct,8-Oct,11-Nov-09,This study was terminated early due to poor enrollment.,,2,29,Actual,238,Anticipated,TRUE,,29,29,29,0.12,4,43,0,,2 - No Scientific Data
NCT00488644,1,Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors,Treatment,Single Group Assignment,Open Label,,Drug|Drug,,Cancers and Other Neoplasms|Nervous System Diseases|All Conditions|Gland and Hormone Related Diseases,OTHER,,Single,United States,6-Feb,19-Jun-07,10-Mar,10-Mar,22-Mar-12,Slow accrual.,,2,12,Actual,26,Anticipated,TRUE,,12,12,10,0.46,0,12,0,,2 - No Scientific Data
NCT00491075,1,Pemetrexed Plus Gemcitabine in Renal Cell Cancer,Treatment,Single Group Assignment,Open Label,,Drug|Drug,Phase 2,"Cancers and Other Neoplasms|All Conditions|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Rare Diseases",OTHER,,Single,United States,5-Dec,21-Jun-07,11-Sep,11-Sep,6-Apr-12,Closed early for poor accrual.,,2,16,Actual,40,Anticipated,TRUE,,16,16,14,0.4,1,15,1,22706175,2 - No Scientific Data
NCT00491387,1,Sympathetic Nervous System Modulation in Hypertension,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 4,Heart and Blood Diseases|All Conditions,OTHER,,,,7-Aug,21-Jun-07,9-Jan,9-Jan,22-Feb-11,Publications appeared suggesting increased mortality using beta-blockers as primary therapy for hypertension.,,7,24,Actual,30,Anticipated,TRUE,,24,24,0,0.8,0,24,0,,2 - No Scientific Data
NCT00491400,1,Effect of a Fibrate and a Statin on Endothelial Dysfunction,Basic Science,Crossover Assignment,Double Blind,Randomized,Drug|Drug,,Nutritional and Metabolic Diseases|Gland and Hormone Related Diseases|All Conditions|Symptoms and General Pathology|Rare Diseases,OTHER,,Single,United States,5-Sep,22-Jun-07,8-Dec,8-Dec,23-May-12,Insufficient enrollment,,2,28,Actual,40,Anticipated,TRUE,,28,28,0,0.7,0,28,0,,2 - No Scientific Data
NCT00491738,0,A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 2,"Cancers and Other Neoplasms|All Conditions|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Rare Diseases",INDUSTRY,,,,7-Aug,25-Jun-07,8-Jan,,6-Feb-09,"Based on the data collected, the combination of bevacizumab and sunitinib appeared to be poorly tolerated.",,5,16,Actual,0,,TRUE,,16,16,16,#DIV/0!,,,0,,1 - Scientific Data
NCT00492531,1,Sildenafil Therapy for Pulmonary Hypertension and Sickle Cell Disease,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Respiratory Tract (Lung and Bronchial) Diseases|All Conditions|Heart and Blood Diseases|Blood and Lymph Conditions|Diseases and Abnormalities at or before Birth|Symptoms and General Pathology|Rare Diseases,NIH,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United Kingdom,7-Jun,26-Jun-07,9-Sep,9-Oct,28-Apr-11,Subjects on drug were more likely to have severe pain crises requiring hospitalization.,,5,74,Actual,300,,TRUE,,74,74,74,0.25,25,74,1,21527519,1 - Scientific Data
NCT00493038,1,Study to Evaluate the Efficacy and Safety of Moxifloxacin Versus Amoxicillin/Clavulanate in the Treatment of Acute Bacterial Rhinosinusitis,Treatment,Parallel Assignment,Double-Blind,Randomized,Drug|Drug,Phase 4,"Bacterial and Fungal Diseases|All Conditions|Respiratory Tract (Lung and Bronchial) Diseases|Ear, Nose, and Throat Diseases",INDUSTRY,,Multiple,Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy,6-Feb,26-Jun-07,8-Jan,8-Jan,20-Jan-09,The study was prematurely terminated due to slow enrollment beyond the planned study timelines.,,2,293,Actual,594,,TRUE,,293,293,251,0.49,2,287,0,,2 - No Scientific Data
NCT00493805,1,Study of Response in Chronic Hepatitis C (CHC) Patients Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (Study P04823AM3)(TERMINATED),Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 4,Viral Diseases|Digestive System Diseases|All Conditions|Nutritional and Metabolic Diseases,INDUSTRY,,,,7-Apr,25-Jun-07,9-Oct,9-Oct,27-Oct-10,Slow Enrollment,,2,59,Actual,112,Anticipated,TRUE,,59,59,53,0.53,7,59,0,,2 - No Scientific Data
NCT00493974,1,Zileuton to Treat Adults With Chronic Obstructive Pulmonary Disease (The LEUKO Study),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Respiratory Tract (Lung and Bronchial) Diseases|All Conditions|Symptoms and General Pathology,NIH,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,7-Mar,28-Jun-07,8-Dec,8-Dec,18-Dec-09,Lack of feasibility due to low recruitment,,2,119,Actual,520,Anticipated,TRUE,,119,119,118,0.23,37,119,1,21299475,2 - No Scientific Data
NCT00494026,1,Chemotherapy and Radiotherapy to Treat Patients With Limited Stage of Small Cell Lung Cancer (SCLC),Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug|Procedure,Phase 2,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,INDUSTRY,,Multiple,Italy|Italy|Italy|Italy|Poland|Poland|Spain|Spain|Spain|United Kingdom|United Kingdom|United Kingdom,7-Sep,27-Jun-07,8-Oct,8-Oct,14-Oct-09,"Study stopped early based on interim results of another trial, showing inferior activity of pemetrexed/carboplatin compared to etoposide/carboplatin in SCLC.",,7,4,Actual,47,Anticipated,TRUE,,4,4,0,0.09,0,4,0,,2 - No Scientific Data
NCT00495625,1,Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC),Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,Cancers and Other Neoplasms|Digestive System Diseases|All Conditions|Rare Diseases,OTHER,,Single,United States,6-Oct,29-Jun-07,10-Dec,10-Dec,12-Jan-12,,,9,33,Actual,42,Anticipated,TRUE,,33,33,17,0.79,11,33,0,,3 - No Reason Provided
NCT00496080,1,Doppler-Guided Uterine Artery Occlusion (DUAO) Device for Fibroid Related Bleeding,Treatment,Single Group Assignment,Open Label,,Device,,"Cancers and Other Neoplasms|All Conditions|Skin and Connective Tissue Diseases|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Symptoms and General Pathology",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|Canada|Mexico,7-Jun,3-Jul-07,10-Sep,10-Oct,19-Jun-12,Trial terminated early due to results from a similar study.,,7,87,Actual,200,Anticipated,TRUE,,87,87,82,0.44,4,87,0,,2 - No Scientific Data
NCT00496782,1,Multicenter Pilot Study To Define The Marker As An Alternate For Tropism Assay,Screening,Single Group Assignment,Open Label,Non-Randomized,Drug|Procedure,Phase 1,"Viral Diseases|Immune System Diseases|All Conditions|Symptoms and General Pathology|Bacterial and Fungal Diseases|Urinary Tract, Sexual Organs, and Pregnancy Conditions",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|Canada,7-Jul,3-Jul-07,8-Oct,8-Oct,23-Jun-09,See Detailed Description,"The study A4001060 has been discontinued on April 22, 2008. A review of the poor rate of enrollment has projected difficulties in completing the study in a timely manner, despite the best efforts by the sponsor and the sites. Given the difficulties encountered in this pilot study and the need to conduct an even larger confirmatory study, the decision to discontinue the study has therefore been made. It should be noted that safety concerns have not been seen in this study and have not factored into this decision.",2,16,Actual,100,,TRUE,,16,16,0,0.16,4,16,0,,2 - No Scientific Data
NCT00496964,1,Botox for Non-surgical Lateral Release in Patellofemoral Pain,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,"Muscle, Bone, and Cartilage Diseases|All Conditions|Nervous System Diseases|Symptoms and General Pathology|Wounds and Injuries|Behaviors and Mental Disorders",OTHER,,Single,United States,5-May,5-Jul-07,8-Jun,8-Jun,14-Mar-11,Insufficient recruitment in a reasonable time + expiration of study medication,,2,5,Actual,20,Anticipated,TRUE,,5,5,4,0.25,0,5,0,,2 - No Scientific Data
NCT00499681,1,PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Other,Phase 2,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions,OTHER,,Multiple,United States|United States|United States|United States,7-Jul,10-Jul-07,9-Oct,10-Dec,17-Oct-11,slow accrual,,2,6,Actual,36,,TRUE,,6,6,6,0.17,1,6,0,,2 - No Scientific Data
NCT00499889,1,"Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients",Treatment,Single Group Assignment,Open Label,,Drug|Drug|Drug|Drug|Drug|Drug|Procedure|Procedure,Phase 2,Cancers and Other Neoplasms|All Conditions|Blood and Lymph Conditions|Rare Diseases,OTHER,,Single,United States,3-Feb,10-Jul-07,9-Nov,9-Nov,30-Sep-11,Support issue.,,4,42,Actual,90,Anticipated,TRUE,,42,42,41,0.47,12,41,0,,2 - No Scientific Data
NCT00501228,1,Tissue Repair in Stem Cell Transplant Recipients,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,,Immune System Diseases|All Conditions|Rare Diseases,OTHER,,Single,United States,3-Feb,12-Jul-07,8-Sep,8-Sep,3-Mar-09,,,9,2,Actual,5,Anticipated,TRUE,,2,2,0,0.4,0,2,0,,3 - No Reason Provided
NCT00501345,1,Aspirin in Patients With Myocardial Infarction and Thrombocytopenia,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 3,Heart and Blood Diseases|All Conditions|Symptoms and General Pathology|Blood and Lymph Conditions,OTHER,,Single,United States,2-Feb,13-Jul-07,8-Feb,8-Feb,24-Sep-09,"Low accrual, study terminated.",,2,5,Actual,30,Anticipated,TRUE,,5,5,0,0.17,0,0,0,,2 - No Scientific Data
NCT00503009,1,Study Of RV-39 In Patients Who Also Have Asthma,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 4,Respiratory Tract (Lung and Bronchial) Diseases|Immune System Diseases|All Conditions,INDUSTRY,,Single,United States,7-Oct,17-Jul-07,8-Jul,8-Jul,6-Jul-09,lack of data,,4,16,Actual,45,,TRUE,,16,16,0,0.36,0,16,0,,2 - No Scientific Data
NCT00503698,1,The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Argentina|Brazil|Canada|Denmark|France|Germany|Hungary|Israel|Italy|Poland|Portugal|Puerto Rico|Russian Federation|South Africa|Spain|Sweden|Turkey|United Kingdom,7-Jul,18-Jul-07,9-Jan,9-Jan,15-Dec-09,See termination reason in detailed description,The decision to discontinue the trial is not due to safety concerns. The discontinuation is based on an analysis of the significant delay in recruitment of patients which is expected to have a negative impact on the outcome of the trial.,2,715,Actual,2500,,FALSE,F,712,712,695,0.28,258,695,1,21750157,2 - No Scientific Data
NCT00503776,1,"Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia",Supportive Care,Parallel Assignment,Open Label,Randomized,Behavioral|Drug|Procedure,Phase 2,"Cancers and Other Neoplasms|All Conditions|Digestive System Diseases|Ear, Nose, and Throat Diseases|Mouth and Tooth Diseases|Respiratory Tract (Lung and Bronchial) Diseases|Rare Diseases",OTHER,,Single,United States,6-Jan,17-Jul-07,8-Aug,8-Aug,3-Nov-11,funding became unavailable,,1,42,Actual,60,,TRUE,,42,42,41,0.7,6,41,0,,2 - No Scientific Data
NCT00505414,1,A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 3,Nervous System Diseases|Symptoms and General Pathology|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|Argentina|Argentina|Argentina|Argentina|Argentina|Argentina|Argentina|Argentina|Argentina|Chile|Chile|Chile|Chile|Chile|Chile|Chile|France|France|France|Latvia|Latvia|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine,7-Jun,19-Jul-07,9-Feb,9-Aug,27-May-10,"Recall of rescue medication, alternative rescue medication availability issues.",,3,93,Actual,573,Anticipated,TRUE,,93,93,47,0.16,25,107,0,,2 - No Scientific Data
NCT00505622,1,"Evaluation of the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects With Motor Fluctuations",Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 3,Nervous System Diseases|All Conditions|Cancers and Other Neoplasms|Skin and Connective Tissue Diseases,INDUSTRY,,Single,France,7-Jul,9-Jul-07,8-Apr,8-Apr,23-Oct-12,Study stopped due to lack of efficacy.,,6,328,Actual,726,,FALSE,F,325,325,325,0.45,10,325,0,,1 - Scientific Data
NCT00505635,1,Biochemotherapy With Temozolomide for Metastatic Melanoma,Treatment,Single Group Assignment,Open Label,,Drug|Drug|Drug|Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Rare Diseases,OTHER,,Single,United States,7-Mar,20-Jul-07,10-Apr,10-Apr,26-Mar-12,Slow accrual,,2,5,Actual,60,Anticipated,TRUE,,5,5,5,0.08,5,5,0,,2 - No Scientific Data
NCT00505661,1,Letrozole in Patients With Ovarian Tumors,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 2,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Gland and Hormone Related Diseases|All Conditions|Digestive System Diseases|Rare Diseases",OTHER,,Single,United States,3-Sep,19-Jul-07,10-May,10-May,28-Sep-10,Terminated due to slow patient accrual.,,2,16,Actual,80,Anticipated,TRUE,,16,16,9,0.2,0,16,0,,2 - No Scientific Data
NCT00505921,1,Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma,Diagnostic,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Radiation,Phase 2,Cancers and Other Neoplasms|Blood and Lymph Conditions|Immune System Diseases|All Conditions,OTHER,,Single,United States,3-Mar,20-Jul-07,9-Nov,9-Nov,30-Sep-11,Slow Accrual.,,2,27,Actual,30,Anticipated,TRUE,,27,27,18,0.9,0,18,0,,2 - No Scientific Data
NCT00506064,1,Melatonin Postoperative Sleep Study in Breast Cancer Patients,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Behavioral,Phase 1,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions,OTHER,,Single,United States,4-Feb,23-Jul-07,8-Sep,8-Sep,29-Mar-10,Terminated due to low accrual.,,2,4,Actual,40,Anticipated,FALSE,F,1,1,0,0.03,0,1,0,,2 - No Scientific Data
NCT00506662,1,Comparison of Insulin Detemir and NPH Insulin Given Once Daily in Ageing Subjects With Type 2 Diabetes,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 4,Nutritional and Metabolic Diseases|Gland and Hormone Related Diseases|All Conditions,INDUSTRY,,Multiple,France|United Kingdom,7-Jul,24-Jul-07,8-Dec,8-Dec,19-Oct-10,See termination reason in detailed description,Novo Nordisk has decided to discontinue the trial as it will not be possible to recruit the required number of patients. The discontinuation is based on an analysis of the significant delay in recruitment of patients which is likely to have a negative impact on the validity of the trial.,2,86,Actual,286,,TRUE,,86,86,0,0.3,10,86,0,,2 - No Scientific Data
NCT00506675,1,Combined Patching-Atropine for Residual Amblyopia,Treatment,Parallel Assignment,Open Label,Randomized,Device|Drug|Device|Drug,Phase 3,Nervous System Diseases|Eye Diseases|Symptoms and General Pathology|All Conditions,OTHER,,Single,United States,7-Oct,20-Jul-07,9-Apr,9-Sep,14-Sep-10,Poor enrollment and infeasibility of ever reaching the necessary sample size,,2,55,Actual,240,Anticipated,TRUE,,55,55,55,0.23,0,55,1,21746992,2 - No Scientific Data
NCT00508157,1,A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 4,Nutritional and Metabolic Diseases|All Conditions|Symptoms and General Pathology|Behaviors and Mental Disorders|Rare Diseases,INDUSTRY,,Multiple,Belgium|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|France|France|France|France|France|France|France|France|Germany|Germany|Greece|Greece|Hungary|Hungary|Spain|Spain|Spain|Spain|Switzerland|Turkey,7-Nov,26-Jul-07,9-Mar,9-Mar,22-Jun-10,Slow Accrual,,2,125,Actual,258,Anticipated,FALSE,F,52,52,51,0.2,0,51,0,,2 - No Scientific Data
NCT00508651,1,"A Phase 1/2A Study to Evaluate the Safety, Immunogenicity, and Shedding of MEDI-560 in Infants 1 to < 12 Months of Age",Prevention,Parallel Assignment,Double Blind,Randomized,Biological|Biological,Phase 1|Phase 2,All Conditions|Viral Diseases|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,7-Oct,27-Jul-07,9-Apr,9-Apr,8-Sep-11,The study was closed prior to enrollment of Cohort 2 due to a non-safety related sponsor decision.,,8,30,Actual,190,Anticipated,TRUE,,30,30,28,0.16,1,28,1,21782874,2 - No Scientific Data
NCT00508872,1,Folfox-B Study for Patients With Colorectal Liver Metastases,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|Symptoms and General Pathology|All Conditions|Digestive System Diseases|Rare Diseases,OTHER,,Single,United States,5-Nov,27-Jul-07,9-Jun,9-Jun,8-Oct-10,"Slow accrual, study terminated.",,2,2,Actual,42,Anticipated,TRUE,,2,2,0,0.05,0,0,0,,2 - No Scientific Data
NCT00509496,1,Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes,Treatment,Parallel Assignment,Open Label,Non-Randomized,Drug|Drug|Biological|Biological|Biological,Phase 2,Cancers and Other Neoplasms|All Conditions|Skin and Connective Tissue Diseases|Rare Diseases,NIH,,Single,United States,7-Jun,30-Jul-07,11-Jul,12-Jul,31-Oct-12,Low accrual,,2,21,Actual,41,,TRUE,,21,21,21,0.51,5,21,0,,2 - No Scientific Data
NCT00509600,1,Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Blood and Lymph Conditions|Rare Diseases,OTHER,,Single,United States,4-Sep,27-Jul-07,9-Apr,9-Apr,31-Aug-09,Slow enrollment; study terminated.,,2,1,Actual,30,Anticipated,TRUE,,1,1,0,0.03,1,1,0,,2 - No Scientific Data
NCT00509925,1,Effect of Insulin Detemir on Use of Energy in Type 1 Diabetes,Treatment,Crossover Assignment,Open Label,Randomized,Drug|Drug|Drug,Phase 4,Nutritional and Metabolic Diseases|Gland and Hormone Related Diseases|All Conditions|Immune System Diseases,INDUSTRY,,Single,United Kingdom,7-Jul,31-Jul-07,8-Jul,8-Jul,19-Apr-10,See detailed description,The study had been temporarily halted due to an unplanned interim analysis. The Sponsor is now aware that a further interim analysis has been performed by the site and therefore a decision has been made not to recommence the study,6,23,Actual,30,,TRUE,,23,23,42,0.77,0,46,1,21593292,1 - Scientific Data
NCT00511134,1,Study of Lunesta Versus Placebo for Sleep Problems Related to Smoking Cessation and Zyban,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 4,Nervous System Diseases|Symptoms and General Pathology|Behaviors and Mental Disorders|All Conditions|Substance Related Disorders,OTHER,,Single,United States,7-Apr,1-Aug-07,8-Dec,8-Dec,28-Sep-09,Study has been terminated due low recruitment of participant population.,,2,4,Actual,40,Anticipated,TRUE,,4,4,2,0.1,0,4,0,,2 - No Scientific Data
NCT00512148,1,Study of Autologous Neo-Bladder Construct in Subjects With Neurogenic Bladder Following Spinal Cord Injury,Treatment,Single Group Assignment,Open Label,Non-Randomized,Other,Phase 2,"Nervous System Diseases|Wounds and Injuries|All Conditions|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Symptoms and General Pathology",INDUSTRY,,Single,United States,7-Jul,3-Aug-07,10-Jan,11-Apr,20-Dec-10,24 months of longterm follow up have been completed without substantial change to the profile. No further studies are currently planned,,6,7,Actual,10,Anticipated,TRUE,,7,7,7,0.7,4,7,0,,1 - Scientific Data
NCT00512798,0,Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug|Other|Drug|Drug,Phase 1|Phase 2,Cancers and Other Neoplasms|Nervous System Diseases|All Conditions|Rare Diseases,OTHER,,Single,United States,3-Jun,6-Aug-07,6-Jul,8-Mar,27-Jun-12,This study was terminated due to lack of efficacy,,6,47,Actual,93,,TRUE,,47,47,28,0.51,10,47,1,20028756,1 - Scientific Data
NCT00513305,1,Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 3,Cancers and Other Neoplasms|All Conditions|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Canada,7-Oct,6-Aug-07,9-Jul,9-Dec,29-Jul-10,Study has been stopped by sponsor decision,,8,67,Actual,210,Anticipated,TRUE,,67,67,67,0.32,40,66,0,,2 - No Scientific Data
NCT00514813,1,Dynepo Long-Term Safety Study,,Single Group Assignment,Open Label,Randomized,Drug,Phase 4,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions|Blood and Lymph Conditions",INDUSTRY,,Single,Belgium,7-Jun,9-Aug-07,8-Jul,8-Jul,18-Aug-09,The termination of the study is not linked to a product recall or result of any safety signal. Rather it was sponsor's commercial decision to withdraw the MA,,8,152,Actual,416,Anticipated,TRUE,,152,152,0,0.37,22,150,0,,2 - No Scientific Data
NCT00515086,0,Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM),Treatment,Parallel Assignment,Open Label,Randomized,Drug|Procedure,Phase 2,Cancers and Other Neoplasms|All Conditions|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States,7-Aug,10-Aug-07,9-Aug,9-Aug,15-Dec-10,Early termination due to slow enrollment and protocol-defined stopping rule.,,2,41,Actual,41,Actual,TRUE,,41,41,24,1,10,41,0,,2 - No Scientific Data
NCT00517192,1,Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI,Treatment,Parallel Assignment,,,Drug|Drug|Drug,Phase 4,"Viral Diseases|Immune System Diseases|All Conditions|Symptoms and General Pathology|Bacterial and Fungal Diseases|Urinary Tract, Sexual Organs, and Pregnancy Conditions",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|Bahamas|Belgium|Belgium|Belgium|Belgium|Canada|Canada|Canada|Canada|Canada|France|France|France|France|France|France|France|Germany|Germany|Germany|Greece|Greece|Greece|Italy|Italy|Italy|Italy|Italy|Italy|Portugal|Portugal|Portugal|Puerto Rico|Spain|Spain|Spain|Spain|Spain|Spain|Thailand|Thailand|Thailand|Thailand|Thailand|Thailand,7-Sep,15-Aug-07,8-Sep,,18-Sep-09,,,9,40,Actual,800,,FALSE,F,39,39,0,0.05,2,39,1,22007990,3 - No Reason Provided
NCT00518284,1,Prevention of Restenosis Following Revascularization,Prevention,Parallel Assignment,Open Label,Randomized,Drug,Phase 2,Heart and Blood Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States,8-Jan,16-Aug-07,9-Aug,9-Sep,21-Feb-12,"Study was terminated due to changing sponsor priorities, and was not based on safety or outcomes data.",,8,6,Actual,228,Anticipated,TRUE,,6,6,0,0.03,1,6,0,,2 - No Scientific Data
NCT00518687,1,"Efficacy, Immunogenicity, and Safety of a Single Dose of V710 in Adult Patients Scheduled for Cardiothoracic Surgery (V710-003 AM2)",Prevention,Parallel Assignment,Double Blind,Randomized,Biological|Biological,Phase 2|Phase 3,Bacterial and Fungal Diseases|Symptoms and General Pathology|All Conditions|Respiratory Tract (Lung and Bronchial) Diseases,INDUSTRY,,,,7-Dec,17-Aug-07,11-Aug,11-Aug,2-Oct-12,,,9,8031,Actual,76,Anticipated,FALSE,E,8010,8031,7925,105.67,565,7925,1,23549582,3 - No Reason Provided
NCT00519090,1,Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP),Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 3,Cancers and Other Neoplasms|All Conditions|Blood and Lymph Conditions|Symptoms and General Pathology|Rare Diseases,INDUSTRY,,Multiple,"United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Australia|Australia|Australia|Australia|Australia|Australia|Australia|Belgium|Belgium|Belgium|Brazil|Brazil|Brazil|Czech Republic|Czech Republic|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Italy|Italy|Italy|Italy|Italy|Italy|Japan|Japan|Japan|Korea, Republic of|Korea, Republic of|Spain|Spain|Spain|Spain|Spain",7-Oct,17-Aug-07,8-Oct,8-Oct,11-Nov-10,This study was terminated due to limited enrollment.,,2,6,Actual,586,Anticipated,TRUE,,6,6,0,0.01,0,6,0,,2 - No Scientific Data
NCT00519532,1,Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease,Treatment,Single Group Assignment,Open Label,,Drug,Phase 3,Nervous System Diseases|All Conditions|Cancers and Other Neoplasms|Skin and Connective Tissue Diseases,INDUSTRY,,Multiple,United States|United States|Australia|Finland|Germany|Germany|Germany|Germany|Germany|Germany|Hungary|Hungary|Italy|Italy|New Zealand|Poland|South Africa|Spain|Spain|United Kingdom|United Kingdom,7-Jul,21-Aug-07,9-May,9-May,17-Mar-10,Due to clinical trial supplies shortage,,4,84,Actual,270,Anticipated,TRUE,,84,84,78,0.31,16,84,1,21322021,2 - No Scientific Data
NCT00521924,1,Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED),Treatment,Parallel Assignment,Open Label,Randomized,Biological|Drug,Phase 3,"Muscle, Bone, and Cartilage Diseases|All Conditions|Skin and Connective Tissue Diseases|Immune System Diseases",INDUSTRY,,,,7-Jun,27-Aug-07,10-Sep,10-Sep,3-Apr-09,Slow Enrollment,,2,8,Actual,160,Anticipated,TRUE,,8,8,0,0.05,0,8,0,,2 - No Scientific Data
NCT00522418,1,Study Comparing Best Medical Practice With or Without VNS Therapy in Pharmacoresistant Partial Epilepsy Patients,Treatment,Parallel Assignment,Open Label,Randomized,Device|Drug,Phase 4,Nervous System Diseases|All Conditions,INDUSTRY,,Multiple,Belgium|Belgium|Canada|Canada|Canada|Canada|France|France|France|France|France|France|France|Germany|Germany|Germany|Germany|Germany|Germany|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Netherlands|Netherlands|Netherlands|Netherlands|Netherlands|Norway|Spain|Spain|Spain|Spain|Spain|Sweden|Sweden|Sweden|Sweden|United Kingdom|United Kingdom|United Kingdom|United Kingdom,6-Feb,27-Aug-07,8-Jul,8-Jul,2-Apr-10,Insufficient enrollment,,2,122,Actual,362,Anticipated,TRUE,,122,122,0,0.34,8,122,0,,2 - No Scientific Data
NCT00522457,1,Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 2,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Multiple,United States|United States|United States|Canada|Canada,8-Jan,28-Aug-07,9-Dec,9-Dec,1-Mar-11,"change in development plan, not due to safety concerns.",,8,19,Actual,40,Anticipated,TRUE,,19,19,0,0.48,11,19,0,,2 - No Scientific Data
NCT00523367,1,"COPD Patients Diagnosed With GERD,COPD Exacerbations After Treatment With High Dose PPI",Treatment,Single Group Assignment,Open Label,,Procedure,,"Digestive System Diseases|All Conditions|Respiratory Tract (Lung and Bronchial) Diseases|Ear, Nose, and Throat Diseases",OTHER,,Single,United States,7-Aug,30-Aug-07,10-Oct,10-Oct,8-Mar-12,terminated due to enrollment,,2,25,Actual,20,Anticipated,TRUE,,25,25,2,1.25,0,25,0,,2 - No Scientific Data
NCT00523640,1,"A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma",Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 2,"Cancers and Other Neoplasms|All Conditions|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Rare Diseases",OTHER,,Single,United States,5-Mar,30-Aug-07,11-Apr,11-Apr,15-Aug-11,Too slow accrual,,2,30,Actual,55,Anticipated,TRUE,,30,30,29,0.55,5,29,1,20395787,2 - No Scientific Data
NCT00523809,1,Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor,Treatment,Single Group Assignment,Open Label,,Drug|Procedure|Drug|Drug|Drug,Phase 2,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Gland and Hormone Related Diseases|All Conditions|Skin and Connective Tissue Diseases|Rare Diseases",OTHER,,Single,United States,7-Aug,31-Aug-07,11-Oct,11-Oct,21-Dec-12,Slow accrual.,,2,5,Actual,18,Anticipated,TRUE,,5,5,0,0.28,4,5,0,,2 - No Scientific Data
NCT00523939,1,DepoCyt for Active Lymphomatous or Leukemic Meningitis,Treatment,Parallel Assignment,Open Label,Non-Randomized,Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Blood and Lymph Conditions|Immune System Diseases|Nervous System Diseases|Rare Diseases,OTHER,,Single,United States,6-Jun,31-Aug-07,9-Jun,9-Jun,16-Feb-11,Low accrual.,,2,4,Actual,40,Anticipated,TRUE,,4,4,0,0.1,3,4,0,,2 - No Scientific Data
NCT00524030,1,Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Nervous System Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Czech Republic|Czech Republic|Czech Republic|Hong Kong|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine,7-Sep,30-Aug-07,11-Apr,11-Jun,11-Apr-12,See termination reason in detailed description.,"After review of the interim analysis results, the independent Data Monitoring Committee (DMC) recommended to stop the study based on positive efficacy findings for the primary efficacy endpoint according to pre-specified stopping rules. Pfizer accepted the DMC recommendation and made the decision to stop the study on September 7, 2011.",6,161,Actual,250,,TRUE,,161,161,102,0.64,18,161,0,,1 - Scientific Data
NCT00527397,1,"Long-Term Safety Study Of Inhaled Insulin (CP-464,005, Inhaler) In Japanese Patients With Type1 or Type2 Diabetes",Treatment,Parallel Assignment,Open Label,Non-Randomized,Drug|Drug|Drug,Phase 3,Respiratory Tract (Lung and Bronchial) Diseases|Symptoms and General Pathology|All Conditions|Nutritional and Metabolic Diseases|Gland and Hormone Related Diseases|Immune System Diseases,INDUSTRY,,Multiple,Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan,7-Aug,7-Sep-07,8-Jul,8-Jul,15-Jul-09,See termination reason in detailed description.,"Pfizer announced in October 2007 that it would stop marketing CP-464,005. At that time recruitment for study, A2171105 was placed on hold. Nektar, the company from which Pfizer licensed CP-464,005, announced on April 9, 2008 that it had stopped its search for a new marketing partner. As a result, study A2171105 was terminated on April 10, 2008. Neither safety nor efficacy reasons were the cause of the study termination.",16,24,Actual,189,,TRUE,,24,24,0,0.13,3,,0,,2 - No Scientific Data
NCT00527878,1,Effect of Ranitidine on Hyper-IgE Recurrent Infection (Job's) Syndrome,Treatment,Crossover Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Nervous System Diseases|Symptoms and General Pathology|All Conditions|Blood and Lymph Conditions|Immune System Diseases|Rare Diseases,NIH,,Single,United States,7-Sep,8-Sep-07,11-Jun,11-Jun,1-Feb-13,Failure to enroll adequate patient numbers due to small number of eligible patients,,2,16,Actual,30,,FALSE,F,14,14,18,0.47,8,23,0,,2 - No Scientific Data
NCT00527982,1,Celecoxib as Adjuvant Biologic Therapy in Patients With Head and Neck and Lung Cancer,Treatment,Parallel Assignment,Open Label,Randomized,Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Respiratory Tract (Lung and Bronchial) Diseases,OTHER,,Single,United States,5-Sep,10-Sep-07,8-Sep,8-Sep,6-Jan-11,Termination due to poor accrual.,,2,1,Actual,70,Anticipated,TRUE,,1,1,0,0.01,0,1,0,,2 - No Scientific Data
NCT00529282,1,A Study of Ceftobiprole in Patients With Fever and Neutropenia.,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Bacterial and Fungal Diseases|All Conditions|Blood and Lymph Conditions|Symptoms and General Pathology|Rare Diseases,INDUSTRY,,,,7-Oct,11-Sep-07,8-Jan,8-Jan,26-Jan-10,Study discontinued due to administrative reasons unrelated to safety,,4,2,Actual,342,,TRUE,,2,2,0,0.01,2,2,0,,2 - No Scientific Data
NCT00530270,1,Dexamethasone to Treat Acute Chest Syndrome in People With Sickle Cell Disease,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Respiratory Tract (Lung and Bronchial) Diseases|Blood and Lymph Conditions|Diseases and Abnormalities at or before Birth|All Conditions|Symptoms and General Pathology|Rare Diseases,NIH,,Multiple,United States|United States|United States|United States|United States|United States,6-Dec,14-Sep-07,8-Jun,8-Nov,16-Jul-09,"Study was closed June 23, 2008 due to low enrollment.",,2,12,Actual,112,Anticipated,TRUE,,12,12,11,0.11,1,12,1,21848879,2 - No Scientific Data
NCT00532883,1,Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Other,Phase 2,Respiratory Tract (Lung and Bronchial) Diseases|Blood and Lymph Conditions|Diseases and Abnormalities at or before Birth|All Conditions|Nervous System Diseases|Symptoms and General Pathology|Rare Diseases,OTHER,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,7-Jan,20-Sep-07,9-Mar,9-Aug,1-Apr-10,Enrollment has been terminated due to a slow rate of enrollment.,,2,44,Actual,188,Anticipated,TRUE,,44,44,44,0.23,10,44,1,21275961,2 - No Scientific Data
NCT00533351,1,Safety and Efficacy of AGN201781 in Neuropathic Pain,Treatment,Crossover Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Nervous System Diseases|Symptoms and General Pathology|All Conditions,INDUSTRY,,Multiple,Australia|Germany,8-Mar,19-Sep-07,8-Jun,8-Jun,15-Dec-11,This study was terminated early due to low enrollment.,,2,9,Actual,40,Anticipated,TRUE,,9,9,0,0.23,0,9,0,,2 - No Scientific Data
NCT00534313,1,Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,"Muscle, Bone, and Cartilage Diseases|All Conditions|Skin and Connective Tissue Diseases|Bacterial and Fungal Diseases|Rare Diseases",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Argentina|Argentina|Argentina|Australia|Australia|Australia|Belgium|Belgium|Canada|Canada|Canada|Canada|France|France|France|Germany|Germany|Germany|Italy|Italy|Italy|Netherlands|Norway|South Africa|Spain,7-Nov,20-Sep-07,8-Dec,11-May,29-Oct-10,Lack of efficacy with respect to skin-related lesions in the short-term phase,,6,191,Actual,220,Anticipated,FALSE,F,170,170,170,0.77,28,317,1,21128258,1 - Scientific Data
NCT00537199,1,OraTest in Combination With Visual Examination and Visual Examination Alone,Treatment,Single Group Assignment,Open Label,,Other|Drug,Phase 3,"Cancers and Other Neoplasms|All Conditions|Mouth and Tooth Diseases|Ear, Nose, and Throat Diseases|Rare Diseases",OTHER,,Single,United States,7-Feb,26-Sep-07,8-Dec,8-Dec,11-Dec-09,"Study terminated early as per request by sponsor, Zila Biotechnology, Inc.",,8,1,Actual,4000,Anticipated,TRUE,,1,1,0,0,0,0,0,,2 - No Scientific Data
NCT00537316,1,Efficacy & Safety of Infliximab Monotherapy Vs Combination Therapy Vs AZA Monotherapy in Ulcerative Colitis (Part 1) Maintenance Vs Intermittent Therapy for Maintaining Remission (Part 2)(Study P04807AM3)(TERMINATED),Treatment,Parallel Assignment,Double Blind,Randomized,Biological|Drug|Drug|Drug,Phase 3,Digestive System Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,,,7-Jul,28-Sep-07,10-Feb,10-Feb,11-Nov-11,"Infusion reactions during re-induction cycles after a period of no treatment in another study [P04563, NCT0358670]",,7,242,Actual,600,Anticipated,FALSE,E,239,242,231,0.4,22,553,0,,2 - No Scientific Data
NCT00539617,1,Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery,Treatment,Single Group Assignment,Open Label,,Drug|Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|Digestive System Diseases|All Conditions|Symptoms and General Pathology|Rare Diseases,OTHER,,Single,United States,7-Oct,2-Oct-07,11-May,11-May,12-Sep-12,For slow accrual,,2,7,Actual,25,Anticipated,TRUE,,7,7,4,0.28,4,4,0,,2 - No Scientific Data
NCT00539942,1,Study of Arixtra to Prevent Blood Clots in Women Undergoing Abdominopelvic Surgery for Likely Gynecologic Malignancy,Prevention,Parallel Assignment,Open Label,Randomized,Drug,Phase 3,Heart and Blood Diseases|All Conditions|Symptoms and General Pathology,OTHER,,Single,United States,7-Apr,3-Oct-07,10-Jun,10-Jun,7-Feb-12,Problems with accrual,,2,7,Actual,280,Anticipated,TRUE,,7,7,0,0.03,2,7,0,,2 - No Scientific Data
NCT00542269,1,Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 4,Heart and Blood Diseases|All Conditions|Nutritional and Metabolic Diseases|Symptoms and General Pathology|Rare Diseases,INDUSTRY,,Single,United Kingdom,8-Mar,9-Oct-07,9-Jul,9-Jul,6-Jan-11,Early termination of the study due to slow recruitment.,,2,178,Actual,846,Anticipated,TRUE,,178,178,118,0.21,7,178,0,,2 - No Scientific Data
NCT00542828,1,Rabbit Anti-thymocyte Globulin in the Treatment of Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome,Treatment,Single Group Assignment,Open Label,Non-Randomized,Biological,Phase 2,Cancers and Other Neoplasms|Blood and Lymph Conditions|All Conditions|Symptoms and General Pathology|Rare Diseases,INDUSTRY,,Multiple,France|Germany|Germany|Netherlands|United Kingdom|United Kingdom|United Kingdom,7-Oct,10-Oct-07,9-May,9-Jul,7-Apr-10,Study terminated due to slow enrollment.,,2,16,Actual,43,Anticipated,TRUE,,16,16,13,0.37,7,14,0,,2 - No Scientific Data
NCT00544674,1,PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Other,Phase 2,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,7-Aug,13-Oct-07,8-Jul,9-Jan,13-Jun-11,Terminated early due to discovery of new mechanism of activation.,,7,5,Actual,75,,TRUE,,5,5,4,0.07,2,4,0,,2 - No Scientific Data
NCT00545298,1,Safety and Efficacy of Gaseous Nitric Oxide on Venous Stasis Leg Ulcers,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 2,Heart and Blood Diseases|Skin and Connective Tissue Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Single,United States,7-Oct,16-Oct-07,8-Nov,8-Nov,8-Aug-12,Strategic direction of the sponsor changed,,8,4,Actual,30,Anticipated,TRUE,,4,4,4,0.13,0,4,0,,2 - No Scientific Data
NCT00545506,1,The Influence of a Warmed Surgical Bandage System on Subcutaneous Tissue Oxygen Tension After Cardiac Surgery,Basic Science,Parallel Assignment,Double Blind,Randomized,Device|Device,Phase 3,Bacterial and Fungal Diseases|Wounds and Injuries|All Conditions,OTHER,,Single,Austria,7-Nov,16-Oct-07,9-Nov,9-Nov,22-Jul-10,lack of eligible patients,,2,3,Actual,40,Anticipated,FALSE,F,6,6,0,0.15,0,0,0,,2 - No Scientific Data
NCT00545662,1,Study of Citicoline for the Treatment of Traumatic Brain Injury (COBRIT),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Nervous System Diseases|Wounds and Injuries|All Conditions,NIH,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States,7-Jul,16-Oct-07,11-May,11-May,29-Nov-11,Trial stopped due to futility.,,6,1213,Actual,1292,Anticipated,TRUE,,1213,1213,1017,0.94,234,1213,1,23168823,1 - Scientific Data
NCT00546260,1,Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Heart and Blood Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada,7-Nov,16-Oct-07,8-Jul,8-Jul,23-Nov-10,Administrative reasons.,,4,70,Actual,220,Anticipated,TRUE,,70,70,70,0.32,10,70,1,19958867,2 - No Scientific Data
NCT00546364,1,Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,8-Feb,17-Oct-07,10-Mar,10-Mar,6-May-11,Slow Accrual,,2,62,Actual,150,Anticipated,TRUE,,62,62,62,0.41,17,62,0,,2 - No Scientific Data
NCT00547703,1,Effect of Nortriptyline on Abdominal Pain/Discomfort and Quality of Life in Patients With Nonulcer Dyspepsia,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,,Nervous System Diseases|Symptoms and General Pathology|All Conditions|Digestive System Diseases|Behaviors and Mental Disorders,OTHER,,Single,United States,8-Feb,19-Oct-07,10-Apr,10-Jun,20-Feb-12,Not enough participants - only 5 since the study started,,2,5,Actual,72,Anticipated,TRUE,,5,5,4,0.07,0,4,0,,2 - No Scientific Data
NCT00548145,1,The Clinical Study of Pitavastatin Treatment for Group of Mild to Moderate Alzheimer's Disease,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,,Nervous System Diseases|Behaviors and Mental Disorders|All Conditions|Nutritional and Metabolic Diseases|Symptoms and General Pathology|Rare Diseases,OTHER,,Single,Japan,7-Nov,22-Oct-07,11-Oct,12-Mar,28-Dec-11,,,9,38,Actual,50,Anticipated,TRUE,,38,38,33,0.76,0,38,0,,3 - No Reason Provided
NCT00549328,1,Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 2,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,8-Feb,23-Oct-07,9-Apr,9-Apr,22-Dec-09,,,9,14,Actual,40,Anticipated,TRUE,,14,14,0,0.35,1,14,0,,3 - No Reason Provided
NCT00550654,1,Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain,Treatment,Single Group Assignment,Open Label,,Other|Radiation|Radiation|Radiation|Radiation,Phase 2,"Cancers and Other Neoplasms|All Conditions|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Gland and Hormone Related Diseases|Symptoms and General Pathology|Rare Diseases",NIH,,Single,United States,7-Oct,25-Oct-07,10-May,10-May,20-Aug-12,,,9,1,Actual,40,,TRUE,,1,1,0,0.03,0,1,0,,3 - No Reason Provided
NCT00552578,1,Buprenorphine as a Treatment in Opiate Dependent Pain Patients,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 4,"Muscle, Bone, and Cartilage Diseases|Nervous System Diseases|All Conditions|Symptoms and General Pathology|Behaviors and Mental Disorders|Substance Related Disorders",OTHER,,Single,United States,7-Oct,1-Nov-07,8-Oct,8-Oct,21-Jan-09,Tapering doses protocol arm was not effective for treatment retention outcome.,,6,12,Actual,60,Anticipated,TRUE,,12,12,10,0.2,0,60,1,20959867,1 - Scientific Data
NCT00555009,1,Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 4,"Muscle, Bone, and Cartilage Diseases|Nervous System Diseases|Gland and Hormone Related Diseases|All Conditions|Wounds and Injuries|Diseases and Abnormalities at or before Birth|Rare Diseases",INDUSTRY,,Multiple,France|France|Italy|Italy|Netherlands|Spain|Sweden|Sweden|United Kingdom,8-Mar,24-Oct-07,9-Jan,9-Jan,22-Dec-09,See termination reason in detailed description.,The study was terminated on 15-Dec-2008 due to an inability to recruit the protocol specified patient population. The study has not been terminated due to any safety concerns.,2,10,Actual,120,Anticipated,TRUE,,10,10,0,0.08,0,10,0,,2 - No Scientific Data
NCT00555321,1,Belatacept in Liver Transplant Recipients,Prevention,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug|Drug|Drug,Phase 2,,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Argentina|Austria|Brazil|Brazil|Brazil|Canada|Canada|France|France|France|France|France|France|Germany|Germany|Germany|Germany|Germany|Italy|Italy|Italy|Italy|Spain,8-Jan,7-Nov-07,10-Mar,11-Jun,17-Sep-12,,,9,260,Actual,250,Anticipated,TRUE,,260,260,250,1.04,107,145,0,,3 - No Reason Provided
NCT00556972,1,A Feasibility Study of a Fecal Incontinence Management System for Medical Use,Supportive Care,Single Group Assignment,Open Label,,Device,Phase 1|Phase 2,Digestive System Diseases|All Conditions,INDUSTRY,,Single,United States,8-Jan,9-Nov-07,8-Apr,8-Apr,2-Aug-11,Due to numerous delays in study start-up process...,,4,4,Actual,12,Anticipated,TRUE,,4,4,4,0.33,0,4,0,,2 - No Scientific Data
NCT00557622,1,Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD),Treatment,Parallel Assignment,Single Blind,Randomized,Drug|Other,Phase 2,Behaviors and Mental Disorders|All Conditions,INDUSTRY,,Multiple,Japan|Japan|Japan,8-Jan,12-Nov-07,8-Dec,8-Dec,2-Sep-09,difficulty in achieving target enrollment numbers,,2,5,Actual,30,Anticipated,TRUE,,5,5,2,0.17,0,3,0,,2 - No Scientific Data
NCT00558558,1,Haelan and Nutrition in Cancer Patients,Treatment,Single Group Assignment,Open Label,Non-Randomized,Dietary Supplement,Phase 2,Symptoms and General Pathology|All Conditions,OTHER,,Single,United States,7-Oct,13-Nov-07,9-Aug,9-Aug,2-Sep-11,Study terminated due to low recruitment.,,2,6,Actual,32,Anticipated,TRUE,,6,6,0,0.19,1,4,0,,2 - No Scientific Data
NCT00558636,1,A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,INDUSTRY,,Multiple,"China|China|China|China|China|China|China|China|China|China|China|China|India|India|Korea, Republic of|Korea, Republic of|Singapore|Singapore|Taiwan|Taiwan|Thailand|Thailand",7-Sep,9-Nov-07,8-May,8-May,13-Nov-09,Terminated early when the results from Study NCT00300885 showed an overall lack of efficacy in NSCLC and increased mortality in subjects with squamous subtype.,,7,91,Actual,300,Anticipated,TRUE,,91,91,91,0.3,14,91,0,,2 - No Scientific Data
NCT00560352,1,Safety Study of Dasatinib With Bortezomib (Velcade??) and Dexamethasone for Multiple Myeloma,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug|Drug,Phase 1,Cancers and Other Neoplasms|Heart and Blood Diseases|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Rare Diseases,INDUSTRY,,Multiple,United States|United States|France|France|Italy|Italy|Spain,8-Feb,16-Nov-07,11-Feb,11-Feb,2-Apr-12,,,9,16,Actual,40,Anticipated,FALSE,E,14,16,14,0.4,9,14,0,,3 - No Reason Provided
NCT00561912,1,Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma,Treatment,Single Group Assignment,Open Label,,Drug|Drug,Phase 2,"Cancers and Other Neoplasms|All Conditions|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Rare Diseases",OTHER,,Single,United States,7-Oct,20-Nov-07,9-Nov,9-Nov,22-Nov-11,Low accrual.,,2,2,Actual,60,Anticipated,TRUE,,2,2,0,0.03,0,1,0,,2 - No Scientific Data
NCT00566462,1,Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Nervous System Diseases|All Conditions|Cancers and Other Neoplasms|Skin and Connective Tissue Diseases,INDUSTRY,,Single,United States,7-Oct,29-Nov-07,8-Apr,8-Apr,20-Nov-12,Study stopped due to lack of efficacy.,,6,1,Actual,16,Anticipated,TRUE,,1,1,1,0.06,0,1,0,,1 - Scientific Data
NCT00566579,1,Cryotherapy for Human Papillomavirus Clearance in Biopsy-confirmed Cervical Low-grade Squamous Intraepithelial Lesions,Treatment,Parallel Assignment,Single Blind,Randomized,Procedure,,"Cancers and Other Neoplasms|All Conditions|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Rare Diseases",OTHER,,Single,Thailand,7-Dec,30-Nov-07,9-Mar,9-Mar,1-Jun-10,Lack of additional funding,,1,100,Actual,300,Anticipated,FALSE,F,60,60,60,0.2,0,60,1,19892345,2 - No Scientific Data
NCT00568061,1,Nitric Oxide in Myocardial Infarction Size,Treatment,Single Group Assignment,Double Blind,Randomized,Drug,Phase 2,Respiratory Tract (Lung and Bronchial) Diseases|Symptoms and General Pathology|All Conditions|Heart and Blood Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Belgium|Canada|Canada,6-Jun,3-Dec-07,8-Jun,8-Jun,3-Aug-10,Slow Enrollment,,2,29,Actual,200,Anticipated,TRUE,,29,29,29,0.15,2,29,0,,2 - No Scientific Data
NCT00568451,1,Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma,Treatment,Parallel Assignment,Open Label,Non-Randomized,Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Rare Diseases,OTHER,,Single,United States,6-Jun,5-Dec-07,9-May,11-Dec,1-Nov-11,Slow accrual.,,2,12,Actual,192,,FALSE,E,11,12,11,0.06,1,11,0,,2 - No Scientific Data
NCT00572260,1,A Pilot Study of Daptomycin for Antimicrobial Prophylaxis,,Single Group Assignment,Open Label,,Drug,Phase 4,,OTHER,,Single,United States,8-Jan,12-Dec-07,8-Sep,8-Sep,29-Mar-11,Study closed. PI left the institution.,,4,11,Actual,200,Anticipated,TRUE,,11,11,0,0.06,0,11,0,,2 - No Scientific Data
NCT00573391,1,Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2,Treatment,Parallel Assignment,Open Label,Non-Randomized,Drug|Drug,Phase 3,Cancers and Other Neoplasms|Heart and Blood Diseases|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Rare Diseases,OTHER,,Single,United States,6-Aug,12-Dec-07,8-Jul,8-Jul,15-Apr-11,low accrual,,2,5,Actual,294,Anticipated,TRUE,,5,5,0,0.02,2,10,0,,2 - No Scientific Data
NCT00573937,1,Methadone Versus Morphine for Cancer-Related Pain,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Nervous System Diseases|Symptoms and General Pathology|All Conditions,OTHER,,Single,United States,7-Aug,12-Dec-07,9-Apr,9-Apr,4-Oct-10,Slow accrual.,,2,1,Actual,160,Anticipated,TRUE,,1,1,1,0.01,0,1,0,,2 - No Scientific Data
NCT00574080,1,UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 3,Cancers and Other Neoplasms|Heart and Blood Diseases|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Rare Diseases,OTHER,,Single,United States,6-Jul,12-Dec-07,11-Mar,11-Mar,4-May-11,low accrual,,2,20,Actual,252,Anticipated,TRUE,,20,20,0,0.08,7,20,0,,2 - No Scientific Data
NCT00574275,1,Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 3,Cancers and Other Neoplasms|Digestive System Diseases|Gland and Hormone Related Diseases|All Conditions|Rare Diseases,INDUSTRY,,Multiple,United States|Argentina|Austria|Belgium|Bulgaria|Canada|Chile|Colombia|Cyprus|Czech Republic|France|Germany|Greece|Hungary|India|Italy|Mexico|Poland|Puerto Rico|Romania|Russian Federation|Slovakia|Spain|Switzerland,7-Dec,14-Dec-07,9-Oct,10-Nov,17-Aug-12,Data Monitoring Committee concluded after a planned interim analysis that aflibercept added to gemcitabine would be unable to demonstrate improved survival,,6,546,Actual,630,Anticipated,TRUE,,546,546,546,0.87,270,541,1,23642329,1 - Scientific Data
NCT00575016,1,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder,Treatment,Parallel Assignment,Double Blind,Randomized,Biological|Biological|Biological|Biological,Phase 2,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|Symptoms and General Pathology|All Conditions",INDUSTRY,,Multiple,Egypt|Greece|India|Lebanon|Serbia|Turkey,7-Dec,13-Dec-07,10-Feb,10-Jul,9-Sep-11,The study was terminated early due to enrollment challenges.,,2,74,Actual,160,Anticipated,TRUE,,74,74,73,0.46,12,73,1,23160758,2 - No Scientific Data
NCT00577356,1,Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer,Treatment,Single Group Assignment,Open Label,,Drug|Biological,Phase 2,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions",OTHER,,Single,United States,8-Feb,18-Dec-07,8-Sep,8-Sep,13-Sep-10,"Safety reasons, though no safety issues arose.",,7,6,Actual,30,Anticipated,TRUE,,6,6,0,0.2,0,6,1,23740935,2 - No Scientific Data
NCT00577395,1,Bone Microarchitecture in Osteopenic Postmenopausal Women,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 4,"Muscle, Bone, and Cartilage Diseases|All Conditions",INDUSTRY,,Multiple,United States|United States|United States|Argentina,8-Jul,19-Dec-07,9-Feb,9-Feb,18-Nov-09,,,9,13,Actual,134,Anticipated,TRUE,,13,13,0,0.1,0,13,0,,3 - No Reason Provided
NCT00577772,1,Transit Time and Bacterial Overgrowth Using SmartPill Capsule,Diagnostic,Parallel Assignment,Open Label,Non-Randomized,Drug|Device|Procedure,,Digestive System Diseases|All Conditions,OTHER,,Single,United States,7-Nov,17-Dec-07,10-Jul,10-Jul,30-Aug-12,Enrollment Goal Not Met,,2,17,Actual,20,Anticipated,TRUE,,17,17,0,0.85,0,17,0,,2 - No Scientific Data
NCT00579059,0,Maxim?? Knee Pop-Top?? Tibia vs. Regular Maxim?? Knee Tibia,Treatment,Parallel Assignment,Open Label,Randomized,Device|Device,,"Muscle, Bone, and Cartilage Diseases|All Conditions|Skin and Connective Tissue Diseases|Immune System Diseases",INDUSTRY,,Single,United States,4-May,17-Dec-07,7-Nov,7-Nov,20-May-09,The study sponsor canceled the study.,,8,31,Actual,200,Actual,TRUE,,31,31,11,0.16,0,31,0,,2 - No Scientific Data
NCT00579111,1,Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB),Treatment,Parallel Assignment,Open Label,Non-Randomized,Drug|Drug|Drug|Procedure|Drug,Phase 1|Phase 2,Cancers and Other Neoplasms|All Conditions|Blood and Lymph Conditions|Immune System Diseases|Heart and Blood Diseases|Rare Diseases,OTHER,,Multiple,United States|United States,7-Jun,19-Dec-07,9-Feb,10-Oct,3-Jul-12,slow accrual,,2,4,Actual,53,Anticipated,TRUE,,4,4,4,0.08,2,4,0,,2 - No Scientific Data
NCT00581061,1,Study to Determine Effects of Vesicare on Return to Continence Post- Radical Prostatectomy,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|Symptoms and General Pathology|All Conditions",OTHER,,Single,United States,8-Jun,21-Dec-07,9-Feb,10-Feb,11-Mar-10,Study subjects were not compliant with study protocols.,,4,13,Actual,25,Anticipated,TRUE,,13,13,10,0.52,0,13,0,,2 - No Scientific Data
NCT00581113,1,Neural Stem Cell Preserving Brain Radiation Therapy & Stereotactic Radiosurgery in Patients With 1-6 Brain Metastases,Treatment,Parallel Assignment,Open Label,Randomized,Radiation,Phase 3,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions|Skin and Connective Tissue Diseases|Respiratory Tract (Lung and Bronchial) Diseases|Symptoms and General Pathology|Nervous System Diseases",OTHER,,Single,United States,7-Mar,20-Dec-07,9-Jun,9-Jun,6-Oct-10,New research priorities,,8,8,Actual,30,Anticipated,TRUE,,8,8,0,0.27,2,8,0,,2 - No Scientific Data
NCT00582036,1,Glucose Control In Hematopoetic Stem Cell Transplant,Treatment,Single Group Assignment,Open Label,Randomized,Drug|Device,,Nutritional and Metabolic Diseases|All Conditions,OTHER,,Single,United States,7-Feb,19-Dec-07,9-May,9-May,6-Jan-11,study terminated due to lack of enrollment,,2,11,Actual,140,Anticipated,TRUE,,11,11,0,0.08,0,11,0,,2 - No Scientific Data
NCT00582738,1,Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 2,Viral Diseases|Digestive System Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Single,Argentina,7-Dec,12-Dec-07,10-Jan,10-Jan,10-Jan-12,,,9,43,Actual,50,Anticipated,TRUE,,43,43,13,0.86,11,43,0,,3 - No Reason Provided
NCT00583557,0,A Continuation Trial for Subjects With Rheumatoid Arthritis That Have Completed Protocol LBRA01,Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,"Muscle, Bone, and Cartilage Diseases|All Conditions|Skin and Connective Tissue Diseases|Immune System Diseases",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Poland|Poland|Poland|Poland,5-Jan,20-Dec-07,9-Nov,9-Nov,7-Apr-11,Sponsor decision - not related to safety,,8,155,Actual,155,Actual,TRUE,,155,155,153,1,47,153,0,,2 - No Scientific Data
NCT00584909,1,A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus,Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions",OTHER,,Single,United States,6-Mar,21-Dec-07,10-Sep,11-Sep,21-Sep-11,low accrual,,2,13,Actual,35,Anticipated,TRUE,,13,13,9,0.37,0,9,0,,2 - No Scientific Data
NCT00585221,1,Study of Imatinib and Peginterferon ?-2b in Gastrointestinal Stromal Tumor (GIST) Patients,Treatment,Single Group Assignment,Open Label,,Drug|Drug,Phase 2,Cancers and Other Neoplasms|Digestive System Diseases|All Conditions|Rare Diseases,OTHER,,Single,United States,7-Jul,21-Dec-07,9-Jul,9-Jul,15-Jun-12,PI terminated at the recommendation of DSMC & IRB,,6,8,Actual,30,Anticipated,TRUE,,8,8,0,0.27,0,0,0,,1 - Scientific Data
NCT00585923,1,C-Tek? Fusion Study,Treatment,Parallel Assignment,Single Blind,Randomized,Device|Device,,"Muscle, Bone, and Cartilage Diseases|All Conditions|Nervous System Diseases|Symptoms and General Pathology",INDUSTRY,,Single,United States,2-Apr,21-Dec-07,8-May,8-May,11-Nov-09,Due to lack of follow-up information,,4,115,Actual,154,Anticipated,TRUE,,115,115,115,0.75,2,115,0,,2 - No Scientific Data
NCT00587171,1,Trial Comparing Patching With Active Vision Therapy to Patching With Control Vision Therapy as Treatment for Amblyopia,Treatment,Parallel Assignment,Double Blind,Randomized,Device|Procedure|Procedure|Procedure,Phase 3,Nervous System Diseases|Eye Diseases|Symptoms and General Pathology|All Conditions,OTHER,,Multiple,United States|United States|United States|United States|United States|United States|United States,8-Apr,10-Dec-07,9-Mar,9-Oct,22-Apr-11,This study was stopped due to insufficient recruitment.,,2,19,Actual,222,Anticipated,TRUE,,19,19,17,0.09,0,19,0,,2 - No Scientific Data
NCT00587223,1,Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB),Treatment,Parallel Assignment,Open Label,Randomized,Device|Other,Phase 3,Diseases and Abnormalities at or before Birth|Skin and Connective Tissue Diseases|All Conditions|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States,7-Dec,21-Dec-07,8-Dec,8-Dec,29-Mar-10,Insufficient patient enrollment,,2,1,Actual,68,Anticipated,TRUE,,1,1,0,0.01,0,1,0,,2 - No Scientific Data
NCT00588146,1,Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia,Treatment,Crossover Assignment,Open Label,Randomized,Drug|Other,Phase 2,Digestive System Diseases|All Conditions|Heart and Blood Diseases|Blood and Lymph Conditions|Diseases and Abnormalities at or before Birth|Symptoms and General Pathology|Nutritional and Metabolic Diseases|Rare Diseases,OTHER,,Single,United States,7-Jan,26-Dec-07,11-Sep,11-Sep,20-Dec-12,Schering-Plough discontinued supplying study drug.,,3,10,Actual,9,Anticipated,TRUE,,10,10,0,1.11,3,20,0,,2 - No Scientific Data
NCT00588354,1,Epidural Clonidine for Lumbosacral Radiculopathy,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,,"Nervous System Diseases|All Conditions|Muscle, Bone, and Cartilage Diseases|Symptoms and General Pathology",OTHER,,Single,United States,6-Oct,26-Dec-07,9-Feb,9-Feb,3-Jun-11,Targeted enrollment was not reached.,,2,26,Actual,40,Anticipated,TRUE,,26,26,23,0.65,0,26,1,21192304,2 - No Scientific Data
NCT00588471,1,Effect of Acute Statin Treatment in Patients Undergoing Percutaneous Coronary Intervention,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,,Heart and Blood Diseases|All Conditions|Symptoms and General Pathology,OTHER,,Single,United States,2-Nov,22-Dec-07,11-Apr,11-Apr,9-Oct-12,The study was terminated because not enough subjects could be recruited.,,2,57,Actual,200,Anticipated,TRUE,,57,57,0,0.29,0,57,0,,2 - No Scientific Data
NCT00588861,0,Total Hip Replacement With the Answer?? Hip Stem and Ranawat/Burnstein?? Shell Using Simplex?? or Palacos?? Bone Cement,Treatment,Parallel Assignment,Open Label,Non-Randomized,Device|Device,,"Muscle, Bone, and Cartilage Diseases|All Conditions|Skin and Connective Tissue Diseases",INDUSTRY,,Single,United States,2-Sep,19-Dec-07,10-May,10-May,14-Jun-10,Study was terminated due to insufficient data and lack of patient follow-up,,4,400,Actual,400,Actual,FALSE,F,402,402,0,1.01,23,402,0,,2 - No Scientific Data
NCT00589693,1,To Compare Safety and Efficacy of Doripenem Versus Imipenem-Cilastatin in Patients With Ventilator-Associated Pneumonia,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 3,Bacterial and Fungal Diseases|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions|Wounds and Injuries,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Argentina|Argentina|Argentina|Argentina|Argentina|Argentina|Australia|Australia|Australia|Australia|Australia|Belgium|Belgium|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Canada|Canada|Canada|France|France|France|France|France|Germany|Germany|Germany|Germany|Germany|Germany|Guatemala|Guatemala|Guatemala|Hungary|Hungary|Hungary|Hungary|India|India|India|India|India|Israel|Israel|Israel|Mexico|Mexico|Mexico|Mexico|Mexico|Philippines|Philippines|Portugal|Portugal|Romania|Romania|Romania|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Spain|Spain|Spain|Spain|Spain|Spain|Thailand|Thailand|Thailand|Turkey|Turkey|Turkey|Turkey|Turkey|Turkey|Ukraine|Ukraine|Ukraine,8-Apr,21-Dec-07,11-Jun,11-Jun,13-Jun-12,Observed lower cure rates and higher mortality rates in one of the treatment groups.,,6,274,Actual,524,Anticipated,FALSE,E,227,274,167,0.52,100,227,1,23148736,1 - Scientific Data
NCT00590369,1,Negative Pressure Wound Therapy: Are All Systems Alike?,Treatment,Parallel Assignment,Open Label,Randomized,Device|Device,Phase 3,,OTHER,,Single,United States,6-Jan,26-Dec-07,8-Aug,8-Aug,22-Jun-11,Recruitment challenges,,2,11,Actual,50,Anticipated,TRUE,,11,11,11,0.22,0,11,1,22552107,2 - No Scientific Data
NCT00590460,1,Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia,Treatment,Single Group Assignment,Open Label,,Biological|Biological|Drug|Procedure,Phase 1|Phase 2,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|Diseases and Abnormalities at or before Birth|Nutritional and Metabolic Diseases|All Conditions|Blood and Lymph Conditions|Symptoms and General Pathology|Rare Diseases",OTHER,,Multiple,United States|United States,1-Jul,26-Dec-07,9-Sep,9-Sep,2-Jul-12,slow accrual,,2,5,Actual,27,Anticipated,TRUE,,5,5,5,0.19,1,5,0,,2 - No Scientific Data
NCT00590538,1,Phenylbutyrate/Genistein Duotherapy in Delta F508-Heterozygotes (for Cystic Fibrosis),Basic Science,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 1|Phase 2,Digestive System Diseases|Respiratory Tract (Lung and Bronchial) Diseases|Diseases and Abnormalities at or before Birth|All Conditions|Symptoms and General Pathology|Rare Diseases,OTHER,,Single,United States,3-Feb,27-Dec-07,8-Dec,8-Dec,15-Nov-10,12/15/2008 Voluntarily placed on inactive status-requested by the PI,,4,9,Actual,16,Anticipated,TRUE,,9,9,0,0.56,0,9,0,,2 - No Scientific Data
NCT00591019,1,Use of Modafinil in the Treatment of Tinnitus,Treatment,Crossover Assignment,Single Blind,Randomized,Drug|Other,Phase 1,"Ear, Nose, and Throat Diseases|Nervous System Diseases|Symptoms and General Pathology|All Conditions",OTHER,,Single,United States,6-Aug,27-Dec-07,8-Mar,8-Jun,28-Feb-11,Terminated early due to lack of change in primary and secondary outcome measures.,,6,7,Actual,10,Anticipated,TRUE,,7,7,15,0.7,0,21,0,,1 - Scientific Data
NCT00592319,1,Celebrex (Celecoxib) Treatment of Laryngeal Papilloma,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Device|Procedure,Phase 2,Cancers and Other Neoplasms|All Conditions,OTHER,,Single,United States,5-May,31-Dec-07,9-Jul,9-Jul,3-May-12,"03/01/2009,due to date close to termination of this funding/study period",,1,10,Actual,30,Anticipated,TRUE,,10,10,7,0.33,0,10,0,,2 - No Scientific Data
NCT00592358,1,Invega (Paliperidone) for the Treatment of Mania in Children and Adolescents Ages 6-17 With Bipolar Disorder,Treatment,Single Group Assignment,Open Label,,Drug,Phase 4,Behaviors and Mental Disorders|All Conditions,OTHER,,Single,United States,7-Nov,28-Dec-07,9-Dec,9-Dec,9-Mar-12,Slow enrollment.,,2,17,Actual,40,Anticipated,TRUE,,17,17,15,0.43,0,15,1,23397049,2 - No Scientific Data
NCT00592683,1,Omega-3 Fatty Acid Adjunctive to Open-Label Aripiprazole for the Treatment of Bipolar Disorder in Children and Adolescents,Treatment,Single Group Assignment,Double Blind,Randomized,Drug|Dietary Supplement|Drug,Phase 4,Behaviors and Mental Disorders|All Conditions,OTHER,,Single,United States,7-Dec,28-Dec-07,10-Apr,10-Apr,15-Jul-11,Supply Omega-3 Fatty Acids expired and supplier no longer made same composition.,,3,20,Actual,40,Anticipated,TRUE,,20,20,14,0.5,0,20,0,,2 - No Scientific Data
NCT00592852,1,Fluoxetine for Obsessive-Compulsive Disorder in Children and Adolescents With Bipolar Disorder,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 4,Behaviors and Mental Disorders|All Conditions,OTHER,,Single,United States,5-Dec,28-Dec-07,10-Sep,10-Sep,28-Jul-11,Slow subject recruitment.,,2,13,Actual,20,Anticipated,TRUE,,13,13,11,0.65,0,11,0,,2 - No Scientific Data
NCT00594308,1,In-Vivo Activated T-Cell Depletion to Prevent GVHD,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug|Drug|Drug|Drug,,Cancers and Other Neoplasms|All Conditions|Blood and Lymph Conditions|Immune System Diseases|Heart and Blood Diseases|Symptoms and General Pathology|Rare Diseases,OTHER,,Single,United States,7-Oct,4-Jan-08,8-Oct,,5-Aug-11,Treatment ineffective,,6,10,Actual,43,Anticipated,TRUE,,10,10,10,0.23,4,10,0,,1 - Scientific Data
NCT00594854,1,Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Digestive System Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Single,United States,7-Sep,19-Dec-07,8-Sep,8-Sep,28-May-10,POZEN agreed with FDA to stop study due to low and inadequate enrollment,,2,20,Actual,200,Anticipated,TRUE,,20,20,20,0.1,0,20,0,,2 - No Scientific Data
NCT00595582,1,Early Intervention in Mild Cognitive Impairment (MCI) With Curcumin + Bioperine,Diagnostic,Single Group Assignment,Open Label,,Dietary Supplement,,Behaviors and Mental Disorders|All Conditions|Nervous System Diseases|Symptoms and General Pathology,OTHER,,Single,United States,5-May,4-Jan-08,8-Jun,8-Jun,11-Oct-11,For various reasons.,,10,10,Actual,34,Anticipated,TRUE,,10,10,0,0.29,0,10,0,,2 - No Scientific Data
NCT00596947,1,Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug|Drug|Drug|Drug,Phase 4,,OTHER,,Single,United States,5-Oct,8-Jan-08,9-Mar,9-Mar,18-Feb-11,due to low study enrollment,,2,18,Actual,50,Anticipated,TRUE,,18,18,0,0.36,17,18,0,,2 - No Scientific Data
NCT00597116,1,An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Rare Diseases,INDUSTRY,,Multiple,Germany|Germany|Germany|Germany|Switzerland|Switzerland,7-Dec,9-Jan-08,10-Jan,10-Jan,27-Apr-11,Recruitment stopped according to early stopping rule (by protocol),,6,25,Actual,66,Anticipated,TRUE,,25,25,22,0.38,9,23,0,,1 - Scientific Data
NCT00598871,1,A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Other,Phase 2,Nutritional and Metabolic Diseases|Gland and Hormone Related Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States,7-Dec,19-Dec-07,9-Feb,9-Feb,22-Feb-10,slow recruitment,,2,12,Actual,48,Anticipated,TRUE,,12,12,12,0.25,0,12,0,,2 - No Scientific Data
NCT00599053,1,Early Versus Expectant Treatment of Ureaplasma Infection in Very Low Birth Weight Neonates,Prevention,Parallel Assignment,Open Label,Randomized,Drug,Phase 1|Phase 2,Bacterial and Fungal Diseases|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions|Diseases and Abnormalities at or before Birth|Symptoms and General Pathology|Rare Diseases,OTHER,,Single,United States,7-May,10-Jan-08,9-Jul,9-Aug,30-May-12,Enrollment was terminated early due to a change in practice on the obstetrical side that included administering azithromycin to women with preterm labor.,,7,7,Actual,50,Anticipated,TRUE,,7,7,7,0.14,0,7,0,,2 - No Scientific Data
NCT00602446,1,Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant,Supportive Care,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 2,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Gland and Hormone Related Diseases|All Conditions|Blood and Lymph Conditions|Skin and Connective Tissue Diseases|Immune System Diseases|Heart and Blood Diseases|Nutritional and Metabolic Diseases|Symptoms and General Pathology|Rare Diseases",OTHER,,Single,United States,7-Aug,24-Jan-08,9-Sep,9-Dec,16-Mar-10,Due to slow accrual of patients,,2,4,Actual,10,,FALSE,E,3,4,3,0.4,0,3,0,,2 - No Scientific Data
NCT00603564,1,Helmet Continuous Positive Airway Pressure Versus Oxygen Venturi in Acute Respiratory Failure in CAP: CAPOVeRSO,Treatment,Parallel Assignment,Open Label,Randomized,Procedure,,Bacterial and Fungal Diseases|All Conditions|Respiratory Tract (Lung and Bronchial) Diseases|Wounds and Injuries|Diseases and Abnormalities at or before Birth|Symptoms and General Pathology|Rare Diseases,OTHER,,Single,Italy,6-Jan,16-Jan-08,8-Jun,8-Jul,11-Sep-09,The study was prematurely interrupted because patients randomized to CPAP reached the endpoint quicker than anticipated in the protocol,,6,47,Actual,250,Anticipated,TRUE,,47,47,47,0.19,0,47,1,20154071,1 - Scientific Data
NCT00604461,1,"Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)",Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 1|Phase 2,Cancers and Other Neoplasms|All Conditions,OTHER,,Single,United States,7-Oct,17-Jan-08,11-Jan,11-Jan,17-Nov-11,Slow Accrual,,2,13,Actual,48,Anticipated,TRUE,,13,13,12,0.27,4,13,0,,2 - No Scientific Data
NCT00604721,1,A Phase 2 Study of AZD6244 in Hepatocellular Carcinoma,Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Digestive System Diseases|Rare Diseases,NIH,,Multiple,United States|United States|United States|United States|United States|United States,7-Dec,17-Jan-08,11-Jun,11-Jun,22-Jun-12,"No radiographic response observed, study was stopped at interim analysis.",,6,19,Actual,44,Anticipated,TRUE,,19,19,17,0.43,8,19,1,21519015,1 - Scientific Data
NCT00604968,1,Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059 AM2)(COMPLETED),Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 4,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions,INDUSTRY,,,,7-Feb,21-Jan-08,9-Oct,9-Oct,27-Jan-11,,,9,25,Actual,40,Anticipated,TRUE,,25,25,25,0.63,9,25,1,22056077,3 - No Reason Provided
NCT00605384,1,A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 3,Viral Diseases|Digestive System Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|Belgium|Belgium|Germany|Germany|Germany|Germany|Italy|Italy|Italy|Italy|Italy|Poland|Poland|Poland|Turkey|Turkey|Turkey|Turkey|Turkey|Turkey|Turkey|Turkey|Turkey|Turkey|Turkey,8-Aug,18-Jan-08,9-Feb,9-Feb,13-Jul-10,Business Objectives Have Changed,,8,4,Actual,84,Anticipated,FALSE,F,2,2,0,0.02,0,2,0,,2 - No Scientific Data
NCT00606554,1,Clinical Trial of a Computer-driven Weaning System for Patients Requiring Mechanical Ventilation,Treatment,Parallel Assignment,Open Label,Randomized,Device|Behavioral,,Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,OTHER,,Single,United States,8-Jan,3-Jan-08,10-May,10-May,7-Feb-11,Slow recruitment of subjects,,2,33,Actual,220,Anticipated,TRUE,,33,33,33,0.15,0,33,0,,2 - No Scientific Data
NCT00607477,1,Pilot Study of the Treatment of VEGF-Signaling Pathway Inhibitor-Induced Hypertension,Treatment,Parallel Assignment,Open Label,Non-Randomized,Drug|Drug,,Heart and Blood Diseases|All Conditions,OTHER,,Single,United States,8-Jan,22-Jan-08,9-Jan,9-Jan,22-Nov-10,Study has been terminated due to poor accrual.,,2,2,Actual,20,Anticipated,TRUE,,2,2,0,0.1,0,2,0,,2 - No Scientific Data
NCT00608517,1,Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil,Treatment,Parallel Assignment,Open Label,Non-Randomized,Biological|Drug|Drug|Drug|Radiation,,Viral Diseases|Cancers and Other Neoplasms|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Heart and Blood Diseases|Symptoms and General Pathology|Diseases and Abnormalities at or before Birth|Rare Diseases,OTHER,,Multiple,United States|United States|United States|United States,5-Sep,31-Jan-08,8-Mar,11-May,11-Oct-10,slow accrual,,2,6,Actual,49,,TRUE,,6,6,6,0.12,1,6,0,,2 - No Scientific Data
NCT00608777,1,Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva),Treatment,Single Group Assignment,Open Label,,Drug,Phase 4,Skin and Connective Tissue Diseases|All Conditions,OTHER,,Single,United States,8-Jan,23-Jan-08,9-Feb,9-Feb,5-Mar-12,Withdrawal of marketing autorization of efalizumab by the EMEA.,,16,6,Actual,15,Anticipated,TRUE,,6,6,0,0.4,0,6,0,,2 - No Scientific Data
NCT00609622,1,Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|Digestive System Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Denmark|Denmark|Denmark|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Japan|Japan|Japan|Japan|Japan|Japan,8-Apr,25-Jan-08,11-Jul,11-Jul,6-Jul-12,See termination reason in detailed description.,"The study was terminated on April 26, 2010 due to lack of efficacy, as determined during the interim analysis of data in April 2010, showing that the study did not meet its primary endpoint to demonstrate a statistically significant improvement in PFS. The decision to terminate the trial was not based on any safety concerns.",6,191,Actual,290,Anticipated,TRUE,,191,191,191,0.66,66,189,0,,1 - Scientific Data
NCT00609739,1,Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug|Drug|Drug|Drug|Drug|Procedure|Procedure|Drug,Phase 1|Phase 2,Cancers and Other Neoplasms|All Conditions|Blood and Lymph Conditions|Rare Diseases,OTHER,,Single,United States,Jun-99,6-Feb-08,10-Jun,10-Jun,22-Nov-11,Low accrual,,2,1,Actual,10,,TRUE,,1,1,1,0.1,1,1,0,,2 - No Scientific Data
NCT00609765,1,"Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors",Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug|Drug|Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|Digestive System Diseases|Gland and Hormone Related Diseases|All Conditions|Rare Diseases,OTHER,,Single,United States,7-Aug,24-Jan-08,8-Mar,8-Mar,21-Feb-11,Development of new chemotherapy standard of care for treatment rendered the trial obsolete.,,7,1,Actual,45,Anticipated,TRUE,,1,1,0,0.02,0,1,0,,2 - No Scientific Data
NCT00610207,1,Treatment of Crohn's Fistula Using a Porcine Intestine Submucosa Graft,Treatment,Single Group Assignment,Open Label,Non-Randomized,Device,,Digestive System Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Multiple,United States|United States|United States,7-Mar,24-Jan-08,10-Apr,10-Apr,25-Apr-11,Study stopped early due to staffing changes at the site.,,4,21,Actual,50,Anticipated,TRUE,,21,21,18,0.42,0,18,0,,2 - No Scientific Data
NCT00610311,1,Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug|Biological|Biological|Biological,Phase 2,Cancers and Other Neoplasms|All Conditions|Skin and Connective Tissue Diseases|Rare Diseases,NIH,,Single,United States,8-Jan,6-Feb-08,11-Feb,11-Feb,14-Mar-12,The study was terminated due to low accrual.,,2,3,Actual,41,,TRUE,,3,3,3,0.07,1,3,0,,2 - No Scientific Data
NCT00611715,1,"Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.",Treatment,Parallel Assignment,Open Label,Non-Randomized,Drug|Drug|Genetic|Other|Other,Phase 2,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions,OTHER,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States,3-Nov,8-Feb-08,8-Dec,8-Dec,12-Mar-12,low accrual,,2,48,Actual,154,,TRUE,,48,48,40,0.31,21,48,0,,2 - No Scientific Data
NCT00612222,1,Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma,Treatment,Single Group Assignment,Open Label,Non-Randomized,Biological|Biological|Biological|Drug|Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Skin and Connective Tissue Diseases|Rare Diseases,NIH,,Single,United States,8-Jan,8-Feb-08,11-Mar,11-Mar,13-Mar-12,The study was terminated due to low accrual.,,2,4,Actual,41,,TRUE,,4,4,4,0.1,1,4,0,,2 - No Scientific Data
NCT00612677,0,Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug,Phase 2,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,OTHER,,Single,United States,7-Jun,29-Jan-08,8-Jan,8-Jan,21-Feb-11,slow accrual - the 1 patient accrued did not go on treatment,,2,1,Actual,50,Anticipated,TRUE,,1,1,0,0.02,0,1,0,,2 - No Scientific Data
NCT00613509,1,Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma,Treatment,Parallel Assignment,Open Label,Randomized,Biological|Biological,Phase 2,Cancers and Other Neoplasms|All Conditions|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Canada|Canada|Canada|Canada,8-Jun,16-Jan-08,10-Apr,10-Jun,14-Sep-10,"No safety concerns, the study was terminated due to slow enrollment. All enrolled patients were followed per protocol.",,2,23,Actual,120,Anticipated,TRUE,,23,23,23,0.19,10,23,0,,2 - No Scientific Data
NCT00614458,1,MK-0518 Intensification And HDAC Inhibition In Depletion Of Resting CD4+ T Cell HIV Infection,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 2,"Viral Diseases|Immune System Diseases|All Conditions|Symptoms and General Pathology|Bacterial and Fungal Diseases|Urinary Tract, Sexual Organs, and Pregnancy Conditions",OTHER,,Single,United States,7-Apr,31-Jan-08,8-Sep,8-Sep,15-Apr-11,Due to insufficient funds,,1,6,Actual,20,Anticipated,TRUE,,6,6,6,0.3,0,6,1,20186346,2 - No Scientific Data
NCT00616902,1,The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions|Heart and Blood Diseases|Symptoms and General Pathology",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Australia|Australia|Australia|Australia|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Germany|Germany|Germany|Germany|Germany|Greece|Greece|Italy|Italy|Italy|Italy|Poland|Poland|Poland|Poland|Poland|Puerto Rico|Puerto Rico|Romania|Romania|Romania|Romania|Romania|Russian Federation|Russian Federation|Russian Federation|Spain|Spain|Spain|Spain|Spain|Taiwan|Taiwan|Taiwan|Taiwan|United Kingdom|United Kingdom|United Kingdom,9-Jan,5-Feb-08,9-May,9-May,21-May-10,This study was prematurely terminated due to low enrollment,,2,12,Actual,220,Anticipated,TRUE,,12,12,0,0.05,0,12,0,,2 - No Scientific Data
NCT00617058,1,"Improving Metabolic Parameters of Antipsychotic Child Treatment With Ziprasidone, Aripiprazole, and Clozapine",Treatment,Parallel Assignment,Open Label,Randomized,Drug|Behavioral,Phase 2,Symptoms and General Pathology|All Conditions,OTHER,,Single,United States,7-Mar,5-Feb-08,10-Jun,10-Sep,29-Oct-12,"Terminated in lieu of similar,competing large, multi-site study.",,7,1,Actual,60,Anticipated,TRUE,,1,1,1,0.02,0,1,0,,2 - No Scientific Data
NCT00617279,1,GORE PROPATEN Vascular Graft vs. Disadvantaged Autologous Vein Graft,Treatment,Parallel Assignment,Open Label,Randomized,Device|Procedure,Phase 4,Heart and Blood Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,7-Dec,18-Dec-07,10-Feb,10-Feb,7-Feb-11,Study terminated due to low enrollment,,2,31,Actual,280,Anticipated,TRUE,,31,31,31,0.11,6,31,0,,2 - No Scientific Data
NCT00619151,1,CarboMedics Top Hat vs St. Jude Medical Regent Valve Comparing Sizing and Hemodynamics,,Parallel Assignment,Open Label,Randomized,Device|Device,,,INDUSTRY,,Multiple,United States|United States,7-Dec,10-Jan-08,8-May,8-May,7-Jun-11,Study stopped due to lack of elegible patient enrollment,,2,2,Actual,320,Anticipated,TRUE,,2,2,0,0.01,0,2,0,,2 - No Scientific Data
NCT00619229,1,Alprostadil in Maculopathy Study (AIMS),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Other,Phase 3,Eye Diseases|All Conditions,INDUSTRY,,Multiple,Germany|Germany|Germany|Germany|Germany|Germany,6-Jul,24-Dec-07,10-Feb,10-Feb,27-Jan-11,Interim Analysis: Optimization of study design required.,,6,37,Actual,52,Anticipated,FALSE,F,36,36,33,0.69,0,36,1,23627650,1 - Scientific Data
NCT00620074,1,"Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)",Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug,Phase 4,Bacterial and Fungal Diseases|All Conditions|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States,8-Aug,8-Feb-08,9-Feb,9-Feb,21-Jan-10,See Detailed Description,"The study was terminated on January 12, 2009 due to the overall low rate of enrollment. The decision to terminate the trial was not based on any safety concerns. Patients who were enrolled in the study prior to January 12, 2009 were allowed to remain in the study until completing their participation as specified in the protocol.",2,6,Actual,50,Anticipated,TRUE,,6,6,6,0.12,4,6,0,,2 - No Scientific Data
NCT00620659,1,Treatment of Refractory Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea/Hypopnea Syndrome (OSA/HS) Using Nasal Continuous Positive Airway Pressure (nCPAP) Therapy (0249-015),Treatment,Crossover Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 2,Respiratory Tract (Lung and Bronchial) Diseases|Symptoms and General Pathology|All Conditions|Nervous System Diseases|Behaviors and Mental Disorders,INDUSTRY,,,,8-Feb,10-Jan-08,9-Mar,9-Mar,13-Oct-10,,,9,125,Actual,200,Anticipated,TRUE,,125,125,155,0.63,2,348,1,23920422,3 - No Reason Provided
NCT00622167,1,Comparison of DSCT With IB-IVUS and Angiography in the Assessment of Coronary Artery Disease,Diagnostic,Single Group Assignment,Open Label,,Device|Device,,Heart and Blood Diseases|All Conditions|Symptoms and General Pathology,OTHER,,Single,United States,8-Jan,12-Feb-08,8-Apr,9-Jun,28-Jul-11,"Subject recruitment was slow, so enrollment has been closed.",,2,24,Actual,30,Anticipated,TRUE,,24,24,0,0.8,0,4,0,,2 - No Scientific Data
NCT00623727,1,BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A,Treatment,Parallel Assignment,Double Blind,Randomized,Biological|Biological,Phase 2,Blood and Lymph Conditions|Diseases and Abnormalities at or before Birth|All Conditions|Heart and Blood Diseases|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Argentina|Argentina|Argentina|Australia|Austria|Austria|Belgium|Belgium|Belgium|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Chile|Chile|Croatia|Denmark|Estonia|Estonia|France|France|France|France|France|France|France|France|France|Germany|Germany|Germany|Israel|Italy|Italy|Italy|Italy|Italy|Italy|Lithuania|Lithuania|Netherlands|Netherlands|Netherlands|New Zealand|New Zealand|Norway|Poland|Poland|Poland|Poland|Poland|Romania|Romania|Romania|South Africa|Spain|Spain|Spain|Spain|Spain|Spain|Switzerland|Taiwan|Taiwan|Taiwan|Turkey|Turkey|Turkey|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom,8-Jun,9-Jan-08,10-Apr,10-Oct,10-Jun-11,,,9,143,Actual,250,Anticipated,TRUE,,143,143,131,0.57,9,185,1,23014711,3 - No Reason Provided
NCT00625586,1,Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer,Treatment,Single Group Assignment,Open Label,,Biological,Phase 2,Cancers and Other Neoplasms|Symptoms and General Pathology|All Conditions|Digestive System Diseases|Gland and Hormone Related Diseases|Rare Diseases,INDUSTRY,,Multiple,United States|United States,8-Mar,26-Feb-08,9-Jan,9-Mar,20-Aug-12,Corporate decision,,8,2,Actual,81,,TRUE,,2,2,0,0.02,1,2,0,,2 - No Scientific Data
NCT00625729,1,"Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia",Treatment,Single Group Assignment,Open Label,,Biological|Biological|Biological|Drug|Drug,Phase 1|Phase 2,Viral Diseases|Cancers and Other Neoplasms|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Heart and Blood Diseases|Rare Diseases,OTHER,,Single,United States,8-Jan,26-Feb-08,9-Dec,10-Apr,2-Jul-10,No patients exhibited natural killer cell expansion (primary endpoint).,,6,6,Actual,12,,TRUE,,6,6,6,0.5,5,6,1,20680271,1 - Scientific Data
NCT00625872,1,Neuromuscular Changes In Small For Gestational Age Children During Somatropin Therapy,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 3,,INDUSTRY,,Multiple,Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany,8-Jul,19-Feb-08,11-Mar,11-Mar,27-Jan-12,The study terminated on 19-Jan-2011 due to insufficient recruitment of patients. No safety reasons contributed to the termination of the study.,,2,23,Actual,88,Anticipated,TRUE,,23,23,21,0.26,0,23,0,,2 - No Scientific Data
NCT00626548,1,A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions",INDUSTRY,,Multiple,"United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Argentina|Argentina|Argentina|Australia|Australia|Australia|Australia|Australia|Australia|Australia|Austria|Austria|Austria|Belgium|Belgium|Belgium|Belgium|Belgium|Belgium|Belgium|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Chile|Chile|Chile|Chile|China|China|China|China|China|China|China|China|China|China|China|Colombia|Colombia|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Denmark|Denmark|Denmark|Denmark|Denmark|Denmark|Denmark|Finland|Finland|Finland|Finland|Finland|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Hungary|Hungary|Hungary|Hungary|Hungary|Hungary|Hungary|India|India|India|India|India|India|India|India|Ireland|Ireland|Ireland|Israel|Israel|Israel|Israel|Israel|Israel|Israel|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of|Latvia|Latvia|Mexico|Mexico|Netherlands|Netherlands|Netherlands|Netherlands|Netherlands|Netherlands|Netherlands|Norway|Norway|Peru|Peru|Peru|Peru|Poland|Poland|Poland|Poland|Poland|Poland|Portugal|Portugal|Romania|Romania|Romania|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Serbia|Serbia|Serbia|South Africa|South Africa|South Africa|South Africa|South Africa|South Africa|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Sweden|Sweden|Sweden|Sweden|Sweden|Sweden|Switzerland|Switzerland|Switzerland|Switzerland|Taiwan|Turkey|Turkey|Turkey|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom",8-Jan,24-Jan-08,11-Jan,11-May,26-Apr-12,early efficacy review by the Independent Data Monitoring Committee indicated it was unlikely to meet its primary efficacy endpoints,,6,2577,Actual,1500,Anticipated,FALSE,F,1421,1421,1181,0.95,286,1415,1,23381694,1 - Scientific Data
NCT00626574,1,Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa,Treatment,Single Group Assignment,Double Blind,Randomized,Drug|Drug,Phase 4,Nervous System Diseases|Heart and Blood Diseases|Symptoms and General Pathology|All Conditions,OTHER,,Single,United States,7-Jul,7-Feb-08,9-Feb,9-Feb,8-Sep-11,This study is terminated as a result of data from a study that showed increased mortality in stroke patients.,,7,3,Actual,20,Anticipated,TRUE,,3,3,3,0.15,1,3,0,,2 - No Scientific Data
NCT00627497,1,"DIAM? Spinal Stabilization System vs. Decompression, Formerly vs. Posterolateral Fusion",Treatment,Parallel Assignment,Open Label,Randomized,Procedure|Device|Device|Device,Phase 3,"Muscle, Bone, and Cartilage Diseases|All Conditions|Symptoms and General Pathology",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States,8-Feb,21-Feb-08,10-Dec,10-Dec,29-Nov-11,slow patient recruitment,,2,32,Actual,660,Anticipated,TRUE,,32,32,30,0.05,14,32,0,,2 - No Scientific Data
NCT00627861,1,Combined Renin Inhibition/Beta-blockade,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug,,Heart and Blood Diseases|All Conditions,OTHER,,Single,United States,8-Nov,24-Feb-08,10-May,10-May,19-Aug-11,The renin laboratory used in the study is no longer available.,,4,1,Actual,20,Anticipated,TRUE,,1,1,1,0.05,0,1,0,,2 - No Scientific Data
NCT00629850,1,Respiratory Resistance Training on Sleep Quality in Persons With Spinal Cord Injury,Treatment,Parallel Assignment,Single Blind,Randomized,Device,Phase 1,Nervous System Diseases|Wounds and Injuries|All Conditions,OTHER,,Single,United States,8-Feb,25-Feb-08,9-Sep,9-Sep,19-Jul-11,unable to recruit participants.,,2,1,Actual,20,Anticipated,TRUE,,1,1,0,0.05,0,1,0,,2 - No Scientific Data
NCT00630292,1,Feasibility Study of Vessel Analysis for Noninvasive Diagnosis of Malignancy in Breast Tumors,Diagnostic,Single Group Assignment,Open Label,,Other,,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions,OTHER,,Single,United States,8-Mar,28-Feb-08,8-Dec,9-Dec,3-Feb-10,Existing vessel analysis software could not be applied to breast MRI data.,,4,6,Actual,10,Anticipated,TRUE,,6,6,0,0.6,0,5,0,,2 - No Scientific Data
NCT00630994,1,Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis,Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,Cancers and Other Neoplasms|Symptoms and General Pathology|All Conditions|Blood and Lymph Conditions|Rare Diseases,OTHER,,Single,United States,8-Mar,6-Mar-08,9-Aug,12-Apr,9-Jan-12,Stopped due to slow accrual,,2,4,Actual,22,,TRUE,,4,4,4,0.18,1,4,0,,2 - No Scientific Data
NCT00632203,1,Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146AM4),Treatment,Parallel Assignment,Open Label,Randomized,Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Respiratory Tract (Lung and Bronchial) Diseases,INDUSTRY,,,,8-Mar,29-Feb-08,11-Jan,11-Jan,22-Dec-11,,,9,53,Actual,100,Anticipated,TRUE,,53,53,45,0.53,12,53,0,,3 - No Reason Provided
NCT00632424,1,Phase 1 Trial of Oral Ixabepilone,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 1,,INDUSTRY,,Multiple,United States|United States,8-May,3-Mar-08,9-Jun,9-Jun,15-Sep-10,Business Objectives Changed,,8,23,Actual,36,Anticipated,FALSE,F,18,18,18,0.5,5,18,1,22331549,2 - No Scientific Data
NCT00633477,1,Efficacy and Safety of Resatorvid in Patients With Sepsis-induced Cardiovascular and Respiratory Failure,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Bacterial and Fungal Diseases|Symptoms and General Pathology|All Conditions|Respiratory Tract (Lung and Bronchial) Diseases,INDUSTRY,,Single,Japan,8-Feb,4-Mar-08,9-Feb,9-Feb,5-Dec-12,Business Decision; No Safety Or Efficacy Concerns.,,8,18,Actual,2500,Anticipated,TRUE,,18,18,17,0.01,4,17,0,,2 - No Scientific Data
NCT00634088,1,Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,Treatment,Parallel Assignment,Open Label,Non-Randomized,Drug|Drug|Drug|Drug,Phase 1,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions,INDUSTRY,,Multiple,United States|Australia|Italy,8-Jun,5-Mar-08,10-Jun,10-Jun,1-Apr-11,Slow Accrual,,2,13,Actual,60,Anticipated,FALSE,E,6,13,0,0.22,3,10,0,,2 - No Scientific Data
NCT00635024,1,Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma,Treatment,Single Group Assignment,Open Label,,Biological|Drug,Phase 2,Cancers and Other Neoplasms|Heart and Blood Diseases|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Rare Diseases,OTHER,,Single,United States,8-May,12-Mar-08,8-Jul,10-Nov,27-Aug-10,"Due to competing trials, this study is permanenlty closed to patient acrrual.",,7,1,Actual,28,,TRUE,,1,1,1,0.04,0,1,0,,2 - No Scientific Data
NCT00636155,1,EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,Treatment,Single Group Assignment,Open Label,,Drug|Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Blood and Lymph Conditions|Immune System Diseases|Rare Diseases,OTHER,,Single,United States,8-Feb,22-Jan-08,11-Aug,12-May,29-May-12,funding,,1,20,Actual,37,Anticipated,TRUE,,20,20,17,0.54,8,20,1,21827374,2 - No Scientific Data
NCT00638378,1,Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer,Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,8-Feb,12-Mar-08,9-Jan,9-Jan,15-Dec-11,"According to the protocol, the sponsor terminated the study after it was determined that less than 2 of the first 22 patients showed a PSA50 response.",,6,22,Actual,41,Anticipated,TRUE,,22,22,22,0.54,9,22,0,,1 - Scientific Data
NCT00638820,1,Reduced Intensity AlloTransplant For Osteopetrosis,Treatment,Single Group Assignment,Open Label,,Procedure|Drug|Procedure,Phase 2,"Muscle, Bone, and Cartilage Diseases|All Conditions|Diseases and Abnormalities at or before Birth|Skin and Connective Tissue Diseases|Nutritional and Metabolic Diseases|Rare Diseases",OTHER,,Single,United States,7-Sep,11-Mar-08,8-May,8-May,26-Aug-09,Excess toxicity,,5,3,Actual,20,Anticipated,TRUE,,3,3,3,0.15,3,3,0,,1 - Scientific Data
NCT00638963,1,Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2),Prevention,Parallel Assignment,Open Label,Randomized,Drug,Phase 2,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions|Symptoms and General Pathology|Nervous System Diseases,INDUSTRY,,,,8-Oct,10-Jan-08,10-Jun,10-Jun,23-Jun-11,Terminated due to poor accrual,,2,6,Actual,158,Anticipated,TRUE,,6,6,0,0.04,0,6,0,,2 - No Scientific Data
NCT00640978,1,Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer,Treatment,Single Group Assignment,Open Label,,Drug|Drug,Phase 2,Cancers and Other Neoplasms|Digestive System Diseases|Gland and Hormone Related Diseases|All Conditions|Rare Diseases,OTHER,,Single,United States,8-Mar,17-Mar-08,10-Mar,10-Mar,22-Jul-11,Significant Adverse Effects - Futility,,5,16,Actual,40,Anticipated,FALSE,E,15,16,15,0.4,0,16,1,20630061,1 - Scientific Data
NCT00642356,1,Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 4,Nervous System Diseases|All Conditions|Cancers and Other Neoplasms|Skin and Connective Tissue Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,8-Mar,19-Mar-08,9-May,9-May,14-Dec-10,slow enrollment,,2,14,Actual,172,Anticipated,TRUE,,14,14,12,0.08,0,14,0,,2 - No Scientific Data
NCT00642603,1,A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|Digestive System Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,8-May,19-Mar-08,9-Mar,12-Sep,10-Jun-10,,,9,41,Actual,230,Anticipated,TRUE,,41,41,0,0.18,11,39,0,,3 - No Reason Provided
NCT00642694,1,Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Other,Phase 3,Behaviors and Mental Disorders|All Conditions|Nervous System Diseases|Symptoms and General Pathology,OTHER,,Single,United States,7-May,19-Mar-08,10-May,10-May,29-Mar-12,Enrollment discontinued based on mutually agreed upon decision by PI and funding sponsor,,8,29,Actual,44,Anticipated,TRUE,,29,29,21,0.66,0,29,0,,2 - No Scientific Data
NCT00644592,1,LXRA Gene Polymorphisms and Response to Fenofibrate,Basic Science,Crossover Assignment,Double Blind,Randomized,Drug|Drug,,,OTHER,,Single,United States,8-Mar,21-Mar-08,9-Aug,9-Aug,12-Mar-12,supply issues with the formulation of fenofibrate that was used.,,3,11,Actual,60,Anticipated,TRUE,,11,11,11,0.18,0,22,0,,2 - No Scientific Data
NCT00646763,1,A Randomized Study of the Site for Growth Factor Injection for Patients Undergoing Autologous Stem Cell Transplantation,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 2,,OTHER,,Single,United States,8-Apr,25-Mar-08,9-Sep,11-Feb,14-Mar-12,Accrual goal met,,11,35,Actual,30,Anticipated,TRUE,,35,35,35,1.17,0,35,1,21332729,2 - No Scientific Data
NCT00649220,1,Memantine and Antipsychotics Use,Treatment,Single Group Assignment,Open Label,,Drug,Phase 4,Nervous System Diseases|Behaviors and Mental Disorders|All Conditions|Symptoms and General Pathology|Rare Diseases,INDUSTRY,,Single,Germany,8-Jul,27-Mar-08,9-May,9-Jun,9-Aug-11,Study terminated due to too slow enrollment,,2,19,Actual,144,Anticipated,TRUE,,19,19,19,0.13,2,19,0,,2 - No Scientific Data
NCT00652899,1,"Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer",Treatment,Single Group Assignment,Open Label,Non-Randomized,Biological|Drug|Drug|Radiation|Biological|Biological,Phase 2,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Gland and Hormone Related Diseases|All Conditions|Digestive System Diseases|Rare Diseases",OTHER,,Single,United States,8-Mar,3-Apr-08,9-Aug,9-Aug,20-Aug-10,Withdrawn due to toxicity,,5,14,Actual,14,,TRUE,,14,14,12,1,9,14,0,,1 - Scientific Data
NCT00653328,1,Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug,Phase 2,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Gland and Hormone Related Diseases|All Conditions|Digestive System Diseases|Rare Diseases",OTHER,,Multiple,United States|United States|United States|United States|United States|United States,3-May,3-Apr-08,9-Mar,9-Mar,30-Sep-10,Abbott (drug manufacturer) discontinued manufacture of ABT-627,,3,15,Actual,60,,TRUE,,15,15,14,0.25,5,15,0,,2 - No Scientific Data
NCT00654641,1,Prevention of Wound Complications After Cesarean Delivery in Obese Women Utilizing Negative Pressure Wound Therapy,Prevention,Parallel Assignment,Open Label,Randomized,Procedure|Procedure,,Bacterial and Fungal Diseases|Wounds and Injuries|All Conditions|Nutritional and Metabolic Diseases|Symptoms and General Pathology,OTHER,,Multiple,United States|United States,7-Sep,2-Apr-08,10-Feb,10-Feb,3-Feb-10,Poor enrollment. No apparent treatment effect.,,6,54,Actual,220,Anticipated,TRUE,,54,54,54,0.25,0,54,0,,1 - Scientific Data
NCT00655642,1,"Comparison of Ondansetron, Metoclopramide and Promethazine for the Treatment of Nausea and Vomiting in the Adult ED",Treatment,Single Group Assignment,Double Blind,Randomized,Drug|Drug|Drug|Drug,,Symptoms and General Pathology|All Conditions,OTHER,,Single,United States,7-Mar,4-Apr-08,8-Oct,8-Oct,21-Mar-11,Conditional analysis showed observed differences were significantly less than power calculations,,6,171,Actual,600,Anticipated,TRUE,,171,171,163,0.29,0,163,1,20825792,1 - Scientific Data
NCT00655668,1,A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma,Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,Cancers and Other Neoplasms|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|Australia|Australia|Australia|Australia|Australia|Australia|Australia|Australia|Australia|Australia|Australia|Australia|Australia|Belgium|Belgium|Belgium|Belgium|Belgium|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France,8-Mar,4-Apr-08,10-Mar,10-Apr,30-Nov-11,Decision not to pursue as single agent in the study population.,,8,54,Actual,80,Anticipated,TRUE,,54,54,54,0.68,29,54,1,23731832,2 - No Scientific Data
NCT00656916,1,Inhaled Corticosteroids Versus Observation for Patients With Decreased Lung Function Status,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 2,Respiratory Tract (Lung and Bronchial) Diseases|All Conditions|Symptoms and General Pathology|Bacterial and Fungal Diseases|Rare Diseases,OTHER,,Single,United States,8-Mar,7-Apr-08,10-Dec,10-Dec,7-Feb-12,Terminated due to slow accrual.,,2,1,Actual,40,Anticipated,TRUE,,1,1,0,0.03,0,1,0,,2 - No Scientific Data
NCT00657553,1,Preemptive Strike With Bortezomib in Multiple Myeloma Patients,Treatment,Single Group Assignment,Open Label,Randomized,Drug,Phase 3,Cancers and Other Neoplasms|Heart and Blood Diseases|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Rare Diseases,OTHER,,Single,United States,8-Feb,9-Apr-08,9-Jan,9-Jan,14-Apr-11,Due to poor accrual,,2,10,Actual,270,Anticipated,TRUE,,10,10,0,0.04,0,10,0,,2 - No Scientific Data
NCT00658333,1,A Study Designed to Compare the Tolerability of an Increased Dose of Enteric-coated Mycophenolate Acid (MPA) in Renal Transplant Patients Whose Dose of Mycophenolate Mofetil (MMF) Was Reduced Due to Gastrointestinal Symptoms,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug|Drug,Phase 4,Digestive System Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,8-Mar,23-Jan-08,9-Mar,9-Mar,2-Dec-10,,,9,30,Actual,232,Anticipated,TRUE,,30,30,30,0.13,2,30,0,,3 - No Reason Provided
NCT00659334,1,"Imaging of Intravenous (IV) Combidex to Brain, Intra-cerebral Tumors and in Central Nervous System (CNS) Inflammation",Diagnostic,Parallel Assignment,Open Label,Non-Randomized,Drug|Procedure,Phase 2,Cancers and Other Neoplasms|Nervous System Diseases|All Conditions|Symptoms and General Pathology,OTHER,,Single,United States,Aug-00,10-Apr-08,10-Mar,10-Mar,15-May-12,"AMAG not continuing with Combidex, the study drug",,16,116,Actual,185,Anticipated,TRUE,,116,116,111,0.63,23,116,0,,2 - No Scientific Data
NCT00660595,1,Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 3,Behaviors and Mental Disorders|All Conditions,INDUSTRY,,Multiple,Finland|Finland|Finland|Finland,8-Sep,14-Apr-08,8-Dec,8-Dec,4-Dec-09,To difficult to recruit patients in the acute setting,,2,29,Actual,30,Anticipated,TRUE,,29,29,0,0.97,0,2,0,,2 - No Scientific Data
NCT00661570,0,Long-term Clinical Feasibility of the New Indwelling Provox Vega 20 Voice Prosthesis,Treatment,Single Group Assignment,Open Label,,Device,Phase 2,"Respiratory Tract (Lung and Bronchial) Diseases|Ear, Nose, and Throat Diseases|All Conditions",INDUSTRY,,Single,Netherlands,8-Mar,9-Apr-08,9-Mar,9-Mar,2-Aug-10,"Primary endpoint reached, slow accrual, leakage around",,6,26,Actual,26,Actual,TRUE,,26,26,16,1,0,26,1,20513030,1 - Scientific Data
NCT00664105,1,Ph II Concurrent Chemo t/Docetaxel/Carboplatin/Radio Therapy-consolidation t/Locally Adv Inoperable Non-Small Cell Lung Cancer (NSCLC),Treatment,Single Group Assignment,Open Label,,Drug|Drug|Radiation,Phase 2,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,OTHER,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,4-Feb,19-Apr-08,8-Jun,8-Jun,30-Sep-10,Treatment became standard.,,7,63,Actual,90,,TRUE,,63,63,63,0.7,37,63,1,19404213,2 - No Scientific Data
NCT00664430,1,Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug,Phase 4,Cancers and Other Neoplasms|Symptoms and General Pathology|All Conditions|Gland and Hormone Related Diseases,INDUSTRY,,Multiple,Brazil|Brazil,9-Jan,21-Apr-08,9-Jun,9-Jun,3-Jun-10,Low enrollment rate,,2,13,Actual,100,Anticipated,TRUE,,13,13,0,0.13,0,13,0,,2 - No Scientific Data
NCT00668265,1,Anxiety in Recovering Opiate Dependence,Treatment,Parallel Assignment,Double Blind,Randomized,Drug,Phase 4,Behaviors and Mental Disorders|All Conditions|Substance Related Disorders,OTHER,,Single,United States,8-Jan,28-Apr-08,11-Aug,11-Aug,19-Oct-12,"The study was not completed, the funding sponsor lost interest.",,1,14,Actual,40,Anticipated,TRUE,,14,14,0,0.35,0,0,0,,2 - No Scientific Data
NCT00668317,1,Bronchial Hyper-responsiveness in Reflux Cough,Health Services Research,Single Group Assignment,Open Label,,Drug|Drug,Phase 3,Digestive System Diseases|All Conditions|Respiratory Tract (Lung and Bronchial) Diseases|Symptoms and General Pathology|Nervous System Diseases,OTHER_GOV,,Single,United Kingdom,6-Sep,24-Apr-08,9-Sep,10-Jan,16-Mar-12,Primary care physicians began prescribing antacid therapy for chronic cough,,7,5,Actual,30,Anticipated,TRUE,,5,5,3,0.17,0,3,0,,2 - No Scientific Data
NCT00668564,1,Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism,Treatment,Single Group Assignment,Open Label,,Procedure|Drug|Drug|Drug,Phase 2,Nervous System Diseases|Diseases and Abnormalities at or before Birth|Nutritional and Metabolic Diseases|All Conditions|Blood and Lymph Conditions|Symptoms and General Pathology|Behaviors and Mental Disorders|Skin and Connective Tissue Diseases|Rare Diseases,OTHER,,Single,United States,8-Mar,25-Apr-08,10-Feb,10-Feb,14-Jun-11,Replaced by another study,,7,18,Actual,45,Anticipated,TRUE,,18,18,18,0.4,8,18,0,,2 - No Scientific Data
NCT00669071,1,Treatment w/ Tri-Luma?? Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma,Treatment,Single Group Assignment,Single Blind,Randomized,Drug|Drug,Phase 4,Symptoms and General Pathology|All Conditions|Skin and Connective Tissue Diseases,INDUSTRY,,Multiple,United States|United States,8-Jan,24-Apr-08,8-Oct,8-Oct,25-Sep-09,Enrollment closed,,11,56,Actual,60,Anticipated,TRUE,,56,56,112,0.93,0,56,1,21269349,2 - No Scientific Data
NCT00669461,1,Lubiprostone as a Treatment for Constipation in Parkinson's Disease,Treatment,Crossover Assignment,Open Label,Non-Randomized,Drug,,Nervous System Diseases|All Conditions|Symptoms and General Pathology|Cancers and Other Neoplasms|Skin and Connective Tissue Diseases,OTHER,,Single,United States,9-Jun,28-Apr-08,10-Sep,10-Sep,25-Oct-11,Lack of recruitment,,2,1,Actual,40,Anticipated,TRUE,,1,1,0,0.03,0,1,0,,2 - No Scientific Data
NCT00669903,1,"Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia",Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Behaviors and Mental Disorders|All Conditions,INDUSTRY,,Multiple,United States|United States,8-Apr,29-Apr-08,8-Nov,8-Nov,4-Feb-10,"Since AZD0328 is unlikely to meet the current Target Product Profile, Astrazeneca decided to stop further development of AZD0328",,8,100,Actual,100,Anticipated,TRUE,,100,100,87,1,1,100,0,,2 - No Scientific Data
NCT00670228,1,Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug,Phase 3,Heart and Blood Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Multiple,United States|Argentina|Brazil|Canada|Mexico,8-Apr,29-Apr-08,9-Nov,9-Nov,16-Nov-10,Due to Negative feasibility assessment of recruiting the planned number of subjects within the study timelines,,2,34,Actual,588,Anticipated,FALSE,F,33,33,23,0.06,9,29,0,,2 - No Scientific Data
NCT00671528,1,Safety and Efficacy of Quadriderme?? in the Treatment of Impetiginous Eczema (Study P05134AM4),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 4,Diseases and Abnormalities at or before Birth|Skin and Connective Tissue Diseases|Immune System Diseases|All Conditions,INDUSTRY,,,,9-Jul,1-May-08,10-May,10-May,19-May-11,terminated early due to lack of recruitment [only 3 of 207 subjects were enrolled],,2,3,Actual,207,Anticipated,TRUE,,3,3,0,0.01,0,3,0,,2 - No Scientific Data
NCT00671606,1,Hysteroscopic Lymphatic Mapping for Endometrial Cancer,Diagnostic,Single Group Assignment,Open Label,Non-Randomized,Procedure,Phase 2,"Cancers and Other Neoplasms|All Conditions|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Rare Diseases",OTHER,,Multiple,United States|United States,8-Apr,29-Apr-08,10-Jun,10-Jun,30-Jun-11,Slow accrual.,,2,5,Actual,20,Anticipated,TRUE,,5,5,0,0.25,0,5,0,,2 - No Scientific Data
NCT00672178,1,"Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer (RCC)",Treatment,Single Group Assignment,Open Label,Non-Randomized,Radiation,Phase 1|Phase 2,"Cancers and Other Neoplasms|All Conditions|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Rare Diseases",OTHER,,Single,United States,8-Mar,4-May-08,9-Sep,9-Sep,21-Sep-10,Slow accrual,,2,1,Actual,44,Anticipated,TRUE,,1,1,0,0.02,0,1,0,,2 - No Scientific Data
NCT00673595,1,Endothelial Function and Autonomic Regulation After Short-term Smoking Cessation: Varenicline Versus Placebo,Basic Science,Parallel Assignment,Double Blind,Randomized,Drug|Drug,,Symptoms and General Pathology|All Conditions|Behaviors and Mental Disorders,OTHER,,Single,United States,7-Mar,5-May-08,9-Feb,10-Feb,21-Feb-12,Difficulty with recruiting sujects and subjects complying with the protocol,,2,19,Actual,40,Anticipated,TRUE,,19,19,0,0.48,0,19,0,,2 - No Scientific Data
NCT00673816,1,Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 1|Phase 2,Nervous System Diseases|Heart and Blood Diseases|All Conditions|Symptoms and General Pathology|Diseases and Abnormalities at or before Birth|Skin and Connective Tissue Diseases|Rare Diseases,NIH,,Single,United States,8-May,6-May-08,11-Feb,11-Feb,27-Sep-11,Inability to recruit and adequate number of participants,,2,2,Actual,8,,TRUE,,2,2,2,0.25,0,2,0,,2 - No Scientific Data
NCT00674128,1,Comparison of Cyanoacrylate Tissue Adhesive and Suture for Closure of Cardiac Device Pockets,Treatment,Parallel Assignment,Open Label,Randomized,Device|Device,,,OTHER,,Single,United States,8-May,5-May-08,9-May,9-May,5-Oct-10,Slow accrual.,,2,103,Actual,600,Anticipated,FALSE,E,94,103,46,0.17,0,0,0,,2 - No Scientific Data
NCT00674206,1,A Phase II Trial of Gemcitabine and Oxaliplatin for Triple Negative Metastatic Breast Cancer,Treatment,Single Group Assignment,Open Label,,Drug|Drug,Phase 2,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions,OTHER,,Single,United States,8-Oct,6-May-08,9-Aug,9-Oct,30-Mar-12,Sponsor funding stopped,,1,6,Actual,51,Anticipated,TRUE,,6,6,6,0.12,2,6,0,,2 - No Scientific Data
NCT00675922,1,Study of the Treatment of Burn Wounds With Antimicrobial Topical Soaks,Treatment,Single Group Assignment,Open Label,,Drug,Phase 2|Phase 3,Bacterial and Fungal Diseases|Wounds and Injuries|All Conditions,OTHER,,Single,United States,Jul-95,26-Dec-07,8-May,8-May,6-Aug-12,Data inconclusive.,,6,98,Actual,200,Anticipated,TRUE,,98,98,196,0.49,9,98,0,,1 - Scientific Data
NCT00677924,1,Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer,Treatment,Parallel Assignment,Open Label,Randomized,Drug,Phase 1|Phase 2,Cancers and Other Neoplasms|All Conditions|Digestive System Diseases,INDUSTRY,,Multiple,Belgium|Belgium|Belgium,8-Apr,13-May-08,9-Apr,9-Apr,12-Sep-11,Due to changes in portfolio review,,8,9,Actual,97,Anticipated,TRUE,,9,9,9,0.09,5,9,0,,2 - No Scientific Data
NCT00678288,1,A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 2,"Cancers and Other Neoplasms|All Conditions|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Rare Diseases",INDUSTRY,,Multiple,Austria|Austria|France|France|France|France|France|France|France|France|France|France|France|France|Ireland|Ireland|Italy|Italy|Italy|Italy|Italy|Italy|Poland|Poland|Poland|Poland|Spain|Spain|Spain|Spain|Spain|Spain|United Kingdom|United Kingdom|United Kingdom,8-Apr,14-May-08,9-Jun,9-Jun,10-Sep-10,,,9,16,Actual,130,Anticipated,TRUE,,16,16,0,0.12,8,16,0,,3 - No Reason Provided
NCT00678587,1,Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,"Viral Diseases|Immune System Diseases|All Conditions|Digestive System Diseases|Blood and Lymph Conditions|Symptoms and General Pathology|Bacterial and Fungal Diseases|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Rare Diseases",INDUSTRY,,Multiple,"United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Argentina|Argentina|Argentina|Argentina|Argentina|Belgium|Belgium|Belgium|Canada|Canada|Canada|Canada|France|France|France|France|France|France|France|France|France|France|India|India|India|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of|Pakistan|Pakistan|Poland|Poland|Poland|Poland|Poland|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Taiwan|Taiwan|Taiwan|Taiwan|Taiwan",8-Jun,13-May-08,9-Oct,9-Oct,10-Oct-10,GSK decision,,8,292,Actual,500,Anticipated,TRUE,,292,292,292,0.58,36,288,1,22913681,2 - No Scientific Data
NCT00679081,1,A Pilot Study of CelTx(TM) (Apligraf??) in the Treatment of Gingival Recession Requiring Root Coverage,Treatment,Parallel Assignment,Open Label,Randomized,Device|Other,Phase 1|Phase 2,Mouth and Tooth Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Single,United States,8-May,14-May-08,10-Sep,10-Sep,10-Oct-11,,,9,15,Actual,26,Anticipated,TRUE,,15,15,45,0.58,0,45,0,,3 - No Reason Provided
NCT00680316,1,A Study of Pulmozyme?? (Dornase Alpha) in 3- to 5-Year-Old Patients With Cystic Fibrosis,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 4,Digestive System Diseases|Respiratory Tract (Lung and Bronchial) Diseases|Diseases and Abnormalities at or before Birth|All Conditions|Symptoms and General Pathology|Rare Diseases,INDUSTRY,,,,8-Jun,16-May-08,9-May,9-May,31-Aug-10,"Most patients were unable to perform the test being used to measure lung function, thus it became clear the study would not yield clinically meaningful data",,4,3,Actual,40,Anticipated,TRUE,,3,3,0,0.08,0,3,0,,2 - No Scientific Data
NCT00681629,1,Schizophrenic Patients in Integrated Care,Treatment,Parallel Assignment,Open Label,Non-Randomized,Drug|Other,Phase 4,Behaviors and Mental Disorders|All Conditions,INDUSTRY,,Multiple,Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany,8-Jul,20-May-08,8-Nov,8-Nov,7-Apr-10,Difficulty finding eligible sites/patients; current situation in health policy cause negative effect on existing/planned contracts for integrated care program,,2,7,Actual,200,Anticipated,TRUE,,7,7,0,0.04,0,7,0,,2 - No Scientific Data
NCT00681668,1,Quetiapine in Postpartum Depression,Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|Behaviors and Mental Disorders|All Conditions",INDUSTRY,,Single,Germany,7-Aug,20-May-08,8-Oct,8-Oct,29-Oct-09,"Recruitment behind plan, no increase expected",,2,5,Actual,12,Anticipated,TRUE,,5,5,5,0.42,0,5,0,,2 - No Scientific Data
NCT00683085,1,Human Leukocyte Antigen-A*02:01-restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer,Treatment,Single Group Assignment,Open Label,Non-Randomized,Biological,Phase 1|Phase 2,Cancers and Other Neoplasms|Digestive System Diseases|Gland and Hormone Related Diseases|All Conditions|Rare Diseases,OTHER,,Single,Japan,8-May,16-May-08,9-May,9-May,9-Jun-09,Lack of eligible patient,,2,2,Actual,14,Anticipated,TRUE,,2,2,2,0.14,1,2,0,,2 - No Scientific Data
NCT00683449,1,Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma,Treatment,Parallel Assignment,Single Blind,Randomized,Drug|Drug|Drug|Drug,Phase 2,Respiratory Tract (Lung and Bronchial) Diseases|Immune System Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States,8-Jun,21-May-08,9-Mar,9-Mar,16-Feb-11,"Data from Dose Groups 1,2 and other MN-221 studies resulted in the determination of a more appropriate dosing scheme for MN-221 in subjects with asthma.",,6,29,Actual,36,Anticipated,TRUE,,29,29,29,0.81,6,29,0,,1 - Scientific Data
NCT00684242,1,Lenalidomide (Revlimid) for the Treatment of Refractory Cancer Pain,Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,Nervous System Diseases|Symptoms and General Pathology|All Conditions,OTHER,,Single,United States,8-May,22-May-08,11-Oct,11-Oct,20-Dec-12,Low accrual.,,2,4,Actual,15,Anticipated,FALSE,F,3,3,2,0.2,2,3,0,,2 - No Scientific Data
NCT00684255,1,Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc),Treatment,Parallel Assignment,Open Label,Non-Randomized,Procedure|Drug|Drug|Drug,Phase 1,Skin and Connective Tissue Diseases|Immune System Diseases|All Conditions|Symptoms and General Pathology|Rare Diseases,OTHER,,Single,United States,7-Aug,22-May-08,8-Jul,8-Jul,22-Dec-08,inactive,,10,1,Actual,12,Anticipated,TRUE,,1,1,0,0.08,0,1,0,,2 - No Scientific Data
NCT00685880,1,Prolotherapy Versus Steroids for Thumb Carpo-metacarpal Joint Arthritis,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,,"Muscle, Bone, and Cartilage Diseases|All Conditions|Skin and Connective Tissue Diseases",OTHER,,Single,United States,8-May,26-May-08,10-Jul,10-Jul,27-Jul-12,Unable to recruit adequate numbers of patients,,2,2,Actual,40,Anticipated,TRUE,,2,2,0,0.05,0,2,0,,2 - No Scientific Data
NCT00686036,1,Trial Assessing Zactima Against Placebo in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions",INDUSTRY,,Multiple,Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada,8-May,27-May-08,10-Apr,10-Oct,27-Apr-11,Slow recruitment,,2,17,Actual,100,Anticipated,TRUE,,17,17,0,0.17,2,17,0,,2 - No Scientific Data
NCT00686842,1,PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma,Treatment,Single Group Assignment,Open Label,,Drug|Genetic|Genetic|Genetic|Other|Other|Other|Procedure,Phase 1|Phase 2,Viral Diseases|Immune System Diseases|All Conditions|Cancers and Other Neoplasms|Rare Diseases,NETWORK,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States,8-Sep,29-May-08,10-Nov,10-Dec,30-Jan-12,Drug supply unavailable.,,3,17,Actual,45,,TRUE,,17,17,17,0.38,3,17,0,,2 - No Scientific Data
NCT00686881,1,Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773),Treatment,Parallel Assignment,Open Label,Randomized,Biological|Drug,Phase 3,Viral Diseases|Digestive System Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,,,6-Dec,27-May-08,11-Feb,11-Feb,3-Feb-12,This study was terminated due to low enrollment,,2,261,Actual,500,Anticipated,TRUE,,261,261,249,0.52,55,252,0,,2 - No Scientific Data
NCT00686894,1,Enthesitis With Ultra Sonography Doppler in Spondyloarthropathies Treated With Infliximab (Study P04440AM1)(TERMINATED),Diagnostic,Single Group Assignment,Open Label,,Procedure|Drug,Phase 4,"Bacterial and Fungal Diseases|Muscle, Bone, and Cartilage Diseases|All Conditions|Rare Diseases",INDUSTRY,,,,8-Jan,27-May-08,8-Nov,8-Nov,24-Nov-09,Poor Enrollment,,2,7,Actual,100,Anticipated,TRUE,,7,7,7,0.07,0,7,0,,2 - No Scientific Data
NCT00687531,0,"Clinical Trial to Assess Efficacy, Safety, Treatment Adherence and Quality of Life Impact of Mometasone Furoate in Asthmatic Patients (Study P04879)(TERMINATED)",Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 4,Respiratory Tract (Lung and Bronchial) Diseases|Immune System Diseases|All Conditions|Behaviors and Mental Disorders,INDUSTRY,,,,6-Nov,27-May-08,9-Sep,9-Sep,17-Jun-11,,,9,385,Actual,360,Actual,TRUE,,385,385,250,1.07,0,281,0,,3 - No Reason Provided
NCT00687544,0,Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED),Treatment,Single Group Assignment,Open Label,,Biological|Drug,Phase 4,"Viral Diseases|Immune System Diseases|All Conditions|Digestive System Diseases|Symptoms and General Pathology|Bacterial and Fungal Diseases|Urinary Tract, Sexual Organs, and Pregnancy Conditions",INDUSTRY,,,,5-Dec,27-May-08,8-Jun,8-Jun,22-Sep-11,,,9,11,Actual,11,Actual,TRUE,,11,11,0,1,1,11,0,,3 - No Reason Provided
NCT00687609,1,Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE,Treatment,Single Group Assignment,Open Label,,Drug,Phase 4,Nervous System Diseases|Symptoms and General Pathology|All Conditions|Substance Related Disorders|Behaviors and Mental Disorders,INDUSTRY,,Single,Netherlands,8-Sep,28-May-08,9-Jun,9-Jun,22-Jul-10,"The study was discontinued early, owing to difficulties in recruiting the target sample after seven patients had been recruited.",,2,7,Actual,30,Anticipated,TRUE,,7,7,0,0.23,0,7,0,,2 - No Scientific Data
NCT00687674,1,"Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug|Drug,Phase 1|Phase 2,Cancers and Other Neoplasms|Heart and Blood Diseases|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Rare Diseases,OTHER,,Single,United States,8-Aug,30-May-08,11-Nov,11-Nov,23-Nov-11,"Due to study design (and toxicity), this trial closed to accrual prior to opening the phase II portion.",,5,13,Actual,80,,TRUE,,13,13,12,0.16,3,13,0,,1 - Scientific Data
NCT00689052,1,Pramipexole ER vs. Placebo in Fibromyalgia,Treatment,Parallel Assignment,,,Drug,Phase 2,"Muscle, Bone, and Cartilage Diseases|Nervous System Diseases|All Conditions|Symptoms and General Pathology|Skin and Connective Tissue Diseases",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,8-Jul,29-May-08,8-Nov,,23-Oct-09,,,9,61,Actual,350,Anticipated,TRUE,,61,61,0,0.17,1,61,0,,3 - No Reason Provided
NCT00689884,1,Feasibility and Cost Analysis of PBSC Mobilization Using Pegfilgrastim in Hematologic Malignancies,Treatment,Single Group Assignment,Open Label,,Drug,,Cancers and Other Neoplasms|Blood and Lymph Conditions|All Conditions,OTHER,,Single,United States,7-Jan,30-May-08,9-Jan,9-Jan,16-Jan-12,Lack of enrollment.,,2,7,Actual,9,Anticipated,TRUE,,7,7,0,0.78,0,0,0,,2 - No Scientific Data
NCT00691652,1,Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma,Treatment,Single Group Assignment,Open Label,,Biological|Drug|Genetic|Genetic|Genetic|Genetic|Other|Other,Phase 1|Phase 2,Viral Diseases|Cancers and Other Neoplasms|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Rare Diseases,OTHER,,Single,United States,8-May,4-Jun-08,9-Jan,9-Apr,11-Aug-11,,,9,2,Actual,38,,TRUE,,2,2,2,0.05,0,2,0,,3 - No Reason Provided
NCT00692003,1,Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Nervous System Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Multiple,Australia|Australia|Australia|Australia|Australia|Croatia|Croatia|Croatia|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Estonia|Estonia|Estonia|Finland|Finland|Germany|Germany|Germany|Germany|Germany|Hungary|Hungary|Hungary|Hungary|Hungary|Hungary|Hungary|Hungary|Hungary|Lithuania|Lithuania|Lithuania|Poland|Poland|Poland|Poland|Poland|Poland|Romania|Romania|Romania|Romania|Romania|Romania|Romania|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Serbia|Serbia|Serbia|Serbia|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine,8-Aug,3-Jun-08,8-Nov,,13-Aug-12,Sponsor's decision,,8,21,Actual,154,Anticipated,FALSE,F,6,6,0,0.04,0,6,0,,2 - No Scientific Data
NCT00693017,1,Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Nervous System Diseases|All Conditions|Symptoms and General Pathology|Rare Diseases,INDUSTRY,,Multiple,Australia|Australia|Australia|Australia|Croatia|Croatia|Croatia|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Estonia|Estonia|Estonia|Finland|Finland|Germany|Germany|Germany|Germany|Germany|Hungary|Hungary|Hungary|Hungary|Hungary|Hungary|Hungary|Hungary|Hungary|Lithuania|Lithuania|Lithuania|Poland|Poland|Poland|Poland|Poland|Poland|Romania|Romania|Romania|Romania|Romania|Romania|Romania|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Serbia|Serbia|Serbia|Serbia|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine,8-Jun,3-Jun-08,8-Nov,,13-Aug-12,Sponsor's decision,,8,10,Actual,10,Anticipated,FALSE,F,4,4,0,0.4,1,4,0,,2 - No Scientific Data
NCT00694603,1,Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy,Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,OTHER,,Multiple,United States|United States|United States,6-Sep,28-Dec-07,9-Sep,9-Sep,28-Apr-12,Slow accrual,,2,56,Actual,56,Anticipated,FALSE,F,18,18,18,0.32,4,18,1,20975380,2 - No Scientific Data
NCT00695396,1,"A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion",Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug|Drug,Phase 3,Cancers and Other Neoplasms|Blood and Lymph Conditions|All Conditions|Symptoms and General Pathology|Rare Diseases,INDUSTRY,,,,8-Jun,5-Jun-08,10-Jan,10-Jan,8-Feb-11,The study was stopped due to low subject enrollment. No safety issue or other concern factored into this decision.,,2,25,Actual,450,Anticipated,TRUE,,25,25,25,0.06,8,25,0,,2 - No Scientific Data
NCT00695903,1,"Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia",Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Bacterial and Fungal Diseases|All Conditions|Symptoms and General Pathology|Heart and Blood Diseases|Rare Diseases,INDUSTRY,,Multiple,United States|United States,8-Sep,10-Jun-08,10-Aug,10-Oct,23-Aug-11,terminated due to lack of enrollment,,2,38,Actual,80,Anticipated,TRUE,,38,38,36,0.48,7,36,0,,2 - No Scientific Data
NCT00696787,1,A Study Evaluating Desvenlafaxine Sustained Release (DVS SR) in Adult Female Outpatients With Fibromyalgia,Treatment,Parallel Assignment,Double-Blind,Randomized,Drug|Drug|Drug,Phase 2,"Muscle, Bone, and Cartilage Diseases|Nervous System Diseases|All Conditions|Symptoms and General Pathology|Skin and Connective Tissue Diseases",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,8-Jun,11-Jun-08,9-Jan,9-Jan,29-Jan-10,,,9,125,Actual,420,Anticipated,TRUE,,125,125,125,0.3,1,125,0,,3 - No Reason Provided
NCT00697593,1,ChangE From Any Systemic psoriasiS therapY to Raptiva,Treatment,Single Group Assignment,Open Label,,Drug,Phase 4,Skin and Connective Tissue Diseases|All Conditions,INDUSTRY,,Single,Canada,8-Jan,11-Jun-08,9-Apr,9-Apr,29-Jun-10,The study was terminated after the European Medicines Agency recommended to suspend the marketing authorisation of Raptiva in the European Union,,16,70,Actual,182,Anticipated,TRUE,,70,70,69,0.38,0,70,0,,2 - No Scientific Data
NCT00697827,1,A Study of the In-Space Device for Treatment of Moderate Spinal Stenosis,Treatment,Parallel Assignment,Open Label,Randomized,Device|Device,Phase 3,"Muscle, Bone, and Cartilage Diseases|All Conditions|Symptoms and General Pathology",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,8-Jun,11-Jun-08,11-Jun,11-Jun,3-May-12,Study terminated due to low enrollment.,,2,44,Actual,500,Anticipated,TRUE,,44,44,41,0.09,28,44,0,,2 - No Scientific Data
NCT00698009,1,Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma,Treatment,Single Group Assignment,Open Label,,Drug|Drug|Biological|Drug|Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Rare Diseases,OTHER,,Single,United States,8-Jun,12-Jun-08,12-Jun,12-Jun,23-Oct-12,Slow accrual.,,2,1,Actual,10,Anticipated,TRUE,,1,1,0,0.1,0,1,0,,2 - No Scientific Data
NCT00698685,1,Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation,Treatment,Single Group Assignment,Open Label,,Drug|Biological|Procedure,Phase 2,"Cancers and Other Neoplasms|All Conditions|Blood and Lymph Conditions|Immune System Diseases|Heart and Blood Diseases|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Symptoms and General Pathology|Rare Diseases",OTHER,,Multiple,United States|United States,5-Nov,14-Jun-08,9-Nov,10-Nov,28-Dec-10,Data indicate pentostatin/alemtuzumab regimen assocciated w/greater risk of graft failure when compared w/standard-reduced intensity regimen.,,5,14,Actual,115,,TRUE,,14,14,13,0.12,8,13,0,,1 - Scientific Data
NCT00699374,1,Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 3,Cancers and Other Neoplasms|All Conditions|Digestive System Diseases|Rare Diseases,INDUSTRY,,Multiple,"United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Australia|Australia|Australia|Australia|Australia|Belgium|Belgium|Belgium|Canada|Canada|Canada|Canada|Canada|China|China|China|China|China|China|China|China|China|China|China|China|China|China|China|China|China|France|France|France|France|France|France|France|France|France|France|France|France|France|Germany|Germany|Germany|Germany|Hong Kong|Hong Kong|Hong Kong|Hong Kong|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of|Malaysia|Malaysia|Malaysia|Philippines|Philippines|Philippines|Philippines|Philippines|Philippines|Philippines|Philippines|Poland|Poland|Russian Federation|Russian Federation|Russian Federation|Singapore|Singapore|South Africa|Spain|Spain|Spain|Spain|Spain|Sweden|Taiwan|Taiwan|Taiwan|Taiwan|Taiwan|Taiwan|Taiwan|Taiwan|Taiwan|Taiwan|Taiwan|Thailand|Thailand|Thailand|Turkey|Turkey|United Kingdom|United Kingdom|United Kingdom",8-Jul,16-Jun-08,11-Dec,11-Dec,7-Dec-12,See termination reason in detailed description.,"This study was terminated on April 22th, 2010, based on a higher incidence of serious adverse events in the sunitinib arm compared to the sorafenib arm, and the fact that sunitinib did not meet the criteria to demonstrate that it was either superior or non-inferior to sorafenib in the survival of patients with advanced hepatocellular cancer. Patients on sunitinib who are judged by the investigator as receiving clinical benefit may chose to remain on study and continue treatment with sunitinib until clinical benefit as per the investigator's judgment.",5,1075,Actual,1200,Anticipated,FALSE,F,1074,1074,1074,0.9,444,1068,1,24081937,1 - Scientific Data
NCT00700011,1,Clofarabine for Myelodysplastic Syndrome (MDS) Patients Who Failed Vidaza Treatment (tx),Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug,Phase 2,Cancers and Other Neoplasms|Blood and Lymph Conditions|All Conditions|Symptoms and General Pathology|Rare Diseases,INDUSTRY,,Single,United States,8-Mar,17-Jun-08,10-Mar,10-Mar,6-Dec-12,poor accrual,,2,10,Actual,20,Anticipated,TRUE,,10,10,10,0.5,8,10,1,21067443,2 - No Scientific Data
NCT00701935,1,Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Nutritional and Metabolic Diseases|Gland and Hormone Related Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada,8-Aug,17-Jun-08,12-Jan,12-Jan,11-Jan-13,"Enrollment was much slower than anticipated, leading to a decision to terminate the study early for enrollment futility.",,2,80,Actual,94,Anticipated,TRUE,,80,80,56,0.85,4,80,0,,2 - No Scientific Data
NCT00703339,1,Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis,Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,Respiratory Tract (Lung and Bronchial) Diseases|All Conditions|Symptoms and General Pathology|Heart and Blood Diseases|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States,8-Jun,19-Jun-08,9-Dec,9-Dec,25-Feb-11,Lack of enrollment to the trial. Very difficult population to recruit.,,2,1,Actual,16,Anticipated,TRUE,,1,1,0,0.06,0,1,0,,2 - No Scientific Data
NCT00704847,1,Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (OA 2 Study),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,"Muscle, Bone, and Cartilage Diseases|All Conditions|Skin and Connective Tissue Diseases",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|Belgium|Canada|Czech Republic|Denmark|Denmark|Denmark|Hong Kong|Poland|Poland|Romania|Spain|United Kingdom,8-Jun,24-Jun-08,11-May,11-Jun,13-Aug-12,Male subjects were terminated due to an imbalance in prostate cancer events,,5,1030,Actual,920,Anticipated,TRUE,,1030,1030,1028,1.12,157,1028,0,,1 - Scientific Data
NCT00704938,1,"Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer",Treatment,Single Group Assignment,Open Label,Non-Randomized,Biological|Biological|Biological|Biological|Drug|Drug,Phase 2,"Cancers and Other Neoplasms|All Conditions|Symptoms and General Pathology|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Rare Diseases",NIH,,Single,United States,8-Jun,24-Jun-08,9-Aug,9-Aug,10-Jul-12,Terminated due to withdrawal of support from our collaborator.,,1,3,Actual,82,,TRUE,,3,3,3,0.04,0,3,0,,2 - No Scientific Data
NCT00706355,1,A Study of PF-04217903 in Patients With Advanced Cancer,Treatment,Single Group Assignment,Open Label,,Drug,Phase 1,,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States,8-Aug,25-Jun-08,11-Jun,11-Jun,26-Apr-12,See termination reason in detailed description.,The study was prematurely discontinued due to a strategic development decision by Pfizer on 10FEB2012. The decision to terminate was not based on any safety concerns.,8,16,Actual,40,Anticipated,FALSE,E,3,16,16,0.4,6,16,0,,2 - No Scientific Data
NCT00706797,1,Study Evaluating Efficacy / Safety of Etanercept + Methotrexate Compared to Usual Treatment in Moderate RA Subjects,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 4,"Muscle, Bone, and Cartilage Diseases|All Conditions|Skin and Connective Tissue Diseases|Immune System Diseases",INDUSTRY,,Multiple,Czech Republic|Czech Republic|Czech Republic|France|France|France|France|France|France|France|France|France|France|France|France|Germany|Germany|Germany|Germany|Germany|Germany|Hungary|Hungary|Hungary|Hungary|Hungary|Hungary|Italy|Italy|Poland|Poland|Poland|Poland|Poland|Poland|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Turkey|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom,8-Sep,25-Jun-08,9-Dec,10-May,22-Dec-10,,,9,141,Actual,700,Anticipated,TRUE,,141,141,0,0.2,9,134,0,,3 - No Reason Provided
NCT00707161,1,Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma,Treatment,Single Group Assignment,Open Label,,Radiation|Drug|Procedure,Phase 2,Cancers and Other Neoplasms|All Conditions|Rare Diseases,OTHER,,Multiple,United States|United States,5-Sep,26-Jun-08,10-Feb,10-Feb,20-Apr-11,Study was closed due to low accrual.,,2,6,Actual,25,Anticipated,TRUE,,6,6,0,0.24,0,6,0,,2 - No Scientific Data
NCT00707239,1,Study Evaluating Safety and Efficacy of Tigecycline Versus Imipenem/Cilastatin Subjects With Hospital-Acquired Pneumonia,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 2,Bacterial and Fungal Diseases|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,INDUSTRY,,Multiple,"United States|United States|United States|Argentina|Argentina|Argentina|Argentina|Australia|Australia|Brazil|Brazil|Brazil|Canada|Canada|Chile|Colombia|Colombia|Croatia|France|Hungary|Hungary|Hungary|Hungary|Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of|Latvia|Latvia|Latvia|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Taiwan|Taiwan|Taiwan|Taiwan",8-Dec,26-Jun-08,11-Jun,11-Jun,5-Jun-12,See termination reason in detailed description.,"The sponsor internal decision has been taken to close the study on 15 of July 2011, due to difficulties in enrollment. This decision was not based on any safety issues.",2,108,Actual,210,Anticipated,TRUE,,108,108,67,0.51,31,105,1,23357775,2 - No Scientific Data
NCT00707655,1,Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 1|Phase 2,Cancers and Other Neoplasms|All Conditions|Rare Diseases,INDUSTRY,,Multiple,Belgium|France|France|France|United Kingdom|United Kingdom|United Kingdom|United Kingdom,8-Sep,27-Jun-08,10-Oct,10-Oct,7-Oct-11,The decision is based on company re-evaluation of indications to be pursued within SCCHN,,8,8,Actual,24,Anticipated,TRUE,,8,8,8,0.33,5,8,0,,2 - No Scientific Data
NCT00708877,1,Liver Transplantation for Cholangiocarcinoma,Treatment,Single Group Assignment,Open Label,,Procedure,,Cancers and Other Neoplasms|All Conditions,OTHER,,Single,United States,7-Mar,27-Jun-08,11-Jul,11-Jul,13-Dec-11,study procedures have become standard of care as patients seeking Model for End-Stage Liver Disease (MELD) exception points for cholangiocarcinoma,,7,5,Actual,50,Anticipated,TRUE,,5,5,5,0.1,0,5,0,,2 - No Scientific Data
NCT00710905,1,Visual Function With Contralateral AcrySof?? ReSTOR?? Aspheric SN6AD1 and SN6AD3,Treatment,Single Group Assignment,Open Label,Non-Randomized,Device,Phase 4,Eye Diseases|All Conditions,INDUSTRY,,Multiple,Canada|Canada,9-Oct,3-Jul-08,10-Sep,10-Sep,4-Oct-11,Postmarket study terminated as the SN6AD3 is no longer promoted.,,16,50,Actual,40,Anticipated,TRUE,,50,50,34,1.25,1,50,0,,2 - No Scientific Data
NCT00713258,1,The Effect of PTH(1-84) or Alendronate on Reduction of Back Pain in Postmenopausal Women With an Osteoporosis Related Vertebral Fracture(s) (FP-005-IM),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 4,"Muscle, Bone, and Cartilage Diseases|All Conditions|Nervous System Diseases|Symptoms and General Pathology|Wounds and Injuries",INDUSTRY,,Single,Denmark,8-Apr,2-Jul-08,10-May,10-Sep,28-Jul-11,Slow enrolment,,2,75,Actual,300,Anticipated,TRUE,,75,75,0,0.25,6,75,0,,2 - No Scientific Data
NCT00713596,1,Study Evaluating Benefit of Using Fibrin Glue in Septorhinoplasty,Treatment,Factorial Assignment,Double Blind,Randomized,Drug|Procedure|Procedure|Procedure|Other,,Symptoms and General Pathology|All Conditions|Wounds and Injuries,OTHER,,Single,United States,8-Jul,9-Jul-08,10-Jan,10-Jan,19-Apr-12,Lead investigator moved to a new medical center; study was stopped when he left.,,4,25,Actual,60,Anticipated,TRUE,,25,25,0,0.42,0,25,0,,2 - No Scientific Data
NCT00715559,1,Cysteamine Therapy for Major Depressive Disorder,Treatment,Single Group Assignment,Open Label,,Drug,,Behaviors and Mental Disorders|All Conditions,INDIV,,Single,United States,8-Jul,11-Jul-08,9-May,9-May,18-Apr-11,Change in resources available for study procedures.,,1,3,Actual,20,Anticipated,TRUE,,3,3,3,0.15,0,3,0,,2 - No Scientific Data
NCT00716443,1,"Evaluate Efficacy, Safety & Subject Satisfaction of Pain Management With Pliaglis?? Cream for Dermal Filler Injections",Treatment,Single Group Assignment,Single Blind,Randomized,Drug|Drug,Phase 4,Nervous System Diseases|Symptoms and General Pathology|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States,8-Jul,14-Jul-08,8-Sep,8-Sep,25-Sep-09,Sponsor decision,,8,51,Actual,60,Anticipated,TRUE,,51,51,102,0.85,0,51,0,,2 - No Scientific Data
NCT00717275,1,Study of Temozolomide to Treat Newly Diagnosed Brain Metastases,Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,Cancers and Other Neoplasms|Symptoms and General Pathology|All Conditions|Nervous System Diseases,OTHER,,Single,United States,8-Sep,15-Jul-08,11-Jan,11-Jun,10-Jul-12,Slow accrual.,,2,3,Actual,30,Anticipated,TRUE,,3,3,0,0.1,0,3,0,,2 - No Scientific Data
NCT00719914,0,A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug,Phase 2,Heart and Blood Diseases|All Conditions|Symptoms and General Pathology,OTHER,,Multiple,United States|United States|United States,7-Nov,7-Jan-08,8-Nov,9-Jan,24-Jul-12,Poor enrollment,,2,31,Actual,31,Actual,FALSE,F,17,17,0,0.55,0,0,0,,2 - No Scientific Data
NCT00720096,1,Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Gland and Hormone Related Diseases|All Conditions|Rare Diseases",OTHER,,Single,United States,8-Jul,21-Jul-08,9-Oct,9-Oct,15-Oct-10,"Funds for this project have been spent, and it is thereby terminated.",,1,4,Actual,48,Anticipated,TRUE,,4,4,4,0.08,2,4,0,,2 - No Scientific Data
NCT00722072,1,Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy,Treatment,Single Group Assignment,Open Label,,Drug|Drug,Phase 2,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions|Rare Diseases,OTHER,,Single,United States,8-Jul,24-Jul-08,10-Jul,12-Jul,4-Aug-11,,,9,12,Actual,43,Anticipated,TRUE,,12,12,12,0.28,3,9,0,,3 - No Reason Provided
NCT00723554,1,Iloprost Power Disc-15 in Pulmonary Arterial Hypertension,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug,Phase 3,Respiratory Tract (Lung and Bronchial) Diseases|Symptoms and General Pathology|All Conditions|Heart and Blood Diseases|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,8-Jul,24-Jul-08,10-Aug,11-Apr,14-Jan-13,sponsor's decision,,8,63,Actual,150,Anticipated,TRUE,,63,63,63,0.42,18,63,0,,2 - No Scientific Data
NCT00726739,1,Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma,Treatment,Crossover Assignment,Open Label,Randomized,Biological|Biological,Phase 2,Cancers and Other Neoplasms|All Conditions|Rare Diseases,OTHER,,Single,United States,8-Jun,31-Jul-08,11-Jun,11-Jun,29-Aug-12,Pre-planned analysis established it unlikely study would meet primary objective.,,6,21,Actual,102,Anticipated,TRUE,,21,21,21,0.21,4,20,1,23241505,1 - Scientific Data
NCT00726830,1,"Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer",Supportive Care,Single Group Assignment,Open Label,Randomized,Drug|Drug|Drug,,Bacterial and Fungal Diseases|All Conditions|Viral Diseases|Immune System Diseases|Cancers and Other Neoplasms|Blood and Lymph Conditions|Heart and Blood Diseases|Nervous System Diseases|Symptoms and General Pathology|Diseases and Abnormalities at or before Birth|Nutritional and Metabolic Diseases|Rare Diseases,OTHER,,Multiple,United States|United States,9-Mar,31-Jul-08,10-Sep,10-Oct,9-Nov-12,Low Accrual.,,2,1,Actual,300,Anticipated,TRUE,,1,1,0,0,0,1,0,,2 - No Scientific Data
NCT00727090,1,Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients,Treatment,Parallel Assignment,Single Blind,Randomized,Drug,Phase 4,Nutritional and Metabolic Diseases|All Conditions,OTHER,,,,8-Aug,30-Jul-08,9-Aug,10-Feb,21-Jul-10,Enrollment below goal.,,2,6,Actual,20,Anticipated,TRUE,,6,6,6,0.3,4,6,1,20568023,2 - No Scientific Data
NCT00729781,1,Study of Polyester Implants for the Treatment of External Nasal Valve Collapse (NVC),Treatment,Single Group Assignment,Open Label,Non-Randomized,Device,Phase 1|Phase 2,"Respiratory Tract (Lung and Bronchial) Diseases|Ear, Nose, and Throat Diseases|All Conditions|Diseases and Abnormalities at or before Birth|Symptoms and General Pathology",INDUSTRY,,Multiple,United States|United States|United States|United States|United States,8-Apr,5-Aug-08,9-Nov,11-Jan,23-Aug-11,Strategic Business Decision,,8,45,Actual,72,Anticipated,TRUE,,45,45,45,0.63,0,45,0,,2 - No Scientific Data
NCT00730041,0,Palatal Implants in Combination With Continuous Positive Airway Pressure to Treat Obstructive Sleep Apnea,Treatment,Parallel Assignment,Double Blind,Randomized,Device|Device,Phase 4,Respiratory Tract (Lung and Bronchial) Diseases|Symptoms and General Pathology|All Conditions|Nervous System Diseases|Behaviors and Mental Disorders,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States,7-Nov,6-Aug-08,8-Sep,9-Mar,7-Aug-09,"Medtronic acquisition of Restore Medical, business decision",,8,51,Actual,52,Actual,TRUE,,51,51,50,0.98,0,51,0,,2 - No Scientific Data
NCT00730847,1,Evaluate Safety of a Vaccine Against Cervical Cancer (HPV-16/18 L1/AS04) in Healthy Filipino Females Aged 10 Yrs & Above,Prevention,Single Group Assignment,Open Label,,Biological,Phase 4,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions",INDUSTRY,,Multiple,Philippines|Philippines,8-Sep,6-Aug-08,12-Jan,12-Jan,21-Nov-12,GSK received exemption from PDFDA on conduct of this post-marketing surveillance (PMS) study,,7,596,Actual,3000,Anticipated,TRUE,,596,596,596,0.2,4,596,0,,2 - No Scientific Data
NCT00732940,1,Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE),Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 2,Skin and Connective Tissue Diseases|Immune System Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Mexico,8-Oct,8-Aug-08,9-Oct,12-Mar,7-Apr-11,Sponsor terminated study for business reasons.,,8,56,Actual,56,Anticipated,TRUE,,56,56,56,1,6,56,0,,2 - No Scientific Data
NCT00735436,1,A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM),Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Rare Diseases,OTHER,,Single,United States,8-Dec,13-Aug-08,11-Jul,12-Oct,31-Dec-12,Study enrollment was halted due to slow accrual.,,2,18,Actual,50,Anticipated,TRUE,,18,18,18,0.36,8,18,0,,2 - No Scientific Data
NCT00737061,0,Safety & Efficacy Study of the Adiana System for Women Who Desire Permanent Birth Control (Sterilization),Basic Science,Single Group Assignment,Open Label,,Device,,,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Australia|Mexico,2-Nov,14-Aug-08,5-Dec,15-Dec,26-Aug-09,Product Pre-Market Approval withdrawn,,16,770,Actual,770,Actual,FALSE,F,645,645,570,0.84,60,645,1,19037035,2 - No Scientific Data
NCT00737360,1,Phase II Study of TAS-106 to Treat Head and Neck Cancer,Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,Cancers and Other Neoplasms|All Conditions,INDUSTRY,,Multiple,United States|United States|Hong Kong|Singapore|Taiwan,8-Aug,18-Aug-08,11-Jun,12-Feb,20-Apr-12,,,9,27,Actual,52,Anticipated,TRUE,,27,27,26,0.52,15,27,1,23930212,3 - No Reason Provided
NCT00737633,1,Open-Label Study to Evaluate the Long-Term Safety and Efficacy of VI-0521 in Type 2 Diabetic Adults,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 2,Nutritional and Metabolic Diseases|Gland and Hormone Related Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States,8-Aug,17-Aug-08,9-Mar,9-Jun,31-Jul-12,Limited regulatory value to uncontrolled trials. No safety/efficacy concerns.,,8,101,Actual,120,Anticipated,TRUE,,101,101,101,0.84,1,101,0,,2 - No Scientific Data
NCT00739024,1,A Study of a Melatonin Receptor Agonist to Prevent Migraine,Prevention,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Nervous System Diseases|Symptoms and General Pathology|All Conditions,OTHER,,Single,United States,8-Apr,19-Aug-08,9-Apr,10-Sep,22-Jul-11,Recruitment slow and administrative reasons,,2,18,Actual,30,Anticipated,FALSE,F,13,13,0,0.43,0,13,0,,2 - No Scientific Data
NCT00739050,1,Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus (0733-271)(TERMINATED),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 4,Skin and Connective Tissue Diseases|Immune System Diseases|All Conditions,INDUSTRY,,,,7-Aug,19-Aug-08,9-Jun,9-Jun,26-Aug-10,,,9,4,Actual,20,Anticipated,TRUE,,4,4,0,0.2,0,4,0,,3 - No Reason Provided
NCT00739063,1,"Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer",Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions,OTHER,,Single,United States,8-Jul,19-Aug-08,10-Nov,10-Nov,21-Dec-11,Poor Accrual,,2,11,Actual,50,Anticipated,TRUE,,11,11,0,0.22,2,3,0,,2 - No Scientific Data
NCT00739882,1,TRUST Study: Raptiva ?? in Hand & Foot Psoriasis,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 4,Skin and Connective Tissue Diseases|All Conditions,INDUSTRY,,Single,Austria,8-Apr,20-Aug-08,9-Jun,9-Jun,28-Jun-10,The study was terminated after the European Medicines Agency recommended to suspend the marketing authorisation of Raptiva in the European Union,,16,76,Actual,168,Anticipated,TRUE,,76,76,0,0.45,4,107,0,,2 - No Scientific Data
NCT00740714,1,Effects of Coenzyme Q10 (CoQ) in Parkinson Disease,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Nervous System Diseases|All Conditions|Cancers and Other Neoplasms|Skin and Connective Tissue Diseases,OTHER,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada,8-Dec,22-Aug-08,11-Aug,11-Aug,24-Jul-12,"The investigational drug is unlikely to demonstrate efficacy over placebo for this indication. However, no safety issues were discovered.",,6,600,Actual,600,Anticipated,TRUE,,600,600,600,1,33,600,0,,1 - Scientific Data
NCT00741611,1,Study of HD Mesh Ablation System for Treatment of Paroxysmal Atrial Fibrillation,Treatment,Parallel Assignment,Single Blind,Randomized,Device|Drug,Phase 3,Heart and Blood Diseases|Symptoms and General Pathology|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,8-Jul,25-Aug-08,9-Nov,9-Nov,27-Aug-12,Business reasons,,8,44,Actual,369,Anticipated,FALSE,F,36,36,36,0.1,18,36,0,,2 - No Scientific Data
NCT00742053,1,Electrocardiogram (ECG) Guided Peripherally Inserted Central Catheter (PICC) Placement,Basic Science,Single Group Assignment,Open Label,,Device,,,INDUSTRY,,Single,United States,8-Jun,25-Aug-08,8-Dec,9-Mar,25-Apr-12,Enrollment rate was too slow.,,2,7,Actual,15,Anticipated,TRUE,,7,7,6,0.47,0,7,1,20206940,2 - No Scientific Data
NCT00743197,1,Women With Chest Pain and Normal Coronary Arteries Study,Prevention,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug|Drug|Behavioral,,Nervous System Diseases|Symptoms and General Pathology|All Conditions|Heart and Blood Diseases,OTHER,,Single,United States,8-May,26-Aug-08,10-May,10-May,13-Sep-11,Terminated due to departure of PI from institution.,,4,3,Actual,100,Anticipated,TRUE,,3,3,0,0.03,0,3,0,,2 - No Scientific Data
NCT00745030,1,Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,,Nervous System Diseases|Behaviors and Mental Disorders|All Conditions|Heart and Blood Diseases|Symptoms and General Pathology|Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|Rare Diseases,OTHER,,Single,United States,8-Jun,28-Aug-08,9-Dec,9-Dec,12-Oct-10,Low subject recruitment and enrollment.,,2,3,Actual,20,Anticipated,TRUE,,3,3,0,0.15,0,3,0,,2 - No Scientific Data
NCT00745823,1,A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 3,Viral Diseases|Immune System Diseases|All Conditions,INDUSTRY,,,,8-Sep,2-Sep-08,10-Oct,11-May,6-Mar-12,Primary efficacy analysis at Week 48 did not demonstrate non-inferiority of raltegravir 800 mg once daily versus raltegravir 400 mg twice daily,,6,775,Actual,750,Anticipated,TRUE,,775,775,770,1.03,75,770,1,21933752,1 - Scientific Data
NCT00747812,1,Study of Occipital Nerve Stimulation for Drug Refractory Migraine,Treatment,Crossover Assignment,Double Blind,Randomized,Device,Phase 2,Nervous System Diseases|Symptoms and General Pathology|All Conditions,INDUSTRY,,Single,United Kingdom,6-May,4-Sep-08,8-Nov,12-May,28-Jun-12,Sponsor closed enrollment early based on interim data from the PRISM US Pivotal Study.,,7,11,Actual,25,Anticipated,FALSE,F,8,8,8,0.32,6,9,0,,2 - No Scientific Data
NCT00748579,1,Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug,Phase 2,Heart and Blood Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|Canada,8-Sep,21-Apr-08,8-Nov,9-Jul,30-Jul-10,Decision to discontinue was due to the challenges of the trial design and the constraints on enrolling eligible and consenting patients.,,4,2,Actual,18,Anticipated,TRUE,,2,2,0,0.11,0,2,0,,2 - No Scientific Data
NCT00752622,1,Treatment With Infliximab in a Medical Setting (Study P05587)(COMPLETED),Treatment,Parallel Assignment,Open Label,Randomized,Biological|Biological|Biological,Phase 4,Digestive System Diseases|All Conditions,INDUSTRY,,,,8-Nov,12-Sep-08,10-Jun,10-Jun,23-Jun-11,"Factors that led to termination: recruitment challenges and a lower incidence of flares than estimated, causing a high risk of the study being underpowered.",,2,100,Actual,120,Anticipated,TRUE,,100,100,98,0.83,10,100,0,,2 - No Scientific Data
NCT00754013,1,"Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10",Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Nervous System Diseases|Diseases and Abnormalities at or before Birth|All Conditions|Symptoms and General Pathology|Behaviors and Mental Disorders,INDUSTRY,,Multiple,United States|United States,8-Sep,15-Sep-08,8-Oct,8-Dec,21-Jul-11,Sufficient evidence of efficacy not met.,,6,9,Actual,140,Anticipated,TRUE,,9,9,0,0.06,0,9,0,,1 - Scientific Data
NCT00754793,1,Sinusitis and Facial Pain Disorders Anti-Depression Trial,Treatment,Single Group Assignment,Double Blind,Randomized,Drug|Drug,Phase 4,"Respiratory Tract (Lung and Bronchial) Diseases|Ear, Nose, and Throat Diseases|All Conditions|Nervous System Diseases|Symptoms and General Pathology|Behaviors and Mental Disorders|Bacterial and Fungal Diseases",OTHER,,Single,United States,9-Jan,16-Sep-08,10-Aug,12-Dec,13-Jun-12,poor recruitment,,2,3,Actual,20,Anticipated,TRUE,,3,3,0,0.15,0,3,0,,2 - No Scientific Data
NCT00758342,0,Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 4,Eye Diseases|All Conditions|Heart and Blood Diseases,INDUSTRY,,Single,United States,6-May,23-Sep-08,8-Mar,,10-Sep-09,difficulty of enrolling patients,,2,37,Actual,37,Actual,TRUE,,37,37,37,1,0,37,0,,2 - No Scientific Data
NCT00758680,1,A Multiple-Dose Study of MK-1006 (MK-1006-004)(TERMINATED),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 1,Nutritional and Metabolic Diseases|Gland and Hormone Related Diseases|All Conditions,INDUSTRY,,,,8-Aug,23-Sep-08,10-Mar,10-Mar,24-Jul-12,,,9,112,Actual,128,Anticipated,TRUE,,112,112,112,0.88,2,112,0,,3 - No Reason Provided
NCT00759577,1,"Feasibility of ""At-home"" Titration of Solifenacin",Treatment,Single Group Assignment,Open Label,,Drug,Phase 4,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|Symptoms and General Pathology|All Conditions|Behaviors and Mental Disorders",OTHER,,,,8-Sep,24-Sep-08,10-May,10-May,18-Nov-11,difficulty with enrollment,,2,36,Actual,100,Anticipated,TRUE,,36,36,0,0.36,0,0,0,,2 - No Scientific Data
NCT00759655,1,Study Evaluating The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of Age,Treatment,Single Group Assignment,Open Label,Non-Randomized,Biological,Phase 3,Heart and Blood Diseases|Blood and Lymph Conditions|All Conditions|Diseases and Abnormalities at or before Birth|Symptoms and General Pathology|Rare Diseases,INDUSTRY,,,,9-Jun,23-Sep-08,9-Dec,9-Dec,14-Dec-10,See termination reason in detailed description.,The study was terminated on 22 Sept 2009 due to competition with another Wyeth study for a similar patient population. The decision to terminate the trial was not based on any safety issues.,7,1,Actual,30,Anticipated,TRUE,,1,1,1,0.03,1,1,0,,2 - No Scientific Data
NCT00761514,0,Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With Humira,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 4,"Muscle, Bone, and Cartilage Diseases|All Conditions|Skin and Connective Tissue Diseases|Immune System Diseases|Behaviors and Mental Disorders",INDUSTRY,,Multiple,Puerto Rico|Puerto Rico|Puerto Rico|Puerto Rico|Puerto Rico|Puerto Rico|Puerto Rico|Puerto Rico|Puerto Rico|Puerto Rico,6-Nov,25-Sep-08,8-Aug,8-Aug,26-Aug-09,The study was terminated due to low enrollment.,,2,14,Actual,50,Anticipated,TRUE,,14,14,14,0.28,2,14,0,,2 - No Scientific Data
NCT00762359,1,A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Digestive System Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Multiple,Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan,7-May,26-Sep-08,8-Nov,8-Nov,3-Feb-11,AG-1749 superior to Gefarnate in ulcer prevention,,6,461,Actual,812,Anticipated,TRUE,,461,461,460,0.57,53,460,1,21499703,1 - Scientific Data
NCT00765102,1,Trial of Romidepsin and Bortezomib for Multiple Myeloma,Treatment,Single Group Assignment,Open Label,,Drug|Drug,Phase 2,Cancers and Other Neoplasms|Heart and Blood Diseases|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,8-Sep,30-Sep-08,10-Mar,10-Mar,26-Sep-12,There was a change in the Sponsor's research strategy; safety concerns were not a factor.,,8,32,Actual,60,Anticipated,TRUE,,32,32,0,0.53,14,32,0,,2 - No Scientific Data
NCT00765726,1,Study Evaluating The Safety Of Xyntha In Usual Care Settings,Treatment,Single Group Assignment,Open Label,Non-Randomized,Biological|Procedure,Phase 4,Heart and Blood Diseases|Blood and Lymph Conditions|All Conditions|Diseases and Abnormalities at or before Birth|Symptoms and General Pathology|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|New Zealand,9-Feb,2-Oct-08,11-Jul,11-Aug,16-Dec-11,See termination reason in detailed description.,"The study was terminated on May 12, 2011 due to poor enrollment prospects and the study's similarity to another ongoing trial with ReFacto AF.",2,12,Actual,250,Anticipated,TRUE,,12,12,12,0.05,2,12,0,,2 - No Scientific Data
NCT00767000,1,Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Biological|Drug,Phase 2,"Cancers and Other Neoplasms|Muscle, Bone, and Cartilage Diseases|Diseases and Abnormalities at or before Birth|All Conditions|Nutritional and Metabolic Diseases|Gland and Hormone Related Diseases",INDUSTRY,,,,8-Oct,3-Oct-08,10-Apr,10-Jun,19-Jun-12,,The termination of this study has no impact on subject safety or well being. The decision to terminate the trial was not based on any safety concerns.,9,813,Actual,550,Anticipated,TRUE,,813,813,813,1.48,55,813,1,21994424,3 - No Reason Provided
NCT00767039,1,Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 4,Respiratory Tract (Lung and Bronchial) Diseases|Diseases and Abnormalities at or before Birth|All Conditions|Heart and Blood Diseases|Symptoms and General Pathology|Rare Diseases,OTHER,,Single,United States,5-Jan,17-Dec-07,8-Sep,9-Jan,27-Apr-11,"Slow recruitment,changes in protocols, larger than anticipated differences",,2,52,Actual,70,Anticipated,TRUE,,52,52,50,0.74,28,52,1,20336076,2 - No Scientific Data
NCT00768040,1,Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Eye Diseases|Heart and Blood Diseases|Gland and Hormone Related Diseases|All Conditions|Nutritional and Metabolic Diseases|Immune System Diseases|Symptoms and General Pathology,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Denmark|Denmark,8-Sep,6-Oct-08,11-Feb,11-Feb,2-Feb-12,Inadequate enrollment,,2,39,Actual,110,Anticipated,TRUE,,39,39,0,0.35,4,39,0,,2 - No Scientific Data
NCT00768989,1,Phase IIB Pilot of Atazanavir + Raltegravir,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug|Drug|Drug,Phase 2,Viral Diseases|Immune System Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|Argentina|Argentina|Argentina|Argentina|France|France|France,8-Nov,6-Oct-08,10-Jan,10-May,19-Oct-11,"Efficacy endpoint met, but overall experimental dosing regimen not considered optimal to support further clinical development in this population.",,6,167,Actual,90,Anticipated,FALSE,F,93,93,93,1.03,9,93,1,22592092,1 - Scientific Data
NCT00771316,1,Clinical Trial to Study the Safety and Effectiveness of MK0826 and Other Antibiotic Therapy in Patients With Complicated Urinary Tract Infection,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,"Bacterial and Fungal Diseases|Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions",INDUSTRY,,,,8-Dec,9-Oct-08,9-Jun,9-Jun,22-Apr-10,feasibility and low enrollment,,2,6,Actual,410,Anticipated,TRUE,,6,6,0,0.01,1,6,0,,2 - No Scientific Data
NCT00771602,1,Alemtuzumab + Rituximab Consolidation in CLL,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Blood and Lymph Conditions|Immune System Diseases|Rare Diseases,OTHER,,Single,United States,8-Aug,10-Oct-08,10-Dec,10-Dec,4-Apr-11,Lack of accrual.,,2,1,Actual,100,Anticipated,TRUE,,1,1,0,0.01,0,1,0,,2 - No Scientific Data
NCT00772629,0,"Antibody Responses Following Meningococcal Tetravalent (A, C, Y, and W-135) Conjugate Vaccination in Healthy Adults",Prevention,Parallel Assignment,Open Label,Non-Randomized,Biological|Biological,Phase 2,Nervous System Diseases|All Conditions|Rare Diseases,INDUSTRY,,Multiple,United Kingdom|United Kingdom,4-Jan,13-Oct-08,4-Apr,4-Apr,16-Mar-09,See detailed description for termination reason,Enrollment was terminated before the planned sample size was achieved because the principal investigator and the Sponsor decided that sufficient sera had been obtained to meet the secondary objective of the study.,6,18,Actual,18,Actual,TRUE,,18,18,17,1,0,17,0,,1 - Scientific Data
NCT00772954,0,"Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study, Safety, Tolerability and Immunogenicity",Treatment,Parallel Assignment,Double Blind,Randomized,Biological|Biological|Biological,Phase 1,Symptoms and General Pathology|All Conditions|Bacterial and Fungal Diseases|Rare Diseases,INDUSTRY,,,,6-Mar,10-Oct-08,6-Jun,6-Jun,13-Mar-12,Issues with CTM stability.,"There were no safety concerns involved in the decision to stop enrollment. Subjects that were enrolled at the time completed the study as per protocol, the last subject last visit was on 29 April 2004.",3,36,Actual,36,Actual,TRUE,,36,36,36,1,0,36,0,,2 - No Scientific Data
NCT00773383,1,A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.,Treatment,Single Group Assignment,Open Label,Randomized,Drug|Drug,Phase 2,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|Canada|Canada|Canada|Canada|France|France|France|Poland|Poland|Poland,8-Oct,15-Oct-08,10-Feb,10-Feb,31-Mar-11,,,9,35,Actual,43,Anticipated,TRUE,,35,35,34,0.81,12,34,0,,3 - No Reason Provided
NCT00776295,1,Autologous SCT Followed by Dendritic Cell p53 Vaccination in Patients With Limited Stage Small Cell Lung Cancer,Treatment,Single Group Assignment,Open Label,,Biological,Phase 2,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,OTHER,,Single,United States,7-May,20-Oct-08,10-Jun,10-Aug,4-Oct-11,Low accrual,,2,2,Actual,53,Anticipated,TRUE,,2,2,2,0.04,0,2,0,,2 - No Scientific Data
NCT00776555,1,Compare Subjective Drug Liking & Pharmacokinetics of Vyvanse? and ADDERALL XR?? When Administered as an Oral Solution,,Crossover Assignment,Single Blind,Randomized,Drug|Drug,Phase 1,,INDUSTRY,,Single,United States,8-Nov,20-Oct-08,9-Mar,9-Mar,5-May-10,The study was stopped by the sponsor based on a non-safety related business priority decision.,,8,3,Actual,16,Anticipated,TRUE,,3,3,0,0.19,0,3,0,,2 - No Scientific Data
NCT00777335,1,Study of Panobinostat Monotherapy in Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) Positive Locally Recurrent or Metastatic Breast Cancer,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Skin and Connective Tissue Diseases|Blood and Lymph Conditions|Rare Diseases,OTHER,,Single,United States,9-Feb,21-Oct-08,10-Mar,10-Mar,6-Jan-12,Very low recruitement rate.,,2,4,Actual,132,Anticipated,TRUE,,4,4,4,0.03,1,4,0,,2 - No Scientific Data
NCT00779038,0,Safety and Efficacy Study of Fentanyl Iontophoretic Transdermal System (ITS) for Management of Moderate to Severe Acute Pain in Participants Who Have Undergone Elective Spine or Orthopedic Surgery,Treatment,Single Group Assignment,Open Label,,Drug,Phase 4,Nervous System Diseases|Symptoms and General Pathology|All Conditions,INDUSTRY,,Multiple,Belgium|Belgium|Belgium,8-Aug,23-Oct-08,8-Sep,8-Sep,10-Jan-13,Stopped prematurely in 2008 due to IONSYS withdrawal off the market globally,,16,13,Actual,150,Anticipated,TRUE,,13,13,0,0.09,1,13,0,,2 - No Scientific Data
NCT00779285,0,Safety Study of CAELYX in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines (Study P04057)(TERMINATED),Treatment,Single Group Assignment,Open Label,,Drug,Phase 4,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions,INDUSTRY,,,,6-Feb,23-Oct-08,6-Aug,6-Aug,11-Feb-10,,,9,1,Actual,50,Actual,TRUE,,1,1,1,0.02,0,1,0,,3 - No Reason Provided
NCT00779311,1,A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer,Treatment,Single Group Assignment,Open Label,,Drug|Drug|Drug,Phase 1,Cancers and Other Neoplasms|Digestive System Diseases|All Conditions,OTHER,,Multiple,United States|United States|United States,8-Oct,23-Oct-08,11-Mar,11-Mar,9-Sep-11,Dose limiting toxicity at the lowest planned dose level.,,5,8,Actual,45,Anticipated,TRUE,,8,8,8,0.18,5,8,0,,1 - Scientific Data
NCT00782639,1,Renal Safety of Iopamidol Versus Iodixanol During Coronary Angiography in Diabetic Patients,Diagnostic,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 4,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions|Nutritional and Metabolic Diseases|Gland and Hormone Related Diseases",INDUSTRY,,Single,United States,9-Mar,28-Oct-08,9-Sep,9-Sep,29-Jun-11,This study was terminated early due to slow enrollment.,,2,23,Actual,220,Anticipated,TRUE,,23,23,23,0.1,0,23,0,,2 - No Scientific Data
NCT00782834,0,Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST),Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 2,Cancers and Other Neoplasms|Digestive System Diseases|All Conditions|Rare Diseases,OTHER,,Single,United States,8-Jul,29-Oct-08,8-Jul,9-Oct,17-Dec-10,"Stopped early for futility, unable to meet accrual goals",,2,14,Actual,34,Anticipated,FALSE,E,15,14,13,0.41,12,13,1,22119758,2 - No Scientific Data
NCT00783614,1,Aspirin and Antiretroviral Therapy in HIV Infected Patients,Prevention,Factorial Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,"Viral Diseases|Immune System Diseases|All Conditions|Symptoms and General Pathology|Bacterial and Fungal Diseases|Urinary Tract, Sexual Organs, and Pregnancy Conditions",OTHER,,Single,United States,8-Oct,31-Oct-08,10-Jan,10-Jun,16-Jan-12,Lack of funding,,1,22,Actual,40,Anticipated,TRUE,,22,22,22,0.55,0,22,0,,2 - No Scientific Data
NCT00785772,1,A Post-Marketing Clinical Pharmacokinetics Study Of Gabapentin In Japanese Epileptic Subjects With Renal Impairment,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug|Drug,Phase 4,"Nervous System Diseases|All Conditions|Urinary Tract, Sexual Organs, and Pregnancy Conditions",INDUSTRY,,Single,Japan,10-Mar,3-Nov-08,10-Apr,10-Apr,29-Mar-11,See termination reason in detailed description.,"Only one subject was able to be enrolled. Given enrollment challenges to identify additional appropriate subjects, discussion was held with the Japan Pharmaceuticals and Medical Devices Agency (PMDA) and it was agreed with the PMDA to terminate this study. The study was terminated on December 14, 2010. The study was not terminated due to any safety findings.",2,1,Actual,10,Anticipated,TRUE,,1,1,1,0.1,0,1,0,,2 - No Scientific Data
NCT00787137,1,Single Dose PG102 in Patients With Active Psoriatic Arthritis,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 1,"Muscle, Bone, and Cartilage Diseases|All Conditions|Skin and Connective Tissue Diseases|Bacterial and Fungal Diseases|Rare Diseases",INDUSTRY,,Single,Serbia,8-Dec,6-Nov-08,10-Apr,10-May,12-Aug-10,poor recruitment,,2,17,Actual,44,Anticipated,TRUE,,17,17,17,0.39,0,17,0,,2 - No Scientific Data
NCT00787332,1,A Comparative Sudy Comparing Argatroban?? IV vs Desirudin SC for Suspected HIT With or Without Thrombosis Syndrome,Prevention,Parallel Assignment,Open Label,Randomized,Drug,Phase 4,Heart and Blood Diseases|All Conditions|Blood and Lymph Conditions|Symptoms and General Pathology|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,8-Sep,6-Nov-08,9-Dec,9-Dec,29-Nov-12,Low enrollment,,2,16,Actual,120,Anticipated,TRUE,,16,16,16,0.13,3,16,1,21079512,2 - No Scientific Data
NCT00787917,1,An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 4,Bacterial and Fungal Diseases|All Conditions|Respiratory Tract (Lung and Bronchial) Diseases|Immune System Diseases|Digestive System Diseases|Diseases and Abnormalities at or before Birth|Symptoms and General Pathology|Rare Diseases,INDUSTRY,,Multiple,Belgium|Germany|Germany|Germany|Italy|Italy|Netherlands|Netherlands|United Kingdom|United Kingdom,8-Nov,7-Nov-08,10-Jul,10-Jul,11-Jul-11,,,9,14,Actual,60,Anticipated,TRUE,,14,14,0,0.23,11,21,0,,3 - No Reason Provided
NCT00790296,1,Evaluation of Synthetic Thyrotropin Releasing Hormone (TRH) as a Treatment for Cancer-related Fatigue,Supportive Care,Crossover Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Symptoms and General Pathology|All Conditions,OTHER,,Single,United States,6-Dec,10-Nov-08,10-Feb,10-Mar,31-Jan-11,Interim analyses showed statistically and clinically significant results.,,6,11,Actual,24,Anticipated,TRUE,,11,11,8,0.46,0,16,0,,1 - Scientific Data
NCT00790452,1,Aspirin Prophylaxis for Venous Thromboembolism in Glioblastoma,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Heart and Blood Diseases|Blood and Lymph Conditions|Rare Diseases,OTHER,,Single,United States,8-Nov,7-Nov-08,9-Oct,9-Oct,4-Nov-11,Low accrual.,,2,1,Actual,224,Anticipated,TRUE,,1,1,0,0,0,1,0,,2 - No Scientific Data
NCT00790855,1,Bendamustine in Acute Leukemia and MDS,Treatment,Single Group Assignment,Open Label,,Drug,Phase 1|Phase 2,Cancers and Other Neoplasms|All Conditions|Blood and Lymph Conditions|Immune System Diseases|Symptoms and General Pathology|Rare Diseases,OTHER,,Single,United States,8-Nov,13-Nov-08,12-Mar,12-Mar,22-Jun-12,Lack of Response,,6,27,Actual,153,Anticipated,FALSE,F,25,25,25,0.16,3,25,0,,1 - Scientific Data
NCT00793520,1,Effect of Milnacipran on Pain Processing and Functional Magnetic Resonance Imaging (fMRI) Activation Patterns in Patients With Fibromyalgia,Treatment,Crossover Assignment,Double Blind,Randomized,Drug|Drug|Drug|Drug,Phase 3,"Muscle, Bone, and Cartilage Diseases|Nervous System Diseases|All Conditions|Symptoms and General Pathology|Skin and Connective Tissue Diseases",INDUSTRY,,Single,United States,8-Nov,17-Nov-08,9-Apr,,15-Apr-10,,,9,2,Actual,36,Anticipated,FALSE,E,1,2,0,0.06,0,2,0,,3 - No Reason Provided
NCT00793546,1,Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Australia|Belgium|Belgium|Belgium|Belgium|Canada|China|Hong Kong|Hong Kong|Hungary|India|India|Poland|South Africa|Spain|Spain|Spain,9-Feb,29-Oct-08,10-Jun,10-Jun,4-Oct-12,See termination reason in detailed description.,This study was terminated on 19 Apr 2010 due to unfavorable risk benefit ratio which did not support continuation in part 2 of the study. Even if the safety profile of the combination of Bosutinib and Exemestane was acceptable 25% of subjects had treatment related liver events including 14% of severe liver events.,5,42,Actual,224,Anticipated,TRUE,,42,42,0,0.19,9,42,0,,1 - Scientific Data
NCT00793650,1,Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Procedure,Phase 1|Phase 2,Cancers and Other Neoplasms|Heart and Blood Diseases|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Rare Diseases,OTHER,,Single,United States,5-May,17-Nov-08,9-Oct,11-Sep,14-Mar-12,,,9,39,Actual,40,Anticipated,TRUE,,39,39,39,0.98,6,39,1,20739431,3 - No Reason Provided
NCT00794963,1,Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Other,,Nutritional and Metabolic Diseases|All Conditions|Symptoms and General Pathology|Behaviors and Mental Disorders|Rare Diseases,OTHER,,Single,United States,8-Nov,19-Nov-08,10-May,10-May,19-Jul-11,Difficulty recruiting,,2,8,Actual,120,Anticipated,TRUE,,8,8,3,0.07,0,8,0,,2 - No Scientific Data
NCT00795639,1,Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Respiratory Tract (Lung and Bronchial) Diseases|All Conditions|Heart and Blood Diseases|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Argentina|Argentina|Argentina|Argentina|Bulgaria|Bulgaria|Bulgaria|Chile|China|China|China|China|China|Colombia|Costa Rica|Czech Republic|Dominican Republic|Dominican Republic|Guatemala|India|India|India|India|India|India|India|India|Malaysia|Mexico|Mexico|Mexico|Peru|Peru|Philippines|Romania|Romania|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Saudi Arabia|Serbia|Slovakia|South Africa|South Africa|South Africa|South Africa|Thailand|Thailand|Turkey|Ukraine|Ukraine,8-Dec,20-Nov-08,11-Mar,11-Mar,30-Jan-12,"Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.",,5,183,Actual,180,Anticipated,TRUE,,183,183,183,1.02,21,182,0,,1 - Scientific Data
NCT00796510,1,Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety,Treatment,Parallel Assignment,Open Label,Non-Randomized,Drug|Drug,Phase 3,Respiratory Tract (Lung and Bronchial) Diseases|All Conditions|Heart and Blood Diseases|Rare Diseases,INDUSTRY,,Multiple,United States|Romania|Ukraine,10-Jul,20-Nov-08,11-Jan,11-Jan,9-Dec-11,"Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury",,5,3,Actual,180,Anticipated,TRUE,,3,3,0,0.02,1,3,0,,1 - Scientific Data
NCT00796666,1,Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Respiratory Tract (Lung and Bronchial) Diseases|All Conditions|Heart and Blood Diseases|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Argentina|Argentina|Argentina|Argentina|Bulgaria|Chile|China|China|China|China|Colombia|Czech Republic|India|India|India|India|India|India|India|India|India|Malaysia|Mexico|Peru|Romania|Romania|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Serbia|South Africa|Thailand|Turkey|Ukraine|Ukraine,9-May,20-Nov-08,11-Mar,11-Mar,26-Jan-12,"Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.",,5,131,Actual,180,Anticipated,TRUE,,131,131,131,0.73,29,130,0,,1 - Scientific Data
NCT00796705,1,Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 4,"Muscle, Bone, and Cartilage Diseases|All Conditions|Skin and Connective Tissue Diseases|Immune System Diseases",NIH,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,8-Nov,20-Nov-08,10-Oct,10-Oct,5-Jul-12,Lack of Enrollment,,2,13,Actual,144,Anticipated,TRUE,,13,13,13,0.09,0,13,0,,2 - No Scientific Data
NCT00803179,1,Growth Hormone Therapy for Wasting in Cystic Fibrosis,Treatment,Single Group Assignment,Open Label,,Drug,Phase 1,Digestive System Diseases|Respiratory Tract (Lung and Bronchial) Diseases|Diseases and Abnormalities at or before Birth|All Conditions|Symptoms and General Pathology|Rare Diseases,OTHER,,Single,United States,8-Nov,4-Dec-08,12-Mar,12-Mar,13-Nov-12,"Poor enrollment, patients were lost to follow up",,2,5,Actual,30,Anticipated,TRUE,,5,5,0,0.17,0,5,0,,2 - No Scientific Data
NCT00803270,1,Mixed Incontinence: Medical Or Surgical Approach?,Treatment,Single Group Assignment,Open Label,Randomized,Drug|Procedure,Phase 4,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|Symptoms and General Pathology|All Conditions",NIH,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,8-Oct,4-Dec-08,9-Mar,9-Mar,26-Mar-12,Feasibility Period ended.,,10,27,Actual,425,Anticipated,TRUE,,27,27,24,0.06,0,27,0,,2 - No Scientific Data
NCT00806351,1,An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Bacterial and Fungal Diseases|All Conditions|Symptoms and General Pathology|Blood and Lymph Conditions|Rare Diseases,INDUSTRY,,Multiple,Bosnia and Herzegovina|France|France|Italy|Italy|Poland|Poland|Poland|Russian Federation|Slovakia,9-Aug,26-Nov-08,11-Oct,11-Oct,20-Nov-12,"The study was prematurely terminated on May 18, 2012 due to slow enrollment. The study was not terminate due to any safety issues or concerns.",,2,21,Actual,45,Anticipated,TRUE,,21,21,14,0.47,9,21,0,,2 - No Scientific Data
NCT00807209,1,Dose Finding Posterolateral Thoracotomy Study,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug|Drug|Drug,Phase 2,Nervous System Diseases|Symptoms and General Pathology|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States,8-Dec,9-Dec-08,9-Feb,9-Feb,29-Nov-11,Sponsor decision unrelated to safety,,8,3,Actual,45,Anticipated,TRUE,,3,3,2,0.07,0,3,0,,2 - No Scientific Data
NCT00807235,0,Feasibility Study of Aerosolized Surfaxin in the Prevention of Respiratory Distress Syndrome (RDS) in Premature Infants,Prevention,Parallel Assignment,Open Label,Non-Randomized,Drug|Drug,Phase 2,Respiratory Tract (Lung and Bronchial) Diseases|Diseases and Abnormalities at or before Birth|All Conditions|Symptoms and General Pathology|Rare Diseases,INDUSTRY,,Single,United States,5-Jan,10-Dec-08,5-Aug,5-Sep,2-Apr-12,Slow enrollment,,2,17,Actual,17,Actual,TRUE,,17,17,17,1,6,17,0,,2 - No Scientific Data
NCT00808899,1,Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug|Procedure|Drug|Drug|Drug|Drug|Drug|Procedure|Radiation|Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Rare Diseases,OTHER,,Single,United States,8-Dec,11-Dec-08,9-Jul,9-Jul,19-Apr-10,Voluntarily closed and terminated by the PI due to lack of feasibility,,4,4,Actual,50,Anticipated,TRUE,,4,4,0,0.08,1,4,0,,2 - No Scientific Data
NCT00809185,1,RAD001(Everolimus) in Treating Patients With Myelodysplastic Syndromes,Treatment,Single Group Assignment,Open Label,,Drug|Other|Procedure,Phase 2,Cancers and Other Neoplasms|Blood and Lymph Conditions|All Conditions|Symptoms and General Pathology|Rare Diseases,OTHER,,Single,United States,5-Nov,16-Dec-08,9-Feb,9-Mar,20-Jan-12,slow accrual,,2,7,Actual,33,Anticipated,TRUE,,7,7,7,0.21,1,7,0,,2 - No Scientific Data
NCT00810576,1,Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma,Treatment,Single Group Assignment,Open Label,,Drug|Drug,Phase 2,Bacterial and Fungal Diseases|All Conditions|Cancers and Other Neoplasms|Blood and Lymph Conditions|Immune System Diseases|Rare Diseases,OTHER,,Single,United States,9-Jan,16-Dec-08,10-Apr,10-Apr,11-Jun-10,Terminated due to slow accrual.,,2,1,Actual,40,Anticipated,TRUE,,1,1,1,0.03,0,1,0,,2 - No Scientific Data
NCT00811018,0,"A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension",,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 3,Heart and Blood Diseases|All Conditions|Respiratory Tract (Lung and Bronchial) Diseases|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Argentina|Argentina|Australia|Australia|Australia|Australia|Austria|Austria|Belgium|Belgium|Brazil|Brazil|Brazil|Canada|Canada|Canada|Canada|Canada|Canada|Canada|France|France|France|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Israel|Israel|Italy|Mexico|Mexico|Mexico|Netherlands|Poland|Poland|Poland|Spain|United Kingdom|United Kingdom|United Kingdom|United Kingdom,3-Mar,9-Dec-08,11-Jul,11-Jul,29-Mar-12,"This trial was prematurely terminated on Dec 9 2010 due to safety concerns, specifically emerging evidence of hepatic injury.",,5,1192,Actual,1208,Actual,TRUE,,1192,1192,1192,0.99,586,1192,0,,1 - Scientific Data
NCT00811590,1,Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome,Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,Cancers and Other Neoplasms|Digestive System Diseases|Diseases and Abnormalities at or before Birth|Skin and Connective Tissue Diseases|All Conditions|Symptoms and General Pathology|Rare Diseases,OTHER,,Single,United States,8-Nov,17-Nov-08,11-Mar,11-Mar,6-Mar-12,The study was ended early due to low enrollment.,,2,3,Actual,10,Anticipated,TRUE,,3,3,0,0.3,0,3,0,,2 - No Scientific Data
NCT00815347,1,Bosentan for Poorly Controlled Asthma,Treatment,Crossover Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Respiratory Tract (Lung and Bronchial) Diseases|Immune System Diseases|All Conditions,OTHER,,Single,United States,8-Dec,29-Dec-08,10-Sep,10-Sep,16-Jun-12,Difficulty in recruitment.,,2,11,Actual,20,Anticipated,TRUE,,11,11,14,0.55,1,20,1,23363065,2 - No Scientific Data
NCT00816829,0,Effect of Fenofibrate on Sleep Apnea Syndrome,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Respiratory Tract (Lung and Bronchial) Diseases|Symptoms and General Pathology|All Conditions|Nervous System Diseases|Nutritional and Metabolic Diseases|Behaviors and Mental Disorders,INDUSTRY,,Single,France,5-Sep,2-Jan-09,8-Jan,8-Jan,8-Jan-09,The study was prematurely terminated because of slow recruitment,,2,34,Actual,71,Actual,TRUE,,34,34,34,0.48,1,,1,20297950,2 - No Scientific Data
NCT00817531,1,Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients,Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions,OTHER,,Single,United States,8-Dec,5-Jan-09,11-Feb,11-Feb,7-May-12,terminated due to futility after interim analysis,,6,22,Actual,45,Anticipated,TRUE,,22,22,22,0.49,1,22,0,,1 - Scientific Data
NCT00818389,1,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),Treatment,Crossover Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 2|Phase 3,Nervous System Diseases|Nutritional and Metabolic Diseases|All Conditions|Symptoms and General Pathology|Rare Diseases,OTHER,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada,9-Jan,6-Jan-09,9-Oct,9-Oct,10-May-10,NINDS DSMB recommended trial be terminated for futility after reviewing an interim analysis of 84 subjects.,,6,84,Actual,250,Anticipated,TRUE,,84,84,84,0.34,18,84,1,20363190,1 - Scientific Data
NCT00819637,1,A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 4,Respiratory Tract (Lung and Bronchial) Diseases|Immune System Diseases|All Conditions|Symptoms and General Pathology,OTHER,,Single,United States,9-Jan,8-Jan-09,9-Nov,9-Nov,17-Feb-10,Unable to enroll r/t study design & staffing issues. The trial terminated.,,2,2,Actual,90,Anticipated,TRUE,,2,2,2,0.02,0,2,0,,2 - No Scientific Data
NCT00819832,1,Anderson Circulating Tumor Cell Burden (CTCB) Study,Treatment,Single Group Assignment,Open Label,Randomized,Procedure|Procedure|Device,Phase 4,"Cancers and Other Neoplasms|Symptoms and General Pathology|All Conditions|Muscle, Bone, and Cartilage Diseases|Nervous System Diseases|Wounds and Injuries",OTHER,,Single,United States,8-Dec,7-Jan-09,10-May,10-May,16-Aug-10,Terminated by sponsor.,,8,3,Actual,100,Anticipated,TRUE,,3,3,0,0.03,0,3,0,,2 - No Scientific Data
NCT00820612,1,Rectal Indomethacin in the Prevention of Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis in High Risk Patients,Prevention,Parallel Assignment,Double Blind,Randomized,Drug|Other,Phase 4,Digestive System Diseases|All Conditions,OTHER,,Multiple,United States|United States|United States|United States,9-Jan,9-Jan-09,11-Jul,11-Jul,10-Jan-13,Stopped by DSMB for overwhelming benefit of indomethacin (unethical to withhold indomethacin from patients),,6,602,Actual,870,Anticipated,TRUE,,602,602,602,0.69,13,602,1,22494121,1 - Scientific Data
NCT00821184,0,Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive Bladder,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Behavioral,Phase 3,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|Symptoms and General Pathology|All Conditions",OTHER,,Single,United States,6-Sep,9-Jan-09,8-Sep,8-Sep,4-Dec-09,Insufficient subject availability/findings for data analysis,,2,12,Actual,40,Anticipated,TRUE,,12,12,12,0.3,0,12,0,,2 - No Scientific Data
NCT00823472,1,Trial Comparing Start Stimulation of Recombinant Follicle Stimulating Hormone (rFSH) on Cycle Day 2 Versus Cycle Day 5 in In Vitro Fertilization (IVF),Treatment,Parallel Assignment,Open Label,Randomized,Drug,Phase 4,Rare Diseases|All Conditions,OTHER,,Multiple,Belgium|Netherlands,9-Jan,13-Jan-09,10-Oct,10-Oct,2-Nov-10,"Inclusion of the study didn't go as fast as expected. Expect: 234 patients in 1 year in 2 centers. After 1,5 year only 147 patients were recruited.",,2,147,Actual,234,Anticipated,TRUE,,147,147,147,0.63,0,0,0,,2 - No Scientific Data
NCT00824161,1,Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 2,Cancers and Other Neoplasms|Digestive System Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States,9-Jan,14-Jan-09,9-Nov,10-Dec,21-Jun-11,,,9,28,Actual,54,Anticipated,TRUE,,28,28,28,0.52,9,26,0,,3 - No Reason Provided
NCT00825227,1,Safety and Efficacy of Armodafinil for Fatigue Associated With Taxanes Alone or in Combination With Other Agents,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Symptoms and General Pathology|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,8-Dec,15-Jan-09,9-Oct,10-Feb,28-Jul-11,,,9,10,Actual,160,Anticipated,TRUE,,10,10,0,0.06,4,10,0,,3 - No Reason Provided
NCT00827099,1,"Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer",Treatment,Single Group Assignment,Open Label,,Biological|Drug|Drug|Drug|Drug|Procedure,Phase 2,Bacterial and Fungal Diseases|All Conditions|Cancers and Other Neoplasms|Blood and Lymph Conditions|Immune System Diseases|Heart and Blood Diseases|Symptoms and General Pathology|Diseases and Abnormalities at or before Birth|Rare Diseases,OTHER,,Single,United States,6-Jun,21-Jan-09,9-Nov,9-Nov,28-Jul-11,Unacceptable morbidity & mortality,,5,5,Actual,21,Anticipated,TRUE,,5,5,5,0.24,0,5,0,,1 - Scientific Data
NCT00827567,1,Trial of RAD001 in Triple Negative Metastatic Breast Cancer,Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions,OTHER,,Single,United States,9-Apr,21-Jan-09,11-Feb,11-Feb,16-Aug-11,Slow accrual,,2,6,Actual,30,Anticipated,FALSE,F,4,4,0,0.13,0,4,0,,2 - No Scientific Data
NCT00829049,0,Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris,Treatment,Parallel Assignment,Single Blind,Randomized,Drug|Drug,Phase 4,Skin and Connective Tissue Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Single,United States,7-Oct,22-Jan-09,8-Oct,8-Oct,22-Sep-11,Study enrollment was terminated due to company decision before the target enrollment of 220 patients was reached.,,8,165,Actual,180,Actual,TRUE,,165,165,135,0.92,0,157,1,20480800,2 - No Scientific Data
NCT00830791,1,A Single Dose Study to Investigate the Pharmacokinetics of MK-0941 in Participants With Renal Insufficiency (MK-0941-015-02),Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug,Phase 1,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions|Nutritional and Metabolic Diseases|Gland and Hormone Related Diseases",INDUSTRY,,,,9-Jan,26-Jan-09,9-Aug,9-Sep,1-May-12,,,9,32,Actual,48,Anticipated,TRUE,,32,32,16,0.67,0,32,0,,3 - No Reason Provided
NCT00831233,1,Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug,Phase 3,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions|Symptoms and General Pathology",INDUSTRY,,Multiple,Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom,9-Apr,27-Jan-09,10-Jun,10-Jul,14-Jun-11,Poor recruitment due to rare targeted population,,2,42,Actual,280,Anticipated,TRUE,,42,42,40,0.15,1,40,1,23258223,2 - No Scientific Data
NCT00831493,1,Vorinostat Plus Radiation Therapy in Pancreatic Cancer,Treatment,Single Group Assignment,Open Label,,Radiation|Drug,Phase 1|Phase 2,Cancers and Other Neoplasms|Digestive System Diseases|Gland and Hormone Related Diseases|All Conditions|Rare Diseases,OTHER,,Single,United States,9-May,27-Jan-09,10-Oct,10-Oct,13-Feb-12,Slow Accrual.,,2,3,Actual,37,Anticipated,TRUE,,3,3,2,0.08,0,3,0,,2 - No Scientific Data
NCT00832520,1,Phase II Study of Remeron for Cancer Patients Losing More Than 10% of Their Body Weight,Prevention,Single Group Assignment,Open Label,,Drug,Phase 2,Symptoms and General Pathology|All Conditions,OTHER,,Multiple,United States|United States,8-Nov,29-Jan-09,10-Jul,11-Jun,20-Jul-12,Low accrual rate.,,2,13,Actual,59,Anticipated,TRUE,,13,13,0,0.22,0,13,0,,2 - No Scientific Data
NCT00832624,1,The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118),Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 4,Nutritional and Metabolic Diseases|Gland and Hormone Related Diseases|All Conditions,INDUSTRY,,,,8-Nov,28-Jan-09,9-Sep,9-Sep,6-Jul-10,Business Reasons,,8,10,Actual,20,Anticipated,TRUE,,10,10,0,0.5,0,0,0,,2 - No Scientific Data
NCT00832650,1,Multiple Dose Study To Investigate The Effects Of Fesoterodine And Solifenacin On Gastrointestinal Transit,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 1,,INDUSTRY,,Single,United States,9-Apr,28-Jan-09,9-Dec,9-Dec,2-Dec-10,"Protocol A0221057 was terminated on December 25, 2009 for futility. There were no safety concerns related to this decision.",,6,60,Actual,200,Anticipated,TRUE,,60,60,60,0.3,0,59,1,23171069,1 - Scientific Data
NCT00833053,1,Dose Optimization of Infliximab in Moderate to Severe Plaque Psoriasis (Study P05315),Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 3,Skin and Connective Tissue Diseases|All Conditions,INDUSTRY,,,,9-Oct,29-Jan-09,11-Apr,11-Apr,15-Mar-12,"In Amendment 1 of P05319 [NCT 00779675], the option to enroll into this study, was discontinued due to low numbers of participants with suboptimal response.",,4,39,Actual,200,Anticipated,TRUE,,39,39,36,0.2,1,37,0,,2 - No Scientific Data
NCT00833859,1,"Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery",Treatment,Single Group Assignment,Open Label,,Drug|Radiation,Phase 2,Cancers and Other Neoplasms|Digestive System Diseases|Gland and Hormone Related Diseases|All Conditions|Rare Diseases,OTHER,,Single,United States,9-Mar,30-Jan-09,10-Mar,10-Mar,30-Mar-11,Abandoned - Lack of funding after only 2 patients enrolled,,1,2,Actual,24,Anticipated,TRUE,,2,2,0,0.08,0,2,0,,2 - No Scientific Data
NCT00835679,1,Cetuximab and/or Dasatinib in Treating Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery,Treatment,Parallel Assignment,Open Label,Non-Randomized,Biological|Drug,,Cancers and Other Neoplasms|Symptoms and General Pathology|All Conditions|Digestive System Diseases|Rare Diseases,NIH,,Multiple,United States|United States|United States,9-Dec,3-Feb-09,11-Feb,11-Aug,12-Mar-12,slow accrual,,2,9,Actual,65,Anticipated,TRUE,,9,9,0,0.14,0,9,0,,2 - No Scientific Data
NCT00836498,1,A Study of the Safety and Immune Response to RotaTeq? Vaccine in the Elderly (V260-027),Prevention,Parallel Assignment,Double Blind,Randomized,Biological|Biological|Biological,Phase 1,,INDUSTRY,,,,9-Feb,3-Feb-09,10-Jan,10-Apr,12-Jan-11,Strategic business decision not to pursue indication due to lack of demonstrable medical need,,8,66,Actual,260,Anticipated,TRUE,,66,66,66,0.25,2,66,0,,2 - No Scientific Data
NCT00837759,1,Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes,Treatment,Single Group Assignment,Open Label,,Drug|Drug|Drug|Biological|Drug,Phase 2,Nutritional and Metabolic Diseases|Gland and Hormone Related Diseases|All Conditions|Immune System Diseases,NIH,,Single,United States,9-Feb,4-Feb-09,11-Mar,11-Mar,24-Mar-12,Changes to study personnel.,,4,7,Actual,164,,TRUE,,7,7,3,0.04,0,7,0,,2 - No Scientific Data
NCT00837824,0,Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme,Treatment,Parallel Assignment,Open Label,Randomized,Biological|Biological,Phase 2,"Nervous System Diseases|Diseases and Abnormalities at or before Birth|Nutritional and Metabolic Diseases|All Conditions|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Rare Diseases",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States,2-Dec,23-Oct-08,3-Aug,3-Aug,5-Dec-08,The trial was terminated early due to inadequate study design.,,4,20,Actual,20,Actual,TRUE,,20,20,1,1,5,,0,,2 - No Scientific Data
NCT00838682,0,Effect of High-dose Oral Rabeprazole on Recurrent Bleeding After the Endoscopic Treatment of Bleeding Peptic Ulcers,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 4,Digestive System Diseases|All Conditions|Symptoms and General Pathology,OTHER,,Multiple,"Korea, Republic of|Korea, Republic of",6-Apr,5-Feb-09,9-Jan,9-Mar,2-Aug-10,Terminated before the complete enrollment due to slow enrollment,,2,106,Actual,106,Actual,TRUE,,106,106,106,1,0,106,1,23049546,2 - No Scientific Data
NCT00839917,0,A Study of ProQuad? in Healthy Children in Korea (V221-023),Prevention,Parallel Assignment,Open Label,Randomized,Biological|Biological,Phase 3,Viral Diseases|All Conditions|Mouth and Tooth Diseases|Rare Diseases,INDUSTRY,,,,8-Feb,6-Feb-09,8-May,8-May,7-Sep-12,Study terminated early because of insufficient enrollment before expiration date of the investigational vaccine lot,,2,30,Actual,360,Anticipated,TRUE,,30,30,18,0.08,1,29,0,,2 - No Scientific Data
NCT00840450,1,Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin,Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Gland and Hormone Related Diseases|All Conditions|Rare Diseases",OTHER,,Single,United States,7-Apr,9-Feb-09,10-Apr,12-Oct,18-Aug-11,Due to slow accrual,,2,14,Actual,50,Anticipated,FALSE,E,12,14,12,0.28,3,12,0,,2 - No Scientific Data
NCT00842829,1,Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients,,Parallel Assignment,Open Label,Randomized,Drug,Phase 4,Nervous System Diseases|Symptoms and General Pathology|All Conditions,INDUSTRY,,Multiple,France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Ireland|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom,9-Jan,29-Jan-09,11-May,11-May,17-Aug-12,Recruitment stopped at the end of the recruitment timeframe,,11,330,Actual,880,Anticipated,TRUE,,330,330,312,0.38,67,312,0,,2 - No Scientific Data
NCT00843050,1,A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma,Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,Cancers and Other Neoplasms|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|India|India|India|India|India|India|India,9-Nov,12-Feb-09,11-Feb,12-Aug,29-Feb-12,The study was terminated based on interim results and all subjects were off study at that time. No major safety or tolerability concerns,,6,13,Actual,35,Anticipated,TRUE,,13,13,0,0.37,2,13,0,,1 - Scientific Data
NCT00843986,1,Safety and Efficacy of Conivaptan in Hyponatremic Patients With Symptomatic Acute Decompensated Heart Failure (ADHF),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Heart and Blood Diseases|All Conditions|Nutritional and Metabolic Diseases,INDUSTRY,,Multiple,India|India|India|India,9-Apr,11-Feb-09,9-Aug,9-Aug,9-Sep-10,The clinical study has been terminated based on difficulties to enroll eligible subjects per protocol inclusion and exclusion criteria.,,2,9,Actual,105,Anticipated,TRUE,,9,9,0,0.09,2,9,0,,2 - No Scientific Data
NCT00845702,1,Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF),Diagnostic,Single Group Assignment,Open Label,Non-Randomized,Drug|Other,Phase 3,"Symptoms and General Pathology|All Conditions|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Heart and Blood Diseases",INDUSTRY,,Single,United States,9-Apr,16-Feb-09,10-Feb,10-Feb,22-Sep-11,lack of recruitment.,,2,33,Actual,220,Anticipated,TRUE,,33,33,0,0.15,1,66,0,,2 - No Scientific Data
NCT00846391,1,A Study to Assess the Safety and Efficacy of MK8245 in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK8245-005 AM2),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 2,Nutritional and Metabolic Diseases|Gland and Hormone Related Diseases|All Conditions,INDUSTRY,,,,8-Dec,17-Feb-09,9-Aug,9-Aug,26-Aug-10,Study was terminated due to inability to recruit patients.,,2,14,Actual,60,Anticipated,TRUE,,14,14,8,0.23,0,14,0,,2 - No Scientific Data
NCT00846573,1,Hyperpolarized Noble Gas MR Imaging for Pulmonary Disorders,Diagnostic,Parallel Assignment,Open Label,Non-Randomized,Drug,,Digestive System Diseases|Respiratory Tract (Lung and Bronchial) Diseases|Diseases and Abnormalities at or before Birth|All Conditions|Immune System Diseases|Symptoms and General Pathology|Rare Diseases,OTHER,,Single,United States,8-Nov,16-Feb-09,11-Apr,11-Apr,21-Aug-12,The study was halted prematurely as the PI was no longer an employee of UMass Medical School.,,4,14,Actual,100,Anticipated,TRUE,,14,14,14,0.14,0,14,0,,2 - No Scientific Data
NCT00847002,1,Flexitouch Treatment for Venous Ulcers,Treatment,Parallel Assignment,Open Label,Randomized,Device|Device,Phase 4,Heart and Blood Diseases|Skin and Connective Tissue Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Multiple,United States|United States,7-Sep,18-Feb-09,10-Aug,10-Aug,31-May-12,Lack of Enrollment,,2,8,Actual,16,Anticipated,TRUE,,8,8,0,0.5,0,8,0,,2 - No Scientific Data
NCT00848783,1,"Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers",Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Procedure|Drug|Drug,Phase 2,Cancers and Other Neoplasms|Digestive System Diseases|All Conditions|Rare Diseases,OTHER,,Multiple,United States|United States|United States,8-May,19-Feb-09,11-Aug,12-Sep,9-Nov-12,Due to slow accrual,,2,8,Actual,62,Anticipated,TRUE,,8,8,7,0.13,2,7,0,,2 - No Scientific Data
NCT00850499,1,Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Rare Diseases,INDUSTRY,,Multiple,France|France|France|France|France|France|France|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Greece|Greece|Israel|Israel|Israel|Israel|Israel|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Spain|Spain|Spain|Switzerland,9-Sep,24-Feb-09,11-Sep,11-Oct,3-Oct-12,,,9,12,Actual,110,Anticipated,TRUE,,12,12,12,0.11,4,12,0,,3 - No Reason Provided
NCT00852631,1,Seroquel XR in Adults With Schizophrenia,Treatment,Single Group Assignment,Open Label,,Drug,Phase 3,Behaviors and Mental Disorders|All Conditions,INDUSTRY,,Multiple,Thailand|Thailand|Thailand,9-Feb,26-Feb-09,10-May,10-May,18-May-11,The study was prematurely terminated due to insufficient recruitment.,,2,28,Actual,100,Anticipated,TRUE,,28,28,28,0.28,1,28,0,,2 - No Scientific Data
NCT00855062,1,Minocycline for HIV+ Cognitive Impairment in Uganda,Treatment,Single Group Assignment,Double Blind,Randomized,Drug|Drug,Phase 1|Phase 2,"Viral Diseases|Immune System Diseases|All Conditions|Nervous System Diseases|Behaviors and Mental Disorders|Symptoms and General Pathology|Bacterial and Fungal Diseases|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Rare Diseases",OTHER,,Single,Uganda,8-Apr,2-Mar-09,9-Dec,9-Dec,17-Dec-10,The Neurologic AIDS Research Consortium Data Safety and Monitoring Board committee recommended to terminate the study early due to futility on 11/6/2009.,,6,73,Actual,100,Anticipated,TRUE,,73,73,59,0.73,3,73,1,23269596,1 - Scientific Data
NCT00855842,1,Pilot Study of the Addition of Osmotic Dilators to Preparation Prior to Labor Induction Abortion,Treatment,Single Group Assignment,Open Label,Non-Randomized,Device,,,OTHER,,Single,United States,9-Mar,2-Mar-09,10-Jan,10-Jan,4-Apr-11,inadequate enrollment,,2,4,Actual,20,Anticipated,TRUE,,4,4,4,0.2,0,4,0,,2 - No Scientific Data
NCT00857233,1,Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease,Treatment,Single Group Assignment,Open Label,,Drug,Phase 3,Nervous System Diseases|Behaviors and Mental Disorders|All Conditions|Symptoms and General Pathology|Rare Diseases,INDUSTRY,,Multiple,Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada,4-Jun,5-Mar-09,10-Jul,10-Oct,26-Jul-12,Please see explanation in the Detailed Description field.,In agreement with Health Canada the study was prematurely terminated due to recruitment difficulties in the lead-in Study 10158. Patients ongoing in the study when the decision to terminate was taken were allowed to complete it.,7,297,Actual,450,Anticipated,TRUE,,297,297,297,0.66,27,297,0,,2 - No Scientific Data
NCT00857259,1,The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Eye Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom,9-Feb,4-Mar-09,10-Jul,,22-Jul-11,,,9,16,Actual,63,Anticipated,TRUE,,16,16,13,0.25,0,15,0,,3 - No Reason Provided
NCT00857649,1,Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Nervous System Diseases|Behaviors and Mental Disorders|All Conditions|Symptoms and General Pathology|Rare Diseases,INDUSTRY,,Multiple,Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada,3-Dec,5-Mar-09,10-Apr,10-Sep,26-Oct-11,,,9,369,Actual,450,Anticipated,TRUE,,369,369,324,0.82,29,369,1,23472619,3 - No Reason Provided
NCT00857818,1,Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 3,Nutritional and Metabolic Diseases|All Conditions|Symptoms and General Pathology|Behaviors and Mental Disorders|Rare Diseases,INDUSTRY,,Multiple,Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada,9-Apr,6-Mar-09,10-Mar,10-Mar,17-May-11,Slow Accrual,,2,64,Actual,200,Anticipated,FALSE,F,28,28,25,0.14,2,26,0,,2 - No Scientific Data
NCT00858403,1,Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation,Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,OTHER,,Single,United States,9-Mar,5-Mar-09,10-Jul,10-Jul,12-Jul-11,Slow Accrual,,2,7,Actual,40,Anticipated,TRUE,,7,7,0,0.18,3,7,0,,2 - No Scientific Data
NCT00859573,1,Modafinil for Methamphetamine Dependence,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,,OTHER,,Single,United States,9-Apr,10-Mar-09,10-Jan,10-Jan,15-Apr-11,Terminated due to lack of funding.,,1,9,Actual,50,Anticipated,TRUE,,9,9,5,0.18,0,9,0,,2 - No Scientific Data
NCT00860249,1,Outreach for Patients That Are Newly Eligible for Colorectal Cancer Screening,Health Services Research,Parallel Assignment,Single Blind,Randomized,Behavioral|Behavioral,,Cancers and Other Neoplasms|Digestive System Diseases|All Conditions,OTHER,,Single,United States,9-Mar,11-Mar-09,9-Dec,9-Dec,2-Sep-11,Lack of sufficient participants meeting the eligibility criteria to complete study in proposed and acceptable time frame.,,2,60,Actual,420,Anticipated,TRUE,,60,60,0,0.14,0,60,0,,2 - No Scientific Data
NCT00860314,0,Antero-Posterior Versus Antero-Lateral Electrode Position for Electrical Cardioversion of Typical Atrial Flutter,Treatment,Parallel Assignment,Open Label,Randomized,Procedure|Procedure,,Heart and Blood Diseases|Symptoms and General Pathology|All Conditions,OTHER,,Single,Germany,5-Jan,10-Nov-08,5-Dec,5-Dec,10-Nov-08,Statistical interim analysis showed valid and significant results,,6,96,Actual,96,Actual,TRUE,,96,96,96,1,,,1,19932790,1 - Scientific Data
NCT00860535,1,Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED),Diagnostic,Single Group Assignment,Open Label,Non-Randomized,Other,Phase 1,Cancers and Other Neoplasms|All Conditions|Blood and Lymph Conditions|Immune System Diseases|Symptoms and General Pathology|Diseases and Abnormalities at or before Birth|Rare Diseases,INDUSTRY,,,,9-Jun,5-Mar-09,10-Apr,10-Jun,28-Jun-11,,,9,9,Actual,50,Anticipated,TRUE,,9,9,9,0.18,0,9,0,,3 - No Reason Provided
NCT00861471,1,Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer,Treatment,Single Group Assignment,Open Label,,Drug|Drug,Phase 1|Phase 2,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions",OTHER,,Multiple,United States|United States|United States,5-May,12-Mar-09,10-May,10-May,29-Apr-11,due to slow accrual,,2,24,Actual,37,Anticipated,FALSE,F,12,12,12,0.32,3,12,0,,2 - No Scientific Data
NCT00862121,1,A Study With Pentasa in Patients With Active Crohn's Disease,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Digestive System Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|Belgium|Denmark|France|Germany|Germany|Germany|Sweden|United Kingdom,9-Apr,13-Mar-09,10-Oct,10-Oct,3-Oct-11,Terminated due to poor recruitment,,2,20,Actual,510,Anticipated,TRUE,,20,20,18,0.04,0,19,0,,2 - No Scientific Data
NCT00862134,1,"Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC)",Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Canada|New Zealand,9-Mar,12-Mar-09,10-Jan,10-May,31-May-11,Interim analysis indicated low probability of clinically significant result,,6,42,Actual,100,Anticipated,TRUE,,42,42,38,0.42,13,40,0,,1 - Scientific Data
NCT00862836,1,Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD),Treatment,Single Group Assignment,Open Label,Randomized,Drug,Phase 1|Phase 2,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Gland and Hormone Related Diseases|All Conditions|Rare Diseases",INDUSTRY,,Multiple,Germany|Germany|Germany|Germany|Germany,9-Apr,16-Mar-09,10-Sep,10-Sep,2-Nov-11,Lack of efficacy,,6,15,Actual,70,Anticipated,TRUE,,15,15,14,0.21,3,14,0,,1 - Scientific Data
NCT00863057,1,Combination Pain Therapy in HIV Neuropathy,Treatment,Crossover Assignment,Double Blind,Randomized,Drug|Drug|Drug|Drug,Phase 2,"Viral Diseases|Immune System Diseases|All Conditions|Nervous System Diseases|Symptoms and General Pathology|Diseases and Abnormalities at or before Birth|Substance Related Disorders|Bacterial and Fungal Diseases|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Behaviors and Mental Disorders|Rare Diseases",NIH,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States,9-May,16-Mar-09,10-Dec,10-Dec,14-Dec-11,Due to slow accrual,,2,15,Actual,120,Anticipated,TRUE,,15,15,41,0.13,0,41,1,23565581,2 - No Scientific Data
NCT00869167,1,Ramelteon for Insomnia Comorbid With Asthma,Treatment,Parallel Assignment,Double Blind,Randomized,Drug,Phase 3,Respiratory Tract (Lung and Bronchial) Diseases|Immune System Diseases|All Conditions|Nervous System Diseases|Behaviors and Mental Disorders|Symptoms and General Pathology,OTHER,,Single,United States,8-Mar,19-Mar-09,9-Jun,9-Jun,28-Jun-11,PI terminating study due to personal reasons.,,4,2,Actual,60,Anticipated,FALSE,F,3,3,2,0.05,0,3,0,,2 - No Scientific Data
NCT00871689,1,"Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML",Treatment,Single Group Assignment,Open Label,,Biological|Drug|Drug|Procedure|Radiation,Phase 2,Cancers and Other Neoplasms|All Conditions|Symptoms and General Pathology|Diseases and Abnormalities at or before Birth|Rare Diseases,OTHER,,Single,United States,9-Jan,27-Mar-09,10-Mar,11-Oct,11-Jun-12,Due to graft failure.,,5,2,Actual,30,Anticipated,TRUE,,2,2,2,0.07,2,2,0,,1 - Scientific Data
NCT00872001,1,The Effect Of Acadesine On Reducing Cardiovascular and Cerebrovascular Adverse Events In Coronary Artery Bypass Graft (CABG) Surgery (Study P05633 AM1)(TERMINATED),Prevention,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Nervous System Diseases|Heart and Blood Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,,,9-Apr,27-Mar-09,10-Oct,10-Oct,20-Nov-12,,,9,3080,Actual,7500,Anticipated,TRUE,,3080,3080,3080,0.41,656,2899,1,22782417,3 - No Reason Provided
NCT00878501,1,"Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Osteoarthritis (OA) of the Knee",Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 2,"Muscle, Bone, and Cartilage Diseases|All Conditions|Nervous System Diseases|Symptoms and General Pathology|Skin and Connective Tissue Diseases",INDUSTRY,,Multiple,Bulgaria|Bulgaria|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Finland|Finland|Finland|Finland|Finland|Finland|Hungary|Hungary|Hungary|Hungary|Hungary|Hungary|Japan|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Slovakia|Slovakia|Slovakia|Slovakia|Slovakia|Slovakia|Slovakia|Slovakia,9-Mar,8-Apr-09,9-Jul,9-Jul,27-Jan-11,The study was terminated after the planned interim analysis.,,6,241,Actual,520,Anticipated,TRUE,,241,241,231,0.46,2,240,0,,1 - Scientific Data
NCT00879970,1,Thiazolidinedione Intervention With Vitamin D Evaluation,Treatment,,Double Blind,Randomized,Dietary Supplement|Drug|Drug|Drug|Dietary Supplement,Phase 4,Nutritional and Metabolic Diseases|Gland and Hormone Related Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Chile|Chile|Chile|Chile|Chile|Colombia|Colombia|Colombia|Colombia|Colombia|Colombia|Colombia|Colombia|Colombia|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Denmark|Denmark|Denmark|Denmark|Denmark|Finland|Finland|Finland|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|India|India|India|India|India|India|India|India|India|India|India|India|India|India|Italy|Latvia|Latvia|Latvia|Latvia|Latvia|Mexico|Mexico|Mexico|Mexico|Mexico|Mexico|Mexico|Netherlands|Netherlands|Netherlands|Netherlands|Netherlands|Norway|Norway|Pakistan|Pakistan|Pakistan|Peru|Philippines|Romania|Romania|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Slovakia|Slovakia|South Africa|South Africa|South Africa|South Africa|South Africa|South Africa|South Africa|South Africa|South Africa|South Africa|South Africa|South Africa|Sweden|Sweden|Sweden|Sweden|Sweden|Sweden|Sweden|Sweden|Sweden|Sweden|Sweden|Sweden|Sweden|United Kingdom,9-May,2-Apr-09,15-Oct,15-Oct,10-Nov-11,FDA has placed the trial on full clinical hold.,,5,1332,Actual,16000,Anticipated,TRUE,,1332,1332,1332,0.08,14,1332,1,22038523,1 - Scientific Data
NCT00880009,1,Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|Belgium|China|Hong Kong|Hungary|Poland|Singapore,9-Jul,8-Apr-09,10-May,10-May,4-Oct-12,See termination reason in detailed description.,This study was terminated on 19 April 2009 due to unfavorable risk benefit ratio of Bosutinib in combination with Letrozole including one confirmed Hy's law case. 37.5% of patients had treatment related liver events with the majority of severe events resulting in permanent study treatment discontinuation.,5,16,Actual,250,Anticipated,TRUE,,16,16,0,0.06,5,16,0,,1 - Scientific Data
NCT00880542,1,Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery,Treatment,Single Group Assignment,Open Label,,Drug|Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Rare Diseases,OTHER,,Single,United States,8-Aug,10-Apr-09,10-Nov,,13-Apr-11,The study lost funding.,,1,7,Actual,20,Anticipated,TRUE,,7,7,0,0.35,4,7,0,,2 - No Scientific Data
NCT00881205,1,Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 4,Nervous System Diseases|Immune System Diseases|All Conditions|Symptoms and General Pathology|Behaviors and Mental Disorders,INDUSTRY,,Multiple,Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany,9-Apr,14-Apr-09,11-Jan,11-Jan,20-Jan-12,Termination of study due to low enrollment,,2,86,Actual,200,Anticipated,TRUE,,86,86,0,0.43,12,172,1,23069874,2 - No Scientific Data
NCT00884039,1,Anecortave Acetate Injection to Treat Steroid-responsive Intraocular Pressure Increase in Cornea Transplant Patients,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,,Eye Diseases|All Conditions,OTHER,,Single,United States,9-May,17-Apr-09,10-Aug,10-Sep,20-Sep-10,Preliminary data analysis showed insufficient efficacy to justify continuation.,,6,7,Actual,100,Anticipated,TRUE,,7,7,7,0.07,0,7,0,,1 - Scientific Data
NCT00886769,1,Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,"Muscle, Bone, and Cartilage Diseases|All Conditions|Skin and Connective Tissue Diseases|Immune System Diseases|Rare Diseases",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Argentina|Argentina|Argentina|Belgium|Belgium|Belgium|Belgium|Brazil|Brazil|Brazil|Brazil|Canada|Canada|Canada|Canada|Canada|Denmark|France|France|France|France|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Greece|Hungary|Israel|Israel|Israel|Israel|Israel|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Netherlands|Norway|Peru|Poland|South Africa|South Africa|South Africa|Spain|Spain|Spain|Sweden|Switzerland|Switzerland|Switzerland|Turkey|Turkey|Turkey|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom,9-Jul,22-Apr-09,10-Dec,11-Jan,21-Nov-11,recommendation by Data Monitoring Committee,,6,84,Actual,122,Anticipated,TRUE,,84,84,84,0.69,4,84,1,23252526,1 - Scientific Data
NCT00888329,1,Aprepitant for Prevention of Postoperative Nausea and Vomiting in Elective Hysterectomy,Prevention,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 4,Symptoms and General Pathology|All Conditions,OTHER,,Single,United States,7-Jul,24-Apr-09,11-Oct,11-Oct,1-Feb-12,Slow accrual.,,2,256,Actual,400,Anticipated,TRUE,,256,256,94,0.64,5,71,0,,2 - No Scientific Data
NCT00893997,0,PR1 Vaccination in Myelodysplastic Syndrome (MDS),Treatment,Single Group Assignment,Open Label,,Biological,Phase 2,Cancers and Other Neoplasms|All Conditions|Blood and Lymph Conditions|Symptoms and General Pathology|Rare Diseases,OTHER,,Single,United States,6-Jul,4-May-09,9-Mar,9-Mar,17-Mar-11,The trial was ended per sponsor due to slow accrual rates.,,2,12,Actual,12,Actual,FALSE,E,10,12,10,1,1,10,0,,2 - No Scientific Data
NCT00894790,1,Celecoxib Efficacy And Safety Versus Diclofenac In Acute Pain Due To Cervical Sprain Related To A Traffic Accident,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 4,Nervous System Diseases|Symptoms and General Pathology|All Conditions|Wounds and Injuries,INDUSTRY,,Multiple,Mexico|Mexico,9-Nov,27-Mar-09,10-Jan,10-Jan,28-Jan-11,See termination reason in detailed description.,On 21Oct2010 study was prematurely terminated due to poor enrollment with subsequent low number of participants. No safety or efficacy issues were involved in the decision to terminate prematurely.,2,8,Actual,150,Anticipated,TRUE,,8,8,0,0.05,0,8,0,,2 - No Scientific Data
NCT00895895,1,Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug|Drug|Drug,Phase 2,Nervous System Diseases|Behaviors and Mental Disorders|All Conditions|Symptoms and General Pathology|Rare Diseases,INDUSTRY,,Multiple,"United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Argentina|Argentina|Argentina|Argentina|Chile|Chile|Chile|Chile|Chile|Colombia|Colombia|Colombia|Colombia|Colombia|Hong Kong|Hong Kong|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Korea, Republic of|Korea, Republic of|Mexico|Mexico|New Zealand|New Zealand|Poland|Poland|Poland|Romania|Romania|Romania|Romania|Romania|Romania|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|South Africa|South Africa|South Africa|South Africa|South Africa",9-May,7-May-09,11-May,11-May,21-Dec-12,See termination reason in detailed description.,The study was stopped (date of termination was 13April2011) due to a 6 month interim analysis: all of the 3 SAM-531 dosage levels were declared futile. There were no safety concerns.,6,526,Actual,460,Anticipated,TRUE,,526,526,501,1.14,57,1036,0,,1 - Scientific Data
NCT00898443,1,Continuous Labor Epidural Catheter for Tubal Ligation Study,Supportive Care,Parallel Assignment,Double Blind,Randomized,Other|Other,,,OTHER,,Single,United States,8-Oct,8-May-09,10-Aug,10-Aug,19-Apr-12,,,9,18,Actual,80,Anticipated,TRUE,,18,18,17,0.23,0,17,0,,3 - No Reason Provided
NCT00900146,1,"Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients",Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 2|Phase 3,Nutritional and Metabolic Diseases|Gland and Hormone Related Diseases|All Conditions,INDUSTRY,,Multiple,"United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Argentina|Argentina|Argentina|Argentina|Argentina|Argentina|Argentina|Argentina|Belgium|Belgium|Belgium|China|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Hungary|Hungary|Hungary|Hungary|Hungary|Hungary|India|India|India|India|India|India|India|India|India|India|India|India|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of|Peru|Peru|Peru|Peru|Romania|Romania|Romania|Romania|South Africa|South Africa|South Africa|South Africa|South Africa|South Africa|South Africa|Turkey|Turkey|Turkey|Turkey|Turkey|Turkey|Turkey|United Kingdom|United Kingdom|United Kingdom|United Kingdom",9-Apr,6-May-09,10-Nov,10-Nov,22-Nov-11,Numerically modest lowering of HbA1c with canakinumab in combination with metformin was inadequate to continue patients with T2DM into Period IV of this study.,,6,556,Actual,600,Anticipated,FALSE,E,551,556,551,0.93,24,551,1,23129601,1 - Scientific Data
NCT00903695,1,MemoryXL Effects on Mild Cognitive Impairment Patients,Prevention,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Behaviors and Mental Disorders|All Conditions|Nervous System Diseases|Symptoms and General Pathology,OTHER,,Multiple,United States|United States,9-Jun,14-May-09,11-May,11-May,26-Jul-11,"Risk/benefit ratio did not indicate further study would be useful, or fair to future subjects.",,6,10,Actual,60,Anticipated,TRUE,,10,10,8,0.17,0,10,0,,1 - Scientific Data
NCT00905021,1,Exemestane With Sunitinib (SUTENT??) in Metastatic Breast Cancer,Treatment,Single Group Assignment,Open Label,,Drug|Drug,Phase 1|Phase 2,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions,OTHER,,Single,United States,10-Mar,18-May-09,11-Jan,12-Feb,6-Feb-12,Sponsor withdrew support,,1,4,Actual,51,Anticipated,TRUE,,4,4,2,0.08,1,4,0,,2 - No Scientific Data
NCT00906243,1,RNActive??-Derived Therapeutic Vaccine,Treatment,Single Group Assignment,Open Label,,Biological,Phase 1|Phase 2,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions",OTHER,,Single,United States,9-May,14-May-09,10-Dec,10-Dec,29-Feb-12,Study Closed after completion of Phase I,,5,6,Actual,24,Anticipated,TRUE,,6,6,6,0.25,0,6,0,,1 - Scientific Data
NCT00906776,1,Emdogain and Straumann Bone Ceramic in Infrabony Defects,Treatment,Single Group Assignment,Open Label,Randomized,Device|Device,,Mouth and Tooth Diseases|All Conditions,INDUSTRY,,Single,France,7-Apr,19-May-09,12-Jul,12-Jul,30-Aug-12,Difficulty to recruit patients fulfilling inclusion criteria,,2,19,Actual,30,Anticipated,TRUE,,19,19,19,0.63,0,19,0,,2 - No Scientific Data
NCT00910299,1,Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Heart and Blood Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany,9-Jul,28-May-09,11-Apr,11-Apr,10-Apr-12,Due to the low rate of primary endpoint events experienced in the study to date,,6,423,Actual,2150,Anticipated,TRUE,,423,423,423,0.2,78,420,1,22520250,1 - Scientific Data
NCT00912288,1,A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Nervous System Diseases|Behaviors and Mental Disorders|All Conditions|Symptoms and General Pathology|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Canada|Canada|Canada|Germany|Germany|Germany|Germany|Germany|Germany|Hungary|Hungary|Hungary|Portugal|Portugal|Slovakia|Slovakia|Slovakia|Slovakia|Spain|Spain|Spain|Spain|Spain|Turkey|Turkey|Turkey,9-Sep,1-Jun-09,10-Aug,10-Aug,30-Jul-12,See termination reason in detailed description.,"This study was terminated on May 7, 2010 due to modification of the dimebon development plan following the lack of demonstration of efficacy in the completed DIM14 (CONNECTION) Study. The study was not terminated due to any safety findings. Dimebon has been well-tolerated in clinical trials. Demonstration of efficacy for dimebon in Alzheimer's disease is pending completion of the ongoing DIM18 (CONCERT) Study.",7,86,Actual,500,Anticipated,TRUE,,86,86,0,0.17,7,86,0,,2 - No Scientific Data
NCT00913692,1,A Randomized Double-Blind Control-Comparison Crossover Trial of Oral Glutamine to Suppress Frequently Recurrent Herpes Labialis,Prevention,Crossover Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Viral Diseases|Skin and Connective Tissue Diseases|All Conditions|Mouth and Tooth Diseases|Bacterial and Fungal Diseases,NIH,,Single,United States,9-Jun,3-Jun-09,11-Dec,11-Dec,29-Feb-12,Terminated due to slow recruitment.,,2,11,Actual,125,,TRUE,,11,11,0,0.09,0,4,0,,2 - No Scientific Data
NCT00918931,1,Obatoclax for Systemic Mastocytosis,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Skin and Connective Tissue Diseases|Immune System Diseases|Rare Diseases,OTHER,,Single,United States,9-Jun,9-Jun-09,10-Oct,10-Oct,30-Mar-11,,,9,3,Actual,25,Anticipated,TRUE,,3,3,3,0.12,0,3,0,,3 - No Reason Provided
NCT00923949,1,Pioglitazone to Treat Adults Undergoing Surgery for Non-small Cell Lung Cancer,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 2,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,NIH,,Multiple,United States|United States,8-Aug,17-Jun-09,10-Mar,10-Mar,11-Jan-12,Study never published; terminated early due to low accrual.,,2,1,Actual,25,,TRUE,,1,1,0,0.04,0,1,0,,2 - No Scientific Data
NCT00924001,1,Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma,Treatment,Single Group Assignment,Open Label,,Drug|Drug|Drug|Drug,Phase 1|Phase 2,Cancers and Other Neoplasms|All Conditions|Rare Diseases,NIH,,Single,United States,7-Aug,17-Jun-09,10-Oct,10-Oct,22-Dec-11,study was stopped due to low accrual,,2,1,Actual,30,,TRUE,,1,1,1,0.03,0,1,0,,2 - No Scientific Data
NCT00924040,1,Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Blood and Lymph Conditions|Immune System Diseases|Rare Diseases,NIH,,Single,United States,9-Feb,17-Jun-09,10-Aug,10-Aug,20-Sep-11,The supply of BL22 has expired and MedImmune the sponsor is not interested in producing any new supply.,,3,1,Actual,25,,TRUE,,1,1,1,0.04,0,1,0,,2 - No Scientific Data
NCT00924209,1,"A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer",Treatment,Single Group Assignment,Open Label,,Drug|Drug|Drug|Procedure|Drug,Phase 2,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,NIH,,Multiple,United States|Croatia,9-Mar,17-Jun-09,11-Sep,11-Sep,19-Jul-12,Study was terminated due to poor accrual.,,2,7,Actual,70,,TRUE,,7,7,0,0.1,3,7,0,,2 - No Scientific Data
NCT00924287,1,Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer,Treatment,Single Group Assignment,Open Label,,Drug|Drug|Drug|Drug,Phase 1|Phase 2,Cancers and Other Neoplasms|Symptoms and General Pathology|All Conditions,NIH,,Single,United States,8-Nov,17-Jun-09,10-Dec,10-Dec,5-Jan-12,This study was terminated after the first patient treated on study died as a result of the treatment.,,5,1,Actual,100,,TRUE,,1,1,1,0.01,1,1,0,,1 - Scientific Data
NCT00924781,1,A Study of the Efficacy and Safety of MK2578 for the Treatment of Anemia in Patients With Kidney Disease (MK2578-003-AM03-EXT12),Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug,Phase 2,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions|Blood and Lymph Conditions",INDUSTRY,,,,9-Jun,18-Jun-09,10-Apr,10-May,25-Oct-11,,,9,39,Actual,150,Anticipated,TRUE,,39,39,39,0.26,3,39,0,,3 - No Reason Provided
NCT00927953,1,Treatment of West Nile Virus With MGAWN1,Treatment,Parallel Assignment,Double Blind,Randomized,Biological|Biological,Phase 2,Viral Diseases|Nervous System Diseases|All Conditions|Symptoms and General Pathology|Rare Diseases,INDUSTRY,,,,9-May,24-Jun-09,11-Feb,11-May,10-Apr-12,Early termination due to the inability to enroll (13 of 120 subjects enrolled),,2,13,Actual,60,Anticipated,TRUE,,13,13,13,0.22,4,13,0,,2 - No Scientific Data
NCT00929162,1,ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug|Drug,Phase 2,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Gland and Hormone Related Diseases|All Conditions|Rare Diseases",INDUSTRY,,Multiple,Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Italy|Italy|Italy|Italy|Italy|Italy|Italy,9-Jun,25-Jun-09,11-Jun,11-Jun,26-Apr-12,Primary objective of the trial was not met and so there was no benefit in collecting further information,,6,120,Actual,122,Anticipated,TRUE,,120,120,120,0.98,32,116,1,23234805,1 - Scientific Data
NCT00931411,0,Tolerance and Efficacy of Formulation 609580 20 Versus Formulation 609209 in Children With Atopic Dermatitis,Treatment,Crossover Assignment,Double Blind,Randomized,Other|Other,,Diseases and Abnormalities at or before Birth|Skin and Connective Tissue Diseases|Immune System Diseases|All Conditions,INDUSTRY,,Multiple,Canada|Canada|Canada|Canada|Canada,9-Jan,29-Jun-09,9-Jun,9-Jul,3-Aug-10,Patients would improve naturally due to weather conditions,,7,73,Actual,100,Anticipated,TRUE,,73,73,66,0.73,0,146,0,,2 - No Scientific Data
NCT00931996,1,Oculomotor and Spatial Cognition Deficits in Schizophrenia,Basic Science,Single Group Assignment,Open Label,,Drug,,Behaviors and Mental Disorders|All Conditions,OTHER,,Single,United States,9-Jun,25-Jun-09,11-Nov,11-Nov,8-Nov-11,Study was terminated due to low accrual.,,2,12,Actual,50,Anticipated,TRUE,,12,12,5,0.24,0,12,0,,2 - No Scientific Data
NCT00934635,1,A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy Controls,Treatment,Parallel Assignment,Open Label,Non-Randomized,Drug|Drug|Other|Drug|Drug|Drug|Drug|Drug|Drug,Phase 4,Behaviors and Mental Disorders|All Conditions,INDUSTRY,,,,9-Sep,6-Jul-09,9-Dec,9-Dec,13-Dec-10,Unable to meet recruitment and enrollment goals,,2,2,Actual,34,Anticipated,TRUE,,2,2,2,0.06,1,2,0,,2 - No Scientific Data
NCT00936598,1,Sleep and Endometrial Cancer,Supportive Care,Parallel Assignment,Double Blind,Randomized,Drug|Drug,,"Cancers and Other Neoplasms|Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions|Nervous System Diseases|Symptoms and General Pathology",OTHER,,Multiple,United States|United States,9-Jul,8-Jul-09,11-Apr,11-Apr,15-Jun-12,Investigator-initiated termination of approval due to problems with recruitment.,,2,6,Actual,144,Anticipated,FALSE,F,5,5,0,0.03,0,0,0,,2 - No Scientific Data
NCT00938314,1,Study of NTx??-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug|Drug,Phase 2,Nervous System Diseases|Heart and Blood Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Multiple,United States|Canada|Canada|Canada|Canada|India|India|India|India|India|India|India|India|India|India|India|India|India|India|India|India|India|India,9-Aug,9-Jul-09,10-Apr,10-Apr,1-Sep-11,Slow Enrollment,,2,96,Actual,128,Anticipated,FALSE,E,32,96,96,0.75,11,96,0,,2 - No Scientific Data
NCT00938457,1,Stereotactic Radiation Therapy in Treating Patients With Liver Metastases,Treatment,Single Group Assignment,Open Label,,Radiation|Procedure|Procedure,Phase 1|Phase 2,Cancers and Other Neoplasms|Symptoms and General Pathology|All Conditions,OTHER,,Single,United States,9-Jul,9-Jul-09,11-Apr,11-Dec,4-Jun-12,,,9,3,Actual,60,Anticipated,TRUE,,3,3,0,0.05,0,3,0,,3 - No Reason Provided
NCT00939094,1,AZD2066 Neuropathic Pain - Mechanical Hypersensitivity,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Nervous System Diseases|Symptoms and General Pathology|All Conditions|Immune System Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,9-Aug,13-Jul-09,10-Nov,10-Nov,28-Aug-12,,,9,87,Actual,100,Anticipated,TRUE,,87,87,68,0.87,1,86,0,,3 - No Reason Provided
NCT00939783,1,An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 3,Nervous System Diseases|Behaviors and Mental Disorders|All Conditions|Symptoms and General Pathology|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Puerto Rico|Puerto Rico|Puerto Rico|Puerto Rico,9-Sep,13-Jul-09,10-Aug,10-Aug,11-Oct-12,See termination reason in detailed description.,"This study was terminated on May 7, 2010 as part of modification of the dimebon development plan following lack of demonstration of efficacy in the completed DIM14 (CONNECTION) Study. The study was not terminated due to any safety findings. Dimebon has been well -tolerated in clinical trials. Demonstration of efficacy for dimebon in Alzheimer's disease is pending completion of the ongoing DIM18 (CONCERT) Study.",7,649,Actual,750,Anticipated,TRUE,,649,649,648,0.87,76,648,0,,2 - No Scientific Data
NCT00943605,1,PEAK PlasmaBlade? 4.0 Versus Traditional Electrosurgery in Mastectomy,Treatment,Parallel Assignment,Single Blind,Randomized,Device|Device,,,INDUSTRY,,Multiple,United States|United States|United States|United States,9-Jun,21-Jul-09,11-Dec,12-Mar,29-Nov-12,Termination due to acquisition of PEAK Surgical by Medtronic,,8,60,Actual,60,Anticipated,TRUE,,60,60,0,1,0,60,0,,2 - No Scientific Data
NCT00946985,1,28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years,Prevention,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 4,Behaviors and Mental Disorders|All Conditions,INDUSTRY,,Multiple,"United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Brazil|Brazil|Brazil|Bulgaria|Bulgaria|Bulgaria|Canada|Canada|Canada|Canada|Canada|China|China|China|China|China|China|China|China|Colombia|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|India|India|India|India|India|India|India|India|India|Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of|Malaysia|Malaysia|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Ukraine|Ukraine|Ukraine|Ukraine|Ukraine",9-Jun,2-Jul-09,10-Mar,10-Mar,8-Mar-11,The recruitment rate for the study was inadequate to achieve its enrollment goals.,,2,163,Actual,936,Anticipated,FALSE,F,162,162,0,0.17,6,162,0,,2 - No Scientific Data
NCT00948389,1,Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM),Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 1|Phase 2,Cancers and Other Neoplasms|All Conditions|Rare Diseases,INDUSTRY,,Multiple,France|Italy|Netherlands|Netherlands|Switzerland,9-Oct,28-Jul-09,11-May,11-May,25-Jul-12,Inability to meet protocol objectives,,6,28,Actual,108,Anticipated,FALSE,F,26,26,26,0.24,13,26,1,23090987,1 - Scientific Data
NCT00948857,1,Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF),Treatment,Factorial Assignment,Double Blind,Randomized,Dietary Supplement|Dietary Supplement,Phase 2|Phase 3,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions|Gland and Hormone Related Diseases|Heart and Blood Diseases|Diseases and Abnormalities at or before Birth|Rare Diseases",OTHER,,Single,United States,9-Jun,28-Jul-09,11-Oct,11-Oct,2-Aug-12,Lack of recruitment.,,2,5,Actual,240,Anticipated,TRUE,,5,5,5,0.02,0,0,0,,2 - No Scientific Data
NCT00951171,1,Effect of Cervical Occlusion During Intrauterine Insemination (IUI),Treatment,Parallel Assignment,Open Label,Randomized,Procedure|Procedure,Phase 3,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions",OTHER,,Single,United States,9-Feb,31-Jul-09,11-Dec,11-Dec,10-Jul-12,Randomization flawed. Results were poor in the innovative catheter group,,6,93,Actual,160,Anticipated,FALSE,E,95,93,93,0.58,0,95,0,,1 - Scientific Data
NCT00953160,1,Radio Frequency (RF) Device for Reduction in Size of Localized Areas of the Body,Treatment,Single Group Assignment,Open Label,,Device,,,INDUSTRY,,Multiple,United States|United States|United States|United States|United States,9-Apr,4-Aug-09,10-Jul,10-Jul,25-Feb-11,The preliminary data from this pilot study did not indicate efficacy.,,6,76,Actual,80,Anticipated,TRUE,,76,76,49,0.95,0,49,0,,1 - Scientific Data
NCT00953290,1,Thigh Circumference Reduction Study,Treatment,Parallel Assignment,Open Label,Randomized,Device,,,INDUSTRY,,Single,United States,9-Jan,4-Aug-09,10-Jan,10-Jan,17-Feb-11,The study was terminated because the preliminary data did not indicate efficacy.,,6,4,Actual,56,Anticipated,TRUE,,4,4,4,0.07,0,4,0,,1 - Scientific Data
NCT00953329,0,Alefacept in Subjects With Chronic Plaque Psoriasis Who Failed to Respond to Anti-TNF Therapy,Treatment,Single Group Assignment,Open Label,,Drug,Phase 4,Skin and Connective Tissue Diseases|All Conditions,OTHER,,,,8-Feb,22-Jul-09,8-Dec,8-Dec,18-Oct-12,Subjects declined enrollment; sponsor/PI elected to close study.,,2,1,Actual,1,Actual,TRUE,,1,1,0,1,0,0,0,,2 - No Scientific Data
NCT00953615,0,Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC),Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,Digestive System Diseases|All Conditions|Rare Diseases,OTHER,,Single,United States,6-Apr,4-Aug-09,9-May,9-May,8-Aug-11,Lack of enrollment,,2,1,Actual,24,Anticipated,TRUE,,1,1,0,0.04,0,1,0,,2 - No Scientific Data
NCT00954915,1,Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis,Treatment,Single Group Assignment,Open Label,,Biological,Phase 1|Phase 2,"Muscle, Bone, and Cartilage Diseases|All Conditions|Skin and Connective Tissue Diseases",INDUSTRY,,Multiple,United States|United States,9-Dec,4-Aug-09,10-Jul,10-Jul,27-Mar-12,Injection site reaction met protocol-defined stopping criteria.,,5,1,Actual,60,Anticipated,TRUE,,1,1,1,0.02,0,1,0,,1 - Scientific Data
NCT00957034,1,Assessing the Safety/Efficacy of Transdermal Testosterone in Female Patients With Symptomatic Heart Failure,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Heart and Blood Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,9-Jul,10-Aug-09,10-Apr,10-May,3-Aug-11,Due to difficult patient enrollment.,,2,17,Actual,162,Anticipated,TRUE,,17,17,0,0.1,4,17,0,,2 - No Scientific Data
NCT00960154,1,PEAK PlasmaBlade? 4.0 Versus Traditional Electrosurgery in Lumpectomy,Treatment,Parallel Assignment,Single Blind,Randomized,Device|Procedure,,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States,9-Jul,13-Aug-09,12-Feb,12-Feb,29-Nov-12,Termination due to acquisition of PEAK Surgical by Medtronic,,8,50,Actual,30,Anticipated,TRUE,,50,50,0,1.67,1,50,0,,2 - No Scientific Data
NCT00960934,1,A Dose-Ranging Study of MK-5442 in Postmenopausal Women With Osteoporosis (MK-5442-001 AM4),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Dietary Supplement|Dietary Supplement,Phase 2,"Muscle, Bone, and Cartilage Diseases|All Conditions",INDUSTRY,,,,9-Oct,17-Aug-09,10-Dec,10-Dec,14-Aug-12,,,9,383,Actual,480,Anticipated,TRUE,,383,383,380,0.8,19,380,0,,3 - No Reason Provided
NCT00964743,1,Depocyt?? With Sorafenib in Neoplastic Meningitis,Treatment,Single Group Assignment,Open Label,,Drug|Drug,,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions|Nervous System Diseases,OTHER,,Single,United States,9-Aug,24-Aug-09,11-Feb,11-Feb,19-Jan-12,Low Accrual,,2,2,Actual,10,Anticipated,TRUE,,2,2,2,0.2,2,2,0,,2 - No Scientific Data
NCT00965146,0,Scorpio?? Cruciate Retaining (CR) Outcomes Study,Treatment,Single Group Assignment,Open Label,,Device,,"Muscle, Bone, and Cartilage Diseases|All Conditions|Symptoms and General Pathology",INDUSTRY,,Multiple,United States|United States|United States|United States|United States,1-Jun,11-Aug-09,18-Jul,,9-Nov-12,Terminated due to lagging follow-up.,,4,215,Actual,228,Actual,FALSE,E,210,215,0,0.94,6,210,0,,2 - No Scientific Data
NCT00968617,1,A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis (2578-002),Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug|Drug,Phase 2,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions|Blood and Lymph Conditions",INDUSTRY,,,,9-Nov,27-Aug-09,10-Apr,10-May,7-Oct-11,,,9,7,Actual,75,Anticipated,TRUE,,7,7,7,0.09,0,7,0,,3 - No Reason Provided
NCT00972543,0,Raptiva in Palm and Sole Psoriasis,Treatment,Parallel Assignment,,Randomized,Biological|Biological,Phase 4,Skin and Connective Tissue Diseases|All Conditions,INDUSTRY,,,,8-Sep,4-Sep-09,9-May,,28-Jun-10,The study was terminated after the European Medicines Evaluation Agency recommended to suspend the marketing authorisation of Raptiva in the European Union,,16,6,Actual,165,Anticipated,TRUE,,6,6,0,0.04,2,6,0,,2 - No Scientific Data
NCT00976027,1,Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone?? Vaccine in Adults Aged 65 Years and Older,Prevention,Parallel Assignment,Double Blind,Randomized,Biological|Biological,Phase 3,Bacterial and Fungal Diseases|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions|Viral Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Puerto Rico|Puerto Rico,9-Sep,11-Sep-09,11-May,12-Apr,19-Jun-12,"No safety concerns, study terminated due to lack of primary endpoint cases in 2009-2010 Flu season (coincided with H1N1 Pandemic) Subjects followed per-protocol",,6,9172,Actual,33000,Anticipated,FALSE,E,9158,9172,9021,0.28,729,9158,1,23261045,1 - Scientific Data
NCT00978341,0,Study to Determine if a Reduction in Pain Can be Measured in Spinal Cord Injured Patients Using a New Study Design,,Crossover Assignment,Double Blind,Randomized,Drug|Drug,,Nervous System Diseases|Wounds and Injuries|All Conditions|Symptoms and General Pathology,INDUSTRY,,Multiple,Australia|Australia|Australia|Australia,7-Feb,15-Sep-09,8-Oct,8-Oct,28-Sep-09,See Detailed Description,"This methodology study was terminated on October 13, 2008 based on interim results for an exploratory, novel endpoint. The results of the primary analysis at the interim for N=12 patients showed results that generally favored pregabalin but were not statistically significant compared to placebo. Based on the estimated conditional power, this result is unlikely to change with full recruitment of N=24 patients and therefore the data monitoring committee recommended termination of the trial. The decision to terminate the trial was not based on any safety concerns.",6,15,Actual,15,Actual,TRUE,,15,15,29,1,1,29,0,,1 - Scientific Data
NCT00982280,1,Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking WHO Step III Analgesics But Showing a Lack of Tolerability.,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 3,"Muscle, Bone, and Cartilage Diseases|All Conditions|Nervous System Diseases|Symptoms and General Pathology|Skin and Connective Tissue Diseases",INDUSTRY,,Multiple,Australia|Australia|Denmark|Denmark|Denmark|Denmark|Denmark|Germany|Germany|Germany|Germany|Germany|Poland|Poland|Poland|Spain|Spain|Spain|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom,9-Sep,22-Sep-09,10-May,10-Aug,2-Aug-11,Slow Recruitment and supply of Investigational Medicinal Product Issues,,2,82,Actual,180,Anticipated,TRUE,,82,82,53,0.46,2,63,1,23912473,2 - No Scientific Data
NCT00984490,1,Metformin Hydrochloride in Treating Women With Stage I or Stage II Breast Cancer That Can Be Removed By Surgery,Treatment,Single Group Assignment,Open Label,,Drug|Other,,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions,OTHER,,Multiple,United States|United States|United States,9-Sep,24-Sep-09,10-Jul,11-Jul,12-Mar-12,slow accrual,,2,5,Actual,30,Anticipated,TRUE,,5,5,0,0.17,0,5,0,,2 - No Scientific Data
NCT00986856,0,Fucidin?? Cream in the Treatment of Impetigo,Treatment,Parallel Assignment,Double Blind,Randomized,Drug,Phase 4,Bacterial and Fungal Diseases|Skin and Connective Tissue Diseases|All Conditions,INDUSTRY,,Multiple,Norway|Sweden,4-May,29-Sep-09,5-Mar,5-Mar,19-Mar-10,Enrollment failed,,2,58,Actual,58,Actual,TRUE,,58,58,46,1,0,56,0,,2 - No Scientific Data
NCT00993421,1,A Weight Loss Study in Overweight Men and Women,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug|Drug|Drug|Drug,Phase 2,Nutritional and Metabolic Diseases|Symptoms and General Pathology|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,9-Oct,9-Oct-09,10-Jun,10-Jun,11-May-11,Clinical trial terminated due to results from recent nonclinical studies,,7,343,Actual,350,Anticipated,TRUE,,343,343,180,0.98,7,343,0,,2 - No Scientific Data
NCT00995449,1,Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis,Treatment,Parallel Assignment,Double Blind,Randomized,Biological|Other,Phase 2,"Muscle, Bone, and Cartilage Diseases|All Conditions|Skin and Connective Tissue Diseases|Immune System Diseases",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,10-Jan,5-Oct-09,11-Mar,12-Feb,7-May-12,Program refocus,,8,9,Actual,208,Anticipated,TRUE,,9,9,9,0.04,1,9,0,,2 - No Scientific Data
NCT00996944,1,Clinical Evaluation of Ropinirole IR (Immediate Release) Tablets in Patients Who Are Diagnosed With Symptomatic Restless Legs Syndrome (RLS) Associated With Chronic Kidney Disease (CKD) Managed With Haemodialysis (Including Haemofiltration and Haemodiafiltration),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,"Nervous System Diseases|Symptoms and General Pathology|All Conditions|Behaviors and Mental Disorders|Urinary Tract, Sexual Organs, and Pregnancy Conditions",INDUSTRY,,Multiple,Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan,9-Nov,8-Oct-09,10-Jun,10-Jun,10-Feb-11,Because GSK concluded that it was impossible to recruit sufficient participants within a reasonable timeframe.,,2,34,Actual,220,Anticipated,TRUE,,34,34,34,0.15,2,34,0,,2 - No Scientific Data
NCT00998582,1,Artery Elasticity After Switch From Epzicom to Truvada,Treatment,Parallel Assignment,Open Label,Randomized,Drug,Phase 4,"Viral Diseases|Immune System Diseases|All Conditions|Symptoms and General Pathology|Bacterial and Fungal Diseases|Urinary Tract, Sexual Organs, and Pregnancy Conditions",OTHER,,Multiple,United States|United States,9-Oct,19-Oct-09,11-Jun,11-Dec,16-Jan-12,Low enrollment,,2,27,Actual,70,Anticipated,TRUE,,27,27,27,0.39,0,27,0,,2 - No Scientific Data
NCT01004185,1,Assessing the Safety/Efficacy of Asacol?? Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Digestive System Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Canada|Canada|Canada|Canada|Canada|Croatia|Croatia|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Romania|Romania|Romania|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation,9-Oct,27-Oct-09,11-Mar,11-Mar,27-Mar-12,Pediatric enrollment very slow.,,2,39,Actual,100,Anticipated,TRUE,,39,39,39,0.39,2,39,0,,2 - No Scientific Data
NCT01004510,1,Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer,Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,Cancers and Other Neoplasms|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions,OTHER,,Single,United States,9-Nov,29-Oct-09,10-Sep,11-Apr,14-Aug-12,failure to accrue projected number of patients,,2,3,Actual,40,Anticipated,TRUE,,3,3,0,0.08,1,3,0,,2 - No Scientific Data
NCT01004705,1,A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Low Density Lipoprotein (LDL) Cholesterol,Prevention,Crossover Assignment,Open Label,Randomized,Drug|Drug,Phase 2,,INDUSTRY,,Single,United States,9-Sep,23-Oct-09,11-Mar,11-Mar,1-Jun-12,,,9,36,Actual,60,Anticipated,FALSE,E,44,36,42,0.6,0,106,0,,3 - No Reason Provided
NCT01005290,1,A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Blood Pressure,,Crossover Assignment,Open Label,Randomized,Drug|Drug,Phase 2,Heart and Blood Diseases|All Conditions,INDUSTRY,,Single,United States,9-Oct,22-Oct-09,10-Oct,10-Oct,30-Mar-12,,,9,38,Actual,60,Anticipated,FALSE,E,52,38,34,0.63,0,60,0,,3 - No Reason Provided
NCT01007643,1,Use of Wii Fit (TM) to Increase Compliance With Home Exercises in Treating Patellofemoral Syndrome,Treatment,Parallel Assignment,Single Blind,Randomized,Other|Other,,"Muscle, Bone, and Cartilage Diseases|All Conditions|Nervous System Diseases|Symptoms and General Pathology|Behaviors and Mental Disorders",OTHER,,Single,Canada,9-Oct,3-Nov-09,10-Sep,10-Sep,23-Jul-12,Difficulty in recruitment of study participants in alloted time and funding,,2,22,Actual,46,Anticipated,TRUE,,22,22,22,0.48,0,22,0,,2 - No Scientific Data
NCT01018810,1,A Study for Adults With Plaque Psoriasis,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug|Drug,Phase 2,Skin and Connective Tissue Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada,9-Dec,24-Nov-09,10-May,10-Aug,1-Jun-11,"The trial was terminated for several reasons, including complexities in development of LY2525623, but not because of safety concerns",,8,8,Actual,155,Anticipated,TRUE,,8,8,0,0.05,0,8,0,,2 - No Scientific Data
NCT01019980,1,Efficacy of Diclofenac Potassium Versus Acetaminophen in Febrile Children With Acute Upper Respiratory Tract Infections,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 4,Bacterial and Fungal Diseases|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions|Viral Diseases|Symptoms and General Pathology,INDUSTRY,,Multiple,Venezuela|Venezuela,10-Mar,20-Nov-09,10-Mar,,15-Mar-12,Placebo - Active Drug Not Available. No patients received drug. There are no study results to disclose.,,3,2,Actual,300,Anticipated,TRUE,,2,2,0,0.01,0,0,0,,2 - No Scientific Data
NCT01021423,1,A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Other,Phase 3,Cancers and Other Neoplasms|Blood and Lymph Conditions|Immune System Diseases|All Conditions|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Israel|Israel|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Poland|Poland|Poland|Portugal|Portugal|Portugal|Puerto Rico|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Spain|Spain|Spain|Spain|Spain|Spain|Spain|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom,10-Apr,25-Nov-09,11-Mar,11-Mar,31-Oct-11,Terminated by sponsor due to new unpublished data that rendered the current design of the study no longer clinically relevant. There were no safety concerns.,,7,9,Actual,382,Anticipated,TRUE,,9,9,0,0.02,1,9,0,,2 - No Scientific Data
NCT01024244,1,A Study of LY2599506 in Patients With Type 2 Diabetes,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Nutritional and Metabolic Diseases|Gland and Hormone Related Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|Australia|Australia|Australia|Puerto Rico|Puerto Rico|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Spain|Spain|Spain|Spain,9-Dec,1-Dec-09,10-Jul,10-Jul,15-Sep-11,Terminated due to nonclinical safety findings,,5,78,Actual,120,Anticipated,TRUE,,78,78,0,0.65,3,78,0,,1 - Scientific Data
NCT01029795,1,A Study of LY2599506 (Oral Agent Medication: Glucokinase Activator 1) in Type 2 Diabetes Mellitus,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 2,Nutritional and Metabolic Diseases|Gland and Hormone Related Diseases|All Conditions,INDUSTRY,,Multiple,Australia|Australia|Australia|Austria|Czech Republic|Czech Republic|Germany|Germany|Israel|Israel|Russian Federation|Russian Federation|Spain|Spain|Spain|Spain,10-Feb,9-Dec-09,10-Jun,10-Jun,15-Sep-11,Terminated due to nonclinical safety findings,,5,38,Actual,192,Anticipated,TRUE,,38,38,0,0.2,1,38,0,,1 - Scientific Data
NCT01030666,0,Effect of Postsurgical Systemic Doxycycline After Regenerative Periodontal Therapy,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 4,Mouth and Tooth Diseases|All Conditions,OTHER,,Multiple,Germany|Germany,7-Apr,10-Dec-09,11-Jan,11-Feb,22-Sep-12,shelf life of investigational drug ran out before 90 patients could be included,,3,61,Actual,61,Actual,TRUE,,61,61,58,1,0,61,1,22385260,2 - No Scientific Data
NCT01032837,1,A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 4,Viral Diseases|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions|Bacterial and Fungal Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,9-Nov,10-Dec-09,10-Oct,10-Oct,12-Jul-12,Study closed prematurely due to the end of the influenza (H1N1) 2009 pandemic,,7,102,Actual,400,Anticipated,TRUE,,102,102,70,0.26,0,101,0,,2 - No Scientific Data
NCT01035346,1,Study Evaluating The Efficacy Of A Novel Ibuprofen Formulation On Fever In Patients With An Uncomplicated Acute Infection,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Bacterial and Fungal Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Multiple,United States|United States|United States|United States|United States,10-Jan,8-Dec-09,11-May,11-May,13-Jul-12,,,9,16,Actual,90,Anticipated,TRUE,,16,16,16,0.18,0,16,0,,3 - No Reason Provided
NCT01048593,1,Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery,Treatment,Parallel Assignment,Double Blind,Randomized,Drug,Phase 2,Eye Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Single,United States,10-Jan,11-Jan-10,10-May,10-Jun,24-May-12,Study was terminated in order to examine study data.,,11,6,Actual,228,Anticipated,TRUE,,6,6,6,0.03,0,6,0,,2 - No Scientific Data
NCT01048723,1,Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas,Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Rare Diseases,OTHER,,Single,United States,10-Jan,13-Jan-10,11-Oct,11-Oct,13-Jul-12,Novartis terminated funding,,1,2,Actual,40,Anticipated,TRUE,,2,2,0,0.05,0,2,0,,2 - No Scientific Data
NCT01050218,0,Study Evaluating the Long-Term Safety of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Subjects With Pain Associated With Diabetic Peripheral Neuropathy,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 3,Nervous System Diseases|Gland and Hormone Related Diseases|All Conditions|Symptoms and General Pathology|Diseases and Abnormalities at or before Birth|Substance Related Disorders|Nutritional and Metabolic Diseases|Behaviors and Mental Disorders|Rare Diseases,INDUSTRY,,,,6-Jul,13-Jan-10,9-Jan,9-Jan,29-Jan-10,Business reasons,,8,237,Actual,240,Actual,TRUE,,237,237,0,0.99,26,237,0,,2 - No Scientific Data
NCT01051440,1,Magnetic Resonance Imaging Study of Lisdexamfetamine for Bipolar Depression,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 4,Behaviors and Mental Disorders|All Conditions,OTHER,,Single,United States,10-Feb,14-Jan-10,11-Jun,11-Jun,30-Jul-12,Slow enrollment,,2,2,Actual,30,Anticipated,TRUE,,2,2,2,0.07,0,2,0,,2 - No Scientific Data
NCT01056315,1,A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983Y,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Nervous System Diseases|Gland and Hormone Related Diseases|All Conditions|Symptoms and General Pathology|Diseases and Abnormalities at or before Birth|Substance Related Disorders|Nutritional and Metabolic Diseases|Behaviors and Mental Disorders|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,9-Nov,21-Dec-09,11-Jan,11-Jan,5-Apr-12,Trial was stopped due to difficult enrolment,,2,553,Actual,394,Anticipated,FALSE,F,50,50,0,0.13,3,50,0,,2 - No Scientific Data
NCT01056601,1,Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy,Treatment,Single Group Assignment,Open Label,,Drug|Drug,Phase 2,Cancers and Other Neoplasms|Digestive System Diseases|Gland and Hormone Related Diseases|All Conditions|Rare Diseases,OTHER,,Single,United States,10-Sep,25-Jan-10,11-Feb,11-Feb,28-Jul-11,Funding not available,,1,7,Actual,65,Anticipated,TRUE,,7,7,7,0.11,4,7,1,22399627,2 - No Scientific Data
NCT01063868,1,"A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)",Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 3,Nervous System Diseases|Gland and Hormone Related Diseases|All Conditions|Symptoms and General Pathology|Diseases and Abnormalities at or before Birth|Substance Related Disorders|Nutritional and Metabolic Diseases|Behaviors and Mental Disorders|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,10-Jan,4-Feb-10,10-Apr,10-Jun,14-Apr-11,Business decision,,8,47,Actual,800,Anticipated,TRUE,,47,47,47,0.06,0,47,0,,2 - No Scientific Data
NCT01066546,1,An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's Disease,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 3,Nervous System Diseases|Behaviors and Mental Disorders|All Conditions|Symptoms and General Pathology|Rare Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States|United States,10-Apr,9-Feb-10,10-Jul,10-Jul,30-Jul-12,See termination reason in detailed description.,"This study was terminated on May 7, 2010 due to modification of the dimebon development plan, following the lack of demonstration of efficacy in the completed DIM14 (CONNECTION) Study. The study was not terminated due to any safety findings. Dimebon has been well-tolerated in clinical trials. Demonstration of efficacy for dimebon in Alzheimer's disease is pending completion of the ongoing DIM18 (CONCERT) Study.",7,5,Actual,576,Anticipated,TRUE,,5,5,5,0.01,0,5,0,,2 - No Scientific Data
NCT01067326,1,The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Heart and Blood Diseases|All Conditions,OTHER,,Single,United States,10-Feb,8-Feb-10,11-Dec,11-Dec,9-Jan-13,Novartis ended all studies regarding Aliskiren.,,8,22,Actual,60,Anticipated,TRUE,,22,22,17,0.37,0,17,1,23615219,2 - No Scientific Data
NCT01067352,0,"A Trial to Evaluate the Correlation Between Spontaneous Catch-up Growth, Clinical Response to Saizen (Recombinant Human Growth Hormone, r-hGH) and Gene Expression Profiling in Children Small for Gestational Age (SGA)",Treatment,Parallel Assignment,Open Label,Randomized,Drug,Phase 3,,INDUSTRY,,Single,Italy,4-Feb,10-Feb-10,9-Jul,9-Jul,5-Oct-11,This study was discontinued prematurely due to difficulty in participant recruitment.,,2,25,Actual,26,Actual,TRUE,,25,25,0,0.96,0,22,0,,2 - No Scientific Data
NCT01069861,1,Study To Investigate Safety And Efficacy Of Sildenafil In The Newborns With Persistent Pulmonary Hypertension (PPHN),Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,Respiratory Tract (Lung and Bronchial) Diseases|All Conditions|Diseases and Abnormalities at or before Birth|Heart and Blood Diseases|Symptoms and General Pathology,INDUSTRY,,Single,United Kingdom,10-Dec,15-Feb-10,11-Nov,11-Nov,1-Nov-12,See termination reason in detailed description.,"Letter to investigator dated 18 June 2012 that study was to be terminated. Study terminated due to evolved and widespread use of standard of care, relevance of study questioned. No safety reasons or issues.",7,4,Actual,40,Anticipated,TRUE,,4,4,0,0.1,1,4,0,,2 - No Scientific Data
NCT01071200,0,"Study to Evaluate if the Addition of r-hLH (Luveris??) to FSH From Day 8 of Ovarian Stimulation is Able to Decrease Total FSH Dose and to Improve Cycle Outcome in Infertile Women Undergoing ART, Who Required High FSH Dose in a Previous Cycle",Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 3,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions",INDUSTRY,,Single,Italy,5-Mar,18-Feb-10,9-Apr,9-Apr,14-May-12,,,9,133,Actual,156,Actual,TRUE,,133,133,128,0.85,3,133,0,,3 - No Reason Provided
NCT01072136,1,Empiric Therapy of Mucopurulent Cervicitis (MPC),Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 3,"Bacterial and Fungal Diseases|Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions",NIH,,Multiple,United States|United States|United States|United States,10-Mar,18-Feb-10,11-Sep,11-Dec,20-Sep-12,,,9,87,Actual,772,Anticipated,TRUE,,87,87,33,0.11,0,87,1,23588127,3 - No Reason Provided
NCT01074502,1,Apremilast in the Treatment of Moderate to Severe Acne,Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,Skin and Connective Tissue Diseases|All Conditions|Symptoms and General Pathology,OTHER,,Single,United States,10-Feb,22-Feb-10,10-Jul,10-Oct,6-Oct-11,lack of funding due to Celgene administrative decision,,1,3,Actual,12,Anticipated,TRUE,,3,3,0,0.25,0,3,0,,2 - No Scientific Data
NCT01075815,1,A Clinical Trial to Determine the Effect of Lutropin Alfa on Embryo Quality and Implantation Rate in Advanced Reproductive Age,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 2,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions",INDUSTRY,,Single,Spain,8-Nov,24-Feb-10,10-Oct,10-Oct,29-Aug-12,,,9,76,Actual,134,Anticipated,FALSE,E,75,76,75,0.57,3,75,0,,3 - No Reason Provided
NCT01080768,1,Assessment of Aliskiren/Amlodipine and Amlodipine on Ankle Foot Volume (AFV) in Patients With Hypertension,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug|Drug,Phase 2,Heart and Blood Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Multiple,Netherlands|Netherlands|Netherlands|Netherlands|Netherlands|Netherlands|Netherlands|Netherlands|Netherlands,10-Feb,3-Mar-10,10-Nov,10-Nov,22-Nov-11,Publication of data from a similar study made the current study redundant.,,7,31,Actual,88,Anticipated,TRUE,,31,31,0,0.35,0,31,0,,2 - No Scientific Data
NCT01081886,1,PEAK PlasmaBlade 4.0 Versus Traditional Electrosurgery in Total Knee Replacement.,Treatment,Parallel Assignment,Single Blind,Randomized,Device|Device,,"Muscle, Bone, and Cartilage Diseases|All Conditions|Skin and Connective Tissue Diseases",INDUSTRY,,Multiple,United States|United States,10-Jun,4-Mar-10,11-Sep,11-Sep,29-Nov-12,Termination due to acquisition of PEAK Surgical by Medtronic,,8,24,Actual,40,Anticipated,TRUE,,24,24,0,0.6,4,24,0,,2 - No Scientific Data
NCT01090973,1,Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL),Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Blood and Lymph Conditions|Immune System Diseases|Rare Diseases,OTHER,,Single,United States,10-Mar,18-Mar-10,11-Mar,11-Mar,27-Jan-12,Pharmaceutical company request.,,8,1,Actual,30,Anticipated,TRUE,,1,1,0,0.03,1,1,0,,2 - No Scientific Data
NCT01100437,1,Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients,,Crossover Assignment,Double Blind,Randomized,Drug|Drug,Phase 4,Nervous System Diseases|Symptoms and General Pathology|All Conditions,INDUSTRY,,Single,United States,10-Apr,7-Apr-10,11-Mar,11-Mar,27-Feb-12,See termination reason in detailed description.,"The decision to terminate the trial was due to a lack of study drug supply. Decision was not based on any safety concerns. The date of the notification of termination letter was March 11, 2011.",3,14,Actual,80,Anticipated,TRUE,,14,14,12,0.18,0,34,1,23709323,2 - No Scientific Data
NCT01100658,1,Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors,Treatment,Crossover Assignment,Double Blind,Randomized,Drug|Drug,,Cancers and Other Neoplasms|All Conditions|Blood and Lymph Conditions|Immune System Diseases|Symptoms and General Pathology|Nervous System Diseases|Rare Diseases,OTHER,,Single,United States,10-May,7-Apr-10,10-Nov,10-Nov,28-Jul-11,Due to slow accrual,,2,1,Actual,36,Anticipated,TRUE,,1,1,0,0.03,0,0,0,,2 - No Scientific Data
NCT01101477,1,Target-Controlled Infusion of Propofol for Flexible Bronchoscopy Sedation,Treatment,Parallel Assignment,Double Blind,Randomized,Procedure,,,OTHER,,Single,Taiwan,10-Feb,7-Apr-10,10-Aug,10-Aug,5-Nov-11,Hypoxemia(SPaO2<80%) episodes occured significantly in the arm titration by 0.5ug/ml,,5,144,Actual,327,Anticipated,TRUE,,144,144,135,0.44,0,135,1,23638141,1 - Scientific Data
NCT01102218,1,A Safety Study of Pentoxifylline for the Treatment of Anemia,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug,Phase 2,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions|Blood and Lymph Conditions",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,10-Aug,9-Apr-10,12-Jan,12-Jan,18-Jan-12,Lack of statistical difference between both arms of the trial.,,6,48,Actual,100,Anticipated,TRUE,,48,48,17,0.48,24,48,0,,1 - Scientific Data
NCT01104103,1,Effectiveness Study of the BOA(R)-Constricting IV Band,Supportive Care,Parallel Assignment,Single Blind,Randomized,Device|Device,,Symptoms and General Pathology|All Conditions,OTHER,,Multiple,United States|United States,10-Mar,9-Apr-10,10-May,10-May,16-Jul-12,Pre-determined stopping point met with signficant difference between intervention and control groups.,,6,467,Actual,1600,Anticipated,TRUE,,467,467,467,0.29,0,467,0,,1 - Scientific Data
NCT01107899,1,Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary Syndromes,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 1,Heart and Blood Diseases|Symptoms and General Pathology|All Conditions|Nervous System Diseases,INDUSTRY,,Single,Germany,9-Oct,19-Apr-10,10-Dec,10-Dec,1-Dec-11,Terminated due to Enrollment futility,,2,29,Actual,100,Anticipated,TRUE,,29,29,19,0.29,1,28,1,22372531,2 - No Scientific Data
NCT01113541,1,One-Year Trial of Oral Ziprasidone in Bipolar Patients With Metabolic Syndrome,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 3,Nutritional and Metabolic Diseases|All Conditions|Symptoms and General Pathology|Behaviors and Mental Disorders|Rare Diseases,INDUSTRY,,Multiple,Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada,10-Jul,28-Apr-10,11-Feb,11-Feb,12-Oct-11,See termination reason in detailed description.,"The trial was terminated prematurely on December 14, 2010, due to inability to recruit the planned number of subjects and shifting organizational priorities. The decision to terminate the trial was not based on any safety or efficacy concerns.",2,13,Actual,155,Anticipated,TRUE,,13,13,10,0.08,1,13,0,,2 - No Scientific Data
NCT01116102,1,Study of In-line Pressure Using Various Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT1A),Treatment,Parallel Assignment,Open Label,Randomized,Drug,Phase 4,Nutritional and Metabolic Diseases|Symptoms and General Pathology|All Conditions,INDUSTRY,,Single,United States,10-May,30-Apr-10,10-May,10-Jun,12-Sep-11,Strategic business decision (not related to safety or efficacy concerns),,8,20,Actual,160,Anticipated,TRUE,,20,20,18,0.13,0,20,0,,2 - No Scientific Data
NCT01117948,1,Efficacy and Safety of Lornoxicam in Patients With Mild to Moderate Probable Alzheimer??s Disease.,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Nervous System Diseases|Behaviors and Mental Disorders|All Conditions|Symptoms and General Pathology|Rare Diseases,OTHER,,,,9-Sep,4-May-10,11-Apr,11-Apr,21-May-12,Lack of Efficacy,,6,219,Actual,220,Anticipated,TRUE,,219,219,191,1,13,219,0,,1 - Scientific Data
NCT01119040,1,"Prospective Evaluation of NOTES (Natural Orifice Translumenal Endoscopic Surgery) PEG ""Rescue""",Treatment,Single Group Assignment,Open Label,,Procedure,,Nutritional and Metabolic Diseases|All Conditions,OTHER,,Single,United States,7-Nov,6-May-10,10-Jul,10-Jul,14-Oct-10,Low accrual,,2,1,Actual,30,Anticipated,TRUE,,1,1,1,0.03,0,1,0,,2 - No Scientific Data
NCT01122511,1,Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Biological|Other,Phase 2,Eye Diseases|All Conditions|Symptoms and General Pathology|Rare Diseases,INDUSTRY,,Multiple,United States|United States,10-Aug,11-May-10,11-May,11-May,1-Aug-12,The study was terminated early due to difficulties with patient recruitment.,,2,4,Actual,280,Anticipated,TRUE,,4,4,0,0.01,0,4,0,,2 - No Scientific Data
NCT01125917,0,Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015,Treatment,Single Group Assignment,Open Label,,Drug|Drug|Drug,Phase 3,Nervous System Diseases|Symptoms and General Pathology|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,4-Jun,17-May-10,5-Sep,8-Jan,28-Jul-10,Terminated early due to administrative reasons.,,4,354,Actual,352,Actual,TRUE,,354,354,354,1.01,20,354,0,,2 - No Scientific Data
NCT01127646,1,A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents,Treatment,Parallel Assignment,Double Blind,Non-Randomized,Drug|Drug|Drug,Phase 4,Nervous System Diseases|Symptoms and General Pathology|All Conditions|Behaviors and Mental Disorders,INDUSTRY,,Multiple,Netherlands|Netherlands|Netherlands|Netherlands|Spain|Spain|Spain|Spain|Spain|Sweden|Sweden|Sweden|Sweden|Sweden,10-Jun,19-May-10,11-May,11-May,30-Apr-12,Due to lack of availability of study participants to accommodate the study design,,2,23,Actual,130,Anticipated,TRUE,,23,23,0,0.18,0,23,0,,2 - No Scientific Data
NCT01128114,1,Study of the Broad Clinical Benefit for Seroquel XR With Flexible Dose as an add-on Therapy in the Treatment of Acute Bipolar Mania Patients With Partial Response to Current Therapy,Treatment,Single Group Assignment,Open Label,,Drug,Phase 4,Behaviors and Mental Disorders|All Conditions,INDUSTRY,,Multiple,"Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of|Korea, Republic of",10-Jun,20-May-10,11-Mar,11-Mar,24-May-11,Poor recruitment,,2,32,Actual,125,Anticipated,TRUE,,32,32,0,0.26,0,32,0,,2 - No Scientific Data
NCT01131585,1,Safety and Efficacy of Ranibizumab in Diabetic Macular Edema,Treatment,Parallel Assignment,Double Blind,Randomized,Procedure|Drug|Drug,Phase 3,Nervous System Diseases|Eye Diseases|Symptoms and General Pathology|All Conditions|Heart and Blood Diseases|Gland and Hormone Related Diseases,INDUSTRY,,Multiple,Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany,10-Jun,25-May-10,11-Jul,11-Jul,12-Jul-12,European drug approval.,,7,128,Actual,300,Anticipated,TRUE,,128,128,128,0.43,19,128,0,,2 - No Scientific Data
NCT01133288,1,Yulex Glove Prospective Study in Spina Bifida,,Single Group Assignment,Open Label,,Device,,Nervous System Diseases|Diseases and Abnormalities at or before Birth|All Conditions|Immune System Diseases|Rare Diseases,OTHER,,Single,United States,9-Jul,26-May-10,11-Jul,11-Jul,11-Jul-11,The funder never paid for the study.,,1,7,Actual,50,Anticipated,TRUE,,7,7,0,0.14,0,0,0,,2 - No Scientific Data
NCT01134627,1,Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif??) in Relapsing-Remitting Multiple Sclerosis [RRMS],Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2,Nervous System Diseases|Immune System Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Single,Denmark,6-Feb,28-May-10,11-Apr,11-Apr,2-Aug-12,,,9,305,Actual,320,Anticipated,FALSE,E,304,305,304,0.95,32,304,0,,3 - No Reason Provided
NCT01135524,0,Safety of Buprenorphine Transdermal Patch (BTDS) in Osteoarthritis Pain: a 52-Week Extension Phase,Treatment,Single Group Assignment,Open Label,,Drug|Drug|Drug,Phase 3,"Muscle, Bone, and Cartilage Diseases|All Conditions|Nervous System Diseases|Symptoms and General Pathology|Skin and Connective Tissue Diseases",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,4-Apr,1-Jun-10,5-Aug,5-Aug,15-Jul-10,This study was terminated early for administrative reasons.,,4,196,Actual,196,Actual,TRUE,,196,196,196,1,14,196,0,,2 - No Scientific Data
NCT01136746,1,Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug,Phase 3,Nutritional and Metabolic Diseases|Gland and Hormone Related Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,11-Mar,2-Jun-10,11-Nov,11-Nov,12-Sep-12,Low enrollment,,2,16,Actual,266,Anticipated,TRUE,,16,16,15,0.06,1,16,0,,2 - No Scientific Data
NCT01145755,1,6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 2,Behaviors and Mental Disorders|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,10-May,27-May-10,10-Nov,10-Nov,28-Aug-12,,,9,131,Actual,210,Anticipated,TRUE,,131,131,124,0.62,1,131,0,,3 - No Reason Provided
NCT01151137,1,Permanent Atrial fibriLLAtion Outcome Study Using Dronedarone on Top of Standard Therapy,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Heart and Blood Diseases|Symptoms and General Pathology|All Conditions,INDUSTRY,,Multiple,"United States|Argentina|Australia|Austria|Belgium|Brazil|Bulgaria|Canada|Chile|Czech Republic|Denmark|Finland|France|Germany|Greece|Hong Kong|Hungary|Israel|Italy|Korea, Republic of|Malaysia|Mexico|Netherlands|New Zealand|Norway|Poland|Romania|Russian Federation|Singapore|Slovakia|South Africa|Spain|Sweden|Switzerland|Taiwan|Ukraine|United Kingdom",10-Jul,22-Jun-10,11-Sep,11-Sep,14-Sep-12,The study was stopped because of safety concerns,,5,3236,Actual,10800,Anticipated,TRUE,,3236,3236,3236,0.3,190,3223,1,22082198,1 - Scientific Data
NCT01151904,1,Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients,Treatment,Single Group Assignment,Open Label,,Drug|Drug,Phase 4,Eye Diseases|All Conditions|Heart and Blood Diseases,INDUSTRY,,Single,Thailand,9-Nov,5-Jun-10,12-Feb,12-Feb,3-Jan-13,Difficulty with patient recruitment,,2,17,Actual,53,Anticipated,TRUE,,17,17,0,0.32,0,17,0,,2 - No Scientific Data
NCT01153958,1,Colposeptine for the Treatment of Bacterial Vaginosis,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 4,"Bacterial and Fungal Diseases|Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions",INDUSTRY,,Multiple,China|China|China|China|China,10-Jul,28-Jun-10,10-Nov,10-Nov,18-Jul-12,,,9,133,Actual,480,Anticipated,TRUE,,133,133,65,0.28,0,133,0,,3 - No Reason Provided
NCT01160237,1,Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW?? 2010/2011 or Pandemrix TM,Prevention,Parallel Assignment,Open Label,Randomized,Biological|Biological,Phase 3,Viral Diseases|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions|Bacterial and Fungal Diseases,INDUSTRY,,Multiple,Germany|Germany,10-Aug,8-Jul-10,11-Feb,11-Feb,21-Feb-12,The study was terminated for logistic reasons not related to safety or efficacy of the vaccine.,,4,7,Actual,400,Anticipated,TRUE,,7,7,0,0.02,1,7,0,,2 - No Scientific Data
NCT01160445,1,Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug,Phase 2,"Cancers and Other Neoplasms|All Conditions|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Rare Diseases",NIH,,Single,United States,10-Jun,9-Jul-10,12-Jan,12-Jan,7-Nov-12,The study was terminated because we were not able to obtain the study drug.,,3,9,Actual,70,Anticipated,TRUE,,9,9,9,0.13,0,9,0,,2 - No Scientific Data
NCT01179191,1,Conversion to Embeda With Rescue Trial,Supportive Care,Single Group Assignment,Open Label,,Drug,Phase 4,Nervous System Diseases|Symptoms and General Pathology|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,10-Aug,30-Jul-10,11-Apr,11-Apr,30-Jul-12,See termination reason in detailed description.,The decision to terminate the trial was based on a lack of study drug supply. The decision was not based on any safety concerns. The termination letter was sent on 11March2011.,3,684,Actual,1300,Anticipated,TRUE,,684,684,684,0.53,24,684,0,,2 - No Scientific Data
NCT01181921,1,The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease,Basic Science,Single Group Assignment,Open Label,,Drug,Phase 4,Nervous System Diseases|Behaviors and Mental Disorders|All Conditions|Symptoms and General Pathology|Rare Diseases,INDUSTRY,,Single,Spain,11-Jan,12-Aug-10,11-Jun,11-Jun,4-Apr-12,The recruitment rate was very low (one screening failure and one early withdrawal patient),,2,1,Actual,27,Anticipated,TRUE,,1,1,0,0.04,0,1,0,,2 - No Scientific Data
NCT01182610,1,"Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma",Treatment,Single Group Assignment,Open Label,,Drug|Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|All Conditions,OTHER,,Single,United States,11-Apr,13-Aug-10,12-Mar,12-Mar,30-Oct-12,Safety concern in a similar trial enrolling the same patient population,,7,1,Actual,25,Anticipated,TRUE,,1,1,0,0.04,1,1,0,,2 - No Scientific Data
NCT01193556,1,PEAK PlasmaBlade TnA Versus Traditional Electrosurgery in Subcapsular Tonsillectomy,Treatment,Parallel Assignment,Single Blind,Randomized,Device|Device,,"Mouth and Tooth Diseases|Respiratory Tract (Lung and Bronchial) Diseases|Ear, Nose, and Throat Diseases|All Conditions|Bacterial and Fungal Diseases",INDUSTRY,,Multiple,United States|United States,10-Jul,31-Aug-10,12-Mar,12-Apr,29-Nov-12,Termination due to acquisition of PEAK Surgical by Medtronic,,8,51,Actual,30,Anticipated,TRUE,,51,51,0,1.7,1,51,0,,2 - No Scientific Data
NCT01194674,1,Microplasmin Intravitreal Administration in Participants With Uveitic Macular Edema,Treatment,Single Group Assignment,Open Label,,Drug,Phase 1|Phase 2,Eye Diseases|All Conditions|Symptoms and General Pathology|Rare Diseases,NIH,,Single,United States,11-Jan,2-Sep-10,11-Dec,11-Dec,10-Jul-12,Lack of enrollment.,,2,2,Actual,5,Anticipated,TRUE,,2,2,2,0.4,0,2,0,,2 - No Scientific Data
NCT01195103,1,Lusedra (Fospropofol Disodium) for Minimal to Moderate Sedation for Regional Anesthesia Block Prior to Orthopedic Surgery,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug|Drug,Phase 4,,OTHER,,Single,United States,11-Feb,1-Sep-10,11-Mar,11-Mar,27-Feb-12,Funding terminated by funding source.,,1,13,Actual,150,Anticipated,TRUE,,13,13,12,0.09,1,12,0,,2 - No Scientific Data
NCT01195779,1,Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children,Prevention,Parallel Assignment,Double Blind,Randomized,Biological|Biological|Biological,Phase 2,Viral Diseases|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions|Bacterial and Fungal Diseases,INDUSTRY,,Single,Spain,10-Sep,3-Sep-10,11-Mar,11-Mar,22-Mar-12,The study was terminated for logistic reasons not related to safety or efficacy of the vaccine.,,4,4,Actual,1120,Anticipated,TRUE,,4,4,0,0,0,4,0,,2 - No Scientific Data
NCT01198873,1,Effects of Dronedarone on Cardiac Geometry and Function in Patients With Atrial Fibrillation and Left Atrial Enlargement,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 4,Heart and Blood Diseases|Symptoms and General Pathology|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Canada,10-Sep,9-Sep-10,12-Jan,12-Jan,10-Jan-13,,,9,76,Actual,334,Anticipated,TRUE,,76,76,59,0.23,6,76,0,,3 - No Reason Provided
NCT01204853,1,A 12 Week Safety And Efficacy Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 3,Respiratory Tract (Lung and Bronchial) Diseases|All Conditions|Heart and Blood Diseases|Rare Diseases,INDUSTRY,,Multiple,Japan|Japan,10-Aug,6-Aug-10,10-Nov,10-Nov,26-Oct-11,"Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.",,5,2,Actual,35,Anticipated,TRUE,,2,2,2,0.06,0,2,0,,1 - Scientific Data
NCT01205685,1,Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer,Treatment,Single Group Assignment,Open Label,,Drug|Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|Skin and Connective Tissue Diseases|All Conditions,OTHER,,Multiple,United States|United States|United States,10-May,17-Sep-10,11-Jul,11-Jul,7-Jun-12,"PI closed study early, all patients experienced severe toxicities and progressed",,5,11,Actual,42,Anticipated,TRUE,,11,11,10,0.26,2,11,0,,1 - Scientific Data
NCT01209689,1,A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,"Bacterial and Fungal Diseases|Muscle, Bone, and Cartilage Diseases|All Conditions|Symptoms and General Pathology|Rare Diseases",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Australia|Australia|Australia|Australia|Belgium|Belgium|Belgium|Belgium|Belgium|Brazil|Brazil|Brazil|Brazil|Brazil|Bulgaria|Bulgaria|Bulgaria|Bulgaria|Bulgaria|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Denmark|Denmark|Denmark|France|France|France|France|France|France|France|France|France|France|France|France|France|France|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|India|India|India|India|India|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Lithuania|Lithuania|Netherlands|Netherlands|Netherlands|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Slovakia|Slovakia|South Africa|South Africa|South Africa|South Africa|South Africa|South Africa|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom,10-Oct,24-Sep-10,11-Dec,11-Dec,11-Dec-12,Clinical development program terminated due to failure to achieve efficacy,,6,113,Actual,250,Anticipated,TRUE,,113,113,100,0.45,6,117,0,,1 - Scientific Data
NCT01209702,1,A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs,Treatment,Parallel Assignment,Double Blind,Randomized,Biological|Drug,Phase 3,"Bacterial and Fungal Diseases|Muscle, Bone, and Cartilage Diseases|All Conditions|Rare Diseases",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Australia|Australia|Australia|Australia|Australia|Australia|Australia|Belgium|Belgium|Belgium|Belgium|Brazil|Brazil|Brazil|Brazil|Brazil|Bulgaria|Bulgaria|Bulgaria|Bulgaria|Bulgaria|Bulgaria|Bulgaria|Bulgaria|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|Czech Republic|France|France|France|France|France|France|France|France|Germany|Germany|Germany|Germany|Germany|Germany|India|India|India|India|India|India|India|India|India|India|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Lithuania|Lithuania|Lithuania|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Russian Federation|Slovakia|Slovakia|South Africa|South Africa|South Africa|South Africa|South Africa|South Africa|South Africa|South Africa|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom,10-Sep,24-Sep-10,11-May,11-Dec,26-Nov-12,Recruitment halted: Failed to achieve efficacy,,6,306,Actual,502,Anticipated,TRUE,,306,306,170,0.61,13,413,1,23765873,1 - Scientific Data
NCT01210144,0,EXpression PRofile Endometrium Samples Study,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug|Drug,Phase 4,"Cancers and Other Neoplasms|All Conditions|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Rare Diseases",INDUSTRY,,Single,France,8-Aug,11-Aug-10,10-Aug,10-Aug,30-Aug-12,Study terminated due to recruitment failure,,2,27,Actual,27,Actual,FALSE,E,24,27,23,1,0,24,0,,2 - No Scientific Data
NCT01210443,1,"Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients",Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 3,Respiratory Tract (Lung and Bronchial) Diseases|All Conditions|Heart and Blood Diseases|Rare Diseases,INDUSTRY,,Multiple,Japan|Japan,10-Nov,11-Aug-10,10-Dec,10-Dec,10-Nov-11,"Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.",,5,2,Actual,32,Anticipated,TRUE,,2,2,2,0.06,0,2,0,,1 - Scientific Data
NCT01213329,0,Immunophenotyping of Peripheral T Cells After T Cell Depletion With Alemtuzumab,Treatment,Parallel Assignment,Open Label,Randomized,Drug,Phase 4,,OTHER,,Single,United States,6-Feb,30-Sep-10,9-Apr,9-Apr,3-May-11,,,9,52,Actual,52,Actual,FALSE,E,50,52,0,1,0,51,0,,3 - No Reason Provided
NCT01222195,0,Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS),Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug|Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Blood and Lymph Conditions|Symptoms and General Pathology|Rare Diseases,OTHER,,Single,United States,8-Feb,14-Oct-10,10-Jul,10-Jul,30-Mar-11,Low accrual.,,2,1,Actual,1,Actual,TRUE,,1,1,1,1,1,1,0,,2 - No Scientific Data
NCT01237340,1,Saizen?? Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study,Treatment,Single Group Assignment,Open Label,,Drug,Phase 3,"Muscle, Bone, and Cartilage Diseases|Nervous System Diseases|Gland and Hormone Related Diseases|All Conditions|Diseases and Abnormalities at or before Birth|Rare Diseases",INDUSTRY,,Single,United States,10-Oct,5-Nov-10,11-Dec,11-Dec,11-Sep-12,The Sponsor voluntarily terminated this trial because compliance to strict Good Clinical Practice (GCP) requirements was not ensured - No safety concerns,,4,59,Actual,50,Anticipated,TRUE,,59,59,59,1.18,3,59,0,,2 - No Scientific Data
NCT01244620,1,"A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses",Treatment,Crossover Assignment,Open Label,Randomized,Drug|Drug|Drug|Drug|Drug|Drug,Phase 1,Heart and Blood Diseases|All Conditions|Respiratory Tract (Lung and Bronchial) Diseases|Rare Diseases,INDUSTRY,,Single,Singapore,10-Nov,15-Nov-10,10-Dec,10-Dec,18-Jan-12,"Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.",,5,16,Actual,16,Anticipated,TRUE,,16,16,0,1,0,16,0,,1 - Scientific Data
NCT01246011,1,Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion,,Factorial Assignment,Open Label,Randomized,Drug,Phase 4,,OTHER,,Single,United States,10-Nov,17-Nov-10,11-Jul,11-Jul,3-Jan-12,Enrollment was too slow.,,2,9,Actual,90,Anticipated,TRUE,,9,9,0,0.1,5,8,0,,2 - No Scientific Data
NCT01252095,1,Study of the Safety and Tolerability of PG545 in Patients With Advanced Solid Tumours,Treatment,Single Group Assignment,Open Label,,Drug,Phase 1,,INDUSTRY,,Single,Australia,11-Jan,30-Nov-10,11-Oct,11-Oct,21-May-12,Unexpected injection site reactions.,,5,4,Actual,25,Anticipated,TRUE,,4,4,3,0.16,0,4,0,,1 - Scientific Data
NCT01257542,1,Acute Cough Study In Children,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 4,Viral Diseases|Respiratory Tract (Lung and Bronchial) Diseases|All Conditions|Symptoms and General Pathology|Bacterial and Fungal Diseases,INDUSTRY,,Multiple,United States|United States|United States|United States,10-Dec,7-Dec-10,11-Mar,11-Mar,21-Aug-12,See termination reason in detailed description.,"In light of protocol changes required due to methodological and operational issues, including background noise in cough recordings which could impact data interpretation, the study has been terminated.",4,140,Actual,240,Anticipated,FALSE,F,107,107,105,0.45,0,107,0,,2 - No Scientific Data
NCT01259284,1,Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Dietary Supplement|Other,Phase 2|Phase 3,Cancers and Other Neoplasms|All Conditions|Skin and Connective Tissue Diseases|Respiratory Tract (Lung and Bronchial) Diseases|Digestive System Diseases|Heart and Blood Diseases|Symptoms and General Pathology|Rare Diseases,OTHER,,Single,United States,11-Jan,10-Dec-10,11-Sep,11-Sep,24-Apr-12,Terminated due to low accrual.,,2,2,Actual,252,Anticipated,TRUE,,2,2,0,0.01,2,2,0,,2 - No Scientific Data
NCT01263028,1,Effects of Ergocalciferol on Erythropoetin Stimulating Agent Dose,Treatment,Single Group Assignment,Open Label,,Drug,,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions",OTHER,,Single,United States,10-Aug,16-Dec-10,11-Sep,11-Sep,21-Aug-12,Strong enrollment efforts resulted in few eligible subjects and high screen failures due to CKD patients with higher vitamin D levels than anticipated.,,2,6,Actual,107,Anticipated,TRUE,,6,6,0,0.06,0,6,0,,2 - No Scientific Data
NCT01264835,1,Assessment of a Slotted Anoscope That Facilitates Hemorrhoidectomy,Treatment,Single Group Assignment,Open Label,,Device,,,INDUSTRY,,Multiple,United States|United States|United States,10-Dec,17-Dec-10,11-Jun,11-Jun,28-Nov-11,Slow Enrollment,,2,2,Actual,60,Anticipated,TRUE,,2,2,0,0.03,1,2,0,,2 - No Scientific Data
NCT01271907,1,Drosophila-generated CTL,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug|Drug|Drug,Phase 2,Cancers and Other Neoplasms|All Conditions|Skin and Connective Tissue Diseases|Rare Diseases,NIH,,Single,United States,10-Dec,6-Jan-11,12-Apr,12-Apr,7-Nov-12,Study was terminated due to poor accrual.,,2,3,Actual,90,Anticipated,TRUE,,3,3,3,0.03,0,3,0,,2 - No Scientific Data
NCT01273064,1,Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug|Drug,Phase 2,Viral Diseases|Digestive System Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,11-Jan,21-Dec-10,11-Sep,11-Oct,29-Mar-12,Risk-benefit ratio,,6,114,Actual,260,Anticipated,TRUE,,114,114,0,0.44,4,114,0,,1 - Scientific Data
NCT01284491,1,A Study to Evaluate Cutaneous Scar Quality Following Bilateral Breast Reduction With the PEAK PlasmaBlade 4.0,Treatment,Parallel Assignment,Double Blind,Randomized,Device|Device,,Symptoms and General Pathology|All Conditions|Rare Diseases,INDUSTRY,,Single,United States,11-Jan,25-Jan-11,12-May,12-May,29-Nov-12,Termination due to acquisition of PEAK Surgical by Medtronic,,8,13,Actual,25,Anticipated,TRUE,,13,13,0,0.52,0,26,0,,2 - No Scientific Data
NCT01288079,1,A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug|Drug,Phase 2,Behaviors and Mental Disorders|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Estonia|Estonia|Estonia|Finland|Finland|Finland|Finland|India|India|India|India|India|India|India|India|India|India|India|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan|Japan,11-Feb,26-Jan-11,12-Aug,12-Aug,7-Aug-12,,,9,145,Actual,352,Anticipated,TRUE,,145,145,137,0.41,2,144,0,,3 - No Reason Provided
NCT01292265,1,A 12 Week Study to Assess Changes in Joint Inflammation Using Ultrasonography in Patients With Rheumatoid Arthritis (RA),Treatment,Single Group Assignment,Open Label,,Biological,Phase 3,"Muscle, Bone, and Cartilage Diseases|All Conditions|Skin and Connective Tissue Diseases|Immune System Diseases|Symptoms and General Pathology|Nervous System Diseases",INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States,11-Feb,7-Feb-11,12-Jan,12-Jan,26-Oct-12,Termination of study due to low enrollment. There were no safety issues.,,2,3,Actual,50,Anticipated,TRUE,,3,3,0,0.06,0,3,0,,2 - No Scientific Data
NCT01296698,1,Study to Determine if a New Nicotine Replacement Therapy Can Safely Help Smokers to Quit Smoking,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Substance Related Disorders|Behaviors and Mental Disorders|All Conditions,INDUSTRY,,Multiple,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,11-Mar,14-Feb-11,11-Apr,11-Jun,29-Mar-12,Study terminated due to a technical issue (randomization error).,,4,257,Actual,1500,Anticipated,TRUE,,257,257,0,0.17,5,255,0,,2 - No Scientific Data
NCT01298128,0,NuvaRing vs. Oral Contraceptive Pills (OCP) for In-Vitro Fertilization (IVF) Pre-treatment,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions",OTHER,,,,6-Feb,15-Feb-11,10-Mar,10-Dec,17-Aug-11,,,9,70,Actual,70,Actual,TRUE,,70,70,53,1,0,53,1,21880278,3 - No Reason Provided
NCT01302899,1,To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy,Treatment,Crossover Assignment,Single Blind,Randomized,Drug|Drug|Drug|Drug|Drug,Phase 2,"Urinary Tract, Sexual Organs, and Pregnancy Conditions|All Conditions|Symptoms and General Pathology",INDUSTRY,,Multiple,Netherlands|Netherlands,11-Jan,9-Feb-11,11-Dec,11-Dec,21-Dec-12,In consequence of termination of ALTITUDE. A number of studies were continued in consultation with the Altitude Data Monitoring Committee.,,7,8,Actual,32,Anticipated,TRUE,,8,8,0,0.25,0,28,0,,2 - No Scientific Data
NCT01334710,1,A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer,Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,Cancers and Other Neoplasms|Digestive System Diseases|All Conditions|Rare Diseases,OTHER,,Multiple,United States|United States|United States,11-Mar,6-Apr-11,11-Aug,11-Dec,12-Sep-12,safety issue observed on another hepatocellular study using OSI906,,7,3,Actual,22,Anticipated,TRUE,,3,3,0,0.14,0,3,0,,2 - No Scientific Data
NCT01372813,0,Vandetanib to Treat Advanced Kidney Cancer,Treatment,Single Group Assignment,Open Label,Non-Randomized,Drug,Phase 2,"Cancers and Other Neoplasms|All Conditions|Urinary Tract, Sexual Organs, and Pregnancy Conditions|Rare Diseases",NIH,,Single,United States,7-Dec,11-Jun-11,10-Jun,10-Jun,19-Dec-11,Terminated for insufficient accrual.,,2,3,Actual,3,Actual,TRUE,,3,3,3,1,1,3,0,,2 - No Scientific Data
NCT01415986,0,Interstitial Photodynamic Therapy (PDT) With Temoporfin for Advanced Head and Neck Cancers,Treatment,Single Group Assignment,Open Label,,Drug|Device,Phase 2,Cancers and Other Neoplasms|All Conditions|Rare Diseases,OTHER,,Single,United States,10-Nov,10-Aug-11,11-Aug,12-Mar,11-May-12,"The patient was ""lost to follow-up"" and the PI left the institution.",,4,1,Actual,5,Anticipated,TRUE,,1,1,0,0.2,1,1,0,,2 - No Scientific Data
NCT01417104,1,Aliskiren Effect on Aortic Plaque Progression,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 2|Phase 3,Nervous System Diseases|Heart and Blood Diseases|All Conditions|Symptoms and General Pathology,OTHER,,Single,United States,9-Oct,8-Aug-11,11-Dec,12-Jan,29-Oct-12,Safety concerns with approved medication identified in an unrelated trial,,7,71,Actual,100,Anticipated,TRUE,,71,71,37,0.71,0,71,1,23686372,2 - No Scientific Data
NCT01453049,0,An Efficacy and Safety Study of Fixed-dose Rosiglitazone/Glimepiride to Treat Chinese Type 2 Diabetes Patients,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 3,Nutritional and Metabolic Diseases|Gland and Hormone Related Diseases|All Conditions,INDUSTRY,,Multiple,China|China|China|China|China|China|China|China|China|China|China|China,10-Apr,13-Oct-11,10-Oct,10-Oct,27-Oct-11,"US FDA/EMA/SFDA decisions to rosiglitazone-containing medicines, ethic",,16,86,Actual,86,Actual,TRUE,,86,86,73,1,0,83,0,,2 - No Scientific Data
NCT01463878,1,Enteral Nutrition and Glycemic Variability Neurological Intensive Care Unit Study,Treatment,Parallel Assignment,Double Blind,Randomized,Dietary Supplement|Dietary Supplement,Phase 4,Nervous System Diseases|Heart and Blood Diseases|Symptoms and General Pathology|All Conditions|Wounds and Injuries,OTHER,,Single,United States,11-Nov,24-Oct-11,12-Jun,12-Jun,22-Jun-12,Unlikely to show statistical significance and slow recruitment.,,6,14,Actual,30,Anticipated,FALSE,E,18,14,14,0.47,0,14,0,,1 - Scientific Data
NCT01475175,1,Adaptive Cardiac Resynchronization Therapy Optimization at Rest and During Exercise (AdOPT CRT),Treatment,Single Group Assignment,Open Label,,Device|Other,,Heart and Blood Diseases|All Conditions,INDUSTRY,,Multiple,Austria|Belgium|Belgium|Denmark|Germany|Netherlands|Norway|Serbia,11-Nov,16-Nov-11,12-Mar,12-Mar,12-Sep-12,Decision was made to stop the study based on a pre-planned interim analysis that the sample size would unlikely be sufficient to satisfy the primary objective.,,6,12,Actual,50,Anticipated,TRUE,,12,12,0,0.24,0,12,0,,1 - Scientific Data
NCT01478087,1,Immunoadsorption Therapy for Patients With Non-Ischemic Dilated Cardiomyopathy (DCM),Treatment,Single Group Assignment,Open Label,,Device,,Heart and Blood Diseases|All Conditions|Symptoms and General Pathology|Rare Diseases,INDUSTRY,,Multiple,United States|United States,11-Nov,7-Nov-11,12-Jun,12-Jun,8-Jan-13,Sponsor terminated due to business reasons,,8,2,Actual,20,Anticipated,FALSE,F,3,3,2,0.15,0,3,0,,2 - No Scientific Data
NCT01516034,1,The Efficacy of the Cupola Ultrasonic Tattoo Removal Device,Treatment,Single Group Assignment,Open Label,,Device,,,INDUSTRY,,Single,Israel,11-Nov,16-Jan-12,12-Nov,12-Nov,9-Nov-12,Sponsor decided that the results were not significant enough to continue.,,6,8,Actual,30,Anticipated,TRUE,,8,8,0,0.27,0,8,0,,1 - Scientific Data
NCT01546688,0,A Study to Evaluate the Safety and Tolerability and Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures,Treatment,Parallel Assignment,Double Blind,Randomized,Drug|Drug,Phase 4,Nervous System Diseases|All Conditions|Symptoms and General Pathology,INDUSTRY,,Multiple,Germany|Germany|Germany|Germany|Germany|Germany|Germany|Hungary|Hungary|Hungary|Hungary|Hungary|Hungary|Hungary|Hungary|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Netherlands|Poland|Poland|Poland|Poland|Poland|Poland|Poland|Switzerland|Switzerland|Switzerland|United Kingdom|United Kingdom|United Kingdom,8-Nov,2-Mar-12,10-Nov,11-Aug,12-Nov-12,,,9,41,Actual,43,Actual,FALSE,F,51,51,51,1.19,7,51,0,,3 - No Reason Provided
NCT01565993,0,The Use of Prophylactic Hemoclips in the Endoscopic Resection of Large Pedunculated Polyps,Prevention,Parallel Assignment,Open Label,Randomized,Device|Device,,Symptoms and General Pathology|All Conditions,OTHER,,Single,Spain,7-Jul,27-Mar-12,10-Aug,10-Aug,28-Mar-12,The unexpected increase in morbidity of the hemoclip group,,5,108,Actual,101,Actual,TRUE,,108,108,98,1.07,1,105,1,23687606,1 - Scientific Data
NCT01575899,0,Efficacy of Seven-day Combined Rabeprazole Plus Levofloxacin Plus Augmentin for Eradication of Helicobacter Pylori,Treatment,Parallel Assignment,Open Label,Randomized,Drug|Drug,Phase 4,Bacterial and Fungal Diseases|All Conditions,OTHER,,Single,Taiwan,7-Dec,10-Apr-12,9-Dec,9-Dec,19-Apr-12,Early termination due to efficacy,,6,208,Actual,146,Actual,TRUE,,208,208,146,1.42,1,208,0,,1 - Scientific Data
NCT01582282,0,Study of Metamucil on Blood Glucose and HbA1c in Type II NIDDM Subjects,Basic Science,Parallel Assignment,Double Blind,Randomized,Dietary Supplement|Dietary Supplement|Dietary Supplement,Phase 4,Nutritional and Metabolic Diseases|Gland and Hormone Related Diseases|All Conditions,INDUSTRY,,Multiple,United States|United States,May-88,18-Apr-12,Jan-90,Jan-90,3-Oct-12,due to slow enrollment,,2,37,Actual,37,Actual,TRUE,,37,37,33,1,0,37,0,,2 - No Scientific Data
NCT01634360,0,"Long-Term Safety, Tolerability and Efficacy in Perampanel Treated Parkinson's Disease Patients With Motor Fluctuations",Treatment,Single Group Assignment,Open Label,,Drug,Phase 2,Nervous System Diseases|All Conditions|Symptoms and General Pathology|Cancers and Other Neoplasms|Skin and Connective Tissue Diseases,INDUSTRY,,,,4-Nov,3-Jul-12,8-Jun,8-Jun,23-Oct-12,Due to termination of clinical program for Parkinson's Disease,,8,185,Actual,189,Actual,TRUE,,185,185,170,0.98,52,182,0,,2 - No Scientific Data
NCT01701622,0,The Blood Pressure Effects of Febuxostat in Patients Previously Treated With Allopurinol: A Pilot Study,Treatment,Single Group Assignment,Open Label,,Drug,,"Muscle, Bone, and Cartilage Diseases|Diseases and Abnormalities at or before Birth|Nutritional and Metabolic Diseases|All Conditions|Skin and Connective Tissue Diseases",OTHER,,Single,United States,10-Jan,27-Jan-10,11-Oct,11-Oct,9-Nov-12,unable to enroll participants,,2,1,Actual,1,Actual,TRUE,,1,1,0,1,0,0,0,,2 - No Scientific Data
